Number|B-Junk of|O glucocorticoid|B-protein receptors|I-protein in|O lymphocytes|B-cell_type and|O their|O sensitivity|O to|O hormone|O action|O .|O

The|B-Junk study|O demonstrated|O a|O decreased|O level|O of|O glucocorticoid|B-protein receptors|I-protein (|B-Junk GR|B-protein )|O in|O peripheral|B-cell_type blood|I-cell_type lymphocytes|I-cell_type from|O hypercholesterolemic|O subjects|B-Junk ,|I-Junk and|O an|B-Junk elevated|O level|O in|B-Junk patients|I-Junk with|O acute|O myocardial|O infarction|O .|O

In|B-Junk the|I-Junk lymphocytes|B-cell_type with|O a|O high|O GR|B-protein number|O ,|O dexamethasone|O inhibited|O [|O 3H|O ]|O -thymidine|O and|O [|O 3H|O ]|O -acetate|B-Junk incorporation|O into|O DNA|O and|O cholesterol|O ,|O respectively|O ,|O in|O the|O same|O manner|O as|O in|O the|O control|B-cell_type cells|I-cell_type .|O
On|O the|O other|O hand|O ,|O a|O decreased|B-Junk GR|B-protein number|O resulted|O in|O a|B-Junk less|B-Junk efficient|I-Junk dexamethasone|O inhibition|O of|O the|O incorporation|O of|O labeled|O compounds|O .|O
These|B-Junk data|O showed|O that|B-Junk the|B-Junk sensitivity|I-Junk of|O lymphocytes|B-cell_type to|O glucocorticoids|O changed|O only|O with|O a|O decrease|O of|O GR|B-protein level|O .|O
[|O 1|B-protein ,|I-protein 25-Dihydroxyvitamin|I-protein D3|I-protein receptors|I-protein in|O lymphocytes|B-cell_type and|O T-|B-cell_type and|I-cell_type B-lymphocyte|I-cell_type count|O in|O patients|B-Junk with|O glomerulonephritis|O ]|O
Content|B-Junk of|I-Junk receptors|O to|O hormonal|O form|O of|O vitamin|O D3|B-Junk ,|I-Junk 1.25|O (|O OH|O )|O 2D3|B-Junk ,|O constituted|O 27.3|B-Junk fmole/mg|O of|O protein|O in|O lymphocytes|B-cell_type of|O peripheric|O blood|O of|O children|O with|O glomerulonephritis|O .|O
In|O the|O patients|O concentration|O of|O total|O and|O ionized|O form|O of|O Ca2+|B-Junk was|O decreased|O down|O to|O 2.04|O mmole/L|B-Junk and|O 1.09|B-Junk mmole/L|I-Junk ,|O respectively|O ,|O while|O an|O increase|O in|O parathormone|O (|O PTH|O )|O by|O 36|O %|O and|O a|O distinct|O decrease|O in|O 25|O (|O OH|O )|O D|O concentration|O (|O lower|O than|O 1.25|O ng/ml|O )|O was|O found|O in|O blood|O ;|O content|O of|O cAMP|O was|O also|O decreased|O in|O lymphocytes|O by|O 33|O %|O .|O
At|O the|O same|O time|O ,|O total|O content|O of|O T|B-cell_type lymphocytes|I-cell_type was|O decreased|O 1.5-fold|O in|O peripheric|O blood|O .|O
Treatment|O with|O I-hydroxyvitamin|O D3|O (|O 1-1.5|O mg|O daily|O ,|O within|O 4|O weeks|O )|O led|O to|O normalization|O of|O total|O and|O ionized|O form|O of|O Ca2+|O and|O of|O 25|O (|O OH|O )|O D|O ,|O but|O did|O not|O affect|O the|O PTH|O content|O in|O blood|O .|O
Concentration|O of|O the|O receptors|B-protein to|O 1.25|O (|O OH|O )|O 2D3|O was|O elevated|O up|O to|O 39.7|O fmole/mg|O after|O I|O week|O of|O the|O treatment|O ,|O whereas|O it|O was|O decreased|O to|O the|O initial|O level|O 24.8|O fmole/mg|O within|O 4|O weeks|O ;|O simultaneous|O alteration|O in|O the|O cAMP|O content|O was|O observed|O in|O lymphocytes|B-cell_type .|O
Treatment|O with|O 1-|O (|O OH|O )|O D3|O normalized|O also|O the|O T|B-cell_type lymphocytes|I-cell_type content|O in|O peripheric|O blood|O .|O
The|O data|O obtained|O suggest|O that|O under|O conditions|O of|O glomerulonephritis|O only|O high|O content|O of|O receptors|B-protein to|O 1.25|O (|O OH|O )|O 2D3|O in|O lymphocytes|B-cell_type enabled|O to|O perform|O the|O cell|O response|O to|O the|O hormone|O effect|O .|O
Tumor|O and|O serum|O beta-2-microglobulin|O expression|O in|O women|O with|O breast|O cancer|O .|O
To|O investigate|O whether|O the|O tumor|B-cell_type expression|O of|O beta-2-microglobulin|B-protein (|B-Junk beta|B-protein 2-M|I-protein )|B-Junk could|O serve|O as|O a|O marker|O of|O tumor|O biologic|O behavior|O ,|O the|O authors|O studied|O specimens|O of|O breast|B-cell_type carcinomas|I-cell_type from|O 60|O consecutive|O female|O patients|O .|O
Presence|O of|O beta|B-protein 2-M|I-protein was|O analyzed|O by|O immunohistochemistry|O .|O
No|O significant|B-Junk correlations|O were|B-Junk found|O between|O tumor|B-protein beta|I-protein 2-M|I-protein expression|O and|O several|O histologic|O attributes|O such|O as|O type|O ,|O histologic|O and|O nuclear|O grades|O ,|O mitotic|O index|O ,|O necrosis|O ,|O vascular|O invasion|O ,|O and|O lymphocytic|O infiltration|O .|O
Likewise|O ,|O beta|B-protein 2-M|I-protein was|O not|O associated|O with|O markers|O of|O disease|O extension|O such|O as|O TNM|O ,|O (|O UICC|O ,|O classification|O of|O malignant|B-cell_type tumors|I-cell_type )|O staging|O and|O axillary|O lymph|O node|O involvement|B-Junk or|B-Junk with|B-Junk estrogen|O ,|O progesterone|O ,|O and|O glucocorticoid|O receptor|O levels|O .|O
However|O ,|O there|O was|O a|O significantly|O positive|O association|O between|O tumor|B-protein beta|I-protein 2-M|I-protein expression|B-Junk and|O the|O degree|O of|O lymphocytic|B-Junk infiltration|O in|O the|O tumor|B-Junk tissue|O .|B-Junk
Beta|B-protein 2-M|I-protein serum|O levels|O were|O determined|O by|O an|O enzyme-linked|O immunosorbent|O assay|O in|O samples|O from|O 22|O of|O the|O above|O women|O .|O
Although|O some|O of|O the|O highest|O values|O had|O been|O obtained|O in|O women|O with|O larger|O (|O T4|O )|O primary|O tumors|O ,|O the|O authors|O failed|B-Junk to|I-Junk detect|O any|O statistical|B-Junk relationship|B-Junk between|O beta|B-protein 2-M|I-protein expression|O in|O the|O tumor|O with|O serum|O levels|O or|O between|O serum|B-protein beta|I-protein 2-M|I-protein and|O the|B-Junk above|I-Junk histologic|I-Junk ,|O laboratory|O ,|O and|O clinical|O factors|O .|O
[|O Preliminary|O observation|O of|O level|O free-form|B-protein E|I-protein receptor|I-protein levels|O in|O serum|O of|O normal|B-Junk childbearing-aged|I-Junk and|O pregnant|B-Junk women|I-Junk ]|O
In|O 137|O cases|O of|O childbearing-aged|O and|O pregnant|O women|O ,|O free|B-protein form|I-protein E|I-protein receptor|I-protein levels|O (|O sE|B-protein )|O in|O serum|O were|O measured|O by|O ELISA|O .|O
The|O level|O of|O sE|B-protein was|O significantly|O decreased|O during|O the|O first|O trimester|O ,|O slightly|O higher|O in|O the|O second|O trimester|O ,|O and|O recovered|O to|O normal|O in|O the|O third|O trimester|O .|O
The|O level|O remained|O lower|O in|O 29|O PIH|O women|O but|O appeared|O higher|O in|O overdue|O pregnancies|O as|O compared|O with|O the|O normal|O 3rd|O trimester|O range|O .|O
The|O results|O indicate|O that|O there|O is|O a|O relationship|O between|O a|O change|O in|O T|B-cell_type cell|I-cell_type function|O and|O pregnancy|O .|O
Kappa|B-protein B-specific|I-protein DNA|I-protein binding|I-protein proteins|I-protein :|O role|O in|O the|O regulation|O of|O human|B-DNA interleukin-2|I-DNA gene|I-DNA expression|O .|O
Transcriptional|O activation|O of|O the|O human|B-DNA interleukin-2|I-DNA (|I-DNA IL-2|I-DNA )|I-DNA gene|I-DNA ,|O like|O induction|O of|O the|O IL-2|B-DNA receptor|I-DNA alpha|I-DNA (|I-DNA IL-2R|I-DNA alpha|I-DNA )|I-DNA gene|I-DNA and|O the|O type|O 1|O human|O immunodeficiency|O virus|O (|O HIV-1|O )|O ,|O is|O shown|O to|O be|O modulated|O by|O a|O kappa|B-protein B-like|I-protein enhancer|I-protein element|I-protein .|O
Mutation|O of|O a|O kappa|B-DNA B|I-DNA core|I-DNA sequence|I-DNA identified|O in|O the|O IL-2|B-DNA promoter|I-DNA (|O -206|O to|O -195|O )|O partially|O inhibits|O both|O mitogen-|O and|O HTLV-I|O Tax-mediated|O activation|O of|O this|O transcription|B-protein unit|I-protein and|O blocks|O the|O specific|O binding|O of|O two|O inducible|B-protein cellular|I-protein factors|I-protein .|O
These|O kappa|B-protein B-specific|I-protein proteins|I-protein (|O 80|O to|O 90|O and|O 50|O to|O 55|O kilodaltons|O )|O similarly|O interact|O with|O the|O functional|O kappa|B-protein B|I-protein enhancer|I-protein present|O in|O the|O IL-2R|B-DNA alpha|I-DNA promoter|I-DNA .|O
These|O data|O suggest|O that|O these|O kappa|B-protein B-specific|I-protein proteins|I-protein have|O a|O role|O in|O the|O coordinate|O regulation|O of|O this|O growth|O factor-growth|O factor|O receptor|O gene|O system|O that|O controls|O T|B-cell_type cell|I-cell_type proliferation|O .|O
Novel|O region|O within|O the|O V|B-DNA kappa|I-DNA gene|I-DNA promoter|I-DNA is|O responsible|O for|O tissue|O and|O stage-specific|O expression|O of|O immunoglobulin|B-DNA genes|I-DNA in|O human|B-cell_type lymphoid|I-cell_type neoplasms|I-cell_type .|O
Immunoglobulin|B-protein gene-specific|I-protein transacting|I-protein factors|I-protein have|O been|O shown|O to|O play|O a|O role|O in|O lymphoid|O tissue-specific|O expression|O of|O immunoglobulin|B-DNA genes|I-DNA .|O
The|O role|O of|O these|O factors|O in|O B-cell|B-cell_type differentiation|O and|O stage-specific|O expression|O of|O these|O genes|O is|O ,|O however|O ,|O not|O fully|O understood|O .|O
We|O have|O used|O a|O model|O of|O human|O lymphoid|O neoplasia|O to|O address|O this|O question|O .|O
Different|O fragments|O of|O unrearranged|B-DNA human|I-DNA variable|I-DNA region|I-DNA of|O immunoglobulin|B-DNA kappa|I-DNA gene|I-DNA (|O V|B-DNA kappa|I-DNA )|O were|O used|O for|O cell-free|O in|O vitro|O transcription|O and|O DNA|O mobility|O shift|O assays|O .|O
Previously|O described|O enhancement|O of|O in|O vitro|O transcription|O that|O was|O only|O seen|O with|O nuclear|O extracts|O derived|O from|O B-cell|B-cell_type neoplasms|I-cell_type corresponding|O to|O the|O late|O stages|O of|O B-cell|B-cell_type differentiation|O was|O shown|O to|O be|O dependent|O on|O the|O actions|O of|O these|O factor|O (|O s|O )|O on|O the|O DNA|O region|O within|O the|O V|B-DNA kappa|I-DNA gene|I-DNA promoter|I-DNA .|O
This|O region|O is|O located|O within|O the|O 920|O bp|O fragment|O located|O 210|O bp|O upstream|O from|O the|O coding|O region|O and|O this|O fragment|O represents|O a|O possible|O novel|O DNA|O region|O ,|O which|O plays|O a|O role|O in|O the|O stage-|O and|O tissue-specific|O expression|O of|O immunoglobulin|B-DNA genes|I-DNA .|O
[|O Determination|O of|O the|O sensitivity|O to|O glucocorticoids|B-protein in|O vitro|O ]|O
A|O modified|O method|O for|O the|O determination|O of|O glucocorticoid|B-protein receptors|I-protein in|O human|B-cell_type lymphocytes|I-cell_type is|O suggested|O .|O
The|O principal|O distinction|O of|O the|O method|O is|O standardization|O by|O the|O lymphocyte|B-cell_type count|O in|O a|O sample|O (|O 1|O mln|O )|O and|O the|O labeled|O hormone|B-protein concentration|O .|O
The|O modification|O saves|O time|O and|O money|O ,|O limits|O the|O range|O of|O the|O data|O variations|O ,|O and|O makes|O use|O of|O a|O lesser|O volume|O of|O blood|O .|O
Examinations|O of|O 70|O children|O aged|O 4|O to|O 15|O suffering|O from|O the|O nephrotic|O form|O of|O glomerulonephritis|O have|O made|O it|O possible|O to|O distinguish|O two|O groups|O of|O patients|O :|O with|O relatively|O high|O values|O of|O specific|O binding|O X|O =|O 6820.1|O +/-|O 530.0|O (|O n|O =|O 30|O ,|O p|O =|O 0.95|O ,|O t|O =|O 2.04|O )|O ,|O this|O corresponding|O to|O a|O clinical|O form|O of|O hormone|B-protein -sensitive|O glomerulonephritis|O ,|O and|O with|O relatively|O low|O values|O of|O specific|O binding|O X|O =|O 1815.2|O +/-|O 302.8|O (|O n|O =|O 40|O ,|O p|O =|O 0.95|O ,|O t|O =|O 1.96|O )|O ,|O that|O corresponds|O to|O hormone|B-protein -resistant|O glomerulonephritis|O .|O
Dynamic|O studies|O have|O not|O shown|O any|O statistically|O significant|O changes|O in|O the|O specific|O binding|O values|O .|O
These|O results|O permit|O regarding|O the|O specific|O binding|O value|O as|O a|O prognostic|O criterion|O in|O the|O assessment|O of|O corticosteroid|B-protein therapy|O ;|O this|O allows|O a|O wide|O employment|O of|O the|O described|O method|O in|O practical|O nephrology|O .|O
Octamer-binding|B-protein proteins|I-protein from|O B|B-cell_line or|I-cell_line HeLa|I-cell_line cells|I-cell_line stimulate|O transcription|O of|O the|O immunoglobulin|B-DNA heavy-chain|I-DNA promoter|I-DNA in|O vitro|O .|O
The|O B-cell|B-cell_type -type|O specificity|O of|O the|O immunoglobulin|B-protein (|O Ig|B-protein )|O heavy-chain|O and|O light-chain|O promoters|O is|O mediated|O by|O an|O octanucleotide|B-DNA (|I-DNA OCTA|I-DNA )|I-DNA element|I-DNA ,|O ATGCAAAT|O ,|O that|O is|O also|O a|O functional|O component|O of|O other|O RNA|B-DNA polymerase|I-DNA II|I-DNA promoters|I-DNA ,|O such|O as|O snRNA|O and|O histone|O H2B|O promoters|O .|O
Two|O nuclear|B-protein proteins|I-protein that|O bind|O specifically|O and|O with|O high|O affinity|O to|O the|O OCTA|B-DNA element|I-DNA have|O been|O identified|O .|O
NF-A1|B-protein is|O present|O in|O a|O variety|O of|O cell|O types|O ,|O whereas|O the|O presence|O of|O NF-A2|B-protein is|O essentially|O confined|O to|O B|B-cell_type cells|I-cell_type ,|O leading|O to|O the|O hypothesis|O that|O NF-A2|B-protein activates|O cell-type-specific|O transcription|O of|O the|O Ig|B-DNA promoter|I-DNA and|O NF-A1|B-protein mediates|O the|O other|O responses|O of|O the|O OCTA|B-DNA element|I-DNA .|O
Extracts|O of|O the|O B-cell|B-cell_line line|I-cell_line ,|O BJA-B|B-cell_line ,|O contain|O high|O levels|O of|O NF-A2|B-protein and|O specifically|O transcribe|O Ig|B-DNA promoters|I-DNA .|O
In|O contrast|O ,|O extracts|O from|O HeLa|B-cell_line cells|I-cell_line transcribed|O the|O Ig|B-DNA promoter|I-DNA poorly|O .|O
Surprisingly|O ,|O addition|O of|O either|O affinity-enriched|O NF-A2|O or|O NF-A1|O to|O either|O a|O HeLa|O extract|O or|O a|O partially|O purified|O reaction|O system|O specifically|O stimulates|O the|O Ig|B-DNA promoter|I-DNA .|O
This|O suggests|O that|O the|O constitutive|O OCTA-binding|B-protein factor|I-protein NF-A1|I-protein can|O activate|O transcription|O of|O the|O Ig|B-DNA promoter|I-DNA and|O that|O B-cell|B-cell_type -specific|O transcription|O of|O this|O promoter|O ,|O at|O least|O in|O vitro|O ,|O is|O partially|O due|O to|O a|O quantitative|O difference|O in|O the|O amount|O of|O OCTA-binding|B-protein protein|I-protein .|O
Because|O NF-A1|B-protein can|O stimulate|O Ig|B-protein transcription|O ,|O the|O inability|O of|O this|O factor|O to|O activate|O in|O vivo|O the|O Ig|B-DNA promoter|I-DNA to|O the|O same|O degree|O as|O the|O snRNA|B-DNA promoters|I-DNA probably|O reflects|O a|O difference|O in|O the|O context|O of|O the|O OCTA|B-DNA element|I-DNA in|O these|O two|O types|O of|O promoters|B-DNA .|O
Identification|O of|O a|O putative|O regulator|O of|O early|B-DNA T|I-DNA cell|I-DNA activation|I-DNA genes|I-DNA .|O
Molecules|O involved|O in|O the|O antigen|O receptor-dependent|O regulation|O of|O early|B-DNA T|I-DNA cell|I-DNA activation|I-DNA genes|I-DNA were|O investigated|O with|O the|O use|O of|O functional|O sequences|O of|O the|O T|B-protein cell|I-protein activation-specific|I-protein enhancer|I-protein of|O interleukin-2|B-protein (|O IL-2|B-protein )|O .|O
One|O of|O these|O sequences|O forms|O a|O protein|O complex|O ,|O NFAT-1|B-protein ,|O specifically|O with|O nuclear|O extracts|O of|O activated|O T|B-cell_type cells|I-cell_type .|O
This|O complex|O appeared|O 10|O to|O 25|O minutes|O before|O the|O activation|O of|O the|O IL-2|B-DNA gene|I-DNA .|O
Studies|O with|O inhibitors|O of|O protein|O synthesis|O indicated|O that|O the|O time|O of|O synthesis|O of|O the|O activator|O of|O the|O IL-2|B-DNA gene|I-DNA in|O Jurkat|B-cell_line T|I-cell_line cells|I-cell_line corresponds|O to|O the|O time|O of|O appearance|O of|O NFAT-1|B-protein .|O
NFAT-1|B-protein ,|O or|O a|O very|O similar|O protein|O ,|O bound|O functional|O sequences|O of|O the|O long|B-DNA terminal|I-DNA repeat|I-DNA (|O LTR|B-DNA )|O of|O the|O human|O immunodeficiency|O virus|O type|O 1|O ;|O the|O LTR|B-DNA of|O this|O virus|O is|O known|O to|O be|O stimulated|O during|O early|O T|B-cell_type cell|I-cell_type activation|O .|O
The|O binding|B-DNA site|I-DNA for|O this|O complex|O activated|O a|O linked|O promoter|O after|O transfection|O into|O antigen|B-cell_type receptor-activated|I-cell_type T|I-cell_type cells|I-cell_type but|O not|O other|O cell|O types|O .|O
These|O characteristics|O suggest|O that|O NFAT-1|B-protein transmits|O signals|O initiated|O at|O the|O T|B-protein cell|I-protein antigen|I-protein receptor|I-protein .|O
Characterization|O of|O thyroid|B-protein hormone|I-protein receptors|I-protein in|O human|B-cell_line IM-9|I-cell_line lymphocytes|I-cell_line .|O
Although|O putatively|O identified|O more|O than|O 10|O years|O ago|O ,|O thyroid|B-protein hormone|I-protein receptors|I-protein in|O human|O tissues|O remain|O poorly|O characterized|O .|O
As|O a|O first|O step|O towards|O understanding|O the|O mechanism|O of|O thyroid|O hormone|O action|O in|O man|O we|O have|O characterized|O T3|B-protein binding|I-protein sites|I-protein in|O nuclei|O of|O the|O human|B-cell_line lymphoblastoid|I-cell_line line|I-cell_line ,|O IM-9|B-cell_line cells|I-cell_line .|O
In|O whole|O cell|O experiments|O at|O 37|O degrees|O C|O ,|O nuclear|O binding|O of|O [|B-protein 125I|I-protein ]|I-protein T3|I-protein was|O saturable|O (|O Kd|O 34|O +/-|O 6|O pmol/l|O )|O and|O of|O finite|O capacity|O (|O approximately|O equal|O to|O 350|O sites/cell|O )|O .|O
The|O binding|B-protein sites|I-protein were|O extracted|O from|O a|O nuclear|O pellet|O by|O treatment|O with|O 0.4|O mol/l|O KCl|O and|O sonication|O .|O
Separation|O of|O bound|O from|O free|O [|B-protein 125I|I-protein ]|I-protein T3|I-protein in|O the|O extracts|O was|O achieved|O using|O the|O calcium|O phosphate|O matrix|O ,|O hydroxyapatite|O at|O a|O concentration|O of|O 0.3|O ml|O of|O a|O 150|O g/l|O slurry|O .|O
Rectilinear|O Scatchard|O plots|O were|O obtained|O only|O when|O the|O hydroxyapatite|O was|O washed|O with|O a|O buffer|O containing|O 0.5|O %|O Triton|O X-100|O .|O
Under|O these|O conditions|O T3|B-protein binding|I-protein sites|I-protein in|O the|O nuclear|O extracts|O were|O present|O at|O a|O concentration|O of|O 22.4|O +/-|O 8.6|O fmol/mg|O protein|O and|O showed|O an|O affinity|O of|O (|O Kd|O ,|O room|O temperature|O )|O 140|O +/-|O 10|O pmol/l|O .|O
The|O same|O assay|O system|O was|O used|O to|O determine|O the|O hierarchy|O of|O affinities|O for|O a|O range|O of|O natural|O and|O synthetic|O analogues|O .|O
Calling|O T3|O 100|O ,|O the|O order|O of|O potencies|O observed|O was|O :|O Triac|O ,|O 500|O ;|O 3|O ,|O 5-diiodo-3'-isopropylthyronine|O ,|O 89|O ;|O T4|O ,|O 32|O ;|O 3|O ,|O 5-dimethyl-3'isopropylthyronine|O 2|O ;|O 3|O ,|O 5-T2|O ,|O 0.7|O ,|O rT3|O ,|O 0.4|O ;|O 3'5'-T2|O ,|O less|O than|O 0.01|O .|O
These|O results|O suggest|O that|O the|O T3|B-protein binding|I-protein sites|I-protein present|O in|O human|B-cell_line IM-9|I-cell_line lymphocyte|I-cell_line nuclei|O and|O extracts|O thereof|O are|O thyroid|B-protein hormone|I-protein receptors|I-protein .|O
These|O cells|O may|O be|O a|O useful|O tool|O to|O increase|O our|O understanding|O of|O human|B-protein T3|I-protein receptors|I-protein
Definition|O of|O T-cell|B-protein specific|I-protein DNA-binding|I-protein factors|I-protein that|O interact|O with|O a|O 3'-silencer|B-DNA in|O the|O CD4+|B-DNA T-cell|I-DNA gene|I-DNA Rpt-1|I-DNA .|O
Analysis|O of|O the|O region|O 3|O '|O to|O the|O CD4+|B-DNA T-cell|I-DNA gene|I-DNA Rpt-1|I-DNA (|O encoding|O regulatory|O protein|O T-lymphocyte|B-protein 1|I-protein )|O led|O to|O the|O definition|O of|O a|O silencer|B-DNA element|I-DNA that|O inhibits|O heterologous|B-DNA gene|I-DNA expression|O in|O certain|O CD4+|B-cell_type T-cell|I-cell_type lines|I-cell_type but|O not|O in|O B-cell|B-cell_type or|O non-lymphoid|B-cell_type cell|I-cell_type lines|I-cell_type .|O
Functional|O silencer|B-DNA activity|O in|O vivo|O was|O associated|O with|O the|O presence|O of|O a|O specific|O silencer-DNA-protein|B-protein complex|I-protein in|O electrophoretic|O mobility|O shift|O assays|O with|O T-cell|B-cell_type extracts|O .|O
Formation|O of|O this|O complex|O was|O selectively|O inhibited|O by|O the|O region|O in|O HIV-1|B-DNA containing|O a|O silencer|B-DNA element|I-DNA .|O
We|O discuss|O the|O possibility|O that|O DNA-binding|B-protein factors|I-protein may|O coregulate|O HIV-1|O and|O Rpt-1|O gene|O expression|O through|O a|O common|O transcriptional|B-DNA silencer|I-DNA element|I-DNA .|O
Congenital|O immunodeficiencies|O associated|O with|O absence|O of|O HLA|B-protein class|I-protein II|I-protein antigens|I-protein on|O lymphocytes|B-cell_type result|O from|O distinct|O mutations|O in|O trans-acting|B-protein factors|I-protein .|O
Coordinate|O regulation|O of|O HLA|B-DNA class|I-DNA II|I-DNA gene|I-DNA expression|O during|O development|O and|O coinduction|O of|O class|B-DNA II|I-DNA genes|I-DNA by|O soluble|B-protein factors|I-protein suggests|O that|O common|O trans-acting|B-protein factor|I-protein (|O s|O )|O control|O expression|O of|O these|O genes|O .|O
In|O B-lymphoblastoid|B-cell_type cell|I-cell_type lines|I-cell_type derived|O from|O two|O independent|O class|O II-deficient|O bare|O lymphocyte|O syndrome|O patients|O ,|O we|O observed|O a|O drastic|O decrease|O in|O transcription|O rates|O of|O the|O class|B-DNA II|I-DNA genes|I-DNA .|O
When|O these|O cell|O lines|O are|O fused|O ,|O class|B-DNA II|I-DNA genes|I-DNA are|O reexpressed|O ,|O indicating|O that|O immunodeficiencies|O in|O bare|O lymphocyte|O syndrome|O patients|O are|O the|O result|O of|O two|O distinct|O mutations|O .|O
Further|O studies|O show|O that|O genes|O governing|O the|O expression|O of|O class|B-protein II|I-protein antigens|I-protein fall|O into|O at|O least|O three|O complementation|O groups|O ;|O two|O of|O these|O were|O previously|O unidentified|O in|O mutant|B-cell_line cell|I-cell_line lines|I-cell_line generated|O in|O vitro|O .|O
In|O addition|O ,|O we|O report|O the|O identification|O of|O two|O discrete|O complexes|O ,|O NFX1.1|B-protein and|O NFX1.2|B-protein ,|O that|O bind|O to|O the|O DRA|B-DNA X|I-DNA consensus|I-DNA element|I-DNA .|O
Though|O the|O mutation|O in|O at|O least|O one|O mutant|B-cell_line line|I-cell_line generated|O in|O vitro|O (|O RJ2.2.5|B-cell_line )|O affects|O products|O functioning|O via|O interaction|O with|O the|O X|B-DNA box|I-DNA ,|O clear|O alterations|O in|O either|O NFX1.1|B-protein or|O NFX1.2|B-protein are|O not|O found|O in|O any|O of|O the|O mutant|B-cell_line cell|I-cell_line lines|I-cell_line .|O
In|O vivo|O responsiveness|O to|O glucocorticoid|O correlated|O with|O glucocorticoid|B-protein receptor|I-protein content|O in|O peripheral|B-cell_type blood|I-cell_type leukocytes|I-cell_type in|O normal|O humans|O .|O
Dexamethasone|O loading|O tests|O (|O 0.1|O mg|O dexamethasone/kg|O ,|O iv|O )|O were|O performed|O in|O 18|O normal|O males|O to|O evaluate|O the|O individual|O responsiveness|O to|O glucocorticoid|O .|O
There|O were|O inter-individual|O differences|O in|O increase|O in|O peripheral|B-cell_type blood|I-cell_type polymorphonuclear|I-cell_type leukocyte|I-cell_type count|O ,|O decrease|O in|O peripheral|B-cell_type blood|I-cell_type lymphocyte|I-cell_type count|O ,|O and|O increase|O in|O plasma|O free|O fatty|O acids|O levels|O after|O dexamethasone|O injection|O .|O
In|O addition|O ,|O there|O was|O a|O significant|O correlation|O between|O the|O maximum|O increase|O in|O polymorphonuclear|B-cell_type leukocytes|I-cell_type and|O the|O maximum|O decrease|O in|O lymphocytes|B-cell_type (|O r|O =|O 0.7514|O ,|O p|O less|O than|O 0.0003|O )|O .|O
Simultaneous|O measurements|O of|O glucocorticoid|B-protein receptor|I-protein content|O by|O whole-cell|O assay|O revealed|O that|O glucocorticoid|B-protein receptor|I-protein content|O in|O polymorphonuclear|B-cell_type leukocytes|I-cell_type linearly|O correlated|O with|O that|O in|O the|O corresponding|O lymphocytes|B-cell_type (|O r|O =|O 0.9482|O ,|O p|O less|O than|O 0.0001|O )|O .|O
There|O were|O also|O significant|O correlations|O between|O the|O maximum|O increase|O in|O polymorphonuclear|B-cell_type leukocytes|I-cell_type and|O glucocorticoid|B-protein receptor|I-protein content|O in|O polymorphonuclear|B-cell_type leukocytes|I-cell_type (|O r|O =|O 0.7239|O ,|O p|O less|O than|O 0.0007|O )|O ,|O and|O between|O the|O maximum|O decrease|O in|O lymphocytes|B-cell_type and|O glucocorticoid|B-protein receptor|I-protein content|O in|O lymphocytes|B-cell_type (|O r|O =|O 0.7703|O ,|O p|O less|O than|O 0.0002|O )|O .|O
These|O results|O suggest|O that|O individual|O differences|O are|O preserved|O both|O in|O glucocorticoid|O responsiveness|O and|O in|O glucocorticoid|B-protein receptor|I-protein content|O in|O peripheral|B-cell_type blood|I-cell_type leukocytes|I-cell_type in|O normal|O humans|O .|O
Estradiol|O receptors|O in|O the|O cytosol|O of|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type in|O hepatitis|O B|O virus|O carriers|O treated|O with|O interferon-alpha|B-protein .|O
Estradiol|B-protein receptors|I-protein in|O the|O cytosol|O of|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type and|O the|O effects|O of|O interferon-alpha|B-protein (|O IFN-alpha|B-protein )|O on|O estradiol|B-protein receptors|I-protein were|O studied|O in|O asymptomatic|O hepatitis|O B|O virus|O (|O HBV|O )|O carriers|O ,|O patients|O with|O chronic|O hepatitis|O B|O and|O normal|O controls|O .|O
The|O level|O of|O estradiol|B-protein receptors|I-protein in|O the|O cytosol|O of|O mononuclear|B-cell_type cells|I-cell_type was|O significantly|O lower|O in|O asymptomatic|O HBV|O carriers|O and|O patients|O with|O chronic|O hepatitis|O B|O ,|O compared|O to|O normal|O controls|O .|O
This|O low|O level|O of|O cytosol|O estradiol|B-protein receptors|I-protein in|O patients|O with|O chronic|O hepatitis|O B|O was|O increased|O by|O the|O administration|O of|O IFN-alpha|B-protein .|O
In|O addition|O ,|O when|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type from|O patients|O with|O chronic|O hepatitis|O B|O were|O incubated|O with|O IFN-alpha|B-protein in|O vitro|O ,|O the|O level|O of|O cytosol|O estradiol|B-protein receptors|I-protein also|O increased|O by|O increasing|O the|O concentration|O of|O IFN-alpha|B-protein .|O
We|O previously|O reported|O that|O the|O response|O of|O mononuclear|B-cell_type cells|I-cell_type to|O estrogen|O is|O impaired|O in|O HBV|O carriers|O ,|O and|O our|O present|O results|O suggested|O that|O this|O may|O be|O due|O to|O the|O low|O level|O of|O estradiol|B-protein receptors|I-protein in|O the|O cytosol|O of|O mononuclear|B-cell_type cells|I-cell_type .|O
Association|O of|O increased|O lytic|O effector|O cell|O function|O with|O high|O estrogen|B-protein receptor|I-protein levels|O in|O tumor-bearing|O patients|O with|O breast|O cancer|O .|O
Tumor-bearing|O patients|O with|O breast|O cancer|O were|O assayed|O for|O their|O natural|B-cell_type killer|I-cell_type (|I-cell_type NK|I-cell_type )|I-cell_type cell|I-cell_type activity|O and|O for|O the|O function|O of|O activated|O cytotoxic|B-cell_type T-cells|I-cell_type ,|O as|O assessed|O by|O lectin-dependent|O cellular|O cytotoxicity|O (|O LDCC|O )|O .|O
Tumor-bearing|O patients|O with|O breast|O cancer|O had|O a|O significant|O increase|O in|O NK|B-cell_type activity|O and|O in|O LDCC|O ,|O as|O compared|O with|O healthy|O control|O individuals|O .|O
Although|O the|O enhanced|O NK|B-cell_type cell|I-cell_type activity|O and|O LDCC|O were|O closely|O associated|O with|O high|O levels|O (|O greater|O than|O 31|O fmol/mg|O )|O of|O estrogen|B-protein receptor|I-protein (|O ER|B-protein )|O content|O in|O the|O primary|O tumor|O ,|O no|O other|O clinical|O or|O histologic|O correlation|O between|O the|O increase|O in|O either|O parameter|O of|O cytotoxic|B-cell_type effector|I-cell_type cell|I-cell_type function|O could|O be|O found|O .|O
Thus|O ,|O ER|B-protein levels|O greater|O than|O 31|O fmol/mg|O might|O be|O associated|O with|O increased|O cytotoxic|B-cell_type effector|I-cell_type cell|I-cell_type function|O in|O tumor-bearing|O patients|O with|O breast|O cancer|O .|O
Properties|O of|O glucocorticoid|B-protein receptors|I-protein in|O Epstein-Barr|B-cell_line virus-transformed|I-cell_line lymphocytes|I-cell_line from|O patients|O with|O familial|O cortisol|O resistance|O .|O
In|O a|O previous|O report|O of|O two|O patients|O with|O familial|O glucocorticoid|O resistance|O due|O to|O reduced|O numbers|O of|O glucocorticoid|B-protein receptors|I-protein (|O GR|B-protein )|O ,|O we|O have|O shown|O decreased|O numbers|O of|O GR|B-protein in|O peripheral|B-cell_type mononuclear|I-cell_type cells|I-cell_type and|O cultured|B-cell_line fibroblasts|I-cell_line but|O normal|O affinity|O of|O GR|B-protein in|O both|O patients|O .|O
In|O this|O study|O ,|O peripheral|B-cell_type lymphocytes|I-cell_type from|O these|O patients|O ,|O one|O patient|O 's|O son|O and|O daughter|O ,|O and|O normal|O subjects|O were|O transformed|O with|O Epstein-Barr|O virus|O .|O
Reduced|O numbers|O and|O normal|O affinity|O of|O GR|B-protein were|O found|O in|O the|O Epstein-Barr|B-cell_line virus-transformed|I-cell_line lymphocytes|I-cell_line from|O both|O patients|O while|O the|O son|O and|O daughter|O had|O normal|O numbers|O and|O affinity|O of|O GR|B-protein .|O
The|O thermal|O stability|O of|O GR|B-protein and|O thermal|O activation|O of|O cytosolic|B-protein receptors|I-protein in|O both|O patients|O were|O found|O to|O be|O normal|O .|O
Although|O the|O percentages|O of|O nuclear|O bound|O GR|B-protein were|O similar|O in|O both|O patients|O and|O normal|O controls|O ,|O the|O absolute|O amounts|O of|O nuclear|O bound|O GR|B-protein of|O the|O patients|O were|O about|O one-half|O that|O of|O normal|O controls|O .|O
These|O abnormal|O properties|O of|O GR|B-protein (|O reduced|O numbers|O of|O GR|B-protein )|O were|O preserved|O in|O the|O transformed|B-cell_line cells|I-cell_line from|O the|O patients|O .|O
Octamer|O transcription|O factors|O 1|O and|O 2|O each|O bind|O to|O two|O different|O functional|B-DNA elements|I-DNA in|O the|O immunoglobulin|B-DNA heavy-chain|I-DNA promoter|I-DNA .|O
Immunoglobulin|B-DNA heavy-chain|I-DNA genes|I-DNA contain|O two|O conserved|B-DNA sequence|I-DNA elements|I-DNA 5|O '|O to|O the|O site|O of|O transcription|O initiation|O :|O the|O octamer|O ATGCAAAT|O and|O the|O heptamer|O CTCATGA|O .|O
Both|O of|O these|O elements|O are|O required|O for|O normal|B-DNA cell-specific|I-DNA promoter|I-DNA function|O .|O
The|O present|O study|O demonstrates|O that|O both|O the|O ubiquitous|B-protein and|I-protein lymphoid-cell-specific|I-protein octamer|I-protein transcription|I-protein factors|I-protein (|O OTF-1|B-protein and|O OTF-2|B-protein ,|O respectively|O )|O interact|O specifically|O with|O each|O of|O the|O two|O conserved|B-DNA sequence|I-DNA elements|I-DNA ,|O forming|O either|O homo-|B-protein or|I-protein heterodimeric|I-protein complexes|I-protein .|O
This|O was|O surprising|O ,|O since|O the|O heptamer|O and|O octamer|O sequence|O motifs|O bear|O no|O obvious|O similarity|O to|O each|O other|O .|O
Binding|O of|O either|O factor|O to|O the|O octamer|B-DNA element|I-DNA occurred|O independently|O .|O
However|O ,|O OTF|B-protein interaction|O with|O the|O heptamer|B-DNA sequence|I-DNA appeared|O to|O require|O the|O presence|O of|O an|O intact|O octamer|O motif|O and|O occurred|O with|O a|O spacing|O of|O either|O 2|B-DNA or|I-DNA 14|I-DNA base|I-DNA pairs|I-DNA between|O the|O two|O elements|O ,|O suggesting|O coordinate|O binding|O resulting|O from|O protein-protein|O interactions|O .|O
The|O degeneracy|O in|O sequences|O recognized|O by|O the|O OTFs|B-protein may|O be|O important|O in|O widening|O the|O range|O over|O which|O gene|O expression|O can|O be|O modulated|O and|O in|O establishing|O cell|O type|O specificity|O .|O
Identification|O of|O a|O novel|O lymphoid|B-protein specific|I-protein octamer|I-protein binding|I-protein protein|I-protein (|O OTF-2B|B-protein )|O by|O proteolytic|O clipping|O bandshift|O assay|O (|O PCBA|O )|O .|O
The|O octamer|O sequence|O ATGCAAAT|O is|O found|O in|O the|O promoters|O of|O immunoglobulin|B-DNA (|I-DNA Ig|I-DNA )|I-DNA heavy|I-DNA and|I-DNA light|I-DNA chain|I-DNA genes|I-DNA and|O in|O the|O heavy|B-DNA chain|I-DNA enhancer|I-DNA and|O is|O a|O major|O determinant|O of|O the|O cell|O type|O specific|O expression|O of|O Ig|B-DNA genes|I-DNA in|O B|B-cell_type cells|I-cell_type .|O
An|O apparent|O paradox|O is|O that|O the|O same|O sequence|O serves|O as|O an|O upstream|B-DNA promoter|I-DNA or|I-DNA enhancer|I-DNA element|I-DNA in|O a|O variety|O of|O housekeeping|B-DNA genes|I-DNA such|O as|O the|O histone|B-DNA H2B|I-DNA and|I-DNA U|I-DNA snRNA|I-DNA genes|I-DNA .|O
The|O differential|O usage|O of|O this|O regulatory|O sequence|O motif|O is|O thought|O to|O be|O mediated|O by|O different|O species|O of|O octamer|B-protein binding|I-protein proteins|I-protein .|O
One|O species|O of|O 100|O kd|O ,|O designated|O OTF-1|B-protein ,|O is|O present|O in|O all|O cell|O types|O and|O may|O exert|O its|O activating|O function|O only|O when|O it|O can|O interact|O with|O additional|O adjacent|O transcription|B-protein factors|I-protein .|O
The|O lymphoid|B-protein cell|I-protein specific|I-protein octamer|I-protein binding|I-protein protein|I-protein of|O 60|O kd|O (|O OTF-2A|B-protein )|O specifically|O stimulates|O Ig|B-DNA promoters|I-DNA which|O consist|O essentially|O of|O a|O TATA-box|B-DNA and|O an|O octamer|B-DNA sequence|I-DNA upstream|O of|O it|O .|O
Here|O we|O present|O evidence|O for|O yet|O another|O B|B-protein cell|I-protein specific|I-protein octamer|I-protein binding|I-protein protein|I-protein of|O 75|O kd|O (|O OTF-2B|B-protein )|O .|O
From|O several|O findings|O ,|O including|O the|O absence|O of|O OTF-2B|B-protein (|O but|O not|O OTF-2A|B-protein )|O from|O a|O lymphocyte|B-cell_line line|I-cell_line that|O can|O not|O respond|O to|O the|O IgH|B-DNA enhancer|I-DNA ,|O we|O propose|O a|O role|O of|O the|O novel|B-protein octamer|I-protein factor|I-protein in|O the|O long|O range|O activation|O by|O the|O IgH|B-DNA enhancer|I-DNA .|O
We|O have|O used|O the|O proteolytic|O clipping|O bandshift|O assay|O (|O PCBA|O )|O technique|O to|O distinguish|O the|O three|O different|O forms|O found|O in|O B|B-cell_type cells|I-cell_type .|O
This|O analysis|O indicates|O that|O the|O 75|O kd-species|O OTF-2B|B-protein is|O closely|O related|O to|O the|O 60|B-protein kd|I-protein species|I-protein OTF-2A|I-protein .|O
Inhibition|O of|O interleukin|B-protein 2|I-protein -induced|O proliferation|O of|O cloned|B-cell_line murine|I-cell_line T|I-cell_line cells|I-cell_line by|O glucocorticoids|O .|O
Possible|O involvement|O of|O an|O inhibitory|B-protein protein|I-protein .|O
The|O ability|O of|O glucocorticoids|O to|O inhibit|O interleukin|B-protein 2|I-protein (|O IL|B-protein 2|I-protein )|O -induced|O T|B-cell_type cell|I-cell_type proliferation|O in|O two|O cytotoxic|B-cell_line T|I-cell_line cell|I-cell_line (|I-cell_line CTL|I-cell_line )|I-cell_line clones|I-cell_line has|O been|O studied|O .|O
A|O complete|O inhibition|O of|O DNA|O synthesis|O by|O dexamethasone|O (|O Dx|O )|O could|O be|O observed|O when|O IL|B-cell_line 2-depleted|I-cell_line cultures|I-cell_line of|O CTL|B-cell_line were|O either|O incubated|O for|O 6|O h|O with|O the|O hormone|B-protein prior|O to|O the|O addition|O of|O IL|B-protein 2|I-protein or|O treated|O simultaneously|O with|O Dx|O and|O a|O low|O concentration|O of|O IL|B-protein 2|I-protein .|O
No|O significant|O reduction|O in|O the|O number|O and|O affinity|O of|O IL|B-protein 2|I-protein receptors|I-protein was|O seen|O after|O 6|O h|O incubation|O with|O Dx|O .|O
The|O order|O of|O potency|O observed|O with|O the|O different|O steroids|O indicated|O that|O this|O inhibitory|O effect|O was|O mediated|O through|O binding|O to|O a|O specific|O glucocorticoid|B-protein receptor|I-protein .|O
The|O action|O of|O these|O hormones|B-protein possibly|O involves|O the|O synthesis|O of|O an|O inhibitory|B-protein protein|I-protein (|O s|O )|O ,|O since|O the|O presence|O of|O cycloheximide|O during|O the|O incubation|O with|O Dx|O prevented|O the|O inhibition|O of|O DNA|O synthesis|O .|O
Furthermore|O ,|O supernatant|O from|O Dx-treated|O CTL|B-cell_line contained|O a|O nondialyzable|O factor|O which|O inhibited|O DNA|O synthesis|O and|O cell|O growth|O of|O CTL|B-cell_line clones|I-cell_line induced|O by|O IL|B-protein 2|I-protein .|O
Blocking|O of|O IL|B-protein 2|I-protein synthesis|O and|O IL|B-protein 2|I-protein receptor|I-protein formation|O have|O been|O proposed|O as|O one|O of|O the|O major|O mechanisms|O of|O glucocorticoid-induced|O immunosuppression|O .|O
Our|O results|O indicate|O that|O these|O hormones|B-protein may|O also|O affect|O T|B-cell_type cell|I-cell_type proliferation|O by|O inhibiting|O IL|B-protein 2|I-protein activity|O .|O
Identification|O and|O purification|O of|O a|O human|B-protein immunoglobulin-enhancer-binding|I-protein protein|I-protein (|O NF-kappa|B-protein B|I-protein )|O that|O activates|O transcription|O from|O a|O human|B-DNA immunodeficiency|I-DNA virus|I-DNA type|I-DNA 1|I-DNA promoter|I-DNA in|O vitro|O .|O
The|O enhancer-binding|B-protein factor|I-protein NF-kappa|I-protein B|I-protein ,|O which|O is|O found|O only|O in|O cells|O that|O transcribe|O immunoglobulin|B-DNA light|I-DNA chain|I-DNA genes|I-DNA ,|O has|O been|O purified|O from|O nuclear|O extracts|O of|O Namalwa|B-cell_line cells|I-cell_line (|O human|B-cell_line Burkitt|I-cell_line lymphoma|I-cell_line cells|I-cell_line )|O by|O sequence-specific|O DNA|O affinity|O chromatography|O .|O
The|O purified|O NF-kappa|B-protein B|I-protein has|O been|O identified|O as|O a|O 51-kDa|B-protein polypeptide|I-protein by|O UV-crosslinking|O analysis|O .|O
``|O Footprint|O ''|O and|O methylation-interference|O analyses|O have|O shown|O that|O purified|O NF-kappa|B-protein B|I-protein has|O a|O binding|O activity|O specific|O for|O the|O kappa|B-DNA light|I-DNA chain|I-DNA enhancer|I-DNA sequence|I-DNA .|O
The|O purified|O factor|O activated|O in|O vitro|O transcription|O of|O the|O human|B-DNA immunodeficiency|I-DNA virus|I-DNA type|I-DNA I|I-DNA promoter|I-DNA by|O binding|O to|O an|O upstream|B-DNA NF-kappa|I-DNA B-binding|I-DNA site|I-DNA
Lymphocyte|B-cell_type glucocorticoid|B-protein receptor|I-protein binding|O in|O depression|O :|O normal|O values|O following|O recovery|O .|O
The|O number|O of|O glucocorticoid|B-protein receptor|I-protein sites|O in|O lymphocytes|B-cell_type and|O plasma|O cortisol|O concentrations|O were|O measured|O in|O 20|O patients|O who|O had|O recovered|O from|O major|O depressive|O disorder|O and|O 20|O healthy|O control|O subjects|O .|O
The|O number|O of|O glucocorticoid|B-protein receptor|I-protein sites|O in|O lymphocytes|B-cell_type from|O the|O recovered|O depressed|O group|O was|O not|O significantly|O different|O from|O that|O of|O the|O control|O group|O .|O
Although|O the|O mean|O plasma|O cortisol|O concentration|O in|O recovered|O depressives|O was|O higher|O than|O in|O control|O subjects|O ,|O the|O difference|O only|O just|O reached|O significance|O .|O
This|O study|O shows|O that|O the|O reduction|O in|O glucocorticoid|B-protein receptor|I-protein numbers|O which|O occurs|O during|O acute|O depressive|O illness|O does|O not|O persist|O on|O recovery|O and|O is|O ,|O therefore|O ,|O state-dependent|O .|O
Identification|O and|O purification|O of|O a|O human|B-protein lymphoid-specific|I-protein octamer-binding|I-protein protein|I-protein (|O OTF-2|B-protein )|O that|O activates|O transcription|O of|O an|O immunoglobulin|B-DNA promoter|I-DNA in|O vitro|O .|O
The|O octamer|O sequence|O 5'-ATGCAAAT|O ,|O in|O either|O orientation|O ,|O serves|O as|O an|O upstream|B-DNA element|I-DNA in|O a|O variety|O of|O promoters|B-DNA and|O also|O occurs|O as|O a|O modular|B-DNA enhancer|I-DNA element|I-DNA .|O
It|O is|O of|O particular|O interest|O in|O immunoglobulin|B-DNA genes|I-DNA since|O it|O is|O found|O in|O the|O upstream|B-DNA regions|I-DNA of|O all|O heavy|B-DNA and|I-DNA light|I-DNA chain|I-DNA promoters|I-DNA and|O in|O the|O heavy|B-DNA chain|I-DNA enhancer|I-DNA ,|O both|O of|O which|O are|O known|O to|O be|O necessary|O for|O cell-specific|O expression|O .|O
We|O report|O here|O the|O chromatographic|O separation|O of|O ubiquitous|B-protein and|I-protein B|I-protein cell-specific|I-protein octamer-binding|I-protein proteins|I-protein .|O
The|O B|B-protein cell|I-protein factor|I-protein was|O purified|O to|O homogeneity|O using|O affinity|O chromatography|O and|O consists|O of|O three|O peptides|O of|O 62|O ,|O 61|O ,|O and|O 58.5|O +/-|O 1.5|O kd|O .|O
Each|O of|O the|O polypeptides|O was|O renatured|O after|O SDS-PAGE|O and|O shown|O to|O bind|O to|O the|O octamer|O sequence|O .|O
The|O specific|O DNA|O binding|O activity|O of|O the|O pure|O B|B-protein cell-specific|I-protein factor|I-protein was|O indistinguishable|O from|O that|O of|O the|O affinity-purified|B-protein ubiquitous|I-protein factor|I-protein .|O
This|O B|B-protein cell-specific|I-protein octamer-binding|I-protein factor|I-protein ,|O in|O pure|O form|O ,|O activated|O transcription|O from|O a|O kappa|B-DNA light|I-DNA chain|I-DNA promoter|I-DNA in|O vitro|O ,|O thus|O demonstrating|O that|O it|O is|O indeed|O a|O B|B-protein cell-specific|I-protein transcription|I-protein factor|I-protein for|O this|O gene|O .|O
In|O addition|O to|O the|O ubiquitous|B-protein and|I-protein B|I-protein cell-specific|I-protein octamer-binding|I-protein factors|I-protein ,|O we|O identified|O several|O additional|O proteins|O ,|O one|O of|O which|O is|O B|B-cell_type cell|I-cell_type -specific|O ,|O that|O interact|O with|O the|O kappa|B-DNA promoter|I-DNA .|O
Decreased|O deoxyribonucleic|O acid|O binding|O of|O glucocorticoid-receptor|B-protein complex|I-protein in|O cultured|O skin|B-cell_line fibroblasts|I-cell_line from|O a|O patient|O with|O the|O glucocorticoid|O resistance|O syndrome|O .|O
A|O patient|O with|O the|O syndrome|O of|O glucocorticoid|O resistance|O was|O studied|O .|O
A|O 27-yr-old|O woman|O initially|O was|O diagnosed|O as|O having|O Cushing|O 's|O disease|O ,|O based|O on|O the|O findings|O of|O high|O plasma|O ACTH|O and|O serum|O cortisol|O levels|O ,|O increased|O urinary|O cortisol|O secretion|O ,|O resistance|O to|O adrenal|O suppression|O with|O dexamethasone|O ,|O and|O bilateral|O adrenal|O hyperplasia|O by|O computed|O tomography|O and|O scintigraphy|O of|O the|O adrenal|O glands|O .|O
However|O ,|O she|O had|O no|O signs|O or|O symptoms|O of|O Cushing|O 's|O syndrome|O .|O
During|O a|O 5-yr|O follow-up|O ,|O no|O clinical|O abnormalities|O developed|O ,|O although|O hypercortisolism|O persisted|O .|O
End-organ|O resistance|O to|O cortisol|O was|O suspected|O .|O
To|O explain|O the|O end-organ|O resistance|O to|O cortisol|O ,|O the|O glucocorticoid|B-protein receptors|I-protein (|O GR|B-protein )|O in|O peripheral|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type and|O cultured|B-cell_line skin|I-cell_line fibroblasts|I-cell_line from|O a|O forearm|O skin|O biopsy|O were|O characterized|O and|O compared|O with|O the|O results|O of|O similar|O studies|O in|O normal|O subjects|O .|O
The|O patient|O 's|O GR|B-protein in|O whole|O cell|O assays|O had|O an|O increased|O dissociation|O constant|O (|O Kd|O )|O .|O
In|O the|O cytosol|O of|O cultured|B-cell_line skin|I-cell_line fibroblasts|I-cell_line from|O the|O patient|O ,|O there|O was|O also|O decreased|O binding|O capacity|O .|O
The|O thermal|O stability|O and|O the|O sedimentation|O coefficient|O in|O a|O sucrose|O density|O gradient|O of|O the|O receptors|O in|O the|O cytosol|O of|O cultured|B-cell_line skin|I-cell_line fibroblasts|I-cell_line from|O the|O patient|O and|O normal|O subjects|O were|O similar|O .|O
GR|B-cell_line complex|I-cell_line activation|I-cell_line ,|O analyzed|O by|O DEAE-cellulose|B-cell_line chromatography|I-cell_line ,|O was|O decreased|O in|O the|O patient|O .|O
DNA|B-DNA binding|O of|O the|O GR|B-protein complex|I-protein after|O temperature-induced|O activation|O was|O lower|O in|O the|O patient|O than|O in|O normal|O subjects|O .|O
Nuclear|O translocation|O of|O GR|B-protein complexes|I-protein from|O the|O patient|O was|O also|O slightly|O decreased|O .|O
These|O results|O suggest|O that|O the|O patient|O 's|O glucocorticoid|O resistance|O was|O due|O to|O a|O decrease|O in|O the|O affinity|O of|O the|O receptor|O for|O glucocorticoids|O and|O a|O decrease|O in|O the|O binding|O of|O the|O GR|B-protein complex|I-protein to|O DNA|B-DNA .|O
Granulocyte-macrophage|B-protein colony-stimulating|I-protein factor|I-protein .|O
Sensitive|O and|O receptor-mediated|O regulation|O by|O 1|O ,|O 25-dihydroxyvitamin|O D3|O in|O normal|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type lymphocytes|I-cell_type .|O
We|O show|O that|O 1|O ,|O 25-dihydroxyvitamin|O D3|O (|O 1|O ,|O 25|O [|O OH|O ]|O 2D3|O )|O ,|O the|O most|O hormonally|O active|O metabolite|O of|O vitamin|O D3|O ,|O modulates|O sensitively|O and|O specifically|O both|O the|O protein|O and|O messenger|B-RNA RNA|I-RNA accumulation|O of|O the|O multilineage|B-protein growth|I-protein factor|I-protein granulocyte-macrophage|B-protein colony-stimulating|I-protein factor|I-protein (|O GM-CSF|B-protein )|O .|O
The|O regulation|O of|O GM-CSF|B-protein expression|O is|O seen|O in|O both|O normal|B-cell_type human|I-cell_type mitogen-activated|I-cell_type T|I-cell_type lymphocytes|I-cell_type and|O T|B-cell_line lymphocytes|I-cell_line from|I-cell_line a|I-cell_line line|I-cell_line (|I-cell_line S-LB1|I-cell_line )|I-cell_line transformed|I-cell_line with|I-cell_line human|I-cell_line T|I-cell_line cell|I-cell_line lymphotropic|I-cell_line virus|I-cell_line 1|I-cell_line (|O HTLV-1|O )|O .|O
In|O contrast|O ,|O cells|O from|O a|O HTLV-1|B-cell_line transformed|I-cell_line T|I-cell_line lymphocyte|I-cell_line line|I-cell_line (|O Ab-VDR|B-cell_line )|O established|O from|O a|O patient|O with|O vitamin|O D-resistant|O rickets|O type|O II|O with|O undetectable|O 1|B-protein ,|I-protein 25|I-protein (|I-protein OH|I-protein )|I-protein 2D3|I-protein cellular|I-protein receptors|I-protein are|O resistant|O to|O the|O action|O of|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O .|O
Inhibition|O of|O GM-CSF|B-protein expression|O by|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O can|O occur|O independently|O of|O interleukin|B-protein 2|I-protein regulation|O and|O is|O probably|O mediated|O through|O cellular|B-protein 1|I-protein ,|I-protein 25|I-protein (|I-protein OH|I-protein )|I-protein 2D3|I-protein receptors|I-protein .|O
We|O conclude|O that|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O may|O be|O important|O in|O the|O physiology|O of|O hematopoiesis|O .|O
Altered|O interaction|O between|O triiodothyronine|O and|O its|O nuclear|B-protein receptors|I-protein in|O absence|O of|O cortisol|O :|O a|O proposed|O mechanism|O for|O increased|O thyrotropin|O secretion|O in|O corticosteroid|O deficiency|O states|O .|O
Thyroid|O hormones|O occasionally|O appear|O less|O effective|O when|O administered|O alone|O to|O patients|O with|O panhypopituitarism|O ,|O and|O manifestations|O suggestive|O of|O hypothyroidism|O have|O been|O reported|O in|O patients|O suffering|O from|O untreated|O Addison|O 's|O disease|O .|O
In|O the|O latter|O condition|O ,|O thyrotropin|O secretion|O is|O increased|O :|O this|O occurs|O already|O after|O as|O little|O as|O 2|O days|O of|O temporary|O withdrawal|O of|O therapy|O with|O substitution|O doses|O of|O corticosteroids|O while|O circulating|O levels|O of|O thyroid|O hormones|O remain|O within|O normal|O limits|O .|O
Therefore|O ,|O a|O possible|O role|O of|O cortisol|O in|O interaction|O between|O triiodothyronine|O and|O its|O nuclear|B-protein receptors|I-protein was|O examined|O at|O the|O level|O of|O circulating|O lymphocytes|O obtained|O from|O patients|O with|O primary|O or|O secondary|O adrenocortical|O failure|O .|O
The|O affinity|O of|O these|O receptors|O was|O found|O to|O be|O decreased|O ,|O by|O more|O than|O 50|O %|O on|O average|O ,|O in|O the|O absence|O of|O cortisol|O treatments|O .|O
This|O change|O was|O promptly|O corrected|O upon|O resumption|O of|O therapy|O .|O
The|O number|O of|O binding|O sites|O was|O not|O significantly|O modified|O .|O
The|O influence|O of|O cortisol|O on|O thyroid|B-protein hormone|I-protein receptors|I-protein discussed|O here|O might|O account|O for|O the|O clinical|O observations|O mentioned|O above|O .|O
Inhibition|O by|O cortisol|O of|O human|B-cell_type natural|I-cell_type killer|I-cell_type (|I-cell_type NK|I-cell_type )|I-cell_type cell|I-cell_type activity|O .|O
The|O effects|O of|O cortisol|O on|O the|O natural|B-cell_type killer|I-cell_type (|O NK|O )|O activity|O of|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type (|I-cell_type PBM|I-cell_type )|I-cell_type cells|I-cell_type were|O studied|O in|O vitro|O using|O a|O direct|O 4-h|O 51Cr-release|O assay|O and|O K|B-cell_line 562|I-cell_line cell|I-cell_line line|I-cell_line as|O a|O target|O .|O
Preincubation|O for|O 20|O h|O of|O PBM|B-cell_type cells|I-cell_type drawn|O from|O healthy|O donors|O with|O 1|O X|O 10|O (|O -8|O )|O to|O 1|O X|O 10|O (|O -5|O )|O M|O cortisol|O resulted|O in|O a|O significant|O decrease|O of|O NK|B-cell_type cell|I-cell_type activity|O .|O
The|O magnitude|O of|O the|O suppression|O was|O directly|O related|O to|O the|O steroid|O concentration|O and|O inversely|O related|O to|O the|O number|O of|O effector|B-cell_type cells|I-cell_type .|O
Cortisol|O was|O able|O to|O minimize|O the|O enhancement|O of|O NK|O cytotoxicity|O obtainable|O in|O the|O presence|O of|O immune|O interferon|O (|O IFN-gamma|O )|O .|O
A|O significantly|O higher|O suppression|O was|O achieved|O after|O sequential|O exposure|O of|O PBM|B-cell_type cells|I-cell_type to|O cortisol|O and|O equimolar|O levels|O of|O prostaglandin|O E2|O (|O PgE2|O )|O .|O
The|O concomitant|O incubation|O with|O theophylline|O and|O isobutyl-methylxanthine|O failed|O to|O enhance|O the|O cortisol-induced|O suppression|O ,|O whereas|O PgE2-dependent|O inhibition|O significantly|O increased|O after|O exposure|O of|O PBM|B-cell_type cells|I-cell_type to|O methyl-xanthines|O .|O
The|O inhibitory|O effect|O of|O cortisol|O was|O partially|O or|O totally|O prevented|O by|O the|O concomitant|O incubation|O with|O equimolar|O amounts|O of|O 11-deoxycortisol|O and|O RU|O 486|O but|O not|O of|O progesterone|O .|O
Treatment|O of|O NK|B-cell_type effectors|I-cell_type with|O a|O monoclonal|B-protein anti-human|I-protein corticosteroid-binding|I-protein globulin|I-protein (|I-protein CBG|I-protein )|I-protein antibody|I-protein produced|O an|O enhancement|O of|O the|O spontaneous|O NK|B-cell_type activity|O and|O a|O partial|O suppression|O of|O cortisol-mediated|O effects|O .|O
Our|O results|O suggest|O that|O endogenous|O glucocorticoids|O play|O a|O role|O in|O the|O regulation|O of|O NK|O cell-mediated|O cytotoxicity|O .|O
Since|O the|O effect|O of|O cortisol|O was|O additive|O to|O that|O of|O PgE2|O and|O was|O not|O changed|O by|O phosphodiesterase|B-protein inhibitors|O ,|O it|O is|O conceivable|O that|O the|O hormone|O acts|O at|O a|O level|O different|O from|O the|O adenylate|B-protein cyclase|I-protein -|O phosphodiesterase|B-protein system|O .|O
Data|O obtained|O with|O the|O use|O of|O antiglucocorticoids|O and|O the|O anti-CBG|B-protein antibody|I-protein are|O compatible|O with|O a|O role|O both|O of|O high-affinity|O glucocorticoid|B-protein receptors|I-protein and|O of|O CBG|B-protein in|O mediating|O cortisol|O action|O on|O the|O human|B-cell_type NK|I-cell_type cell|I-cell_type activity|O .|O
Interaction|O of|O cell-type-specific|B-protein nuclear|I-protein proteins|I-protein with|O immunoglobulin|B-DNA VH|I-DNA promoter|I-DNA region|I-DNA sequences|I-DNA .|O
All|O human|B-DNA and|I-DNA murine|I-DNA immunoglobulin|I-DNA heavy|I-DNA chain|I-DNA variable|I-DNA region|I-DNA (|I-DNA VH|I-DNA )|I-DNA genes|I-DNA contain|O the|O sequence|O ATGCAAAT|O approximately|O 70|O nucleotides|O 5|O '|O from|O the|O site|O of|O transcription|O initiation|O .|O
This|O octanucleotide|O ,|O in|O reverse|O orientation|O ,|O is|O also|O found|O in|O all|O light|B-DNA chain|I-DNA variable|I-DNA region|I-DNA (|I-DNA VL|I-DNA )|I-DNA genes|I-DNA ,|O and|O in|O the|O immunoglobulin|B-DNA heavy|I-DNA chain|I-DNA transcriptional|I-DNA enhancer|I-DNA .|O
Transfection|O studies|O have|O established|O that|O this|O octamer|O is|O involved|O in|O the|O lymphoid-specific|O transcription|O of|O immunoglobulin|B-DNA genes|I-DNA .|O
Octamer-containing|B-DNA fragments|I-DNA have|O been|O reported|O to|O bind|O a|O factor|O present|O in|O nuclear|O extracts|O of|O human|B-cell_line cell|I-cell_line lines|I-cell_line ;|O however|O ,|O identical|O binding|O activity|O was|O detected|O in|O both|O B|B-cell_line lymphoid|I-cell_line and|I-cell_line non-lymphoid|I-cell_line cells|I-cell_line .|O
Here|O we|O establish|O that|O nuclear|O extracts|O from|O distinct|O cell|O types|O differ|O in|O their|O ability|O to|O interact|O with|O octamer-containing|B-DNA fragments|I-DNA .|O
We|O have|O also|O detected|O a|O DNA-protein|O interaction|O that|O may|O be|O involved|O in|O the|O cell-type|O specificity|O of|O immunoglobulin|B-protein expression|O ,|O and|O we|O have|O determined|O that|O a|O sequence|O upstream|O of|O the|O octamer|O participates|O in|O an|O interaction|O with|O a|O nuclear|B-protein protein|I-protein (|O s|O )|O .|O
Preferential|O transcription|O of|O HTLV-I|B-DNA LTR|I-DNA in|O cell-free|O extracts|O of|O human|B-cell_type T|I-cell_type cells|I-cell_type producing|O HTLV-I|B-protein viral|I-protein proteins|I-protein .|O
The|O promoters|B-DNA of|O the|O adenovirus|B-DNA 2|I-DNA major|I-DNA late|I-DNA gene|I-DNA ,|O the|O mouse|B-DNA beta-globin|I-DNA gene|I-DNA ,|O the|O mouse|B-DNA immunoglobulin|I-DNA VH|I-DNA gene|I-DNA and|O the|O LTR|B-DNA of|O the|O human|O T-lymphotropic|O retrovirus|O type|O I|O were|O tested|O for|O their|O transcription|O activities|O in|O cell-free|O extracts|O of|O four|O cell|O lines|O ;|O HeLa|B-cell_line ,|O CESS|B-cell_line (|O Epstein-Barr|B-cell_line virus-transformed|I-cell_line human|I-cell_line B|I-cell_line cell|I-cell_line line|I-cell_line )|O ,|O MT-1|B-cell_line (|O HTLV-I-infected|B-cell_line human|I-cell_line T|I-cell_line cell|I-cell_line line|I-cell_line without|O viral|O protein|O synthesis|O )|O ,|O and|O MT-2|B-cell_line (|O HTLV-I-infected|B-cell_line human|I-cell_line T|I-cell_line cell|I-cell_line line|I-cell_line producing|O viral|B-protein proteins|I-protein )|O .|O
LTR|B-DNA was|O preferentially|O transcribed|O in|O the|O extracts|O of|O MT-2|B-cell_line although|O the|O other|O three|O genes|O were|O transcribed|O with|O relatively|O constant|O efficiencies|O in|O different|O extracts|O .|O
The|O results|O agree|O well|O with|O the|O previous|O in|O vivo|O studies|O on|O the|O promoter|O activity|O of|O HTLV-I|B-DNA LTR|I-DNA .|O
Mixing|O of|O HeLa|O and|O MT-2|O extracts|O revealed|O the|O presence|O of|O a|O LTR-specific|O stimulating|O activity|O in|O MT-2|O extracts|O .|O
A|O nuclear|B-protein factor|I-protein that|O binds|O to|O a|O conserved|O sequence|O motif|O in|O transcriptional|B-DNA control|I-DNA elements|I-DNA of|O immunoglobulin|B-DNA genes|I-DNA .|O
Trans-acting|B-protein factors|I-protein that|O mediate|O B-cell|O specific|O transcription|O of|O immunoglobulin|B-DNA genes|I-DNA have|O been|O postulated|O based|O on|O an|O analysis|O of|O the|O expression|O of|O exogenously|O introduced|O immunoglobulin|B-DNA gene|I-DNA recombinants|I-DNA in|O lymphoid|B-cell_type and|I-cell_type non-lymphoid|I-cell_type cells|I-cell_type .|O
Two|O B-cell-specific|O ,|O cis-acting|B-DNA transcriptional|I-DNA regulatory|I-DNA elements|I-DNA have|O been|O identified|O .|O
One|O element|O is|O located|O in|O the|O intron|O between|O the|O variable|O (|O V|O )|O and|O constant|O (|O C|O )|O regions|O of|O both|O heavy|B-DNA and|I-DNA kappa|I-DNA light-chain|I-DNA genes|I-DNA and|O acts|O as|O a|O transcriptional|O enhancer|O .|O
The|O second|O element|B-DNA is|O found|O upstream|O of|O both|O heavy|B-DNA and|I-DNA kappa|I-DNA light-chain|I-DNA gene|I-DNA promoters|I-DNA .|O
This|O element|O directs|O lymphoid-specific|O transcription|O even|O in|O the|O presence|O of|O viral|B-DNA enhancers|I-DNA .|O
We|O have|O sought|O nuclear|O factors|O that|O might|O bind|O specifically|O to|O these|O two|O regulatory|B-DNA elements|I-DNA by|O application|O of|O a|O modified|O gel|O electrophoresis|O DNA|O binding|O assay|O .|O
We|O report|O here|O the|O identification|O of|O a|O human|B-protein B-cell|I-protein nuclear|I-protein factor|I-protein (|O IgNF-A|B-protein )|O that|O binds|O to|O DNA|B-DNA sequences|I-DNA in|O the|O upstream|B-DNA regions|I-DNA of|O both|O the|O mouse|B-DNA heavy|I-DNA and|I-DNA kappa|I-DNA light-chain|I-DNA gene|I-DNA promoters|I-DNA and|O also|O to|O the|O mouse|B-DNA heavy-chain|I-DNA gene|I-DNA enhancer|I-DNA .|O
This|O sequence-specific|O binding|O is|O probably|O mediated|O by|O a|O highly|O conserved|O sequence|O motif|O ,|O ATTTGCAT|O ,|O present|O in|O all|O three|O transcriptional|B-DNA elements|I-DNA .|O
Interestingly|O ,|O a|O factor|O showing|O similar|O binding|O specificity|O to|O IgNF-A|B-DNA is|O also|O present|O in|O human|B-cell_line HeLa|I-cell_line cells|I-cell_line .|O
The|O new|O world|O primates|O as|O animal|O models|O of|O glucocorticoid|O resistance|O .|O
Many|O New|O World|O primate|O species|O have|O greatly|O increased|O plasma|O cortisol|O concentrations|O ,|O decreased|O plasma|O cortisol|O binding|O globulin|O capacity|O and|O affinity|O ,|O marked|O resistance|O of|O the|O hypothalamic-pituitary-adrenal|O axis|O to|O suppression|O by|O dexamethasone|O ,|O and|O no|O biological|O evidence|O of|O glucocorticoid|O excess|O .|O
These|O primates|O also|O have|O high|O levels|O of|O circulating|O progesterone|O ,|O estrogen|O ,|O mineralocorticoid|O ,|O androgen|O and|O vitamin|O D|O .|O
The|O glucocorticoid|O target|O tissues|O that|O have|O been|O examined|O (|O circulating|B-cell_type mononuclear|I-cell_type lymphocytes|I-cell_type and|O cultured|B-cell_line skin|I-cell_line fibroblasts|I-cell_line )|O have|O normal|O concentrations|O of|O glucocorticoid|B-protein receptors|I-protein with|O decreased|O affinity|O for|O dexamethasone|O .|O
Transformation|O of|O B-lymphocytes|B-cell_type with|O the|O Epstein-Barr|O virus|O leads|O to|O glucocorticoid|B-protein receptor|I-protein induction|O that|O is|O less|O than|O that|O observed|O with|O cells|O from|O Old|O World|O primates|O .|O
The|O receptor|O in|O these|O cells|O has|O a|O low|O affinity|O for|O dexamethasone|O .|O
The|O low|O affinity|O leads|O to|O an|O increased|O loss|O of|O specific|O bound|O ligand|O during|O thermal|O activation|O .|O
Meroreceptor|O generation|O is|O normal|O .|O
The|O molecular|O weight|O of|O the|O receptor|O ,|O determined|O by|O SDS-PAGE|O ,|O is|O similar|O to|O that|O of|O Old|O World|O primates|O (|O approximately|O 92|O ,|O 000|O )|O and|O the|O activation|O pattern|O per|O se|O ,|O examined|O in|O vitro|O by|O heating|O cytosol|O and|O performing|O phosphocellulose|O chromatography|O ,|O appears|O similar|O to|O that|O of|O human|O controls|O .|O
The|O ratios|O of|O nuclear|O to|O cytosolic|B-protein hormone-receptor-complexes|I-protein and|O of|O cytosolic|O activated|O to|O unactivated|B-protein receptor|I-protein complexes|I-protein in|O intact|O cells|O are|O similar|O to|O Old|O World|O primates|O .|O
Results|O from|O mixing|O studies|O do|O not|O support|O the|O hypothesis|O that|O a|O binding|O inhibitor|O (|O s|O )|O or|O a|O deficient|O cytosolic|O positive|O modifier|O (|O s|O )|O of|O binding|O underlies|O the|O findings|O in|O these|O primates|O .|O
The|O New|O World|O primates|O ,|O unlike|O men|O with|O the|O syndrome|O of|O primary|O cortisol|O resistance|O ,|O have|O compensated|O for|O their|O condition|O with|O intra-adrenal|O and|O mineralocorticoid|O receptor|O adaptations|O .|O
Thus|O ,|O unlike|O Old|O World|O primates|O ,|O cortisol|O in|O New|O World|O primates|O has|O only|O weak|O sodium-retaining|O potency|O because|O the|O aldosterone|B-protein receptor|I-protein has|O a|O low|O affinity|O for|O cortisol|O .|O
The|O common|O element|O that|O would|O explain|O the|O apparent|O resistance|O to|O six|O steroid|O hormones|O in|O New|O World|O primates|O
Acetylation|O and|O modulation|O of|O erythroid|B-protein Kruppel-like|I-protein factor|I-protein (|O EKLF|B-protein )|O activity|O by|O interaction|O with|O histone|B-protein acetyltransferases|I-protein .|O
Erythroid|B-protein Kruppel-like|I-protein factor|I-protein (|O EKLF|B-protein )|O is|O a|O red|B-protein cell-specific|I-protein transcriptional|I-protein activator|I-protein that|O is|O crucial|O for|O consolidating|O the|O switch|O to|O high|O levels|O of|O adult|O beta-globin|O expression|O during|O erythroid|O ontogeny|O .|O
EKLF|B-protein is|O required|O for|O integrity|O of|O the|O chromatin|O structure|O at|O the|O beta-like|B-DNA globin|I-DNA locus|I-DNA ,|O and|O it|O interacts|O with|O a|O positive-acting|B-protein factor|I-protein in|O vivo|O .|O
We|O find|O that|O EKLF|B-protein is|O an|O acetylated|B-protein transcription|I-protein factor|I-protein ,|O and|O that|O it|O interacts|O in|O vivo|O with|O CBP|B-protein ,|O p300|B-protein ,|O and|O P/CAF|B-protein .|O
However|O ,|O its|O interactions|O with|O these|O histone|B-protein acetyltransferases|I-protein are|O not|O equivalent|O ,|O as|O CBP|B-protein and|O p300|B-protein ,|O but|O not|O P/CAF|B-protein ,|O utilize|O EKLF|B-protein as|O a|O substrate|O for|O in|O vitro|O acetylation|O within|O its|O trans-activation|O region|O .|O
The|O functional|O effects|O of|O these|O interactions|O are|O that|O CBP|B-protein and|O p300|B-protein ,|O but|O not|O P/CAF|B-protein ,|O enhance|O EKLF|B-protein 's|O transcriptional|O activation|O of|O the|O beta-globin|B-DNA promoter|I-DNA in|O erythroid|B-cell_type cells|I-cell_type .|O
These|O results|O establish|O EKLF|B-protein as|O a|O tissue-specific|B-protein transcription|I-protein factor|I-protein that|O undergoes|O post-translational|O acetylation|O and|O suggest|O a|O mechanism|O by|O which|O EKLF|B-protein is|O able|O to|O alter|O chromatin|O structure|O and|O induce|O beta-globin|O expression|O within|O the|O beta-like|B-DNA globin|I-DNA cluster|I-DNA .|O
Recognition|O of|O herpes|B-protein simplex|I-protein virus|I-protein type|I-protein 2|I-protein tegument|I-protein proteins|I-protein by|O CD4|B-cell_type T|I-cell_type cells|I-cell_type infiltrating|O human|O genital|O herpes|O lesions|O .|O
The|O local|O cellular|O immune|O response|O to|O herpes|O simplex|O virus|O (|O HSV|O )|O is|O important|O in|O the|O control|O of|O recurrent|O HSV|O infection|O .|O
The|O antiviral|O functions|O of|O infiltrating|B-cell_type CD4-bearing|I-cell_type T|I-cell_type cells|I-cell_type may|O include|O cytotoxicity|O ,|O inhibition|O of|O viral|O growth|O ,|O lymphokine|O secretion|O ,|O and|O support|O of|O humoral|O and|O CD8|O responses|O .|O
The|O antigens|O recognized|O by|O many|O HSV-specific|B-cell_type CD4|I-cell_type T|I-cell_type cells|I-cell_type localizing|O to|O genital|O HSV-2|O lesions|O are|O unknown|O .|O
T|B-cell_type cells|I-cell_type recognizing|O antigens|O encoded|O within|O map|O units|O 0.67|O to|O 0.73|O of|O HSV|B-DNA DNA|I-DNA are|O frequently|O recovered|O from|O herpetic|O lesions|O .|O
Expression|O cloning|O with|O this|O region|O of|O DNA|O now|O shows|O that|O tegument|B-protein protein|I-protein VP22|B-protein and|O the|O viral|B-protein dUTPase|I-protein ,|O encoded|O by|O genes|B-DNA UL49|I-DNA and|I-DNA UL50|I-DNA ,|O respectively|O ,|O are|O T-cell|B-protein antigens|I-protein .|O
Separate|O epitopes|B-protein in|O VP22|B-protein were|O defined|O for|O T-cell|B-cell_line clones|I-cell_line from|O each|O of|O three|O patients|O .|O
Reactivity|O with|O the|O tegument|B-protein protein|I-protein encoded|O by|O UL21|B-DNA was|O identified|O for|O an|O additional|O patient|O .|O
Three|O new|O epitopes|O were|O identified|O in|O VP16|B-protein ,|O a|O tegument|B-protein protein|I-protein associated|O with|O VP22|B-protein .|O
Some|O tegument-specific|B-cell_line CD4|I-cell_line T-cell|I-cell_line clones|I-cell_line exhibited|O cytotoxic|O activity|O against|O HSV-infected|B-cell_type cells|I-cell_type .|O
These|O results|O suggest|O that|O herpes|B-protein simplex|I-protein tegument|I-protein proteins|I-protein are|O processed|O for|O antigen|O presentation|O in|O vivo|O and|O are|O possible|O candidate|O compounds|O for|O herpes|O simplex|O vaccines|O .|O
Fibrinogen|B-protein activates|O NF-kappa|B-protein B|I-protein transcription|I-protein factors|I-protein in|O mononuclear|B-cell_type phagocytes|I-cell_type .|O
Adhesion|O to|O extracellular|O matrices|O is|O known|O to|O modulate|O leukocyte|O activation|O ,|O although|O the|O mechanisms|O are|O not|O fully|O understood|O .|O
Mononuclear|B-cell_type phagocytes|I-cell_type are|O exposed|O to|O fibrinous|O provisional|O matrix|O throughout|O migration|O into|O inflammatory|O foci|O ,|O so|O this|O study|O was|O undertaken|O to|O determine|O whether|O fibrinogen|O triggers|O activation|O of|O NF-kappa|B-protein B|I-protein transcription|I-protein factors|I-protein .|O
U937|B-cell_line cells|I-cell_line differentiated|O with|O PMA|O in|O nonadherent|B-cell_line culture|I-cell_line were|O shown|O to|O express|O two|O fibrinogen-binding|B-protein integrins|I-protein ,|O predominately|O CD11b/CD18|B-protein ,|O and|O to|O a|O lesser|O extent|O ,|O CD11c/CD18|B-protein .|O
Cells|O stimulated|O with|O fibrinogen|B-protein (|O 10-100|O microg/ml|O )|O /Mn2+|O (|O 50|O microM|O )|O for|O 2|O h|O were|O examined|O by|O electrophoretic|O mobility|O shift|O assay|O .|O
NF-kappa|B-protein B|I-protein activation|O ,|O minimal|O in|O unstimulated|B-cell_type cells|I-cell_type ,|O was|O substantially|O up-regulated|O by|O fibrinogen|B-protein .|O
Fibrinogen|B-protein also|O caused|O activation|O of|O AP-1|B-protein ,|O but|O not|O SP1|B-protein or|O cAMP|B-protein response|I-protein element-binding|I-protein protein|I-protein (|I-protein CREB|I-protein )|I-protein factors|I-protein .|O
Blocking|O mAbs|B-protein against|O CD18|B-protein and|O CD11b|B-protein abrogated|O fibrinogen|B-protein -induced|O NF-kappa|B-protein B|I-protein activation|O .|O
To|O determine|O the|O effects|O on|O transcriptional|O regulation|O ,|O U937|B-cell_line cells|I-cell_line were|O transfected|O with|O a|O plasmid|O containing|O the|O HIV-1|B-DNA enhancer|I-DNA (|O bearing|O two|O NF-kappa|B-DNA B|I-DNA sites|I-DNA )|O coupled|O to|O a|O chloramphenicol|B-DNA acetyltransferase|I-DNA (|I-DNA CAT|I-DNA )|I-DNA reporter|I-DNA .|O
Cells|O were|O subsequently|O stimulated|O with|O 1|O )|O PMA|O for|O 24|O h|O ,|O inducing|O CAT|O activity|O by|O 2.6-fold|O ,|O 2|O )|O fibrinogen|B-protein /Mn2+|O for|O 2|O h|O ,|O inducing|O CAT|O activity|O by|O 3.2-fold|O ,|O or|O 3|O )|O costimulation|O with|O fibrinogen|B-protein and|O PMA|O ,|O inducing|O 5.7-fold|O the|O CAT|O activity|O induced|O by|O PMA|O alone|O .|O
We|O conclude|O that|O contact|O with|O fibrinogen-derived|B-protein proteins|I-protein may|O contribute|O to|O mononuclear|O phagocyte|O activation|O by|O signaling|O through|O CD11b/CD18|B-protein ,|O resulting|O in|O selective|O activation|O of|O transcriptional|B-protein regulatory|I-protein factors|I-protein ,|O including|O NF-kappa|B-protein B|I-protein .|O
Peripheral|B-cell_type blood|I-cell_type T|I-cell_type cells|I-cell_type and|I-cell_type monocytes|I-cell_type and|O B|B-cell_line cell|I-cell_line lines|I-cell_line derived|O from|O patients|O with|O lupus|O express|O estrogen|O receptor|O transcripts|O similar|O to|O those|O of|O normal|B-cell_type cells|I-cell_type .|O
OBJECTIVE|O :|O To|O identify|O and|O characterize|O estrogen|B-RNA receptor|I-RNA (|I-RNA ER|I-RNA )|I-RNA transcripts|I-RNA expressed|O in|O immune|B-cell_type cells|I-cell_type of|O patients|O with|O systemic|O lupus|O erythematosus|O (|O SLE|O )|O and|O healthy|O donors|O .|O
METHODS|O :|O Peripheral|B-cell_type blood|I-cell_type monocytes|I-cell_type and|I-cell_type T|I-cell_type cells|I-cell_type were|O prepared|O from|O patients|O with|O SLE|O (|O n|O =|O 6|O )|O and|O healthy|O donors|O (|O n|O =|O 8|O )|O .|O
T|B-cell_type cells|I-cell_type were|O separated|O into|O CD4|B-cell_type and|O CD8|B-cell_type .|O
Some|O monocytes|B-cell_type and|O T|B-cell_type cells|I-cell_type were|O stimulated|O with|O estradiol|O ,|O PMA|O ,|O and|O ionomycin|O .|O
Epstein-Barr|O virus-transformed|O B|B-cell_line cell|I-cell_line lines|I-cell_line (|O n|O =|O 7|O )|O and|O B|B-cell_line cell|I-cell_line hybridomas|I-cell_line (|O n|O =|O 2|O )|O established|O from|O patients|O with|O SLE|O and|O a|O healthy|O individual|O were|O used|O as|O a|O B|O cell|O source|O .|O
These|O cells|O were|O examined|O for|O ER|B-RNA mRNA|I-RNA by|O reverse|O transcription|O nested|O polymerase|O chain|O reaction|O .|O
Amplified|O cDNA|B-DNA were|O sequenced|O by|O standard|O methods|O .|O
RESULTS|O :|O In|O all|O cells|O tested|O ,|O ER|B-RNA mRNA|I-RNA was|O expressed|O without|O prior|O in|O vitro|O stimulation|O .|O
Partial|O sequences|O from|O exons|B-DNA 1-8|I-DNA were|O nearly|O identical|O to|O the|O published|O sequence|O of|O the|O human|B-RNA ER|I-RNA mRNA|I-RNA .|O
There|O were|O no|O notable|O differences|O in|O the|O ER|B-RNA transcripts|I-RNA between|O patients|O and|O healthy|O controls|O .|O
Variant|O receptor|O transcripts|O lacking|O exon|B-DNA 5|I-DNA or|O exon|B-DNA 7|I-DNA ,|O which|O encodes|O the|O hormone|B-protein binding|I-protein domain|I-protein ,|O were|O identified|O in|O the|O majority|O of|O the|O cells|O .|O
Precise|O deletion|O of|O the|O exons|O suggests|O that|O they|O are|O alternatively|O spliced|O transcripts|O .|O
Whether|O the|O detected|O transcripts|O are|O translated|O into|O functional|B-protein receptor|I-protein proteins|I-protein remains|O to|O be|O determined|O .|O
In|O vitro|O stimulation|O did|O not|O affect|O ER|B-RNA mRNA|I-RNA expression|O .|O
The|O presence|O of|O variants|O did|O not|O correlate|O with|O disease|O activity|O or|O medication|O .|O
CONCLUSION|O :|O Monocytes|B-cell_type ,|O T|B-cell_type cells|I-cell_type ,|O and|O B|B-cell_type cells|I-cell_type in|O patients|O express|O transcripts|O of|O the|O normal|O wild|B-protein type|I-protein ER|I-protein and|O the|O hormone|B-protein binding|I-protein domain|I-protein variants|I-protein in|O vivo|O .|O
DNA|O damaging|O agents|O induce|O expression|O of|O Fas|B-protein ligand|I-protein and|O subsequent|O apoptosis|O in|O T|B-cell_type lymphocytes|I-cell_type via|O the|O activation|O of|O NF-kappa|B-protein B|I-protein and|O AP-1|B-protein .|O
Apoptosis|O induced|O by|O DNA|O damage|O and|O other|O stresses|O can|O proceed|O via|O expression|O of|O Fas|B-protein ligand|I-protein (|O FasL|B-protein )|O and|O ligation|O of|O its|O receptor|O ,|O Fas|O (|O CD95|O )|O .|O
We|O report|O that|O activation|O of|O the|O two|O transcription|B-protein factors|I-protein NF-kappa|I-protein B|I-protein and|I-protein AP-1|I-protein is|O crucially|O involved|O in|O FasL|B-protein expression|O induced|O by|O etoposide|O ,|O teniposide|O ,|O and|O UV|O irradiation|O .|O
A|O nondegradable|B-protein mutant|I-protein of|O I|B-protein kappa|I-protein B|I-protein blocked|O both|O FasL|B-protein expression|O and|O apoptosis|O induced|O by|O DNA|O damage|O but|O not|O Fas|O ligation|O .|O
These|O stimuli|O also|O induced|O the|O stress-activated|O kinase|O pathway|O (|O SAPK/JNK|O )|O ,|O which|O was|O required|O for|O the|O maximal|O induction|O of|O apoptosis|O .|O
A|O 1.2|O kb|O FasL|B-DNA promoter|I-DNA responded|O to|O DNA|O damage|O ,|O as|O well|O as|O coexpression|O with|O p65|B-protein Rel|I-protein or|O Fos/Jun|B-protein .|O
Mutations|O in|O the|O relevant|O NF-kappa|B-DNA B|I-DNA and|I-DNA AP-1|I-DNA binding|I-DNA sites|I-DNA eliminated|O these|O responses|O .|O
Thus|O ,|O activation|O of|O NF-kappa|B-protein B|I-protein and|O AP-1|B-protein contributes|O to|O stress-induced|O apoptosis|O via|O the|O expression|O of|O FasL|B-protein .|O
A|O small|O ,|O nonpeptidyl|O mimic|O of|O granulocyte-colony-stimulating|B-protein factor|I-protein [|O see|O commetns|O ]|O
A|O nonpeptidyl|O small|O molecule|O SB|O 247464|O ,|O capable|O of|O activating|O granulocyte-colony-stimulating|B-protein factor|I-protein (|O G-CSF|B-protein )|O signal|O transduction|O pathways|O ,|O was|O identified|O in|O a|O high-throughput|O assay|O in|O cultured|B-cell_type cells|I-cell_type .|O
Like|O G-CSF|B-protein ,|O SB|O 247464|O induced|O tyrosine|O phosphorylation|O of|O multiple|B-protein signaling|I-protein proteins|I-protein and|O stimulated|O primary|B-cell_type murine|I-cell_type bone|I-cell_type marrow|I-cell_type cells|I-cell_type to|O form|O granulocytic|B-cell_type colonies|I-cell_type in|O vitro|O .|O
It|O also|O elevated|O peripheral|B-cell_type blood|I-cell_type neutrophil|I-cell_type counts|O in|O mice|O .|O
The|O extracellular|O domain|O of|O the|O murine|B-protein G-CSF|I-protein receptor|I-protein was|O required|O for|O the|O activity|O of|O SB|O 247464|O ,|O suggesting|O that|O the|O compound|O acts|O by|O oligomerizing|B-protein receptor|I-protein chains|I-protein .|O
The|O results|O indicate|O that|O a|O small|O molecule|O can|O activate|O a|O receptor|O that|O normally|O binds|O a|O relatively|O large|O protein|O ligand|O .|O
Minimal|O residual|O disease|O in|O acute|O myelogenous|O leukemia|O with|O PML/RAR|B-protein alpha|I-protein or|O AML1/ETO|B-RNA mRNA|I-RNA and|O phenotypic|O analysis|O of|O possible|O T|B-cell_type and|I-cell_type natural|I-cell_type killer|I-cell_type cells|I-cell_type in|O bone|O marrow|O .|O
Here|O we|O studied|O minimal|O residual|O disease|O (|O MRD|O )|O of|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O who|O have|O PML/RAR|B-protein alpha|I-protein or|O AML1/ETO|B-protein as|O well|O as|O the|O phenotypic|O analysis|O of|O lymphocyte|B-cell_type subsets|I-cell_type involved|O in|O antitumor|O immunity|O .|O
Eight|O patients|O in|O long-term|O (|O LT|O ;|O 3|O to|O 15|O years|O )|O and|O 15|O patients|O in|O short-term|O (|O ST|O ;|O up|O to|O 3|O years|O )|O remission|O were|O studied|O .|O
Using|O the|O reverse|O transcription-polymerase|O chain|O reaction|O (|O RT|O )|O assay|O ,|O the|O limit|O of|O detection|O was|O 10|O (|O -5|O )|O to|O 10|O (|O -6|O )|O for|O PML/RAR|B-RNA alpha|I-RNA transcript|I-RNA and|O 10|O (|O -4|O )|O to|O 10|O (|O -5|O )|O for|O the|O AML1/ETO|B-RNA transcript|I-RNA .|O
Simultaneously|O ,|O T|B-cell_type lymphocyte|I-cell_type subsets|I-cell_type and|O NK|B-cell_type cells|I-cell_type from|O the|O peripheral|O blood|O (|O PB|O )|O and|O bone|O marrow|O (|O BM|O )|O were|O investigated|O by|O flow|O cytometric|O analysis|O .|O
Four|O of|O the|O eight|O patients|O in|O LT|O and|O 7|O of|O the|O 15|O patients|O in|O ST|O remission|O were|O MRD-positive|O .|O
Although|O all|O MRD-positive|O patients|O in|O LT|O remission|O are|O still|O until|O now|O event-free|O ,|O 3|O of|O the|O 7|O MRD-positive|O (|O MRD+|O )|O patients|O in|O ST|O remission|O soon|O relapsed|O .|O
The|O total|O populations|O of|O CD4|B-protein +|O ,|O CD8|B-protein +|O and|O CD56|B-protein +|O [|O possible|O T-cell|B-cell_type and|I-cell_type natural|I-cell_type killer|I-cell_type (|I-cell_type T/NK|I-cell_type )|I-cell_type populations|I-cell_type ]|O in|O the|O BM|O of|O ST|O patients|O and|O MRD+/LT|O patients|O were|O significantly|O (|O p|O <|O .01|O )|O low|O .|O
The|O CD8+|B-cell_type CD28+|I-cell_type population|I-cell_type showed|O the|O same|O tendency|O (|O p|O <|O .01-.02|O )|O .|O
The|O T/NK|B-cell_type subsets|I-cell_type in|O the|O BM|O of|O MRD-negative|O (|O MRD-|O )|O LT|O (|O MRD-/LT|O )|O patients|O showed|O similar|O numbers|O of|O cells|O as|O normal|O volunteers|O .|O
Basically|O ,|O the|O total|O percentage|O of|O the|O CD4+|B-cell_type ,|I-cell_type CD8+|I-cell_type and|I-cell_type CD56+|I-cell_type cell|I-cell_type populations|I-cell_type in|O the|O BM|O was|O increased|O and|O in|O the|O following|O order|O :|O MRD-/LT|O patients|O ,|O normal|O volunteers|O ,|O MRD+/LT|O patients|O and|O MRD+|O or|O -/ST|O patients|O .|O
The|O percentages|O of|O the|O T/NK-cell|B-cell_type subsets|I-cell_type in|O the|O PB|O were|O not|O significantly|O different|O among|O these|O groups|O .|O
Thus|O ,|O the|O difference|O of|O the|O possible|O T/NK-cell|B-cell_type phenotype|O in|O the|O BM|O may|O strongly|O influence|O clinical|O and|O molecular|O remission|O .|O
These|O results|O still|O remain|O to|O be|O confirmed|O by|O further|O studies|O of|O the|O functional|O anti-tumor|O immunity|O of|O T/NK|B-cell_type cells|I-cell_type of|O AML|B-cell_type in|O remission|O .|O
Mycobacterium|O tuberculosis|O mannose-capped|O lipoarabinomannan|O can|O induce|O NF-kappaB|B-protein -dependent|O activation|O of|O human|B-DNA immunodeficiency|I-DNA virus|I-DNA type|I-DNA 1|I-DNA long|I-DNA terminal|I-DNA repeat|I-DNA in|O T|B-cell_type cells|I-cell_type .|O
Tuberculosis|O has|O emerged|O as|O an|O epidemic|O ,|O extended|O by|O the|O large|O number|O of|O individuals|O infected|O with|O human|O immunodeficiency|O virus|O type|O 1|O (|O HIV-1|O )|O .|O
The|O major|O goal|O of|O this|O study|O was|O to|O determine|O whether|O the|O mycobacterial|O cell|O wall|O component|O mannose-capped|O lipoarabinomannan|O (|O ManLAM|O )|O of|O Mycobacterium|O tuberculosis|O (|O M.|O tuberculosis|O )|O could|O activate|O transcription|O of|O HIV-1|O in|O T|B-cell_type cells|I-cell_type with|O the|O use|O of|O an|O in|O vitro|O cell|O culture|O system|O .|O
These|O experiments|O are|O of|O prime|O importance|O considering|O that|O CD4|B-protein -expressing|O T|B-cell_type lymphocytes|I-cell_type represent|O the|O major|O virus|O reservoir|O in|O the|O peripheral|O blood|O of|O infected|O individuals|O .|O
Using|O the|O 1G5|B-cell_line cell|I-cell_line line|I-cell_line harbouring|O the|O luciferase|O reporter|O gene|O under|O the|O control|O of|O the|O HIV-1|B-DNA LTR|I-DNA ,|O it|O was|O first|O found|O that|O culture|O protein|O filtrates|O (|O CFP|O )|O from|O M.|O tuberculosis|O or|O purified|O ManLAM|O could|O activate|O HIV-1|B-DNA LTR-dependent|I-DNA gene|I-DNA expression|O unlike|O similarly|O prepared|O CFP|O extracts|O devoid|O of|O ManLAM|O .|O
The|O implication|O of|O protein|B-protein tyrosine|I-protein kinase|I-protein (|I-protein s|I-protein )|I-protein ,|O protein|B-protein kinase|I-protein A|I-protein and/or|O protein|B-protein kinase|I-protein C|I-protein was|O highlighted|O by|O the|O abrogation|O of|O the|O ManLAM-mediated|O activation|O of|O HIV-1|O LTR-driven|O gene|O expression|O using|O herbimycin|O A|O and|O H7|O .|O
It|O was|O also|O determined|O ,|O using|O electrophoresis|O mobility|O shift|O assays|O ,|O that|O M.|O tuberculosis|O ManLAM|O led|O to|O the|O nuclear|O translocation|O of|O the|O transcription|B-protein factor|I-protein NF-kappaB|I-protein .|O
M.|O tuberculosis|O ManLAM|O resulted|O in|O clear|O induction|O of|O the|O luciferase|B-DNA gene|I-DNA placed|O under|O the|O control|O of|O the|O wild-type|B-DNA ,|I-DNA but|I-DNA not|I-DNA the|I-DNA kappaB-mutated|I-DNA ,|I-DNA HIV-1|I-DNA LTR|I-DNA region|I-DNA .|O
Finally|O ,|O the|O ManLAM-mediated|O activation|O of|O HIV-1|O LTR|O transcription|O was|O found|O to|O be|O independent|O of|O the|O autocrine|O or|O paracrine|O action|O of|O endogenous|B-protein TNF-alpha|I-protein .|O
The|O results|O suggest|O that|O M.|O tuberculosis|O can|O upregulate|O HIV-1|O expression|O in|O T|B-cell_type cells|I-cell_type and|O could|O thus|O have|O the|O potential|O to|O influence|O the|O pathogenesis|O of|O HIV-1|O infection|O .|O
Human|B-DNA immunodeficiency|I-DNA virus|I-DNA type|I-DNA 1|I-DNA long|I-DNA terminal|I-DNA repeat|I-DNA quasispecies|O differ|O in|O basal|O transcription|O and|O nuclear|O factor|O recruitment|O in|O human|B-cell_type glial|I-cell_type cells|I-cell_type and|I-cell_type lymphocytes|I-cell_type .|O
The|O generation|O of|O genomic|O diversity|O during|O the|O course|O of|O infection|O has|O the|O potential|O to|O affect|O all|O aspects|O of|O HIV-1|O replication|O ,|O including|O expression|O of|O the|O proviral|O genome|O .|O
To|O gain|O a|O better|O understanding|O of|O the|O impact|O of|O long|B-DNA terminal|I-DNA repeat|I-DNA (|O LTR|B-DNA )|O sequence|O diversity|O on|O LTR-directed|B-DNA gene|I-DNA expression|O in|O cells|O of|O the|O central|O nervous|O system|O (|O CNS|O )|O and|O immune|O system|O ,|O we|O amplified|O and|O cloned|O LTRs|B-DNA from|O proviral|O DNA|O in|O HIV-1-infected|O peripheral|O blood|O .|O
Sequence|O analysis|O of|O nineteen|O LTRs|B-DNA cloned|O from|O 2|O adult|O and|O 3|O pediatric|O patients|O revealed|O an|O average|O of|O 33|O nucleotide|O changes|O (|O with|O respect|O to|O the|O sequence|O of|O the|O LAI|B-DNA LTR|I-DNA )|O within|O the|O 455-bp|B-DNA U3|I-DNA region|I-DNA .|O
Transient|O expression|O analyses|O in|O cells|O of|O neuroglial|O and|O lymphocytic|O origin|O demonstrated|O that|O some|O of|O these|O LTRs|B-DNA had|O activities|O which|O varied|O significantly|O from|O the|O LAI|B-DNA LTR|I-DNA in|O U-373|B-cell_line MG|I-cell_line cells|I-cell_line (|O an|O astrocytoma|B-cell_line cell|I-cell_line line|I-cell_line )|O as|O well|O as|O in|O Jurkat|B-cell_line cells|I-cell_line (|O a|O CD4-positive|B-cell_line lymphocyte|I-cell_line cell|I-cell_line line|I-cell_line )|O .|O
While|O LTRs|B-DNA which|O demonstrated|O the|O highest|O activities|O in|O U-373|B-cell_line MG|I-cell_line cells|I-cell_line also|O yielded|O high|O activities|O in|O Jurkat|B-cell_line cells|I-cell_line ,|O the|O LTRs|B-DNA were|O generally|O more|O active|O in|O Jurkat|B-cell_line cells|I-cell_line when|O compared|O to|O the|O LAI|B-DNA LTR|I-DNA .|O
Differences|O in|O LTR|B-DNA sequence|I-DNA also|O resulted|O in|O differences|O in|O transcription|O factor|O recruitment|O to|O cis-acting|B-DNA sites|I-DNA within|O the|O U3|B-DNA region|I-DNA of|O the|O LTR|B-DNA ,|O as|O demonstrated|O by|O electrophoretic|O mobility|O shift|O assays|O .|O
In|O particular|O ,|O naturally|O occurring|O sequence|O variation|O impacted|O transcription|B-protein factor|I-protein binding|O to|O an|O activating|B-protein transcription|I-protein factor|I-protein /|O cAMP|B-protein response|I-protein element|I-protein binding|I-protein (|O ATF|B-protein /|O CREB|B-protein )|O binding|O site|O (|O located|O between|O the|O LEF-1|B-DNA and|I-DNA distal|I-DNA NF-kappaB|I-DNA transcription|I-DNA factor|I-DNA binding|I-DNA sites|I-DNA )|O that|O we|O identified|O in|O previous|O studies|O of|O the|O HIV-1|B-DNA LTR|I-DNA .|O
These|O findings|O suggest|O that|O LTR|B-DNA sequence|I-DNA changes|O can|O significantly|O affect|O basal|O LTR|O function|O and|O transcription|O factor|O recruitment|O ,|O which|O may|O ,|O in|O turn|O ,|O alter|O the|O course|O of|O viral|O replication|O in|O cells|O of|O CNS|O and|O immune|O system|O origin|O .|O
HMG|B-protein box|I-protein containing|I-protein transcription|I-protein factors|I-protein in|O lymphocyte|B-cell_type differentiation|O .|O
The|O identification|O of|O the|O mammalian|B-DNA sex-determining|I-DNA gene|I-DNA Sry|I-DNA has|O led|O to|O the|O discovery|O of|O a|O large|O family|O of|O related|O (|O '|O HMG|B-protein box|I-protein '|O )|O transcription|B-protein factors|I-protein that|O control|O developmental|O events|O in|O yeast|O ,|O C.|O elegans|O ,|O Drosophila|O and|O vertebrates|O .|O
In|O lymphocyte|B-cell_type differentiation|O ,|O several|O HMG|B-protein box|I-protein proteins|I-protein play|O a|O decisive|O role|O .|O
Sox-4|B-protein is|O important|O for|O very|O early|O B-cell|O differentiation|O ,|O while|O TCF-1|B-protein /|O LEF-1|B-protein play|O a|O crucial|O role|O in|O early|O thymocyte|O development|O .|O
TCF/LEF|B-protein proteins|I-protein have|O recently|O been|O found|O to|O constitute|O a|O downstream|O component|O of|O the|O Wingless/Wnt|O signal|O transduction|O pathway|O .|O
In|O flies|O ,|O this|O pathway|O controls|O segment|O polarity|O ;|O in|O Xenopus|O it|O controls|O the|O definition|O of|O the|O body|O axis|O .|O
Deregulation|O of|O the|O pathway|O occurs|O in|O several|O human|B-cell_type tumors|I-cell_type .|O
These|O insights|O in|O the|O molecular|O events|O that|O are|O involved|O in|O TCF/LEF|B-protein function|O in|O these|O organisms|O may|O eventually|O lead|O to|O the|O understanding|O of|O the|O function|O of|O these|O HMG|B-protein box|I-protein proteins|I-protein in|O lymphoid|O development|O
Transcriptional|O regulation|O by|O C/EBP|B-protein alpha|I-protein and|I-protein -beta|I-protein in|O the|O expression|O of|O the|O gene|O for|O the|O MRP14|B-protein myeloid|I-protein calcium|I-protein binding|I-protein protein|I-protein .|O
Transcriptional|O regulation|O of|O the|O gene|O for|O the|O myeloid|B-protein calcium|I-protein binding|I-protein protein|I-protein ,|O MRP14|B-protein ,|O was|O investigated|O in|O human|B-cell_line monocytic|I-cell_line leukemia|I-cell_line cell|I-cell_line lines|I-cell_line .|O
The|O MRP14|B-DNA gene|I-DNA was|O not|O expressed|O in|O monoblastic|B-cell_line ML-1|I-cell_line cells|I-cell_line ,|O promonocytic|B-cell_line U-937|I-cell_line cells|I-cell_line ,|O or|O promyelocytic|B-cell_line HL-60|I-cell_line cells|I-cell_line .|O
On|O the|O other|O hand|O ,|O the|O gene|O was|O expressed|O in|O monocytic|B-cell_line THP-1|I-cell_line cells|I-cell_line and|O in|O the|O HL-60|B-cell_line cells|I-cell_line treated|O with|O 1|O ,|O 25-dihydroxyvitamin|O D3|O (|O VD3|O )|O .|O
The|O level|O of|O MRP14|B-protein in|O VD3-treated|O HL-60|B-cell_line cells|I-cell_line was|O two-fold|O higher|O than|O that|O in|O THP-1|B-cell_line cells|I-cell_line .|O
Among|O several|O known|O transcription|B-DNA factor|I-DNA binding|I-DNA motifs|I-DNA ,|O nuclear|B-protein protein|I-protein (|I-protein s|I-protein )|I-protein of|O VD3-treated|B-cell_line HL-60|I-cell_line cells|I-cell_line and|I-cell_line THP-1|I-cell_line cells|I-cell_line bound|O to|O the|O CCAAT/enhancer|B-DNA binding|I-DNA protein|I-DNA (|I-DNA C/EBP|I-DNA )|I-DNA -binding|I-DNA motif|I-DNA that|O was|O located|O in|O the|O upstream|B-DNA region|I-DNA of|O the|O MRP14|B-DNA gene|I-DNA (|O -81|O )|O ,|O as|O evidenced|O by|O the|O competitive|O gel|O mobility-shift|O assay|O .|O
An|O antibody|O for|O C/EBP|B-protein alpha|I-protein super-shifted|O the|O nucleoprotein|B-protein complex|I-protein in|O THP-1|B-cell_line cells|I-cell_line but|O not|O in|O the|O VD3-treated|B-cell_line HL-60|I-cell_line cells|I-cell_line ,|O whereas|O an|O antibody|O for|O C/EBP|B-protein beta|I-protein blocked|O the|O formation|O of|O the|O complex|O with|O the|O nuclear|B-protein factor|I-protein of|O the|O HL-60|B-cell_line cells|I-cell_line but|O not|O with|O that|O of|O THP-1|B-cell_line cells|I-cell_line .|O
An|O anti-C/EBP|B-protein delta|I-protein antibody|I-protein had|O no|O effect|O on|O the|O complex|O in|O either|O cell|O .|O
Thus|O ,|O it|O was|O concluded|O that|O C/EBP|B-protein alpha|I-protein and|I-protein -beta|I-protein were|O able|O to|O bind|O to|O the|O C/EBP|B-protein motif|I-protein ,|O and|O that|O C/EBP|B-protein alpha|I-protein bound|O to|O the|O motif|O in|O THP-1|B-cell_line cells|I-cell_line and|O C/EBP|B-protein beta|I-protein bound|O to|O that|O in|O the|O VD3-treated|B-cell_line HL-60|I-cell_line cells|I-cell_line .|O
Furthermore|O ,|O to|O examine|O the|O transcriptional|O activity|O of|O the|O C/EBP|B-protein motif|I-protein ,|O we|O transfected|O several|O constructed|O luciferase|B-DNA reporter|I-DNA DNAs|I-DNA into|O HL-60|B-cell_line cells|I-cell_line and|O THP-1|B-cell_line cells|I-cell_line .|O
The|O luciferase|O activity|O of|O the|O C/EBP|B-protein motif|I-protein in|O HL-60|B-cell_line cells|I-cell_line was|O increased|O by|O VD3|O treatment|O .|O
The|O C/EBP|B-protein motif|I-protein in|O the|O MRP14|B-DNA gene|I-DNA was|O confirmed|O to|O function|O as|O a|O regulatory|O region|O in|O VD3-treated|B-cell_line HL-60|I-cell_line cells|I-cell_line and|I-cell_line THP-1|I-cell_line cells|I-cell_line by|O the|O assay|O .|O
Since|O C/EBP|B-protein beta|I-protein was|O also|O detected|O in|O VD3-untreated|B-cell_line HL-60|I-cell_line cells|I-cell_line by|O immunoblotting|O ,|O VD3|O activated|O C/EBP|B-protein beta|I-protein to|O bind|O to|O the|O motif|O ,|O probably|O through|O post-translational|O modification|O .|O
Patients|O with|O high-risk|O myelodysplastic|O syndrome|O can|O have|O polyclonal|O or|O clonal|O haemopoiesis|O in|O complete|O haematological|O remission|O .|O
The|O clonality|O of|O mature|B-cell_type peripheral|I-cell_type blood-derived|I-cell_type myeloid|I-cell_type and|I-cell_type lymphoid|I-cell_type cells|I-cell_type and|O bone|B-cell_type marrow|I-cell_type haemopoietic|I-cell_type progenitors|I-cell_type from|O 18|O females|O with|O myelodysplasia|O (|O MDS|O )|O (|O five|O refractory|O anaemia|O ,|O RA|O ;|O one|O RA|O with|O ringed|B-cell_type sideroblasts|I-cell_type ,|O RARS|O ;|O three|O chronic|O myelomonocytic|O leukaemia|O ,|O CMML|O ;|O four|O RA|O with|O excess|O of|O blasts|O ,|O RAEB|O ;|O five|O RAEB|O in|O transformation|O ,|O RAEB-t|O )|O was|O studied|O by|O X-chromosome|B-DNA inactivation|O analysis|O .|O
Using|O the|O human|O androgen-receptor|O (|O HUMARA|O )|O assay|O ,|O we|O analysed|O the|O clonal|O patterns|O of|O highly|B-cell_type purified|I-cell_type immature|I-cell_type CD34+|I-cell_type 38-|I-cell_type and|I-cell_type committed|I-cell_type CD34+|I-cell_type 38+|I-cell_type marrow-derived|I-cell_type progenitors|I-cell_type ,|O and|O CD16+|B-cell_type 14-|I-cell_type granulocytes|I-cell_type ,|O CD14+|B-cell_type monocytes|I-cell_type ,|O CD3+|B-cell_type T|I-cell_type and|I-cell_type CD19+|I-cell_type B|I-cell_type lymphocytes|I-cell_type from|O peripheral|O blood|O .|O
In|O high-risk|O patients|O (|O RAEB|O ,|O RAEB-t|O )|O ,|O clonality|O analysis|O was|O performed|O before|O and|O after|O intensive|O remission-induction|O treatment|O .|O
All|O patients|O ,|O except|O one|O with|O RA|O ,|O had|O predominance|O of|O a|O single|O clone|O in|O their|O granulocytes|B-cell_type and|O monocytes|B-cell_type .|O
The|O same|O clonal|O pattern|O was|O found|O in|O CD34+|B-cell_type progenitor|I-cell_type cells|I-cell_type .|O
In|O contrast|O ,|O CD3+|B-cell_type T|I-cell_type lymphocytes|I-cell_type were|O polyclonal|O or|O oligoclonal|O in|O 14/18|O patients|O .|O
X-chromosome|B-DNA inactivation|O patterns|O of|O CD19+|B-cell_type B|I-cell_type cells|I-cell_type were|O highly|O concordant|O with|O CD3+|B-cell_type T|I-cell_type cells|I-cell_type except|O for|O two|O patients|O (|O one|O RA|O ,|O one|O CMML|O )|O with|O monoclonal|B-cell_type B|I-cell_type and|I-cell_type polyclonal|I-cell_type T|I-cell_type lymphocytes|I-cell_type ,|O therefore|O suggesting|O a|O clonal|O mutation|O in|O a|O progenitor|B-cell_type common|O to|O the|O myeloid|B-cell_type and|I-cell_type B-lymphoid|I-cell_type lineages|I-cell_type or|O the|O coexistence|O of|O MDS|O and|O a|O B-cell|O disorder|O in|O these|O particular|O patients|O .|O
After|O high-dose|O non-myeloablative|O chemotherapy|O ,|O polyclonal|O haemopoiesis|O was|O reinstalled|O in|O the|O mature|B-cell_type myeloid|I-cell_type cells|I-cell_type and|O immature|O and|O committed|B-cell_type marrow|I-cell_type progenitors|I-cell_type in|O three|O of|O four|O patients|O achieving|O complete|O haematological|O remission|O .|O
Therefore|O we|O conclude|O that|O most|O haematological|O remissions|O in|O MDS|O are|O associated|O with|O restoration|O of|O polyclonal|O haemopoiesis|O .|O
Prominent|O sex|O steroid|O metabolism|O in|O human|B-cell_type lymphocytes|I-cell_type .|O
Steroid|O metabolism|O was|O investigated|O in|O cultured|B-cell_line human|I-cell_line B-lymphoblastoid|I-cell_line cells|I-cell_line (|O B-LCL|B-cell_line )|O ,|O and|O peripheral|B-cell_type blood|I-cell_type T|I-cell_type and|I-cell_type B|I-cell_type cells|I-cell_type .|O
Gene|O expression|O was|O examined|O by|O reverse-transcription|O polymerase|O chain|O reaction|O amplification|O (|O RT-PCR|O )|O .|O
Appropriate|O sized|O transcripts|B-RNA were|O detected|O in|O both|O cultured|O and|O fresh|O peripheral|B-cell_type lymphocytes|I-cell_type for|O CYP11A|B-protein ,|O CYP17|B-protein ,|O HSD11L|B-protein (|O 11beta-hydroxysteroid|B-protein dehydrogenase|I-protein I|I-protein )|O ,|O HSD17B1|B-protein (|O 17beta-hydroxysteroid|B-protein dehydrogenase|I-protein type|I-protein I|I-protein )|O and|O SRD5A1|B-protein (|O 5alpha-reductase|B-protein I|I-protein )|O .|O
B-LCL|O ,|O but|O not|O T|B-cell_type and|I-cell_type B|I-cell_type cells|I-cell_type ,|O expressed|O CYP11B|B-protein .|O
There|O was|O minimal|O expression|O of|O HSD3B1|B-protein and|O HSD3B2|B-protein (|O 3beta-hydroxysteroid|B-protein dehydrogenase|I-protein I|I-protein and|I-protein II|I-protein )|O in|O B-LCL|B-cell_line and|O T|B-cell_type cells|I-cell_type .|O
Transcripts|O for|O CYP19|B-protein and|O HSD11K|B-protein were|O not|O detected|O .|O
Corresponding|O enzymatic|O activity|O was|O detectable|O only|O for|O 17-hydroxysteroid|B-protein dehydrogenase|I-protein and|O 5alpha-reductase|B-protein ,|O respectively|O producing|O testosterone|O and|O 5alpha-dihydrotestosterone|O .|O
Steroid|O identities|O were|O confirmed|O by|O gas|O chromatography/mass|O spectrometry|O (|O GC/MS|O )|O .|O
One|O metabolite|O thought|O to|O be|O deoxycorticosterone|O was|O identified|O by|O GC/MS|O as|O 6alpha-hydroxypregnanolone|O .|O
It|O was|O concluded|O that|O sex|O hormone|O metabolism|O ,|O including|O androgen|O synthesis|O ,|O occurs|O in|O lymphocytes|O ,|O and|O may|O modulate|O immune|O response|O .|O
Human|B-cell_type white|I-cell_type blood|I-cell_type cells|I-cell_type and|O hair|O follicles|O are|O good|O sources|O of|O mRNA|B-RNA for|O the|O pterin|B-protein carbinolamine|I-protein dehydratase/dimerization|I-protein cofactor|I-protein of|O HNF1|B-protein for|O mutation|O detection|O .|O
Pterin|B-protein carbinolamine|I-protein dehydratase/dimerization|I-protein cofactor|I-protein of|O HNF1|B-protein (|O PCD/DCoH|B-protein )|O is|O a|O protein|O that|O has|O a|O dual|O function|O .|O
It|O is|O a|O pterin|B-protein 4alpha-carbinolamine|I-protein dehydratase|I-protein that|O is|O involved|O in|O the|O regeneration|O of|O the|O cofactor|B-protein tetrahydrobiopterin|I-protein during|O the|O phenylalanine|O hydroxylase-|O catalyzed|O hydroxylation|O of|O phenylalanine|O .|O
In|O addition|O ,|O it|O is|O the|O dimerization|O cofactor|O of|O HNF1|B-protein that|O is|O able|O to|O activate|O the|O transcriptional|O activity|O of|O HNF1|B-protein .|O
Deficiencies|O in|O the|O gene|O for|O this|O dual|B-protein functional|I-protein protein|I-protein result|O in|O hyperphenylalaninemia|O .|O
Here|O we|O report|O for|O the|O first|O time|O that|O the|O PCD/DCoH|B-RNA mRNA|I-RNA is|O present|O in|O human|B-cell_type white|I-cell_type blood|I-cell_type cells|I-cell_type and|O hair|O follicles|O .|O
Taking|O advantage|O of|O this|O finding|O ,|O a|O sensitive|O ,|O rapid|O and|O convenient|O method|O for|O screening|O mutations|O occurring|O in|O the|O coding|O region|O of|O this|O gene|O has|O been|O described|O .|O
Copyright|O 1998|O Academic|O Press|O .|O
Biochemical|O characterization|O of|O the|O NF-Y|B-protein transcription|I-protein factor|I-protein complex|I-protein during|O B|O lymphocyte|O development|O .|O
The|O transcription|B-protein factor|I-protein ,|O NF-Y|B-protein ,|O plays|O a|O critical|O role|O in|O tissue-specific|O major|B-DNA histocompatibility|I-DNA complex|I-DNA class|I-DNA II|I-DNA gene|I-DNA transcription|O .|O
In|O this|O report|O the|O biochemical|O properties|O of|O the|O heterotrimeric|B-protein NF-Y|I-protein complex|I-protein have|O been|O characterized|O during|O stage-specific|O B-cell|O development|O ,|O and|O in|O several|O class|B-cell_line II-|I-cell_line mutant|I-cell_line B-cell|I-cell_line lines|I-cell_line ,|O which|O represent|O distinct|O bare|O lymphocyte|O syndrome|O class|O II|O genetic|O complementation|O groups|O .|O
The|O NF-Y|B-protein complex|I-protein derived|O from|O class|B-cell_type II+|I-cell_type mature|I-cell_type B-cells|I-cell_type bound|O with|O high|O affinity|O to|O anion|B-protein exchangers|I-protein ,|O and|O eluted|O as|O an|O intact|O trimeric|B-protein complex|I-protein ,|O whereas|O ,|O NF-Y|B-protein derived|O from|O class|B-cell_type II-|I-cell_type plasma|I-cell_type B-cells|I-cell_type ,|O and|O from|O bare|B-cell_line lymphocyte|I-cell_line syndrome|I-cell_line group|I-cell_line II|I-cell_line cell|I-cell_line lines|I-cell_line ,|O RJ2.2.5|B-cell_line and|O RM3|B-cell_line ,|O dissociated|O into|O discrete|O NF-YA|B-protein and|O NF-YB|B-protein :|I-protein C|I-protein subunit|B-protein fractions|I-protein .|O
Recombination|O of|O the|O MPC11|B-protein plasma|I-protein B-cell|I-protein derived|I-protein NF-Y|I-protein A|I-protein :|I-protein B|I-protein :|I-protein C|I-protein complex|I-protein with|O the|O low|O molecular|O mass|O protein|O fraction|O ,|O NF-Y-associated|B-protein factors|I-protein (|O YAFs|B-protein )|O ,|O derived|O from|O mature|O A20|O B-cell|O nuclei|O ,|O conferred|O high|O affinity|O anion|O exchange|O binding|O to|O NF-Y|B-protein as|O an|O intact|B-protein trimeric|I-protein complex|I-protein .|O
Recombination|O of|O the|O native|B-protein NF-YA|I-protein :|I-protein B|I-protein :|I-protein C|I-protein complex|I-protein with|O the|O transcriptional|B-protein cofactor|I-protein ,|O PC4|B-protein ,|O likewise|O conferred|O high|B-protein affinity|I-protein NF-Y|I-protein binding|O to|O anion|B-protein exchangers|I-protein ,|O and|O stabilized|O NF-Y|B-protein interaction|O with|O CCAAT-box|B-DNA DNA|I-DNA motifs|I-DNA in|O vitro|O .|O
Interaction|O between|O PC4|B-protein and|O NF-Y|B-protein was|O mapped|O to|O the|O C-terminal|B-protein region|I-protein of|O PC4|B-protein ,|O and|O the|O subunit|B-protein interaction|I-protein subdomain|I-protein of|O the|O highly|B-protein conserved|I-protein DNA|I-protein binding-subunit|I-protein interaction|I-protein domain|I-protein (|O DBD|B-protein )|O of|O NF-YA|B-protein .|O
These|O results|O suggest|O that|O in|O class|B-cell_type II+|I-cell_type mature|I-cell_type B-cells|I-cell_type NF-Y|B-protein is|O associated|O with|O the|O protein|O cofactor|O ,|O PC4|B-protein ,|O which|O may|O play|O an|O important|O role|O in|O NF-Y-mediated|O transcriptional|O control|O of|O class|B-DNA II|I-DNA genes|I-DNA .|O
Arrest|O of|O B|O lymphocyte|O terminal|O differentiation|O by|O CD40|O signaling|O :|O mechanism|O for|O lack|O of|O antibody-secreting|B-cell_type cells|I-cell_type in|O germinal|O centers|O .|O
Despite|O extensive|O research|O ,|O the|O role|O of|O CD40|B-protein signaling|O in|O B|O cell|O terminal|O differentiation|O remains|O controversial|O .|O
Here|O we|O show|O that|O CD40|B-protein engagement|O arrests|O B|O cell|O differentiation|O prior|O to|O plasma|O cell|O formation|O .|O
This|O arrest|O is|O manifested|O at|O a|O molecular|O level|O as|O a|O reduction|O in|O mRNA|O levels|O of|O secretory|O immunoglobulin|O gene|O products|O such|O as|O mu|O (|O s|O )|O and|O J|O chain|O as|O well|O as|O the|O loss|O of|O the|O transcriptional|B-protein regulator|I-protein BLIMP-1|B-protein .|O
Furthermore|O ,|O the|O inhibition|O of|O B|O cell|O differentiation|O by|O CD40|B-protein engagement|O could|O not|O be|O overcome|O by|O either|O mitogens|B-protein or|O cytokines|B-protein ,|O but|O could|O be|O reversed|O by|O antibodies|O that|O interfere|O with|O the|O CD40|B-protein /|O gp39|B-protein interaction|O .|O
These|O data|O suggest|O that|O secretory|O immunoglobulin|O is|O not|O produced|O by|O B|B-cell_type cells|I-cell_type that|O are|O actively|O engaged|O by|O gp39-expressing|B-cell_type T|I-cell_type cells|I-cell_type .|O
A|O positively|O charged|O alpha-lipoic|O acid|O analogue|O with|O increased|O cellular|O uptake|O and|O more|O potent|O immunomodulatory|O activity|O .|O
alpha-Lipoic|O acid|O (|O LA|O )|O is|O taken|O up|O by|O cells|O and|O reduced|O to|O its|O potent|O dithiol|O form|O ,|O dihydrolipoate|O (|O DHLA|O )|O ,|O much|O of|O which|O is|O rapidly|O effluxed|O out|O from|O cells|O .|O
To|O improve|O retention|O in|O cells|O ,|O the|O LA|O molecule|O was|O modified|O to|O confer|O a|O positive|O charge|O at|O physiological|O pH|O .|O
N|O ,|O N-dimethyl|O ,|O N'-2-amidoethyl-lipoate|O was|O synthesized|O .|O
The|O protonated|O form|O of|O the|O new|O molecule|O is|O referred|O to|O as|O LA-Plus|O .|O
The|O uptake|O of|O LA-Plus|O by|O human|B-cell_type Wurzburg|I-cell_type T|I-cell_type cells|I-cell_type was|O higher|O compared|O to|O that|O of|O LA|O .|O
Several-fold|O higher|O amounts|O of|O DHLA-Plus|O ,|O the|O corresponding|O reduced|O form|O of|O LA-Plus|O ,|O were|O detected|O in|O LA-Plus|O treated|O cells|O compared|O to|O the|O amount|O of|O DHLA|O found|O in|O cells|O treated|O with|O LA|O .|O
At|O 100|O microM|O ,|O LA|O did|O not|O but|O LA-Plus|O inhibited|O H2O2|O induced|O NF-kappaB|B-protein activation|O and|O NF-kappaB|B-protein directed|O IL-2|B-protein receptor|I-protein expression|O .|O
Both|O LA|O and|O LA-Plus|O synergised|O with|O selenium|O in|O inhibiting|O H2O2|O induced|O NF-kappaB|B-protein activation|O .|O
At|O 150|O microM|O LA-Plus|O ,|O but|O not|O LA|O ,|O inhibited|O TNFalpha|B-protein induced|O NF-kappaB|B-protein activation|O .|O
At|O 5|O microM|O LA-Plus|O ,|O but|O not|O LA|O ,|O protected|O against|O both|O spontaneous|O and|O etoposide|O induced|O apoptosis|O in|O rat|B-cell_type thymocytes|I-cell_type .|O
LA-Plus|O is|O thus|O an|O improved|O form|O of|O LA|O with|O increased|O therapeutic|O potential|O .|O
Copyright|O 1998|O Academic|O Press|O .|O
Carrier|O identification|O in|O X-linked|O immunodeficiency|O diseases|O .|O
OBJECTIVE|O :|O Carrier|O identification|O in|O X-linked|O immunodeficiency|O disorders|O can|O be|O based|O on|O the|O demonstration|O of|O non-random|O X|O inactivation|O (|O NRXI|O )|O in|O affected|B-cell_type blood|I-cell_type cell|I-cell_type lineages|I-cell_type when|O growth|O is|O impaired|O in|O cells|O expressing|O the|O abnormal|B-DNA gene|I-DNA .|O
We|O examined|O the|O utility|O of|O seeking|O evidence|O of|O NRXI|O to|O test|O the|O carrier|O status|O of|O women|O in|O families|O affected|O by|O X-linked|O severe|O combined|O immunodeficiency|O (|O XSCID|O )|O and|O X-linked|O hypogammaglobulinaemia|O (|O XLH|O )|O ,|O to|O identify|O as|O carriers|O the|O mothers|O of|O boys|O with|O SCID|O or|O hypogammaglobulinaemia|O whose|O phenotype|O suggested|O X-linkage|O and|O to|O infer|O X-linkage|O in|O boys|O with|O SCID|O or|O hypogammaglobulinaemia|O whose|O disease|O was|O not|O clearly|O X-linked|O on|O the|O basis|O either|O of|O family|O history|O or|O clinical|O and|O immunological|O characteristics|O .|O
METHODOLOGY|O :|O A|O polymerase|O chain|O reaction-based|O method|O was|O used|O to|O amplify|O a|O polymorphic|O CAG|B-DNA repeat|I-DNA in|O the|O first|B-DNA exon|I-DNA of|O the|O androgen|B-DNA receptor|I-DNA gene|I-DNA after|O selective|O digestion|O of|O the|O active|B-DNA X|I-DNA chromosome|I-DNA with|O a|O methylation-sensitive|B-protein enzyme|I-protein ,|O HpaII|B-protein to|O distinguish|O between|O the|O paternal|B-DNA and|I-DNA maternal|I-DNA alleles|I-DNA and|O to|O identify|O their|O methylation|O status|O .|O
RESULTS|O :|O Heterozygosity|O was|O found|O in|O 24|O of|O 31|O female|O subjects|O (|O 77|O %|O )|O .|O
As|O anticipated|O ,|O NRXI|O could|O be|O demonstrated|O in|O all|O lymphoid|B-cell_type cells|I-cell_type studied|O from|O obligate|O carriers|O of|O XSCID|O and|O an|O obligate|O carrier|O of|O XLH|O but|O not|O on|O a|O carrier|O of|O X-linked|O immunodeficiency|O with|O hyper-IgM|B-protein .|O
The|O finding|O of|O NRXI|O in|O the|O mother|O of|O a|O boy|O with|O a|O SCID|O variant|O showed|O her|O to|O be|O a|O carrier|O of|O XSCID|O and|O establishes|O that|O her|O son|O has|O XSCID|O ,|O not|O otherwise|O evident|O from|O available|O data|O .|O
CONCLUSIONS|O :|O This|O PCR|O assay|O provides|O a|O rapid|O method|O for|O carrier|O detection|O of|O X-linked|O immunodeficiencies|O ,|O and|O has|O allowed|O us|O to|O expand|O the|O phenotype|O of|O XSCID|O
Leukocyte-endothelial|O interaction|O is|O augmented|O by|O high|O glucose|O concentrations|O and|O hyperglycemia|O in|O a|O NF-kB-dependent|O fashion|O .|O
We|O addressed|O the|O role|O of|O hyperglycemia|O in|O leukocyte-endothelium|O interaction|O under|O flow|O conditions|O by|O exposing|O human|B-cell_type umbilical|I-cell_type vein|I-cell_type endothelial|I-cell_type cells|I-cell_type for|O 24|O h|O to|O normal|O (|O 5|O mM|O )|O ,|O high|O concentration|O of|O glucose|O (|O 30|O mM|O )|O ,|O advanced|O glycosylation|O end|O product-albumin|B-protein (|O 100|O microg/ml|O )|O ,|O or|O hyperglycemic|O (|O 174-316|O mg/dl|O )|O sera|O from|O patients|O with|O diabetes|O and|O abnormal|O hemoglobin|O A1c|O (|O 8.1+/-1.4|O %|O )|O .|O
At|O the|O end|O of|O incubation|O endothelial|B-cell_type cells|I-cell_type were|O perfused|O with|O total|O leukocyte|O suspension|O in|O a|O parallel|O plate|O flow|O chamber|O under|O laminar|O flow|O (|O 1.5|O dyn/cm2|O )|O .|O
Rolling|O and|O adherent|B-cell_type cells|I-cell_type were|O evaluated|O by|O digital|O image|O processing|O .|O
Results|O showed|O that|O 30|O mM|O glucose|O significantly|O (|O P|O <|O 0.01|O )|O increased|O the|O number|O of|O adherent|B-cell_type leukocytes|I-cell_type to|O endothelial|B-cell_type cells|I-cell_type in|O respect|O to|O control|O (|O 5|O mM|O glucose|O ;|O 151+/-19|O versus|O 33+/-8|O cells/mm2|O )|O .|O
A|O similar|O response|O was|O induced|O by|O endothelial|O stimulation|O with|O IL-1beta|B-protein ,|O here|O used|O as|O positive|O control|O (|O 195+/-20|O cells/mm2|O )|O .|O
The|O number|O of|O rolling|B-cell_type cells|I-cell_type on|O endothelial|O surface|O was|O not|O affected|O by|O high|O glucose|O level|O .|O
Stable|O adhesion|O of|O leukocytes|B-cell_type to|O glucose-treated|O as|O well|O as|O to|O IL-1beta-stimulated|B-cell_type endothelial|I-cell_type cells|I-cell_type was|O preceded|O by|O short|O interaction|O of|O leukocytes|B-cell_type with|O the|O endothelial|O surface|O .|O
The|O distance|O travelled|O by|O leukocytes|B-cell_type before|O arrest|O on|O 30|O mM|O glucose|O ,|O or|O on|O IL-1beta-treated|B-cell_type endothelial|I-cell_type cells|I-cell_type ,|O was|O significantly|O (|O P|O <|O 0.01|O )|O higher|O than|O that|O observed|O for|O leukocytes|B-cell_type adhering|O on|O control|O endothelium|O (|O 30|O mM|O glucose|O :|O 76.7+/-3.5|O ;|O IL1beta|O :|O 69.7+/-4|O versus|O 5|O mM|O glucose|O :|O 21.5+/-5|O microm|O )|O .|O
Functional|O blocking|O of|O E-selectin|B-protein ,|O intercellular|B-protein cell|I-protein adhesion|I-protein molecule-1|I-protein ,|O and|O vascular|B-protein cell|I-protein adhesion|I-protein molecule-1|I-protein on|O endothelial|B-cell_type cells|I-cell_type with|O the|O corresponding|O mouse|B-protein mAb|I-protein significantly|O inhibited|O glucose-induced|O increase|O in|O leukocyte|O adhesion|O (|O 67+/-16|O ,|O 83+/-12|O ,|O 62+/-8|O versus|O 144+/-21|O cells/|O mm2|O )|O .|O
Confocal|O fluorescence|O microscopy|O studies|O showed|O that|O 30|O mM|O glucose|O induced|O an|O increase|O in|O endothelial|O surface|O expression|O of|O E-selectin|B-protein ,|O intercellular|B-protein cell|I-protein adhesion|I-protein molecule-1|I-protein ,|O and|O vascular|B-protein cell|I-protein adhesion|I-protein molecule-1|I-protein .|O
Electrophoretic|O mobility|O shift|O assay|O of|O nuclear|O extracts|O of|O human|B-cell_type umbilical|I-cell_type vein|I-cell_type endothelial|I-cell_type cells|I-cell_type (|O HUVEC|O )|O exposed|O for|O 1|O h|O to|O 30|O mM|O glucose|O revealed|O an|O intense|O NF-kB|B-protein activation|O .|O
Treatment|O of|O HUVEC|O exposed|O to|O high|O glucose|O with|O the|O NF-kB|B-protein inhibitors|I-protein pyrrolidinedithiocarbamate|O (|O 100|O microM|O )|O and|O tosyl-phe-chloromethylketone|O (|O 25|O microM|O )|O significantly|O reduced|O (|O P|O <|O 0.05|O )|O leukocyte|O adhesion|O in|O respect|O to|O HUVEC|O treated|O with|O glucose|O alone|O .|O
A|O significant|O (|O P|O <|O 0.01|O )|O inhibitory|O effect|O on|O glucose-induced|O leukocyte|O adhesion|O was|O observed|O after|O blocking|O protein|B-protein kinase|I-protein C|I-protein activity|O with|O staurosporine|O (|O 5|O nM|O )|O .|O
When|O HUVEC|O were|O treated|O with|O specific|O antisense|O oligodesoxynucleotides|O against|O PKCalpha|B-protein and|I-protein PKCepsilon|I-protein isoforms|I-protein before|O the|O addition|O of|O 30|O mM|O glucose|O ,|O a|O significant|O (|O P|O <|O 0.05|O )|O reduction|O in|O the|O adhesion|O was|O also|O seen|O .|O
Advanced|O glycosylation|O end|O product-albumin|B-protein significantly|O increased|O the|O number|O of|O adhering|B-cell_type leukocytes|I-cell_type in|O respect|O to|O native|B-protein albumin|I-protein used|O as|O control|O (|O 110+/-16|O versus|O 66+/-7|O ,|O P|O <|O 0.01|O )|O .|O
Sera|O from|O diabetic|O patients|O significantly|O (|O P|O <|O 0.01|O )|O enhanced|O leukocyte|O adhesion|O as|O compared|O with|O controls|O ,|O despite|O normal|O levels|O of|O IL-1beta|B-protein and|O TNFalpha|B-protein in|O these|O sera|O .|O
These|O data|O indicate|O that|O high|O glucose|O concentration|O and|O hyperglycemia|O promote|O leukocyte|O adhesion|O to|O the|O endothelium|O through|O upregulation|O of|O cell|O surface|O expression|O of|O adhesive|O proteins|O ,|O possibly|O depending|O on|O NF-kB|B-protein activation|O .|O
Ikaros|B-protein in|O hemopoietic|O lineage|O determination|O and|O homeostasis|O .|O
Studies|O on|O the|O molecular|O mechanisms|O that|O control|O hemopoietic|O differentiation|O have|O focused|O on|O signaling|O cascades|O and|O nuclear|O effectors|O that|O drive|O this|O complex|O developmental|O system|O in|O a|O regulated|O fashion|O .|O
Here|O we|O review|O the|O role|O of|O Ikaros|B-protein ,|O the|O founding|O member|O of|O a|O unique|O family|O of|O zinc|B-protein finger|I-protein transcription|I-protein factors|I-protein in|O this|O developmental|O process|O .|O
Studies|O on|O an|O Ikaros|B-protein null|O mutation|O have|O revealed|O an|O essential|O role|O for|O this|O factor|O in|O lymphoid|O cell|O fate|O determination|O and|O at|O subsequent|O branch|O points|O of|O the|O T|O cell|O differentiation|O pathway|O .|O
Differences|O in|O the|O phenotypes|O of|O a|O null|O and|O a|O dominant|B-DNA negative|I-DNA (|I-DNA DN|I-DNA )|I-DNA Ikaros|I-DNA mutation|I-DNA provide|O insight|O into|O a|O regulatory|O network|O through|O which|O Ikaros|B-protein proteins|I-protein exert|O their|O effects|O in|O development|O .|O
In|O addition|O a|O comparative|O analysis|O of|O the|O hemopoietic|B-cell_type stem|I-cell_type cell|I-cell_type and|O precursor|O compartment|O resulting|O from|O the|O two|O Ikaros|B-DNA mutations|I-DNA reveals|O a|O profound|O yet|O not|O absolute|O requirement|O for|O Ikaros|B-protein
Induction|O of|O early|B-protein B|I-protein cell|I-protein factor|I-protein (|O EBF|B-protein )|O and|O multiple|B-DNA B|I-DNA lineage|I-DNA genes|I-DNA by|O the|O basic|B-protein helix-loop-helix|I-protein transcription|I-protein factor|I-protein E12|B-protein .|O
The|O transcription|B-protein factors|I-protein encoded|O by|O the|O E2A|B-protein and|O early|B-protein B|I-protein cell|I-protein factor|I-protein (|O EBF|B-protein )|O genes|O are|O required|O for|O the|O proper|O development|O of|O B|B-cell_type lymphocytes|I-cell_type .|O
However|O ,|O the|O absence|O of|O B|B-cell_type lineage|I-cell_type cells|I-cell_type in|O E2A-|O and|O EBF-deficient|O mice|O has|O made|O it|O difficult|O to|O determine|O the|O function|O or|O relationship|O between|O these|O proteins|O .|O
We|O report|O the|O identification|O of|O a|O novel|O model|O system|O in|O which|O the|O role|O of|O E2A|B-protein and|O EBF|B-protein in|O the|O regulation|O of|O multiple|O B|O lineage|O traits|O can|O be|O studied|O .|O
We|O found|O that|O the|O conversion|O of|O 70Z/3|B-cell_line pre-B|I-cell_line lymphocytes|I-cell_line to|O cells|O with|O a|O macrophage-like|O phenotype|O is|O associated|O with|O the|O loss|O of|O E2A|B-protein and|O EBF|B-protein .|O
Moreover|O ,|O we|O show|O that|O ectopic|O expression|O of|O the|O E2A|B-protein protein|O E12|B-protein in|O this|O macrophage|B-cell_line line|I-cell_line results|O in|O the|O induction|O of|O many|B-DNA B|I-DNA lineage|I-DNA genes|I-DNA ,|O including|O EBF|B-protein ,|O IL7Ralpha|B-protein ,|O lambda5|B-protein ,|O and|O Rag-1|O ,|O and|O the|O ability|O to|O induce|O kappa|B-protein light|I-protein chain|I-protein in|O response|O to|O mitogen|O .|O
Activation|O of|O EBF|B-protein may|O be|O one|O of|O the|O critical|O functions|O of|O E12|B-protein in|O regulating|O the|O B|O lineage|O phenotype|O since|O expression|O of|O EBF|B-protein alone|O leads|O to|O the|O activation|O of|O a|O subset|O of|O E12|B-protein -inducible|O traits|O .|O
Our|O data|O demonstrate|O that|O ,|O in|O the|O context|O of|O this|O macrophage|B-cell_line line|I-cell_line ,|O E12|B-protein induces|O expression|O of|O EBF|B-protein and|O together|O these|O transcription|B-protein factors|I-protein coordinately|O regulate|O numerous|O B|B-DNA lineage-associated|I-DNA genes|I-DNA .|O
Activation-induced|O down-regulation|O of|O retinoid|B-protein receptor|I-protein RXRalpha|I-protein expression|O in|O human|B-cell_type T|I-cell_type lymphocytes|I-cell_type .|O
Role|O of|O cell|O cycle|O regulation|O .|O
A|O 5.4-kilobase|B-RNA mRNA|I-RNA ,|O the|O expression|O of|O which|O is|O down-regulated|O after|O treatment|O of|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type (|O PBMCs|B-cell_type )|O with|O various|O T|O cell-activating|O agents|O ,|O was|O isolated|O using|O an|O mRNA|O differential|O display|O method|O .|O
Nucleotide|O sequence|O analysis|O identified|O the|O 5|B-RNA '|I-RNA end|I-RNA of|O this|O RNA|B-RNA as|O human|B-RNA retinoid|I-RNA receptor|I-RNA RXRalpha|I-RNA mRNA|I-RNA .|O
Here|O ,|O we|O report|O the|O nucleotide|O sequence|O of|O 3.6|B-DNA kilobases|I-DNA of|O this|O RNA|O ,|O which|O represents|O the|O 3|B-RNA '|I-RNA end|I-RNA of|O RXRalpha|B-RNA mRNA|I-RNA ,|O the|O sequence|O of|O which|O has|O not|O been|O previously|O described|O .|O
Activated|O PBMCs|B-cell_type also|O expressed|O lower|O levels|O of|O RXRalpha|B-protein protein|O ,|O and|O a|O DNA|O binding|O assay|O showed|O that|O the|O activation-induced|O loss|O of|O RXRalpha|B-RNA mRNA|I-RNA and|O protein|O expression|O correlated|O with|O the|O loss|O of|O DNA|O binding|O activity|O of|O this|O protein|O .|O
We|O present|O evidence|O that|O the|O transition|O from|O G0/G1|O to|O S|O phase|O of|O the|O cell|O cycle|O results|O in|O the|O down-regulation|O of|O RXRalpha|B-protein expression|O and|O that|O cell|O cycle|O inhibitors|O ,|O which|O block|O the|O cells|O in|O G1|O phase|O ,|O prevent|O this|O down-regulation|O .|O
The|O decrease|O in|O the|O levels|O of|O RXRalpha|B-RNA mRNA|I-RNA was|O found|O to|O be|O regulated|O at|O the|O post-transcriptional|O level|O and|O involved|O new|O protein|O synthesis|O .|O
These|O observations|O indicate|O that|O the|O levels|O of|O RXRalpha|B-protein expression|O in|O T|O lymphocytes|O are|O coupled|O to|O cell|O cycle|O progression|O ,|O and|O there|O is|O tight|O regulatory|O control|O of|O RXRalpha|B-protein expression|O during|O the|O transition|O from|O G0/G1|O to|O S|O phase|O of|O the|O cell|O cycle|O .|O
Epidemiology|O and|O pathogenesis|O of|O AIDS-related|O lymphomas|O .|O
Among|O patients|O with|O congenital|O and|O acquired|O immunodeficiencies|O ,|O non-Hodgkin|O 's|O lymphoma|O (|O NHLs|O )|O are|O the|O most|O common|O tumors|O of|O the|O immune|O system|O .|O
In|O the|O setting|O of|O human|O immunodeficiency|O virus|O (|O HIV|O )|O infection|O ,|O as|O many|O as|O 10|O %|O to|O 20|O %|O of|O people|O ultimately|O developed|O NHLs|O .|O
These|O tumors|O are|O clinically|O aggressive|O ,|O frequently|O involve|O extranodal|O sites|O ,|O and|O often|O exhibit|O unique|O features|O that|O distinguish|O them|O from|O NHL|O arising|O in|O individuals|O with|O other|O forms|O of|O immunosuppression|O .|O
Important|O in|O the|O development|O of|O HIV-associated|O NHL|O are|O cytokines|B-protein and|O other|O factors|O that|O induce|O B-cell|O proliferation|O and|O increase|O the|O likelihood|O of|O mutations|O of|O c-myc|B-DNA ,|O bcl-6|B-DNA ,|O and|O other|O tumor-suppressor|B-DNA genes|I-DNA with|O carcinogenic|O potential|O .|O
Specific|O forms|O of|O HIV-associated|O NHL|O are|O linked|O to|O expression|O of|O Epstein-Barr|B-protein virus|I-protein (|I-protein EBV|I-protein )|I-protein -latent|I-protein proteins|I-protein ;|O the|O newly|O described|O DNA|O virus|O ,|O Karposi|O 's|O sarcoma-associated|O herpesvirus/human|O herpesvirus-8|O (|O KSHV/HHV-8|O )|O ;|O and|O perhaps|O HIV|O .|O
Elucidation|O of|O the|O factors|O that|O contribute|O to|O the|O high|O incidence|O of|O NHL|O among|O patients|O infected|O with|O HIV|O provides|O insights|O into|O important|O elements|O of|O lymphomagenesis|O .|O
Matrix|B-protein metalloproteinase|I-protein expression|O in|O human|O breast|O cancer|O :|O an|O immunohistochemical|O study|O including|O correlation|O with|O cathepsin|B-protein D|I-protein ,|O type|B-protein IV|I-protein collagen|I-protein ,|O laminin|B-protein ,|O fibronectin|B-protein ,|O EGFR|B-protein ,|O c-erbB-2|B-protein oncoprotein|I-protein ,|O p53|B-protein ,|O steroid|O receptors|O status|O and|O proliferative|O indices|O .|O
Matrix|B-protein metalloproteinase|I-protein s|O (|O MMPs|B-protein )|O are|O a|O group|O of|O enzymes|O thought|O to|O be|O responsible|O for|O both|O normal|O connective|O tissue|O matrix|O remodelling|O and|O accelerated|O breakdown|O associated|O with|O tumour|O development|O .|O
The|O current|O study|O aimed|O to|O investigate|O the|O immunohistochemical|O expression|O of|O matrix|B-protein metalloproteinase|I-protein 3|I-protein (|O MMP-3|B-protein ,|O stromelysin-1|B-protein )|O in|O correlation|O with|O the|O expression|O of|O Basement|B-protein Membrane|I-protein (|I-protein BM|I-protein )|I-protein antigen|I-protein (|O type|B-protein IV|I-protein collagen|I-protein ,|O laminin|B-protein )|O ,|O fibronectin|B-protein ,|O cathepsin|B-protein D|I-protein ,|O p53|B-protein ,|O c-erbB-2|B-protein ,|O proliferative|O activity|O (|O Ki-67|B-protein ,|O PCNA|B-protein )|O ,|O steroid|O receptor|O content|O as|O well|O as|O to|O the|O other|O conventional|O clinicopathological|O parameters|O in|O breast|O cancer|O .|O
This|O study|O was|O performed|O on|O a|O series|O of|O frozen|O and|O paraffin|O sections|O from|O 84|O breast|O cancer|O specimens|O by|O immunohistochemistry|O using|O the|O monoclonal|B-protein antibody|I-protein MMP-3|I-protein (|O Ab-1|B-protein )|O .|O
Stromelysin-1|B-protein (|O ST1|B-protein )|O was|O observed|O in|O about|O 10|O %|O of|O epithelial|B-cell_type cells|I-cell_type in|O the|O control|O groups|O (|O cases|O of|O fibrocystic|O and|O benign|O proliferative|O breast|O disease|O )|O ,|O while|O expression|O (|O >|O 10|O %|O of|O expression|O )|O was|O detected|O in|O 89.7|O %|O of|O tumours|O .|O
The|O expression|O of|O ST1|B-protein in|O carcinoma|O cells|O was|O strongly|O associated|O with|O its|O presence|O in|O the|O stroma|O (|O p|O <|O 0.001|O )|O .|O
A|O significantly|O positive|O correlation|O was|O found|O between|O ST1|B-protein expression|O ,|O and|O p53|B-protein tumour|O suppressor|O gene|O product|O (|O p|O =|O 0.004|O )|O ,|O and|O a|O relationship|O with|O c-erbB-2|B-protein protein|O and|O progesterone|O receptor|O status|O was|O also|O indicated|O .|O
These|O findings|O suggest|O that|O ST1|B-protein expression|O in|O breast|O cancer|O tissue|O is|O irrespective|O of|O the|O expression|O of|O the|O extracellular|O matrix|O component|O ,|O the|O proteolytic|B-protein enzyme|I-protein cathepsin|B-protein D|I-protein and|O the|O growth|O fraction|O of|O the|O tumour|O ,|O and|O that|O it|O could|O be|O a|O potential|O new|O prognostic|O marker|O in|O breast|O cancer|O .|O
Use|O of|O transfected|B-cell_line liver|I-cell_line cells|I-cell_line to|O evaluate|O potential|O mechanisms|O of|O alcohol-induced|O liver|O injury|O [|O see|O comments|O ]|O
There|O is|O increased|O activity|O of|O the|O proinflammatory|B-protein cytokine|I-protein ,|O tumor|B-protein necrosis|I-protein factor|I-protein (|O TNF|B-protein )|O in|O alcoholic|O liver|O disease|O (|O ALD|O )|O .|O
Hepatic|O neutrophil|O infiltration|O is|O a|O principal|O injurious|O manifestation|O of|O ALD|O .|O
TNF|B-protein can|O induce|O cellular|O oxidative|O injury|O directly|O ,|O and|O indirectly|O by|O inducing|O neutrophil|O chemotactic|O factor|O (|O IL-8|B-protein )|O production|O by|O hepatocytes|O .|O
IL-8|B-protein activates|O and|O chemotactically|O attracts|O neutrophils|O to|O the|O liver|O where|O they|O release|O oxidizing|O substances|O .|O
Patients|O with|O ALD|O also|O have|O decreased|O protective|B-protein factors|I-protein for|O cellular|O oxidative|O injury|O .|O
Manganous|B-protein superoxide|I-protein dismutase|I-protein (|O MnSOD|B-protein )|O is|O an|O antioxidant|B-protein protective|I-protein factor|I-protein .|O
The|O objectives|O of|O these|O studies|O were|O to|O investigate|O mechanisms|O for|O induction|O of|O an|O injurious|B-protein factor|I-protein (|O IL-8|B-protein )|O and|O a|O protective|B-protein factor|I-protein (|O MnSOD|B-protein )|O in|O the|O HepG2|B-cell_line human|I-cell_line hepatoma|I-cell_line cell|I-cell_line line|I-cell_line .|O
In|O the|O first|O set|O of|O experiments|O ,|O IL-8|B-DNA gene|I-DNA reporter|I-DNA constructs|I-DNA were|O used|O to|O transiently|O transfect|O a|O derivative|O (|O MVh2E1-9|B-cell_line )|O of|O the|O HepG2|B-cell_line cell|I-cell_line line|I-cell_line which|O expresses|O P-4502E1|B-protein and|O metabolizes|O ethanol|O .|O
Inactivation|O of|O the|O NF-kappaB|B-DNA and|I-DNA 3'NF-IL-6|I-DNA DNA|I-DNA binding|I-DNA sites|I-DNA decreased|O IL-8|B-DNA gene|I-DNA transcriptional|O activation|O in|O response|O to|O TNF|B-protein while|O inactivation|O of|O the|O 5'NF-IL-6|B-DNA binding|I-DNA site|I-DNA increased|O IL-8|B-DNA gene|I-DNA transcriptional|O activity|O in|O response|O to|O TNF|B-protein .|O
This|O system|O may|O be|O useful|O to|O assess|O the|O effects|O of|O ethanol|O on|O TNF|B-protein -induced|O hepatocyte|O IL-8|B-protein production|O .|O
In|O the|O second|O set|O of|O experiments|O ,|O HepG2|B-cell_line cells|I-cell_line were|O cultured|O in|O 25|O to|O 100|O mmol|O concentrations|O of|O ethanol|O .|O
Both|O TNF|B-protein and|O ethanol|O increased|O HepG2|B-cell_line cell|I-cell_line MnSOD|B-protein activity|O in|O short-term|O (|O 72|O hr|O )|O cultures|O with|O ethanol|O .|O
However|O ,|O after|O long-term|O (|O 10|O weeks|O )|O culture|O with|O ethanol|O ,|O there|O was|O no|O induction|O of|O MnSOD|B-protein by|O ethanol|O and|O there|O was|O a|O diminished|O induction|O of|O MnSOD|B-protein in|O response|O to|O TNF|B-protein .|O
Further|O studies|O are|O needed|O to|O assess|O the|O effect|O of|O this|O diminished|O induction|O of|O MnSOD|B-protein with|O chronic|O ethanol|O culture|O on|O HepG2|B-cell_line cell|I-cell_line susceptibility|O to|O TNF|B-cell_line cytotoxicity|I-cell_line .|O
We|O conclude|O that|O transfected|O liver|B-cell_line cell|I-cell_line lines|I-cell_line can|O be|O used|O to|O evaluate|O mechanisms|O for|O increased|O injurious|B-protein factors|I-protein and|O decreased|O protective|B-protein factors|I-protein in|O alcoholic|O liver|O injury|O .|O
Tissue|O factor|O transcription|O driven|O by|O Egr-1|B-protein is|O a|O critical|O mechanism|O of|O murine|B-protein pulmonary|I-protein fibrin|I-protein deposition|O in|O hypoxia|O .|O
Local|O hypoxemia|O and|O stasis|O trigger|O thrombosis|O .|O
We|O have|O demonstrated|O previously|O that|O in|O a|O murine|O model|O of|O normobaric|O hypoxia|O pulmonary|O fibrin|B-protein deposition|O is|O a|O result|O of|O expression|O of|O tissue|B-protein factor|I-protein ,|O especially|O in|O oxygen-deprived|B-protein mononuclear|I-protein phagocytes|I-protein (|O MPs|B-protein )|O .|O
We|O now|O show|O that|O transcription|B-protein factor|I-protein early-growth-response|I-protein gene|I-protein product|I-protein (|O Egr-1|B-protein )|O is|O rapidly|O activated|O in|O hypoxia|O ,|O both|O in|O vitro|O and|O in|O vivo|O ,|O and|O is|O responsible|O for|O transcription|O and|O expression|O of|O tissue|B-protein factor|I-protein in|O hypoxic|O lung|O .|O
MPs|B-protein and|O HeLa|B-cell_line cells|I-cell_line subjected|O to|O hypoxia|O (|O pO2|O approximately|O 13|O torr|O )|O had|O increased|O levels|O of|O tissue|B-RNA factor|I-RNA transcripts|I-RNA (|O approximately|O 18-fold|O )|O and|O an|O increased|O rate|O of|O transcription|O (|O approximately|O 15-fold|O )|O ,|O based|O on|O nuclear|O run-on|O analysis|O .|O
Gel-shift|O analysis|O of|O nuclear|O extracts|O from|O hypoxic|B-protein MPs|I-protein and|O HeLa|B-cell_line cells|I-cell_line demonstrated|O increased|O DNA-binding|O activity|O at|O the|O serum|B-DNA response|I-DNA region|I-DNA (|O SRR|O ;|O -111/+14|O bp|O )|O of|O the|O tissue|B-DNA factor|I-DNA promoter|I-DNA at|O Egr-1|B-DNA motifs|I-DNA .|O
Using|O 32P-labeled|O Egr|O consensus|O oligonucleotide|O ,|O we|O observed|O induction|O of|O DNA-binding|O activity|O in|O nuclear|O extracts|O from|O hypoxic|O lung|O and|O HeLa|B-cell_line cells|I-cell_line because|O of|O activation|O of|O Egr-1|B-protein ,|O by|O means|O of|O supershift|O analysis|O .|O
Transient|O transfection|O of|O HeLa|B-cell_line cells|I-cell_line with|O chimeric|B-DNA plasmids|I-DNA containing|O wild-type|B-protein or|I-protein mutant|I-protein SRR|I-protein from|O the|O tissue|B-DNA factor|I-DNA promoter|I-DNA showed|O that|O intact|B-DNA Sp1|I-DNA sites|I-DNA are|O necessary|O for|O basal|O promoter|O activity|O ,|O whereas|O the|O integrity|O of|O Egr-1|B-DNA sites|I-DNA was|O required|O for|O hypoxia-enhanced|O expression|O .|O
A|O central|O role|O for|O Egr-1|B-protein in|O hypoxia-mediated|O tissue|O factor|O expression|O was|O confirmed|O by|O experiments|O with|O homozygous|O Egr-1|B-protein null|O mice|O ;|O wild-type|O mice|O subjected|O to|O oxygen|B-protein deprivation|I-protein expressed|I-protein tissue|I-protein factor|I-protein and|O showed|O fibrin|B-protein deposition|O ,|O but|O hypoxic|O homozygous|O Egr-1|B-protein null|O mice|O displayed|O neither|O tissue|B-protein factor|I-protein nor|O fibrin|B-protein .|O
These|O data|O delineate|O a|O novel|O biology|O for|O hypoxia-induced|O fibrin|B-protein deposition|O ,|O in|O which|O oxygen|O deprivation-induced|O activation|O of|O Egr-1|B-protein ,|O resulting|O in|O expression|O of|O tissue|B-protein factor|I-protein ,|O has|O an|O unexpected|O and|O central|O role|O .|O
Kinetics|O of|O cytokine|O and|O NFAT|O gene|O expression|O in|O human|B-cell_line interleukin-2-dependent|I-cell_line T|I-cell_line lymphoblasts|I-cell_line stimulated|O via|O T-cell|B-protein receptor|I-protein .|O
T|B-cell_type cells|I-cell_type respond|O to|O mitogenic|O or|O antigenic|O stimulation|O by|O proliferation|O and|O by|O turning|O on|O cytokine|O gene|O expression|O .|O
Here|O we|O have|O analysed|O the|O kinetics|O and|O nature|O of|O cytokine|O production|O in|O human|B-cell_type peripheral|I-cell_type blood-derived|I-cell_type T|I-cell_type lymphoblasts|I-cell_type stimulated|O with|O anti-CD3|B-protein antibodies|I-protein or|O Lens|B-protein culinaris|I-protein lectin|I-protein (|O LCL|B-protein )|O .|O
T|B-cell_type cells|I-cell_type were|O purified|O from|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type (|O PBMC|B-cell_type )|O and|O primarily|O activated|O with|O anti-CD3|B-protein antibodies|I-protein and|O cultured|O in|O the|O presence|O of|O interleukin-2|B-protein (|O IL-2|B-protein )|O .|O
Anti-CD3-restimulated|O T|B-cell_type cells|I-cell_type (|O mainly|O CD8+|O )|O produced|O IL-2|B-protein ,|O interferon-gamma|B-protein (|O IFN-gamma|B-protein )|O and|O tumour|B-protein necrosis|I-protein factor-alpha|I-protein (|O TNF-alpha|B-protein )|O and|O low|O levels|O of|O IL-4|B-RNA and|I-RNA IL-10|I-RNA transcripts|I-RNA and|O proteins|O .|O
No|O IL-6|B-DNA gene|I-DNA expression|O was|O observed|O .|O
In|O LCL-stimulated|B-cell_type cells|I-cell_type the|O cytokine|O production|O pattern|O was|O very|O similar|O .|O
Steady-state|O mRNA|O levels|O of|O IL-2|B-protein ,|O IL-10|B-protein and|O IFN-gamma|B-protein peaked|O at|O 3|O hr|O after|O anti-CD3|O stimulation|O and|O declined|O rapidly|O thereafter|O .|O
The|O kinetics|O of|O TNF-alpha|B-RNA mRNA|I-RNA expression|O was|O faster|O ,|O being|O at|O its|O peak|O level|O 1|O hr|O after|O stimulation|O .|O
Anti-CD3-stimulated|O IL-2|B-DNA gene|I-DNA expression|O was|O down-regulated|O by|O protein|O synthesis|O inhibitor|O ,|O whereas|O IL-10|B-DNA ,|I-DNA IFN-gamma|I-DNA and|I-DNA TNF-alpha|I-DNA genes|I-DNA were|O readily|O induced|O independent|O of|O ongoing|O protein|O synthesis|O .|O
T-cell|B-protein receptor|I-protein stimulation|O also|O induced|O a|O very|O rapid|O expression|O of|O c-jun|B-DNA ,|I-DNA c-fos|I-DNA and|I-DNA NFATc1|I-DNA (|I-DNA NFATc|I-DNA )|I-DNA genes|I-DNA ,|O the|O gene|O products|O of|O which|O are|O involved|O in|O cytokine|O gene|O expression|O .|O
In|O conclusion|O ,|O the|O cytokines|B-protein synthesized|O by|O IL-2-dependent|B-cell_type T|I-cell_type cells|I-cell_type were|O predominantly|O IL-2|B-protein ,|O IFN-gamma|B-protein and|O TNF-alpha|B-protein .|O
An|O animal|O model|O to|O study|O local|O oxidation|O of|O LDL|O and|O its|O biological|O effects|O in|O the|O arterial|O wall|O .|O
Oxidized|O LDL|O (|O oxLDL|O )|O is|O present|O in|O atherosclerotic|O lesions|O and|O is|O believed|O to|O play|O a|O key|O role|O in|O atherogenesis|O .|O
Mainly|O on|O the|O basis|O of|O cell|O culture|O studies|O ,|O oxLDL|O has|O been|O shown|O to|O produce|O many|O biological|O effects|O that|O influence|O the|O atherosclerotic|O process|O .|O
To|O study|O LDL|O oxidation|O in|O vivo|O ,|O we|O have|O established|O a|O model|O in|O which|O Sprague-Dawley|O rats|O are|O given|O a|O single|O injection|O of|O unmodified|O human|O LDL|O (|O >|O or|O =|O 4|O mg/kg|O body|O weight|O )|O .|O
Within|O 6|O hours|O ,|O an|O accumulation|O of|O apolipoprotein|O B|O and|O epitopes|B-protein present|O on|O oxLDL|O are|O detected|O in|O the|O arterial|O endothelium|O and|O media|O .|O
The|O presence|O of|O oxLDL|O is|O associated|O with|O activation|O of|O the|O transcription|B-protein factor|I-protein nuclear|B-protein factor-kappaB|I-protein in|O the|O endothelium|O as|O well|O as|O endothelial|O expression|O of|O intercellular|B-protein adhesion|I-protein molecule-1|I-protein .|O
Injection|O of|O LDL|O enriched|O with|O the|O antioxidant|O probucol|O resulted|O in|O arterial|O accumulation|O of|O apolipoprotein|O B|O ,|O but|O the|O expression|O of|O oxLDL-specific|O epitopes|O was|O reduced|O at|O 24|O hours|O .|O
Thus|O ,|O this|O simple|O model|O has|O the|O potential|O to|O analyze|O the|O mechanisms|O behind|O and|O biological|O effects|O of|O LDL|O oxidation|O in|O vivo|O .|O
Molecular|O mechanisms|O of|O promoter|O regulation|O of|O the|O gp34|B-DNA gene|I-DNA that|O is|O trans-activated|O by|O an|O oncoprotein|B-protein Tax|I-protein of|O human|O T|O cell|O leukemia|O virus|O type|O I|O .|O
We|O investigated|O the|O molecular|O mechanism|O of|O transcriptional|O activation|O of|O the|O gp34|B-DNA gene|I-DNA by|O the|O Tax|B-protein oncoprotein|I-protein of|O human|O T|O cell|O leukemia|O virus|O type|O I|O (|O HTLV-I|O )|O .|O
gp34|B-protein is|O a|O type|B-protein II|I-protein transmembrane|I-protein molecule|I-protein belonging|O to|O the|O tumor|O necrosis|O factor|O family|O and|O is|O constitutively|O expressed|O on|O HTLV-I-producing|B-cell_type cells|I-cell_type but|O not|O normal|B-cell_type resting|I-cell_type T|I-cell_type cells|I-cell_type .|O
The|O transcriptional|O regulatory|O region|O of|O the|O gp34|B-DNA gene|I-DNA was|O activated|O by|O HTLV-I|O Tax|B-protein in|O the|O human|B-cell_line T|I-cell_line cell|I-cell_line line|I-cell_line Jurkat|I-cell_line ,|O in|O which|O endogenous|O gp34|B-protein is|O induced|O by|O Tax|B-protein .|O
Sequence|O analysis|O demonstrated|O that|O two|O NF-kappaB-like|B-DNA elements|I-DNA (|O 1|O and|O 2|O )|O were|O present|O in|O the|O regulatory|B-DNA region|I-DNA .|O
Both|O NF-kappaB-like|B-DNA elements|I-DNA were|O able|O to|O bind|O to|O NF-kappaB|B-protein or|O its|O related|O factor|O (|O s|O )|O in|O a|O Tax|B-protein -dependent|O manner|O .|O
Chloramphenicol|B-protein acetyltransferase|I-protein assays|O indicated|O that|O NF-kappaB-like|B-DNA element|I-DNA 1|I-DNA was|O Tax|B-protein -responsive|O ,|O although|O the|O activity|O was|O lower|O than|O that|O the|O native|B-DNA promoter|I-DNA .|O
NF-kappaB|B-protein -like|O element|O 2|O elevated|O promoter|O activity|O when|O combined|O with|O NF-kappaB-like|B-DNA element|I-DNA 1|I-DNA ,|O indicating|O cooperative|O function|O of|O the|O elements|O for|O maximum|O promoter|O function|O .|O
Unlike|O typical|O NF-kappaB|B-DNA elements|I-DNA ,|O the|O NF-kappaB-like|B-DNA elements|I-DNA in|O gp34|B-protein were|O not|O activated|O by|O treatment|O of|O Jurkat|B-cell_line cells|I-cell_line with|O phorbol|O ester|O despite|O induction|O of|O the|O NF-kappaB|B-protein -like|O binding|O activity|O .|O
Chloramphenicol|B-protein acetyltransferase|I-protein reporter|O assays|O using|O the|O region|O upstream|O of|O the|O NF-kappaB-like|B-DNA elements|I-DNA identified|O an|O upstream|O region|O that|O reduced|O transcription|O from|O cognate|B-DNA and|I-DNA noncognate|I-DNA core|I-DNA promoters|I-DNA in|O a|O Tax-independent|O manner|O .|O
Our|O results|O imply|O complex|O regulation|O of|O expression|O of|O the|O gp34|B-DNA gene|I-DNA and|O suggest|O implication|O of|O gp34|B-protein in|O proliferation|O of|O HTLV-I|O infected|O T|O cells|O .|O
beta-Amyloid|B-protein fibrils|I-protein activate|O parallel|O mitogen-activated|B-protein protein|I-protein kinase|I-protein pathways|O in|O microglia|B-cell_type and|O THP1|B-cell_line monocytes|I-cell_line .|O
The|O senile|O plaques|O of|O Alzheimer|O 's|O disease|O are|O foci|O of|O local|O inflammatory|O responses|O ,|O as|O evidenced|O by|O the|O presence|O of|O acute|B-protein phase|I-protein proteins|I-protein and|O oxidative|O damage|O .|O
Fibrillar|B-protein forms|I-protein of|O beta-amyloid|B-protein (|O Abeta|B-protein )|O ,|O which|O are|O the|O primary|O constituents|O of|O senile|O plaques|O ,|O have|O been|O shown|O to|O activate|O tyrosine|O kinase-dependent|O signal|O transduction|O cascades|O ,|O resulting|O in|O inflammatory|O responses|O in|O microglia|B-cell_type .|O
However|O ,|O the|O downstream|O signaling|O pathways|O mediating|O Abeta|B-protein -induced|O inflammatory|O events|O are|O not|O well|O characterized|O .|O
We|O report|O that|O exposure|O of|O primary|B-cell_type rat|I-cell_type microglia|I-cell_type and|O human|B-cell_line THP1|I-cell_line monocytes|I-cell_line to|O fibrillar|B-protein Abeta|I-protein results|O in|O the|O tyrosine|B-protein kinase|I-protein -dependent|O activation|O of|O two|O parallel|O signal|O transduction|O cascades|O involving|O members|O of|O the|O mitogen-activated|B-protein protein|I-protein kinase|I-protein (|I-protein MAPK|I-protein )|I-protein superfamily|I-protein .|O
Abeta|B-protein stimulated|O the|O rapid|O ,|O transient|O activation|O of|O extracellular|B-protein signal-regulated|I-protein kinase|I-protein 1|I-protein (|O ERK1|B-protein )|O and|O ERK2|B-protein in|O microglia|B-cell_type and|O ERK2|B-protein in|O THP1|B-cell_line monocytes|I-cell_line .|O
A|O second|O superfamily|B-protein member|I-protein ,|O p38|B-protein MAPK|I-protein ,|O was|O also|O activated|O with|O similar|O kinetics|O .|O
Scavenger|B-protein receptor|I-protein and|O receptor|B-protein for|I-protein advanced|I-protein glycated|I-protein end|I-protein products|I-protein (|O RAGE|B-protein )|O ligands|O failed|O to|O activate|O ERK|B-protein and|O p38|B-protein MAPK|I-protein in|O the|O absence|O of|O significant|O increases|O in|O protein|O tyrosine|O phosphorylation|O ,|O demonstrating|O that|O scavenger|B-protein receptors|I-protein and|O RAGE|B-protein are|O not|O linked|O to|O these|O pathways|O .|O
Importantly|O ,|O the|O stress-activated|B-protein protein|I-protein kinases|I-protein (|O SAPKs|B-protein )|O were|O not|O significantly|O activated|O in|O response|O to|O Abeta|B-protein .|O
Downstream|O effectors|O of|O the|O MAPK|O signal|O transduction|O cascades|O include|O MAPKAP|B-protein kinases|I-protein ,|O such|O as|O RSK1|B-protein and|O RSK2|B-protein ,|O as|O well|O as|O transcription|B-protein factors|I-protein .|O
Exposure|O of|O microglia|B-cell_type and|O THP1|B-cell_line monocytes|I-cell_line to|O Abeta|B-protein resulted|O in|O the|O activation|O of|O RSK1|B-protein and|O RSK2|B-protein and|O phosphorylation|O of|O cAMP|B-protein response|I-protein element-binding|I-protein protein|I-protein at|O Ser133|O ,|O providing|O a|O mechanism|O for|O Abeta|B-protein -induced|O changes|O in|O gene|O expression|O
Regulation|O of|O cellular|B-protein retinoic|I-protein acid|I-protein binding|I-protein protein|I-protein (|O CRABP|B-protein II|I-protein )|O during|O human|B-cell_type monocyte|I-cell_type differentiation|O in|O vitro|O .|O
Cellular|B-protein retinoic|I-protein acid|I-protein binding|I-protein proteins|I-protein (|O CRABP|B-protein )|O are|O low|B-protein molecular|I-protein weight|I-protein proteins|I-protein whose|O precise|O function|O remains|O unknown|O .|O
They|O bind|O retinoids|O and|O may|O thereby|O modulate|O the|O intracellular|O steady-state|O concentration|O of|O retinoids|O .|O
Whereas|O CRABP|B-protein I|I-protein is|O ubiquitously|O expressed|O ,|O CRABP|B-protein II|I-protein is|O mainly|O detected|O in|O various|O cell|O types|O of|O the|O skin|O .|O
By|O representative|O difference|O analysis|O we|O found|O that|O CRABP|B-protein II|I-protein is|O also|O strongly|O expressed|O in|O human|B-cell_type monocyte-derived|I-cell_type macrophages|I-cell_type (|O MAC|B-cell_type )|O but|O not|O in|O freshly|B-cell_type isolated|I-cell_type monocytes|I-cell_type (|O MO|B-cell_type )|O .|O
The|O CRABP|B-RNA II|I-RNA mRNA|I-RNA was|O gradually|O upregulated|O during|O differentiation|O from|O MO|B-cell_type to|O MAC|B-cell_type in|O the|O presence|O of|O 2|O %|O serum|O .|O
Adherence|O ,|O which|O is|O important|O for|O MO|B-cell_type differentiation|O ,|O induced|O CRABP|B-protein II|I-protein expression|O ,|O but|O the|O addition|O of|O 10|O (|O -7|O )|O M|O retinoic|O acid|O inhibited|O the|O upregulation|O of|O CRABP|B-protein II|I-protein expression|O during|O MO/MAC|O differentiation|O .|O
As|O MO|B-cell_type can|O differentiate|O along|O the|O classical|O pathway|O not|O only|O to|O MAC|B-cell_type but|O also|O to|O dendritic|O cells|O we|O analyzed|O the|O expression|O of|O CRABP|B-protein II|I-protein in|O MO-derived|B-cell_type dendritic|I-cell_type cells|I-cell_type cultured|O with|O 10|O %|O FCS|B-protein ,|O IL-4|B-protein ,|O and|O GM-CSF|B-protein .|O
In|O contrast|O to|O MAC|B-cell_type ,|O MO-derived|B-cell_type dendritic|I-cell_type cells|I-cell_type showed|O an|O extremely|O low|O expression|O of|O CRABP|B-protein II|I-protein .|O
From|O these|O results|O we|O conclude|O (|O 1|O )|O that|O the|O availability|O and|O the|O metabolism|O of|O retinoids|O may|O be|O different|O in|O MAC|B-cell_type compared|O to|O MO|B-cell_type and|O dendritic|B-cell_type cells|I-cell_type and|O (|O 2|O )|O that|O this|O may|O influence|O differentiation|O and|O activation|O of|O those|O cells|O .|O
Transcription|B-protein factor|I-protein B-cell-specific|I-protein activator|I-protein protein|I-protein (|O BSAP|B-protein )|O is|O differentially|O expressed|O in|O B|B-cell_type cells|I-cell_type and|O in|O subsets|O of|O B-cell|O lymphomas|O .|O
The|O paired|B-DNA box|I-DNA containing|I-DNA gene|I-DNA PAX-5|B-DNA encodes|O the|O transcription|B-protein factor|I-protein BSAP|B-protein (|O B-cell-specific|B-protein activator|I-protein protein|I-protein )|O ,|O which|O plays|O a|O key|O role|O in|O B-lymphocyte|O development|O .|O
Despite|O its|O known|O involvement|O in|O a|O rare|O subtype|O of|O non-Hodgkin|O 's|O lymphoma|O (|O NHL|O )|O ,|O a|O detailed|O examination|O of|O BSAP|B-protein expression|O in|O NHL|O has|O not|O been|O previously|O reported|O .|O
In|O this|O study|O ,|O we|O analyzed|O normal|O and|O malignant|O lymphoid|O tissues|O and|O cell|B-cell_line lines|I-cell_line ,|O including|O 102|O cases|O of|O B-cell|O NHL|O ,|O 23|O cases|O of|O T-|O and|O null-cell|O NHL|O ,|O and|O 18|O cases|O of|O Hodgkin|O 's|O disease|O .|O
Normal|O lymphoid|O tissues|O showed|O strong|O nuclear|O BSAP|B-protein expression|O in|O mantle|B-cell_type zone|I-cell_type B|I-cell_type cells|I-cell_type ,|O less|O intense|O reactivity|O in|O follicular|B-cell_type center|I-cell_type B|I-cell_type cells|I-cell_type ,|O and|O no|O expression|O in|O cells|O of|O the|O T-cell-rich|O zones|O .|O
Monocytoid|B-cell_type B|I-cell_type cells|I-cell_type showed|O weak|O expression|O ,|O whereas|O plasma|B-cell_type cells|I-cell_type and|O extrafollicular|B-cell_type large|I-cell_type transformed|I-cell_type B|I-cell_type cells|I-cell_type were|O negative|O .|O
Of|O the|O 102|O B-cell|O NHLs|O ,|O 83|O (|O 81|O %|O )|O demonstrated|O BSAP|B-protein expression|O .|O
All|O of|O the|O 13|O (|O 100|O %|O )|O B-cell|O chronic|O lymphocytic|O leukemias|O (|O B-CLLs|O )|O ,|O 21|O of|O (|O 100|O %|O )|O mantle|B-cell_type cells|I-cell_type (|O MCLs|B-cell_type )|O ,|O and|O 20|O of|O 21|O (|O 95|O %|O )|O follicular|O lymphomas|O (|O FLs|O )|O were|O positive|O .|O
Moderate|O staining|O intensities|O were|O found|O in|O most|O B-CLL|O and|O FL|O cases|O ,|O whereas|O most|O MCLs|B-cell_type showed|O strong|O reactions|O ,|O paralleling|O the|O strong|O reactivity|O of|O nonmalignant|B-cell_type mantle|I-cell_type cells|I-cell_type .|O
Eight|O of|O 12|O (|O 67|O %|O )|O marginal|O zone|O lymphoma|O cases|O showed|O negative|O or|O low|O BSAP|B-protein levels|O ,|O and|O 17|O of|O 24|O (|O 71|O %|O )|O large|O B-cell|O lymphomas|O displayed|O moderate|O to|O strong|O expression|O .|O
None|O of|O the|O 23|O T-|O and|O null-cell|O lymphomas|O reacted|O with|O the|O BSAP|B-protein antisera|O ,|O whereas|O in|O Hodgkin|O 's|O disease|O ,|O 2|O of|O 4|O (|O 50|O %|O )|O nodular|O lymphocytic|O predominance|O and|O 5|O of|O 14|O (|O 36|O %|O )|O classical|O cases|O showed|O weak|O nuclear|O or|O nucleolar|O BSAP|B-protein reactions|O in|O a|O fraction|O of|O the|O tumor|B-cell_type cells|I-cell_type .|O
Western|O blot|O analysis|O showed|O a|O 52-kD|O BSAP|B-protein band|O in|O B-cell|B-cell_line lines|I-cell_line ,|O but|O not|O in|O non-B-cell|B-cell_line or|I-cell_line plasma|I-cell_line cell|I-cell_line lines|I-cell_line .|O
We|O conclude|O that|O BSAP|B-protein expression|O is|O largely|O restricted|O to|O lymphomas|O of|O B-cell|B-cell_type lineage|I-cell_type and|O that|O BSAP|B-protein expression|O varies|O in|O B-cell|B-cell_type subsets|I-cell_type and|O subtypes|O of|O B-cell|O NHL|O .|O
The|O high|O levels|O of|O BSAP|B-protein ,|O especially|O those|O found|O in|O large-cell|B-cell_type lymphomas|I-cell_type and|O in|O some|O follicular|B-cell_type lymphomas|I-cell_type ,|O may|O be|O a|O consequence|O of|O deregulated|O gene|O expression|O and|O suggest|O a|O possible|O involvement|O of|O PAX-5|B-DNA in|O certain|O B-cell|O malignancies|O .|O
This|O is|O a|O US|O government|O work|O .|O
There|O are|O no|O restrictions|O on|O its|O use|O .|O
Mitogen|O and|O growth|O factor-induced|O activation|O of|O a|O STAT-like|B-protein molecule|I-protein in|O channel|B-cell_type catfish|I-cell_type lymphoid|I-cell_type cells|I-cell_type .|O
This|O article|O describes|O the|O identification|O of|O a|O putative|B-protein STAT|I-protein molecule|I-protein in|O the|O channel|O catfish|O (|O Ictalurus|O punctatus|O )|O ,|O the|O first|O report|O of|O such|O a|O molecule|O in|O a|O 'lower|O '|O vertebrate|O .|O
A|O monoclonal|B-protein antibody|I-protein against|O human|B-protein STAT6|I-protein recognizes|O an|O approximately|O 100|B-protein kDa|I-protein molecule|I-protein that|O becomes|O activated|O and|O translocates|O to|O the|O nucleus|O upon|O both|O growth|O factor|O and|O mitogen|O stimulation|O of|O catfish|O leukocytes|O .|O
This|O presumed|O catfish|B-protein STAT|I-protein binds|O the|O mammalian|B-DNA interferon-gamma|I-DNA activation|I-DNA site|I-DNA ,|O a|O known|O motif|O of|O mammalian|O STAT|O binding|O ,|O as|O shown|O by|O electromobility|O shift|O assays|O .|O
Purification|O of|O the|O proteins|O present|O in|O these|O DNA|B-protein complexes|I-protein confirms|O that|O the|O catfish|O reactive|O molecule|O binds|O to|O the|O interferon-gamma|B-DNA activation|I-DNA site|I-DNA sequence|I-DNA .|O
These|O results|O suggest|O that|O STAT|B-protein molecules|I-protein have|O been|O highly|O conserved|O in|O vertebrate|O evolution|O .|O
Isolation|O and|O analysis|O of|O a|O T|B-cell_line cell|I-cell_line clone|I-cell_line variant|I-cell_line exhibiting|O constitutively|O phosphorylated|B-protein Ser133|I-protein cAMP|I-protein response|I-protein element-binding|I-protein protein|I-protein .|O
In|O driving|O T|O cell|O proliferation|O ,|O IL-2|B-protein stimulates|O a|O new|O program|O of|O gene|O expression|O that|O includes|O proliferating|B-protein cell|I-protein nuclear|I-protein antigen|I-protein (|O PCNA|B-protein )|O ,|O a|O requisite|O processivity|O factor|O for|O DNA|B-protein polymerase|I-protein delta|I-protein .|O
PCNA|B-protein transcription|O is|O regulated|O in|O part|O through|O tandem|O CRE|B-DNA sequences|I-DNA in|O the|O promoter|B-protein and|I-protein CRE|I-protein binding|I-protein proteins|I-protein ;|O IL-2|B-protein stimulates|O CREB|O phosphorylation|O in|O the|O resting|B-cell_line cloned|I-cell_line T|I-cell_line lymphocyte|I-cell_line ,|O L2|B-cell_line .|O
After|O culturing|O L2|B-cell_line cells|I-cell_line for|O greater|O than|O 91|O days|O ,|O we|O consistently|O isolate|O a|O stable|O variant|O that|O exhibits|O constitutive|O CREB|O phosphorylation|O .|O
L2|B-cell_line and|I-cell_line L2|I-cell_line variant|I-cell_line cells|I-cell_line were|O tested|O for|O IL-2|B-protein responsiveness|O and|O rapamycin|O sensitivity|O with|O respect|O to|O specific|O kinase|O activity|O ,|O PCNA|O expression|O and|O proliferation|O .|O
In|O L2|B-cell_line cells|I-cell_line ,|O IL-2|B-protein stimulated|O and|O rapamycin|O inhibited|O the|O following|O :|O cAMP-independent|O CREB|B-protein kinase|I-protein activity|O ,|O PCNA|O expression|O and|O proliferation|O .|O
In|O L2|B-cell_line variant|I-cell_line cells|I-cell_line ,|O CREB|B-protein kinase|I-protein activity|O was|O constitutively|O high|O ;|O IL-2|B-protein stimulated|O and|O rapamycin|O blocked|O PCNA|O expression|O and|O proliferation|O .|O
These|O results|O indicate|O that|O IL-2|B-protein induces|O a|O rapamycin-sensitive|O ,|O cAMP-independent|O CREB|B-protein kinase|I-protein activity|O in|O L2|B-cell_line cells|I-cell_line .|O
However|O ,|O phosphorylation|O of|O CREB|B-protein alone|O is|O not|O sufficient|O to|O drive|O PCNA|B-protein expression|O and|O L2|O cell|O proliferation|O in|O the|O absence|O of|O IL-2|B-protein .|O
Serotonin|O derivative|O ,|O N-|O (|O p-coumaroyl|O )|O serotonin|O ,|O inhibits|O the|O production|O of|O TNF-alpha|B-protein ,|O IL-1alpha|B-protein ,|O IL-1beta|B-protein ,|O and|O IL-6|B-protein by|O endotoxin-stimulated|B-cell_type human|I-cell_type blood|I-cell_type monocytes|I-cell_type .|O
We|O have|O reported|O that|O N-|O (|O p-coumaroyl|O )|O serotonin|O (|O CS|O )|O and|O its|O derivatives|O with|O antioxidative|O activity|O are|O present|O in|O safflower|O seeds|O .|O
As|O reactive|O oxygen|O species|O (|O ROS|O )|O are|O implicated|O in|O the|O signaling|O of|O lipopolysaccharide|O (|O LPS|O )|O ,|O we|O examined|O whether|O CS|O has|O a|O suppressive|O effect|O on|O inflammatory|B-protein cytokine|I-protein generation|O from|O human|B-cell_type monocyte|I-cell_type s|O in|O vitro|O .|O
CS|O at|O 50-200|O microM|O reduced|O tumor|B-protein necrosis|I-protein factor|I-protein (|O TNF|B-protein )|O ,|O interleukin-1|B-protein (|O IL-1|B-protein )|O ,|O and|O IL-6|B-protein activities|O in|O the|O culture|O supernatants|O from|O LPS-stimulated|B-cell_line human|I-cell_line blood|I-cell_line monocytes|I-cell_line without|O cytotoxicity|O .|O
ELISA|O assay|O revealed|O that|O the|O production|O of|O TNF-alpha|B-protein ,|O IL-1alpha|B-protein ,|O IL-1beta|B-protein ,|O and|O IL-6|B-protein was|O inhibited|O by|O CS|O .|O
Northern|O blot|O analysis|O showed|O that|O LPS-induced|O expression|O of|O these|O cytokine|B-RNA mRNA|I-RNA in|O monocytes|B-cell_type was|O suppressed|O by|O CS|O .|O
NF-kappaB|O activation|O was|O also|O inhibited|O by|O CS|O .|O
These|O findings|O indicate|O that|O CS|O has|O a|O suppressive|O effect|O on|O proinflammatory|O cytokine|O production|O from|O monocytes|B-cell_type ,|O and|O this|O effect|O is|O based|O in|O part|O on|O the|O suppression|O of|O cytokine|B-RNA mRNA|I-RNA expression|O through|O inhibition|O of|O NF-kappaB|B-protein activation|O .|O
Elevated|O expression|O of|O differentiation|B-RNA inhibitory|I-RNA factor|I-RNA nm23|I-RNA mRNA|I-RNA in|O monoblastic|O crisis|O of|O a|O patient|O with|O chronic|O myelogenous|O leukemia|O .|O
Differentiation|B-protein inhibitory|I-protein factor|I-protein nm23|B-DNA gene|I-DNA has|O been|O found|O to|O be|O expressed|O in|O high|O quantities|O in|O acute|O myelogenous|O leukemia|O (|O AML|O )|O ,|O especially|O in|O acute|O monocytic|O leukemia|O (|O AML-M5|O )|O and|O is|O suggested|O as|O a|O new|O prognostic|O factor|O in|O AML-M5|O .|O
We|O report|O an|O example|O of|O elevated|O expression|O of|O nm23|B-RNA mRNA|I-RNA in|O a|O patient|O with|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O who|O developed|O monoblastic|O crisis|O .|O
Relative|O levels|O of|O nm23-H1|B-RNA and|I-RNA -H2|I-RNA mRNA|I-RNA extracted|O from|O the|O patient|O 's|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type and|O bone|B-cell_type marrow|I-cell_type mononuclear|I-cell_type cells|I-cell_type were|O measured|O by|O quantitative|O reverse|O transcriptase|O polymerase|O chain|O reaction|O .|O
The|O level|O of|O nm23-H1|B-RNA mRNA|I-RNA in|O CML|B-cell_line cells|I-cell_line at|O the|O chronic|O phase|O was|O as|O high|O as|O that|O in|O bone|B-cell_type marrow|I-cell_type cells|I-cell_type from|O healthy|O volunteers|O .|O
The|O mRNA|O level|O of|O nm23-H2|B-protein was|O slightly|O below|O the|O normal|O level|O .|O
At|O blastic|O crisis|O ,|O however|O ,|O expression|O of|O both|O nm23-H1|B-RNA and|I-RNA -H2|I-RNA mRNA|I-RNA was|O elevated|O to|O about|O three|O to|O nine|O times|O of|O that|O at|O the|O chronic|O phase|O .|O
Proliferated|B-cell_type blastic|I-cell_type cells|I-cell_type were|O positive|O for|O non-specific|B-protein esterase|I-protein ,|O and|O the|O serum|O lysozyme|O level|O was|O elevated|O and|O diagnosed|O as|O monoblastic|O crisis|O .|O
The|O patient|O received|O combined|O chemotherapy|O but|O response|O was|O partial|O .|O
These|O findings|O are|O compatible|O with|O our|O previous|O report|O that|O nm23|B-DNA gene|I-DNA is|O overexpressed|O in|O monocytic|O leukemia|O .|O
Increased|O transcription|O decreases|O the|O spontaneous|O mutation|O rate|O at|O the|O thymidine|B-DNA kinase|I-DNA locus|I-DNA in|O human|B-cell_type cells|I-cell_type .|O
Transcription|O increases|O DNA|O repair|O efficiency|O and|O modulates|O the|O distribution|O of|O certain|O types|O of|O DNA|O damage|O .|O
Furthermore|O ,|O increased|O transcription|O level|O stimulates|O spontaneous|O mutation|O rate|O in|O yeast|O .|O
We|O explored|O whether|O transcription|O level|O affects|O spontaneous|O mutation|O rate|O in|O human|B-cell_type cells|I-cell_type .|O
We|O first|O developed|O two|O thymidine|B-cell_line kinase|I-cell_line (|I-cell_line tk|I-cell_line )|I-cell_line inducible|I-cell_line human|I-cell_line cell|I-cell_line lines|I-cell_line using|O the|O Gal4-Estrogen|O receptor|O system|O .|O
In|O our|O TK6i-G3|B-cell_line and|I-cell_line G9|I-cell_line tk|I-cell_line heterozygous|I-cell_line cell|I-cell_line lines|I-cell_line ,|O the|O active|O tk|B-DNA allele|I-DNA is|O linked|O to|O an|O inducible|O promoter|B-DNA element|I-DNA .|O
Tk|B-RNA mRNA|I-RNA is|O induced|O following|O treatment|O with|O estrogen|O .|O
Spontaneous|O mutation|O rate|O was|O significantly|O decreased|O in|O human|B-cell_line cell|I-cell_line lines|I-cell_line after|O induction|O in|O contrast|O to|O the|O report|O in|O yeast|O .|O
Thus|O ,|O humans|O may|O have|O evolved|O different|O or|O additional|O mechanisms|O to|O deal|O with|O transcription|O related|O spontaneous|O mutagenesis|O .|O
Copyright|O 1998|O Elsevier|O Science|O B.V|O .|O
All|O rights|O reserved|O .|O
Mutation|O of|O BCL-6|B-DNA gene|I-DNA in|O normal|O B|B-cell_type cells|I-cell_type by|O the|O process|O of|O somatic|O hypermutation|O of|O Ig|B-DNA genes|I-DNA .|O
Immunoglobulin|B-DNA (|I-DNA Ig|I-DNA )|I-DNA genes|I-DNA are|O hypermutated|O in|O B|B-cell_type lymphocytes|I-cell_type that|O are|O the|O precursors|O to|O memory|B-cell_type B|I-cell_type cells|I-cell_type .|O
The|O mutations|O are|O linked|O to|O transcription|O initiation|O ,|O but|O non-Ig|B-DNA promoters|I-DNA are|O permissible|O for|O the|O mutation|O process|O ;|O thus|O ,|O other|O genes|O expressed|O in|O mutating|O B|B-cell_type cells|I-cell_type may|O also|O be|O subject|O to|O somatic|O hypermutation|O .|O
Significant|O mutations|O were|O not|O observed|O in|O c-MYC|B-DNA ,|I-DNA S14|I-DNA ,|I-DNA or|I-DNA alpha-fetoprotein|I-DNA (|I-DNA AFP|I-DNA )|I-DNA genes|I-DNA ,|O but|O BCL-6|B-protein was|O highly|O mutated|O in|O a|O large|O proportion|O of|O memory|B-cell_type B|I-cell_type cells|I-cell_type of|O normal|O individuals|O .|O
The|O mutation|O pattern|O was|O similar|O to|O that|O of|O Ig|B-DNA genes|I-DNA .|O
CD28-mediated|O activation|O in|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type T|I-cell_type cells|I-cell_type :|O enhanced|O levels|O of|O reactive|O oxygen|O intermediates|O and|O c-Rel|O nuclear|O translocation|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
We|O have|O analyzed|O the|O effect|O of|O complete|O T|O cell|O activation|O (|O anti-CD3|O plus|O anti-CD28|O )|O on|O the|O activation|O of|O NF-kappaB|B-protein in|O CD45RA+|B-cell_type (|I-cell_type naive|I-cell_type )|I-cell_type and|I-cell_type CD45RO+|I-cell_type (|I-cell_type memory/effector|I-cell_type )|I-cell_type T|I-cell_type cells|I-cell_type .|O
Long|O exposure|O (|O 24|O h|O )|O induced|O stronger|O NF-kappaB|B-protein DNA|O binding|O in|O CD45RA+|B-cell_type cells|I-cell_type than|O in|O CD45RO+|B-cell_type cells|I-cell_type .|O
Analysis|O of|O the|O nuclear|B-protein c-Rel|I-protein protein|I-protein indicated|O that|O after|O anti-CD3+anti-CD28|O stimulation|O the|O level|O of|O c-Rel|B-protein was|O higher|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
Analysis|O of|O the|O cytoplasmic|B-protein inhibitor|I-protein IkappaBalpha|B-protein indicated|O that|O anti-CD3+anti-CD28|O stimulation|O induced|O a|O long-lasting|O degradation|O in|O CD45RA+|B-cell_type cells|I-cell_type but|O in|O CD45RO+|B-cell_type cells|I-cell_type the|O degradation|O process|O was|O more|O rapid|O .|O
Because|O the|O CD28|B-protein costimulus|O is|O known|O to|O induce|O the|O production|O of|O reactive|O oxygen|O intermediates|O (|O ROIs|O )|O ,|O the|O intracellular|O ROI|O levels|O in|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type cells|I-cell_type were|O compared|O by|O flow|O cytometry|O .|O
ROIs|O were|O produced|O in|O both|O cell|O types|O ,|O but|O more|O strongly|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
The|O data|O presented|O in|O this|O study|O further|O emphasize|O the|O differences|O between|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type T|I-cell_type lymphocytes|I-cell_type in|O ROI-dependent|O signaling|O pathways|O .|O
Non-Hodgkin|O 's|O lymphoma|O involving|O bilateral|O breasts|O [|O see|O comments|O ]|O
We|O describe|O here|O two|O cases|O of|O diffuse|O large|O cell|O type|O non-Hodgkin|O 's|O lymphoma|O affecting|O the|O bilateral|O breasts|O .|O
The|O contralateral|O tumor|O in|O one|O case|O appeared|O 17|O months|O after|O the|O first|O mastectomy|O ,|O whereas|O the|O bilateral|O tumors|O occurred|O concurrently|O in|O the|O other|O patient|O who|O was|O pregnant|O and|O showed|O widespread|O dissemination|O at|O initial|O presentation|O .|O
Lymphoma|B-cell_type cells|I-cell_type from|O both|O cases|O showed|O the|O mature|O B-cell|O immunophenotype|O and|O had|O rearrangements|O of|O the|O BCL6|B-DNA gene|I-DNA .|O
Both|O patients|O developed|O progressive|O disease|O despite|O chemo-radiotherapy|O and|O died|O of|O leukemic|O manifestations|O .|O
There|O were|O no|O apparent|O pathological|O features|O of|O lymphomas|O of|O mucosa-associated|O lymphoid|O tissue|O origin|O
Biochemical|O characterization|O of|O MIP-1|B-protein alpha|I-protein nuclear|I-protein protein|I-protein .|O
A|O family|O of|O hematopoietic|B-protein specific|I-protein transcription|I-protein factors|I-protein ,|O MIP-1|B-protein alpha|I-protein nuclear|I-protein protein|I-protein (|I-protein MNP|I-protein )|I-protein family|I-protein ,|O has|O recently|O been|O identified|O .|O
They|O are|O intimately|O involved|O in|O regulating|O the|O transcription|O of|O the|O huMIP-1|B-DNA alpha|I-DNA gene|I-DNA in|O monocytes|B-cell_type ,|O T-cells|B-cell_type ,|O and|O transformed|B-cell_type B-cells|I-cell_type .|O
One|O member|O of|O the|O family|O (|O MNP-1|B-protein )|O is|O essential|O for|O promoter|O activity|O in|O monocytes|B-cell_type and|O B-cells|B-cell_type ,|O while|O another|O (|O MNP-2|B-protein )|O is|O required|O for|O full|O promotor|O activity|O in|O T-cells|B-cell_type .|O
A|O third|O member|O of|O the|O family|O (|O MNP-3|B-protein )|O is|O expressed|O in|O PMA|B-cell_line induced|I-cell_line HL60|I-cell_line cells|I-cell_line and|O probably|O has|O a|O role|O in|O monocyte|O differentiation|O .|O
In|O this|O communication|O we|O demonstrate|O by|O two|O techniques|O that|O MNP-1|B-protein and|O MNP-2|B-protein are|O distinct|O but|O related|O factors|O ,|O and|O we|O present|O further|O evidence|O to|O show|O that|O MNP-1|B-protein acts|O as|O a|O heterodimer|B-protein .|O
Bcl-3|B-protein expression|O and|O nuclear|O translocation|O are|O induced|O by|O granulocyte-macrophage|B-protein colony-stimulating|I-protein factor|I-protein and|O erythropoietin|B-protein in|O proliferating|B-cell_type human|I-cell_type erythroid|I-cell_type precursors|I-cell_type .|O
Bcl-3|B-protein is|O a|O proto-oncogene|B-DNA involved|O in|O the|O chromosomal|O translocation|O t|B-DNA (|I-DNA 14|I-DNA ;|I-DNA 19|I-DNA )|I-DNA found|O in|O some|O patients|O with|O chronic|O lymphocytic|O leukemia|O .|O
It|O shares|O structural|O similarities|O with|O and|O is|O a|O member|O of|O the|O IkappaB|B-protein family|I-protein of|O proteins|O .|O
In|O this|O report|O ,|O involvement|O of|O Bcl-3|B-protein in|O hematopoietic|O growth|O factor-stimulated|O erythroid|O proliferation|O and|O differentiation|O was|O examined|O .|O
In|O TF-1|B-cell_line cells|I-cell_line ,|O an|O erythroleukemia|B-cell_line cell|I-cell_line line|I-cell_line ,|O granulocyte-macrophage|B-protein colony-stimulating|I-protein factor|I-protein (|O GM-CSF|B-protein )|O and|O erythropoietin|B-protein (|O Epo|B-protein )|O greatly|O enhanced|O Bcl-3|B-protein expression|O at|O both|O the|O protein|O and|O mRNA|O levels|O in|O association|O with|O stimulation|O of|O proliferation|O .|O
Bcl-3|B-protein protein|O was|O also|O highly|O expressed|O in|O early|B-cell_type burst-forming|I-cell_type unit-erythroid|I-cell_type (|I-cell_type BFU-E|I-cell_type )|I-cell_type -derived|I-cell_type erythroid|I-cell_type precursors|I-cell_type (|O day|O 7|O )|O and|O decreased|O during|O maturation|O (|O days|O 10|O and|O 14|O )|O ,|O suggesting|O that|O Bcl-3|B-protein is|O involved|O in|O normal|O erythroid|O proliferation|O .|O
In|O these|O hematopoietic|B-cell_type cells|I-cell_type ,|O Bcl-3|B-protein was|O hyperphosphorylated|O .|O
GM-CSF|B-protein and|O Epo|B-protein modulated|O the|O subcellular|O localization|O of|O Bcl-3|B-protein .|O
Upon|O stimulation|O of|O TF-1|B-cell_line cells|I-cell_line with|O GM-CSF|B-protein or|O Epo|B-protein ,|O the|O nuclear|O translocation|O of|O Bcl-3|B-protein was|O dramatically|O enhanced|O .|O
Overexpression|O of|O Bcl-3|B-protein in|O TF-1|B-cell_line cells|I-cell_line by|O transient|O transfection|O along|O with|O the|O NF-kappaB|B-protein factors|I-protein p50|I-protein or|I-protein p52|I-protein resulted|O in|O significant|O induction|O of|O an|O human|B-DNA immunodeficiency|I-DNA virus-type|I-DNA 1|I-DNA (|I-DNA HIV-1|I-DNA )|I-DNA kappaB-TATA-luceriferase|I-DNA reporter|I-DNA plasmid|I-DNA ,|O demonstrating|O that|O Bcl-3|B-protein has|O a|O positive|O role|O in|O transactivation|O of|O kappaB-containing|B-DNA genes|I-DNA in|O erythroid|B-cell_type cells|I-cell_type .|O
Stimulation|O with|O GM-CSF|B-protein enhanced|O c-myb|B-RNA mRNA|I-RNA expression|O in|O these|O cells|O .|O
Bcl-3|B-protein in|O nuclear|O extracts|O of|O TF-1|B-cell_line cells|I-cell_line bound|O to|O a|O kappaB|B-DNA enhancer|I-DNA in|O the|O c-myb|B-DNA promoter|I-DNA together|O with|O NF-kappaB2/p52|B-protein and|O this|O binding|O activity|O was|O enhanced|O by|O GM-CSF|B-protein stimulation|O .|O
Furthermore|O ,|O cotransfection|O of|O Bcl-3|B-protein with|O p52|B-protein or|O p50|B-protein in|O TF-1|B-cell_line cells|I-cell_line resulted|O in|O significant|O activation|O of|O a|O c-myb|B-DNA kappaB-TATA-luceriferase|I-DNA reporter|I-DNA plasmid|I-DNA .|O
These|O findings|O suggest|O that|O Bcl-3|B-protein may|O participate|O in|O the|O transcriptional|O regulation|O of|O certain|O kappaB-containing|B-DNA genes|I-DNA involved|O in|O hematopoiesis|O ,|O including|O c-myb|B-DNA .|O
Copyright|O 1998|O by|O The|O American|O Society|O of|O Hematology|O .|O
5-Lipoxygenase|B-protein compartmentalization|O in|O granulocytic|O cells|O is|O modulated|O by|O an|O internal|B-protein bipartite|I-protein nuclear|I-protein localizing|I-protein sequence|I-protein and|O nuclear|B-protein factor|I-protein kappa|I-protein B|I-protein complex|I-protein formation|O .|O
A|O region|O of|O basic|O amino|O acids|O spanning|O residues|B-protein 639-656|I-protein in|O the|O human|B-protein 5-lipoxygenase|I-protein sequence|I-protein resembles|O a|O consensus|B-protein bipartite|I-protein nuclear|I-protein localizing|I-protein sequence|I-protein .|O
A|O synthetic|O peptide|O consisting|O of|O the|O Kaposi|B-protein fibroblast|I-protein growth|I-protein factor|I-protein signal|I-protein sequence|I-protein fused|O to|O the|O 5-lipoxygenase639-656|B-protein bipartite|I-protein nuclear|I-protein localizing|I-protein sequence|I-protein has|O a|O prominent|O inhibitory|O effect|O on|O 5-lipoxygenase|B-protein catalysis|O in|O granulocytic|O HL-60|B-cell_line cells|I-cell_line activated|O by|O calcium|O ionophor|O A23187|O .|O
Recombinant|O 5-lipoxygenase|B-protein was|O not|O affected|O by|O the|O peptide|O .|O
The|O peptide|O also|O inhibited|O redistribution|O of|O 5-lipoxygenase|B-protein from|O the|O cytosol|O to|O the|O nuclear|O membrane|O of|O HL-60|B-cell_line cells|I-cell_line stimulated|O by|O A23187|O .|O
5-Lipoxygenase|B-protein protein|I-protein was|O detected|O in|O nuclear|B-protein factor|I-protein kappaB|I-protein (|I-protein NF-kappaB|I-protein )|I-protein p65|I-protein subunit|I-protein immunoprecipitate|O fractions|O prepared|O from|O HL-60|B-cell_line cell|I-cell_line lysates|O .|O
The|O amount|O of|O 5-lipoxygenase|B-protein protein|I-protein coimmunoprecipitated|O by|O NF-kappaB|O antiserum|O was|O increased|O following|O A23187|O stimulation|O .|O
In|O cells|O treated|O with|O agents|O that|O block|O 5-lipoxygenase|B-protein translocation|O to|O the|O nucleus|O ,|O 5-lipoxygenase|B-protein protein|O appearing|O in|O the|O NF-kappaB|B-protein immunoprecipitate|O was|O diminished|O .|O
Our|O results|O implicate|O an|O internal|B-protein bipartite|I-protein nuclear|I-protein localizing|I-protein sequence|I-protein as|O a|O regulatory|O domain|O that|O modulates|O 5-lipoxygenase|B-protein redistribution|O and|O catalysis|O in|O granulocytic|B-cell_type cells|I-cell_type .|O
Additionally|O ,|O our|O results|O suggest|O that|O molecular|O determinants|O which|O govern|O 5-lipoxygenase|O and|O NF-kappaB|O redistribution|O to|O the|O nucleus|O may|O be|O coordinately|O controlled|O in|O granulocytic|B-cell_type cells|I-cell_type .|O
Copyright|O 1998|O Academic|O Press|O .|O
Inhibition|O of|O CD28/CD3-mediated|O costimulation|O of|O naive|B-cell_type and|I-cell_type memory|I-cell_type human|I-cell_type T|I-cell_type lymphocytes|I-cell_type by|O intracellular|O incorporation|O of|O polyclonal|B-protein antibodies|I-protein specific|O for|O the|O activator|B-protein protein-1|I-protein transcriptional|I-protein complex|I-protein .|O
A|O number|O of|O indirect|O methods|O have|O been|O utilized|O in|O demonstrating|O activator|B-protein protein-1|I-protein transcription|O factor|O function|O in|O IL-2|O promoter|O activity|O .|O
However|O ,|O there|O has|O been|O no|O direct|O demonstration|O that|O activator|B-protein protein-1|I-protein is|O involved|O in|O CD28-dependent|O costimulation|O of|O IL-2|B-DNA gene|I-DNA transcription|O in|O freshly|O isolated|O naive|B-cell_type and|I-cell_type memory|I-cell_type human|I-cell_type T|I-cell_type lymphocytes|I-cell_type .|O
To|O address|O this|O issue|O ,|O the|O method|O of|O scrape|O loading|O was|O applied|O to|O purified|B-cell_type peripheral|I-cell_type blood|I-cell_type T|I-cell_type lymphocytes|I-cell_type .|O
Since|O scrape|O loading|O relies|O on|O adherent|B-cell_type cells|I-cell_type ,|O peripheral|B-cell_type blood|I-cell_type human|I-cell_type T|I-cell_type (|I-cell_type PB-T|I-cell_type )|I-cell_type cells|I-cell_type were|O immobilized|O on|O the|O nonspecific|O cell|O attachment|O factor|O poly-L-lysine|O .|O
Cells|O scraped|O off|O poly-L-lysine|O in|O the|O presence|O of|O Ig|B-protein FITC|I-protein efficiently|O incorporated|O Ig|O ,|O with|O relatively|O uniform|O fluorescence|O .|O
T|O cells|O retained|O their|O physical|O parameters|O as|O measured|O by|O forward|O and|O side|O light|O scatter|O ,|O and|O functional|O activity|O as|O measured|O by|O costimulation|O of|O proliferation|O and|O IL-2|B-protein production|O after|O being|O scraped|O off|O this|O substrate|O .|O
CD28/CD3-costimulated|B-cell_type T|I-cell_type cells|I-cell_type produced|O intracellular|O IL-2|B-protein from|O all|O subsets|O measured|O (|O CD4+|B-cell_type ,|O CD4-|B-cell_type ,|O CD45RO+|B-cell_type ,|O and|O CD45RO-|B-cell_type )|O .|O
IL-2|B-protein production|O and|O intracellular|O accumulation|O in|O nonscraped|O PB-T|B-cell_type cells|I-cell_type activated|O with|O CD28/CD3|O coligation|O were|O skewed|O favoring|O CD45RO+|B-cell_type and|I-cell_type CD4+|I-cell_type subsets|I-cell_type ,|O as|O was|O IL-2|B-protein production|O in|O scraped|O PB-T|B-cell_type cells|I-cell_type .|O
The|O intracellular|O incorporation|O of|O Abs|O specific|O for|O c-Fos|B-protein and|I-protein c-Jun|I-protein family|I-protein members|I-protein by|O scrape|O loading|O inhibited|O the|O production|O and|O intracellular|O accumulation|O of|O IL-2|B-protein within|O 6|O h|O of|O costimulation|O with|O PMA/ionomycin|O ,|O or|O costimulation|O by|O CD28|O and|O CD3|O ligation|O .|O
Scrape|O loading|O thus|O provides|O an|O efficient|O mechanism|O for|O intracellular|O incorporation|O of|O macromolecules|O ,|O and|O the|O first|O direct|O evidence|O that|O c-Fos|B-protein and|O c-Jun|B-protein are|O involved|O in|O transcription|O of|O the|O IL-2|B-DNA gene|I-DNA within|O its|O correct|O chromosomal|O context|O ,|O in|O resting|O human|O T|O lymphocyte|O subpopulations|O .|O
Differential|O expression|O of|O Nur77|B-protein family|I-protein members|I-protein in|O human|B-cell_type T-lymphotropic|I-cell_type virus|I-cell_type type|I-cell_type 1-infected|I-cell_type cells|I-cell_type :|O transactivation|O of|O the|O TR3/nur77|B-DNA gene|I-DNA by|O Tax|B-protein protein|I-protein .|O
We|O analyzed|O the|O differential|O expression|O and|O regulation|O of|O three|O members|O of|O the|O Nur77|B-protein transcription|I-protein factor|I-protein family|I-protein by|O the|O human|O T-lymphotropic|O virus|O type|O 1|O (|O HTLV-1|O )|O Tax|B-protein protein|I-protein .|O
We|O have|O demonstrated|O that|O in|O both|O HTLV-1-infected|B-cell_type cells|I-cell_type and|O Tax-expressing|B-cell_line JPX-9|I-cell_line cells|I-cell_line ,|O TR3/nur77|B-protein is|O highly|O expressed|O ,|O whereas|O neither|O NOR-1|O nor|O NOT|O expression|O is|O detectable|O .|O
Transient|O transfection|O analysis|O further|O confirmed|O the|O Tax|B-protein transactivation|O of|O the|O TR3/nur77|B-protein promoter|O but|O not|O the|O NOR-1|B-DNA promoter|I-DNA in|O different|O cell|O types|O .|O
Furthermore|O ,|O expression|O of|O a|O luciferase|B-DNA reporter|I-DNA gene|I-DNA driven|O by|O the|O NGFI-B|B-DNA (|I-DNA rat|I-DNA homolog|I-DNA of|I-DNA TR3/Nur77|I-DNA )|I-DNA response|I-DNA element|I-DNA (|O NBRE|B-DNA )|O provided|O evidence|O that|O Tax|B-protein -mediated|O transactivation|O resulted|O in|O the|O induction|O of|O a|O functional|O protein|O .|O
Cotransfection|O assays|O with|O the|O TR3/nur77|B-DNA promoter|I-DNA sequence|I-DNA or|O the|O NBRE|B-DNA binding|O motif|O together|O with|O a|O series|O of|O Tax|B-protein mutants|O have|O shown|O that|O Tax|B-protein -induced|O TR3/nur77|B-protein expression|O is|O mediated|O by|O CREB/ATF-related|B-protein transcription|I-protein factors|I-protein .|O
Negative|O regulation|O of|O the|O heat|O shock|O transcriptional|O response|O by|O HSBP1|B-protein .|O
In|O response|O to|O stress|O ,|O heat|B-protein shock|I-protein factor|I-protein 1|I-protein (|O HSF1|B-protein )|O acquires|O rapid|O DNA|O binding|O and|O transient|O transcriptional|O activity|O while|O undergoing|O conformational|O transition|O from|O an|O inert|O non-DNA-binding|B-protein monomer|I-protein to|O active|O functional|O trimers|O .|O
Attenuation|O of|O the|O inducible|O transcriptional|O response|O occurs|O during|O heat|O shock|O or|O upon|O recovery|O at|O non-stress|O conditions|O and|O involves|O dissociation|O of|O the|O HSF1|B-protein trimer|I-protein and|O loss|O of|O activity|O .|O
We|O have|O used|O the|O hydrophobic|B-protein repeats|I-protein of|O the|O HSF1|B-protein trimerization|O domain|O in|O the|O yeast|O two-hybrid|O protein|O interaction|O assay|O to|O identify|O heat|B-protein shock|I-protein factor|I-protein binding|I-protein protein|I-protein 1|I-protein (|O HSBP1|B-protein )|O ,|O a|O novel|O ,|O conserved|O ,|O 76-amino-acid|B-protein protein|I-protein that|O contains|O two|O extended|O arrays|O of|O hydrophobic|B-protein repeats|I-protein that|O interact|O with|O the|O HSF1|B-protein heptad|I-protein repeats|I-protein .|O
HSBP1|B-protein is|O nuclear-localized|O and|O interacts|O in|O vivo|O with|O the|O active|O trimeric|O state|O of|O HSF1|B-protein that|O appears|O during|O heat|O shock|O .|O
During|O attenuation|O of|O HSF1|B-protein to|O the|O inert|O monomer|O ,|O HSBP1|B-protein associates|O with|O Hsp70|O .|O
HSBP1|B-protein negatively|O affects|O HSF1|B-protein DNA-binding|O activity|O ,|O and|O overexpression|O of|O HSBP1|B-protein in|O mammalian|B-cell_type cells|I-cell_type represses|O the|O transactivation|O activity|O of|O HSF1|B-protein .|O
To|O establish|O a|O biological|O role|O for|O HSBP1|B-protein ,|O the|O homologous|O Caenorhabditis|B-protein elegans|I-protein protein|I-protein was|O overexpressed|O in|O body|B-cell_type wall|I-cell_type muscle|I-cell_type cells|I-cell_type and|O was|O shown|O to|O block|O activation|O of|O the|O heat|O shock|O response|O from|O a|O heat|B-DNA shock|I-DNA promoter-reporter|I-DNA construct|I-DNA .|O
Alteration|O in|O the|O level|O of|O HSBP1|B-protein expression|O in|O C.|O elegans|O has|O severe|O effects|O on|O survival|O of|O the|O animals|O after|O thermal|O and|O chemical|O stress|O ,|O consistent|O with|O a|O role|O for|O HSBP1|B-protein as|O a|O negative|O regulator|O of|O the|O heat|O shock|O response|O .|O
Long-range|O transcriptional|O regulation|O of|O cytokine|O gene|O expression|O .|O
Most|O studies|O on|O the|O control|O of|O cytokine|O gene|O expression|O have|O involved|O the|O functional|O analysis|O of|O proximal|B-DNA promoters|I-DNA .|O
Recent|O work|O has|O identified|O distal|B-DNA elements|I-DNA that|O mediate|O long-range|O cytokine|O gene|O regulation|O and|O has|O implicated|O chromatin|O reorganization|O in|O regulation|O of|O cytokine|B-DNA gene|I-DNA loci|I-DNA .|O
These|O studies|O have|O begun|O to|O elucidate|O the|O basis|O for|O cell-specificity|O and|O high-level|O expression|O of|O cytokine|B-DNA genes|I-DNA .|O
A|O signaling|O complex|O of|O Ca2+-calmodulin-dependent|B-protein protein|I-protein kinase|I-protein IV|I-protein and|O protein|B-protein phosphatase|I-protein 2A|I-protein [|O see|O comments|O ]|O
Stimulation|O of|O T|B-cell_type lymphocytes|I-cell_type results|O in|O a|O rapid|O increase|O in|O intracellular|O calcium|O concentration|O (|O [|O Ca2+|O ]|O i|O )|O that|O parallels|O the|O activation|O of|O Ca2+-calmodulin-dependent|B-protein protein|I-protein kinase|I-protein IV|I-protein (|O CaMKIV|B-protein )|O ,|O a|O nuclear|B-protein enzyme|I-protein that|O can|O phosphorylate|O and|O activate|O the|O cyclic|B-protein adenosine|I-protein monophosphate|I-protein (|I-protein cAMP|I-protein )|I-protein response|I-protein element-binding|I-protein protein|I-protein (|O CREB|B-protein )|O .|O
However|O ,|O inactivation|O of|O CaMKIV|B-protein occurs|O despite|O the|O sustained|O increase|O in|O [|O Ca2+|O ]|O i|O that|O is|O required|O for|O T|O cell|O activation|O .|O
A|O stable|O and|O stoichiometric|O complex|O of|O CaMKIV|B-protein with|O protein|B-protein serine-threonine|I-protein phosphatase|I-protein 2A|I-protein (|O PP2A|B-protein )|O was|O identified|O in|O which|O PP2A|B-protein dephosphorylates|O CaMKIV|B-protein and|O functions|O as|O a|O negative|O regulator|O of|O CaMKIV|B-protein signaling|O .|O
In|O Jurkat|B-cell_line T|I-cell_line cells|I-cell_line ,|O inhibition|O of|O PP2A|B-protein activity|O by|O small|O t|O antigen|O enhanced|O activation|O of|O CREB|B-protein -mediated|O transcription|O by|O CaMKIV|B-protein .|O
These|O findings|O reveal|O an|O intracellular|O signaling|O mechanism|O whereby|O a|O protein|B-protein serine-threonine|I-protein kinase|I-protein (|O CaMKIV|B-protein )|O is|O regulated|O by|O a|O tightly|O associated|O protein|B-protein serine-threonine|I-protein phosphatase|I-protein (|O PP2A|B-protein )|O .|O
Hypoxia|O down-regulates|O MCP-1|B-protein expression|O :|O implications|O for|O macrophage|O distribution|O in|O tumors|O .|O
Monocyte|B-protein chemoattractant|I-protein protein|I-protein 1|I-protein (|O MCP-1|B-protein )|O is|O likely|O to|O contribute|O to|O the|O macrophage|B-cell_type infiltrate|I-cell_type in|O human|O ovarian|O carcinomas|O .|O
Although|O MCP-1|B-protein is|O predominantly|O expressed|O by|O the|O tumor|O parenchyma|O ,|O macrophages|O accumulate|O at|O highest|O density|O in|O necrotic|O regions|O ,|O which|O are|O associated|O with|O low|O oxygen|O tensions|O .|O
Tumor|B-protein necrosis|I-protein factor|I-protein alpha|I-protein (|O TNF-alpha|B-protein )|O can|O stimulate|O MCP-1|B-protein production|O and|O is|O also|O present|O within|O ovarian|O carcinomas|O .|O
We|O have|O investigated|O the|O effect|O of|O hypoxia|O both|O on|O MCP-1|B-protein expression|O in|O ovarian|B-cell_line cancer|I-cell_line cell|I-cell_line lines|I-cell_line and|O monocyte|O migration|O .|O
Hypoxia|O down-regulated|O TNF-alpha-induced|B-RNA MCP-1|I-RNA mRNA|I-RNA and|O protein|O production|O by|O ovarian|B-cell_type cancer|I-cell_type cells|I-cell_type .|O
The|O effect|O was|O mimicked|O by|O cobalt|O chloride|O and|O desferrioxamine|O ,|O consistent|O with|O a|O specific|O oxygen-sensing|O mechanism|O .|O
Unlike|O antioxidants|O ,|O hypoxia|O did|O not|O inhibit|O nuclear|O factor|O KB|O mobilization|O .|O
Monocyte|O migration|O in|O response|O to|O MCP-1|B-protein was|O also|O diminished|O under|O hypoxic|O conditions|O .|O
Down-regulation|O of|O MCP-1|B-protein expression|O and|O the|O inhibition|O of|O monocyte|O migration|O are|O independent|O effects|O of|O hypoxia|O that|O may|O contribute|O to|O the|O distribution|O of|O macrophages|B-cell_type within|O ovarian|O tumors|O .|O
Activation|O of|O nuclear|B-protein factor|I-protein kappa|I-protein B|I-protein inflammatory|O bowel|O disease|O [|O see|O comments|O ]|O
BACKGROUND|O :|O Expression|O of|O pro-inflammatory|B-protein cytokines|I-protein is|O increased|O in|O the|O intestinal|O lamina|O propria|O of|O patients|O with|O inflammatory|O bowel|O disease|O (|O IBD|O )|O .|O
Nuclear|B-protein factor|I-protein kappa|I-protein B|I-protein (|O NF|B-protein kappa|I-protein B|I-protein )|O controls|O transcription|O of|O inflammation|B-DNA genes|I-DNA .|O
On|O activation|O ,|O NF|B-protein kappa|I-protein B|I-protein is|O rapidly|O released|O from|O its|O cytoplasmic|B-protein inhibitor|I-protein (|O I|B-protein kappa|I-protein B|I-protein )|O ,|O transmigrates|O into|O the|O nucleus|O ,|O and|O binds|O to|O DNA|B-DNA response|I-DNA elements|I-DNA in|O gene|O promoter|O regions|O .|O
AIMS|O :|O To|O investigate|O whether|O increased|O activation|O of|O NF|B-protein kappa|I-protein B|I-protein is|O important|O in|O IBD|O and|O may|O be|O down-regulated|O by|O anti-inflammatory|O treatment|O .|O
METHODS|O :|O Activation|O of|O NF|B-protein kappa|I-protein B|I-protein was|O determined|O by|O western|O blot|O assessment|O and|O electrophoretic|O mobility|O shift|O assay|O in|O nuclear|O extracts|O of|O colonic|O biopsy|O samples|O as|O well|O as|O lamina|B-cell_type propria|I-cell_type mononuclear|I-cell_type cells|I-cell_type .|O
RESULTS|O :|O Nuclear|O levels|O of|O NF|B-protein kappa|I-protein B|I-protein p65|B-protein are|O increased|O in|O lamina|O propria|O biopsy|O specimens|O from|O patients|O with|O Crohn|O 's|O disease|O in|O comparison|O with|O patients|O with|O ulcerative|O colitis|O and|O controls|O .|O
Increased|O activation|O of|O NF|B-protein kappa|I-protein B|I-protein was|O detected|O in|O lamina|B-cell_type propria|I-cell_type mononuclear|I-cell_type cells|I-cell_type from|O patients|O with|O active|O IBD|O .|O
Corticosteroids|O strongly|O inhibit|O intestinal|O NF|B-protein kappa|I-protein B|I-protein activation|O in|O IBD|O in|O vivo|O and|O in|O vitro|O by|O stabilising|O the|O cytosolic|B-protein inhibitor|I-protein I|B-protein kappa|I-protein B|I-protein alpha|O against|O activation|O induced|O degradation|O .|O
CONCLUSIONS|O :|O In|O both|O IBDs|O ,|O but|O particularly|O Crohn|O 's|O disease|O ,|O increased|O activation|O of|O NF|B-protein kappa|I-protein B|I-protein may|O be|O involved|O in|O the|O regulation|O of|O the|O inflammatory|O response|O .|O
Inhibition|O of|O NF|B-protein kappa|I-protein B|I-protein activation|O may|O represent|O a|O mechanism|O by|O which|O steroids|O exert|O an|O anti-inflammatory|O effect|O in|O IBD|O
Insufficient|O glycemic|O control|O increases|O nuclear|B-protein factor-kappa|I-protein B|I-protein binding|O activity|O in|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type isolated|O from|O patients|O with|O type|O 1|O diabetes|O .|O
OBJECTIVE|O :|O The|O redox-sensitive|B-protein transcription|I-protein factor|I-protein nuclear|I-protein factor-kappa|I-protein B|I-protein (|O NF-kappa|B-protein B|I-protein )|O is|O believed|O to|O contribute|O to|O late|O diabetic|O complications|O .|O
It|O is|O unknown|O whether|O NF-kappa|B-protein B|I-protein is|O influenced|O by|O glycemic|O control|O .|O
RESEARCH|O DESIGN|O AND|O METHODS|O :|O To|O determine|O whether|O NF-kappa|B-protein B|I-protein is|O activated|O in|O patients|O with|O insufficient|O glycemic|O control|O (|O HbA1c|O >|O 10|O %|O )|O ,|O we|O developed|O a|O tissue|O culture-independent|O electrophoretic|O mobility|O shift|O assay|O (|O EMSA|O )|O -based|O semiquantitative|O detection|O system|O that|O allowed|O us|O to|O determine|O NF-kappa|B-protein B|I-protein activation|O in|O ex|O vivo-isolated|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type (|O PBMCs|B-cell_type )|O .|O
We|O included|O 43|O patients|O with|O type|O 1|O diabetes|O in|O this|O cross-sectional|O study|O .|O
10|O of|O those|O received|O the|O antioxidant|O thioctic|O acid|O (|O 600|O mg/day|O p.o.|O )|O for|O 2|O weeks|O .|O
RESULTS|O :|O Monocytes|O of|O patients|O with|O HbA1c|O levels|O >|O 10|O %|O demonstrated|O significantly|O higher|O NF-kappa|B-protein B|I-protein binding|O activity|O in|O an|O EMSA|O and|O a|O stronger|O NF-kappa|B-protein B|I-protein staining|O in|O immunohistochemistry|O than|O monocytes|B-cell_type of|O patients|O with|O HbA1c|O levels|O of|O 6-8|O %|O .|O
The|O increase|O in|O NF-kappa|B-protein B|I-protein activation|O correlated|O with|O an|O increase|O in|O plasmatic|O markers|O of|O lipid|O peroxidation|O .|O
Treatment|O with|O the|O antioxidant|O thioctic|O acid|O decreased|O NF-kappa|B-protein B|I-protein binding|O activity|O .|O
CONCLUSIONS|O :|O Hyperglycemia|O induces|O activation|O of|O the|O transcription|O factor|O NF-kappa|B-protein B|I-protein in|O ex|O vivo-isolated|O PBMCs|B-cell_type of|O patients|O with|O type|O 1|O diabetes|O .|O
NF-kappa|B-protein B|I-protein activation|O is|O at|O least|O partially|O dependent|O on|O oxidative|O stress|O ,|O since|O the|O antioxidant|O thioctic|O acid|O significantly|O lowered|O the|O extent|O of|O NF-kappa|B-protein B|I-protein binding|O activity|O .|O
Synergistic|O activation|O of|O MAP|B-protein kinase|I-protein (|O ERK1/2|B-protein )|O by|O erythropoietin|B-protein and|O stem|B-protein cell|I-protein factor|I-protein is|O essential|O for|O expanded|O erythropoiesis|O .|O
Stem|B-protein cell|I-protein factor|I-protein (|O SCF|B-protein )|O and|O erythropoietin|B-protein (|O EPO|B-protein )|O work|O synergistically|O to|O support|O erythropoiesis|O ,|O but|O the|O mechanism|O for|O this|O synergism|O is|O unknown|O .|O
By|O using|O purified|B-cell_line human|I-cell_line erythroid|I-cell_line colony-forming|I-cell_line cells|I-cell_line (|O ECFC|B-cell_line )|O ,|O we|O have|O found|O that|O SCF|B-protein and|O EPO|B-protein synergistically|O activate|O MAP|B-protein kinase|I-protein (|O MAPK|B-protein ,|O ERK1/2|B-protein )|O ,|O which|O correlates|O with|O the|O cell|O growth|O and|O thus|O may|O be|O responsible|O for|O the|O synergistic|O effects|O .|O
Treatment|O of|O the|O cells|O with|O PD98059|O and|O wortmannin|O ,|O inhibitors|O of|O MEK|B-protein and|O PI-3|B-protein kinase|I-protein ,|O respectively|O ,|O inhibited|O the|O synergistic|O activation|O of|O MAPK|B-protein and|O also|O the|O cell|O growth|O ,|O further|O supporting|O this|O conclusion|O .|O
Wortmannin|O only|O inhibits|O MAPK|B-protein activation|O induced|O by|O EPO|B-protein but|O not|O that|O by|O SCF|B-protein ,|O suggesting|O that|O SCF|B-protein and|O EPO|B-protein may|O activate|O MAPK|B-protein through|O different|O pathways|O ,|O which|O would|O facilitate|O synergy|O .|O
Furthermore|O ,|O EPO|B-protein ,|O but|O not|O SCF|B-protein ,|O led|O to|O activation|O of|O STAT5|B-protein ,|O whereas|O SCF|B-protein and|O wortmannin|O had|O no|O effect|O on|O the|O EPO|B-protein -induced|O STAT5|B-protein activation|O ,|O suggesting|O that|O STAT5|B-protein is|O not|O involved|O in|O the|O synergistic|O action|O of|O SCF|B-protein and|O EPO|B-protein .|O
Together|O ,|O the|O data|O suggest|O that|O synergistic|O activation|O of|O MAPK|B-protein by|O SCF|B-protein and|O EPO|B-protein is|O essential|O for|O expanded|O erythropoiesis|O .|O
Copyright|O 1998|O by|O The|O American|O Society|O of|O Hematology|O .|O
The|O molecular|O and|O phenotypic|O profile|O of|O primary|O central|O nervous|O system|O lymphoma|O identifies|O distinct|O categories|O of|O the|O disease|O and|O is|O consistent|O with|O histogenetic|O derivation|O from|O germinal|B-cell_type center-related|I-cell_type B|I-cell_type cells|I-cell_type .|O
Primary|O central|O nervous|O system|O lymphoma|O (|O PCNSL|O )|O is|O a|O major|O cause|O of|O morbidity|O and|O mortality|O among|O human|O immunodeficiency|O virus|O (|O HIV|O )|O -infected|O individuals|O .|O
The|O precise|O histogenetic|O derivation|O and|O the|O molecular|O pathogenesis|O of|O PCNSL|O is|O poorly|O understood|O .|O
In|O an|O attempt|O to|O clarify|O the|O histogenesis|O and|O pathogenesis|O of|O these|O lymphomas|O ,|O 49|O PCNSL|O (|O 26|O acquired|O immunodeficiency|O syndrome|O [|O AIDS|O ]|O -related|O and|O 23|O AIDS-unrelated|O )|O were|O analyzed|O for|O multiple|O biologic|O markers|O ,|O which|O are|O known|O to|O bear|O histogenetic|O and|O pathogenetic|O significance|O for|O mature|O B-cell|O neoplasms|O .|O
PCNSL|O associated|O frequently|O (|O 50.0|O %|O )|O with|O mutations|O of|O BCL-6|B-DNA 5|I-DNA '|I-DNA noncoding|I-DNA regions|I-DNA ,|O which|O are|O regarded|O as|O a|O marker|O of|O B-cell|O transition|O through|O the|O germinal|O center|O (|O GC|O )|O .|O
Expression|O of|O BCL-6|B-protein protein|I-protein ,|O which|O is|O restricted|O to|O GC|B-cell_type B|I-cell_type cells|I-cell_type throughout|O physiologic|O B-cell|O maturation|O ,|O was|O detected|O in|O 100|O %|O AIDS-unrelated|O PCNSL|O and|O in|O 56.2|O %|O AIDS-related|O cases|O .|O
Notably|O ,|O among|O AIDS-related|O PCNSL|O ,|O expression|O of|O BCL-6|B-protein was|O mutually|O exclusive|O with|O expression|O of|O Epstein-Barr|B-protein virus|I-protein (|I-protein EBV|I-protein )|I-protein -encoded|I-protein latent|I-protein membrane|I-protein protein|I-protein (|I-protein LMP|I-protein )|I-protein -1|I-protein and|O ,|O with|O few|O exceptions|O ,|O also|O of|O BCL-2|B-protein .|O
All|O but|O one|O PCNSL|O expressed|O hMSH2|O ,|O which|O among|O mature|B-cell_type B|I-cell_type cells|I-cell_type selectively|O stains|O GC|B-cell_type B|I-cell_type cells|I-cell_type .|O
These|O data|O suggest|O that|O PCNSL|O may|O be|O frequently|O related|O to|O GC|B-cell_type B|I-cell_type cells|I-cell_type and|O may|O be|O segregated|O into|O two|O major|O biologic|O categories|O based|O on|O the|O expression|O pattern|O of|O BCL-6|B-protein ,|O LMP-1|B-protein ,|O and|O BCL-2|B-protein .|O
BCL-6|B-protein (|O +|O )|O /|O LMP-1|B-protein (|O -|O )|O /|O BCL-2|B-protein (|O -|O )|O PCNSL|O occur|O both|O in|O the|O presence|O and|O in|O the|O absence|O of|O HIV|O infection|O and|O consistently|O display|O a|O large|O noncleaved|O cell|O morphology|O .|O
Conversely|O ,|O BCL-6|B-protein (|O -|O )|O /|O LMP-1|B-protein (|O +|O )|O /|O BCL-2|B-protein (|O +|O )|O PCNSL|O are|O restricted|O to|O HIV-infected|O hosts|O and|O are|O represented|O by|O lymphomas|O with|O immunoblastic|O features|O .|O
These|O data|O are|O relevant|O for|O the|O pathogenesis|O and|O histogenesis|O of|O PCNSL|O and|O may|O be|O helpful|O to|O segregate|O distinct|O biologic|O and|O prognostic|O categories|O of|O these|O lymphomas|O .|O
Copyright|O 1998|O by|O The|O American|O Society|O of|O Hematology|O .|O
Antioxidant|O regulation|O of|O phorbol|O ester-induced|O adhesion|O of|O human|B-cell_line Jurkat|I-cell_line T-cells|I-cell_line to|O endothelial|B-cell_type cells|I-cell_type .|O
Regulation|O of|O adhesion|O molecule|O expression|O and|O function|O by|O reactive|O oxygen|O species|O via|O specific|O redox|O sensitive|O mechanisms|O have|O been|O reported|O .|O
The|O effects|O of|O clinically|O safe|O antioxidants|O in|O the|O regulation|O of|O adhesion|O molecule|O expression|O in|O human|B-cell_type endothelial|I-cell_type cells|I-cell_type (|O ECV|O )|O ,|O and|O adherence|O of|O human|B-cell_line Jurkat|I-cell_line T|I-cell_line cells|I-cell_line to|O ECV|B-cell_type cells|I-cell_type were|O investigated|O .|O
The|O thiol|O antioxidant|O ,|O alpha-lipoate|O ,|O at|O clinically|O relevant|O doses|O down-regulated|O phorbol|O 12-myristate|O 13-acetate|O (|O PMA|O )|O -induced|O adhesion|O molecule|O expression|O and|O cell-cell|O adhesion|O .|O
Inhibition|O of|O PMA-induced|O ICAM-1|O and|O VCAM-1|O expression|O as|O well|O as|O PMA-induced|O adhesion|O of|O Jurkat|B-cell_line T-cells|I-cell_line to|O ECV|B-cell_type cells|I-cell_type by|O alpha-lipoate|O was|O dose|O dependent|O (|O 50-250|O microM|O )|O .|O
The|O effect|O was|O significant|O for|O ICAM-1|B-protein (|O p|O <|O .01|O )|O and|O VCAM-1|B-protein (|O p|O <|O .01|O )|O expression|O in|O cells|O pretreated|O with|O 100|O microM|O alpha-lipoate|O compared|O to|O PMA-activated|B-cell_type untreated|I-cell_type cells|I-cell_type .|O
Inhibition|O of|O PMA-induced|O adhesion|O molecule|O expression|O and|O cell-cell|O adhesion|O was|O more|O pronounced|O when|O a|O combination|O of|O antioxidants|O ,|O alpha-lipoate|O and|O alpha-tocopherol|O ,|O were|O used|O compared|O to|O the|O use|O of|O either|O of|O these|O antioxidant|O alone|O .|O
The|O regulation|O of|O adhesion|O molecule|O expression|O and|O function|O by|O low|O concentration|O of|O antioxidants|O investigated|O does|O not|O appear|O to|O be|O NF-kappaB|B-protein regulated|O or|O transcription|O dependent|O because|O no|O change|O in|O the|O mRNA|O response|O was|O observed|O .|O
Protein|B-protein kinase|I-protein C|I-protein (|O PKC|B-protein )|O has|O been|O suggested|O to|O regulate|O PMA-induced|O adhesion|O molecule|O expression|O by|O post-transcriptional|O stabilization|O of|O adhesion|B-RNA molecule|I-RNA mRNA|I-RNA .|O
Alpha-lipoate|O pretreatment|O did|O not|O influence|O the|O response|O of|O PKC|B-protein activity|O to|O PMA|O .|O
Oxidants|O are|O known|O to|O be|O involved|O in|O the|O regulation|O of|O cell|O adhesion|O processes|O .|O
Treatment|O of|O ECV|B-cell_type cells|I-cell_type with|O PMA|O induced|O generation|O of|O intracellular|O oxidants|O .|O
Alpha-lipoate|O (|O 100|O or|O 250|O microM|O )|O treatment|O decreased|O PMA-induced|O generation|O of|O intracellular|O oxidants|O .|O
The|O inhibitory|O effect|O of|O low|O concentration|O of|O alpha-lipaote|O alone|O or|O in|O combination|O with|O alpha-tocopherol|O on|O agonist-induced|O adhesion|O processes|O observed|O in|O this|O study|O may|O be|O of|O potential|O therapeutic|O value|O .|O
Binding|O of|O human|O immunodeficiency|O virus|O type|O 1|O to|O CD4|B-protein and|I-protein CXCR4|I-protein receptors|I-protein differentially|O regulates|O expression|O of|O inflammatory|B-DNA genes|I-DNA and|O activates|O the|O MEK|B-protein /ERK|O signaling|O pathway|O .|O
We|O have|O previously|O shown|O that|O binding|O of|O human|O immunodeficiency|O virus|O type|O 1|O (|O HIV-1|O )|O virions|O to|O CD4|B-protein receptors|I-protein stimulates|O association|O of|O Lck|B-protein with|O Raf-1|B-protein and|O results|O in|O the|O activation|O of|O Raf-1|B-protein kinase|O in|O a|O Ras-independent|O manner|O .|O
In|O the|O present|O study|O ,|O we|O demonstrate|O that|O HIV-1|B-protein envelope|I-protein glycoproteins|I-protein of|O both|O T-cell-tropic|O and|O macrophagetropic|O strains|O rapidly|O activate|O the|O ERK/mitogen-activated|O protein|O (|O MAP|O )|O kinase|O pathway|O and|O the|O binding|O of|O nuclear|B-protein transcription|I-protein factors|I-protein (|O AP-1|B-protein ,|O NF-kappaB|B-protein ,|O and|O C/EBP|B-protein )|O and|O stimulate|O expression|O of|O cytokine|B-DNA and|I-DNA chemokine|I-DNA genes|I-DNA .|O
The|O activation|O of|O this|O signaling|O pathway|O requires|O functional|O CD4|B-protein receptors|I-protein and|O is|O independent|O of|O binding|O to|O CXCR4|B-protein .|O
Binding|O of|O the|O natural|O ligand|O stromal|B-protein cell-derived|I-protein factor|I-protein 1|I-protein (|O SDF-1|B-protein )|O to|O CXCR4|B-protein ,|O which|O inhibits|O entry|O of|O T-cell-tropic|O HIV-1|O ,|O activates|O also|O the|O ERK/|O MAP|B-protein kinase|I-protein pathway|O .|O
However|O ,|O SDF-1|B-protein did|O not|O affect|O the|O CD4-mediated|O expression|O of|O cytokine|B-DNA and|I-DNA chemokine|I-DNA genes|I-DNA .|O
These|O results|O provide|O firm|O molecular|O evidence|O that|O binding|O of|O HIV-1|B-protein envelope|I-protein glycoproteins|I-protein to|O CD4|B-protein receptor|I-protein initiates|O a|O signaling|O pathway|O (|O s|O )|O independent|O of|O the|O binding|O to|O the|O chemokine|B-protein receptor|I-protein that|O leads|O to|O the|O aberrant|O expression|O of|O inflammatory|B-DNA genes|I-DNA and|O may|O contribute|O significantly|O to|O HIV-1|O replication|O as|O well|O as|O to|O deregulation|O of|O the|O immune|O system|O .|O
Antigen|O receptor|O signaling|O induces|O MAP|O kinase-mediated|O phosphorylation|O and|O degradation|O of|O the|O BCL-6|B-protein transcription|B-protein factor|I-protein .|O
The|O bcl-6|B-DNA proto-oncogene|I-DNA encodes|O a|O POZ/zinc|B-protein finger|I-protein transcriptional|I-protein repressor|I-protein expressed|O in|O germinal|B-cell_type center|I-cell_type (|I-cell_type GC|I-cell_type )|I-cell_type B|I-cell_type and|I-cell_type T|I-cell_type cells|I-cell_type and|O required|O for|O GC|O formation|O and|O antibody|O affinity|O maturation|O .|O
Deregulation|O of|O bcl-6|B-DNA expression|O by|O chromosomal|O rearrangements|O and|O point|O mutations|O of|O the|O bcl-6|B-DNA promoter|I-DNA region|I-DNA are|O implicated|O in|O the|O pathogenesis|O of|O B-cell|O lymphoma|O .|O
The|O signals|O regulating|O bcl-6|B-DNA expression|O are|O not|O known|O .|O
Here|O we|O show|O that|O antigen|O receptor|O activation|O leads|O to|O BCL-6|B-protein phosphorylation|O by|O mitogen-activated|B-protein protein|I-protein kinase|I-protein (|O MAPK|B-protein )|O .|O
Phosphorylation|O ,|O in|O turn|O ,|O targets|O BCL-6|B-protein for|O rapid|O degradation|O by|O the|O ubiquitin|B-protein /|O proteasome|B-protein pathway|O .|O
These|O findings|O indicate|O that|O BCL-6|B-protein expression|O is|O directly|O controlled|O by|O the|O antigen|O receptor|O via|O MAPK|B-protein activation|O .|O
This|O signaling|O pathway|O may|O be|O crucial|O for|O the|O control|O of|O B-cell|O differentiation|O and|O antibody|O response|O and|O has|O implications|O for|O the|O regulation|O of|O other|O POZ/zinc|B-protein finger|I-protein transcription|I-protein factors|I-protein in|O other|O tissues|O .|O
Glucocorticoid|B-protein receptors|I-protein are|O differentially|O expressed|O in|O the|O cells|O and|O tissues|O of|O the|O immune|O system|O .|O
Cytosolic|B-protein glucocorticoid|I-protein receptor|I-protein (|O GR|B-protein )|O binding|O studies|O on|O immune|O tissues|O demonstrate|O that|O the|O thymus|O exhibits|O three|O to|O four|O times|O higher|O levels|O of|O GR|B-protein protein|I-protein than|O the|O spleen|O .|O
High|O levels|O of|O GR|B-protein are|O consistent|O with|O the|O exquisite|O sensitivity|O of|O the|O thymus|O to|O glucocorticoid|O exposure|O .|O
Nevertheless|O ,|O whole|O cell|O binding|O studies|O reveal|O similar|O levels|O of|O GR|B-protein in|O immature|B-cell_type thymic|I-cell_type T|I-cell_type lymphocytes|I-cell_type and|O more|O mature|O ,|O splenic|B-cell_type T|I-cell_type lymphocytes|I-cell_type .|O
Moreover|O ,|O whole|O cell|O binding|O techniques|O indicate|O that|O neutrophils|B-cell_type (|O which|O represent|O roughly|O 30|O %|O of|O splenic|B-cell_type leukocytes|I-cell_type )|O exhibit|O higher|O GR|B-protein than|O both|O T|B-cell_type and|I-cell_type B|I-cell_type lymphocytes|I-cell_type ,|O further|O contradicting|O results|O from|O cytosolic|O binding|O studies|O .|O
To|O address|O these|O inconsistencies|O ,|O GR|B-protein protein|I-protein was|O assessed|O in|O immune|B-cell_type cells|I-cell_type and|I-cell_type tissues|I-cell_type using|O cytosolic|O radioligand|O binding|O .|O
Western|O blot|O analysis|O ,|O and|O immunocytochemistry|O .|O
Consistent|O with|O previous|O cytosolic|O receptor|O binding|O studies|O on|O immune|O tissue|O homogenates|O ,|O thymic|O T|B-cell_type cells|I-cell_type were|O found|O to|O have|O higher|O levels|O of|O GR|B-protein than|O T|B-cell_type cells|I-cell_type isolated|O from|O the|O spleen|O .|O
In|O addition|O ,|O neutrophils|O were|O found|O to|O have|O fewer|O GR|B-protein than|O lymphocytes|B-cell_type and|O monocytes|B-cell_type .|O
These|O results|O indicate|O a|O meaningful|O relationship|O between|O receptor|O expression|O and|O known|O sensitivity|O to|O glucocorticoids|O .|O
Functional|O replacement|O of|O the|O mouse|B-DNA E2A|I-DNA gene|I-DNA with|O a|O human|B-DNA HEB|I-DNA cDNA|I-DNA .|O
The|O mammalian|B-DNA E2A|I-DNA ,|I-DNA HEB|I-DNA ,|I-DNA and|I-DNA E2-2|I-DNA genes|I-DNA encode|O a|O unique|O class|O of|O basic|B-protein helix-loop-helix|I-protein (|I-protein bHLH|I-protein )|I-protein transcription|I-protein factors|I-protein that|O are|O evolutionarily|O conserved|O and|O essential|O for|O embryonic|O and|O postnatal|O development|O .|O
While|O the|O structural|O and|O functional|O similarities|O among|O the|O gene|B-protein products|I-protein are|O well|O demonstrated|O ,|O it|O is|O not|O clear|O why|O deletion|O of|O E2A|B-DNA ,|O but|O not|O HEB|B-DNA or|O E2-2|B-DNA ,|O leads|O to|O a|O complete|O arrest|O in|O B-lymphocyte|O development|O .|O
To|O understand|O the|O molecular|O basis|O of|O the|O functional|O specificity|O between|O E2A|B-DNA and|O HEB|B-DNA /|O E2-2|B-DNA in|O mammalian|O development|O ,|O we|O generated|O and|O tested|O a|O panel|O of|O E2A|B-DNA knockin|O mutations|O including|O subtle|O mutations|O in|O the|O E12|B-DNA and|I-DNA E47|I-DNA exons|I-DNA and|O substitution|O of|O both|O E12|B-DNA and|I-DNA E47|I-DNA exons|I-DNA with|O a|O human|B-DNA HEB|I-DNA cDNA|I-DNA .|O
We|O find|O that|O the|O alternatively|O spliced|O E12|B-protein and|I-protein E47|I-protein bHLH|I-protein proteins|I-protein of|O the|O E2A|B-DNA gene|I-DNA play|O similar|O and|O additive|O roles|O in|O supporting|O B|B-cell_type lymphopoiesis|I-cell_type .|O
Further|O ,|O we|O find|O that|O HEB|B-DNA driven|O by|O the|O endogenous|B-DNA E2A|I-DNA promoter|I-DNA can|O functionally|O replace|O E2A|B-DNA in|O supporting|O B-cell|O commitment|O and|O differentiation|O toward|O completion|O .|O
Finally|O ,|O the|O postnatal|O lethality|O associated|O with|O E2A|B-DNA disruption|O is|O fully|O rescued|O by|O the|O addition|O of|O HEB|B-DNA .|O
This|O study|O suggests|O that|O the|O functional|O divergence|O among|O E12|B-DNA ,|O E47|B-DNA ,|O and|O HEB|B-DNA in|O different|O cell|O types|O is|O partially|O defined|O by|O the|O context|O of|O gene|O expression|O .|O
Biased|O dependency|O of|O CD80|B-protein versus|O CD86|B-protein in|O the|O induction|O of|O transcription|B-protein factors|I-protein regulating|O the|O human|B-DNA IL-2|I-DNA promoter|I-DNA .|O
In|O addition|O to|O the|O signals|O obtained|O by|O ligation|O of|O the|O TCR|O ,|O T|B-cell_type cells|I-cell_type need|O additional|O ,|O co-stimulatory|O signals|O to|O be|O activated|O .|O
One|O such|O co-stimulatory|O signal|O is|O delivered|O when|O CD28|B-protein on|O T|B-cell_type cells|I-cell_type binds|O to|O CD80|B-protein or|O CD86|B-protein on|O antigen-presenting|B-cell_type cells|I-cell_type (|O APC|B-cell_type )|O .|O
In|O the|O present|O study|O ,|O we|O analyzed|O the|O ability|O of|O CD80|B-protein and|O CD86|B-protein to|O co-stimulate|B-cell_type human|I-cell_type T|I-cell_type cells|I-cell_type activated|O by|O superantigen|O .|O
Using|O the|O Raji|B-cell_line B|I-cell_line cell|I-cell_line lymphoma|I-cell_line ,|O which|O express|O similar|O levels|O of|O CD80|B-protein and|O CD86|B-protein ,|O it|O was|O found|O that|O T|O cell|O proliferation|O was|O mainly|O co-stimulated|O by|O CD80|B-protein .|O
To|O further|O characterize|O the|O consequences|O of|O this|O biased|O co-stimulatory|O dependency|O ,|O we|O employed|O a|O well-defined|O system|O of|O transfected|O CHO|B-cell_line cells|I-cell_line expressing|O human|B-protein MHC|I-protein class|I-protein II|I-protein together|O with|O CD80|B-protein ,|O CD86|B-protein or|O CD80|B-protein and|O CD86|B-protein .|O
Proliferation|O of|O freshly|O prepared|O CD4+|B-cell_type T|I-cell_type cells|I-cell_type required|O the|O presence|O of|O either|O CD80|B-protein or|O CD86|B-protein .|O
However|O ,|O IL-2|B-protein production|O reached|O only|O suboptimal|O levels|O in|O the|O presence|O of|O CD86|B-protein but|O optimal|O levels|O with|O CD80|B-protein .|O
To|O analyze|O IL-2|B-protein transcriptional|O activity|O in|O CD80|B-protein and|O CD86|B-protein co-stimulated|O T|B-cell_type cells|I-cell_type we|O used|O Jurkat|B-cell_line T|I-cell_line cells|I-cell_line transfected|O with|O luciferase|B-DNA reporter|I-DNA gene|I-DNA constructs|I-DNA .|O
CD80|B-protein induced|O higher|O levels|O of|O IL-2|B-DNA promoter|I-DNA -enhancer|O activity|O compared|O to|O CD86|B-protein .|O
Furthermore|O ,|O the|O activity|O of|O transcription|B-protein factors|I-protein regulating|O the|O IL-2|B-DNA promoter-enhancer|I-DNA region|I-DNA including|O activation|B-protein protein-1|I-protein ,|O CD28|B-DNA response|I-DNA element|I-DNA and|O nuclear|B-protein factor|I-protein kappaB|I-protein were|O 4-8|O times|O higher|O after|O CD80|B-protein compared|O to|O CD86|B-protein ligation|O .|O
Our|O results|O suggest|O that|O the|O eventual|O appearance|O of|O CD80|B-protein on|O recently|O activated|O CD86+|B-cell_type APC|I-cell_type is|O important|O for|O the|O superinduction|O of|O IL-2|B-protein production|O and|O to|O support|O vigorous|O T|O cell|O proliferation|O .|O
Duplication|O of|O the|O DR3|B-DNA gene|I-DNA on|O human|B-DNA chromosome|I-DNA 1p36|I-DNA and|O its|O deletion|O in|O human|B-cell_type neuroblastoma|I-cell_type .|O
The|O human|B-DNA DR3|I-DNA gene|I-DNA ,|O whose|O product|O is|O also|O known|O as|O Wsl-1/APO-3/TRAMP/LARD|B-protein ,|O encodes|O a|O tumor|B-protein necrosis|I-protein factor-related|I-protein receptor|I-protein that|O is|O expressed|O primarily|O on|O the|O surface|O of|O thymocytes|B-cell_type and|O lymphocytes|B-cell_type .|O
DR3|B-protein is|O capable|O of|O inducing|O both|O NF-kappa|B-protein B|I-protein activation|O and|O apoptosis|O when|O overexpressed|O in|O mammalian|B-cell_type cells|I-cell_type ,|O although|O its|O ligand|O has|O not|O yet|O been|O identified|O .|O
We|O report|O here|O that|O the|O DR3|B-DNA gene|I-DNA locus|I-DNA is|O tandemly|O duplicated|O on|O human|B-DNA chromosome|I-DNA band|I-DNA 1p36.2-p36.3|I-DNA and|O that|O these|O genes|O are|O hemizygously|O deleted|O and/or|O translocated|O to|O another|O chromosome|O in|O neuroblastoma|B-cell_line (|I-cell_line NB|I-cell_line )|I-cell_line cell|I-cell_line lines|I-cell_line with|O amplified|O MYCN|O .|O
Duplication|O of|O at|O least|O a|O portion|O of|O the|O DR3|B-DNA gene|I-DNA ,|O including|O the|O extracellular|B-protein and|I-protein transmembrane|I-protein regions|I-protein but|O not|O the|O cytoplasmic|B-protein domain|I-protein ,|O was|O demonstrated|O by|O both|O fluorescence|O in|O situ|O hybridization|O and|O genomic|O Southern|O blotting|O .|O
In|O most|O NB|B-cell_line cell|I-cell_line lines|I-cell_line ,|O both|O the|O DR3|B-DNA and|I-DNA the|I-DNA DR3L|I-DNA sequences|I-DNA are|O simultaneously|O deleted|O and/or|O translocated|O to|O another|O chromosome|B-DNA .|O
Finally|O ,|O DR3/|B-protein Wsl-1|I-protein protein|I-protein expression|O is|O quite|O variable|O among|O these|O NB|B-cell_line cell|I-cell_line lines|I-cell_line ,|O with|O very|O low|O or|O undetectable|O levels|O in|O 7|O of|O 17|O NB|B-cell_line cell|I-cell_line lines|I-cell_line
Differential|O protection|O of|O normal|B-cell_type and|I-cell_type malignant|I-cell_type human|I-cell_type myeloid|I-cell_type progenitors|I-cell_type (|O CFU-GM|B-cell_type )|O from|O Ara-C|O toxicity|O using|O cycloheximide|O .|O
Cycloheximide|O ,|O a|O reversible|O protein|O synthesis|O inhibitor|O ,|O is|O thought|O to|O block|O DNA|O replication|O in|O normal|B-cell_type cells|I-cell_type by|O preventing|O synthesis|O of|O a|O labile|B-protein protein|I-protein .|O
In|O animal|O systems|O ,|O cycloheximide|O protects|O normal|B-cell_type cells|I-cell_type from|O cytotoxic|O S-phase|O specific|O agents|O ,|O such|O as|O cytosine|O arabinoside|O (|O Ara-C|O )|O .|O
Malignant|B-cell_type cells|I-cell_type appear|O not|O to|O be|O susceptible|O to|O cycloheximide-induced|O cycle|O arrest|O and|O ,|O subsequently|O ,|O may|O not|O be|O protected|O from|O Ara-C|O cytotoxicity|O .|O
The|O effect|O of|O cycloheximide|O on|O granulocyte/macrophage|B-cell_type progenitors|I-cell_type (|O CFU-GM|B-cell_type )|O after|O in|O vitro|O Ara-C|O exposure|O was|O examined|O using|O normal|O human|O bone|O marrow|O ,|O malignant|B-cell_type progenitors|I-cell_type from|O patients|O with|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O ,|O and|O clonogenic|B-cell_line cells|I-cell_line from|O the|O human|B-cell_line acute|I-cell_line nonlymphocytic|I-cell_line leukemia|I-cell_line cell|I-cell_line lines|I-cell_line HL-60|I-cell_line and|I-cell_line KG-1|I-cell_line .|O
Mononuclear|B-cell_line or|I-cell_line clonogenic|I-cell_line cells|I-cell_line were|O incubated|O for|O one|O hour|O with|O cycloheximide|O ,|O followed|O by|O the|O addition|O ,|O for|O three|O or|O 17|O hours|O ,|O of|O Ara-C|O before|O being|O plated|O in|O a|O methylcellulose|O culture|O system|O .|O
CFU-GM|O survival|O was|O significantly|O increase|O if|O normal|O cells|O were|O treated|O with|O cycloheximide|O before|O Ara-C|O exposure|O .|O
Similar|O cycloheximide|O pretreatment|O of|O CML|B-cell_type progenitors|I-cell_type and|O clonogenic|B-cell_line HL-60|I-cell_line and|I-cell_line KG-1|I-cell_line cells|I-cell_line failed|O to|O protect|O CFU-GM|B-cell_type from|O Ara-C-induced|O cytotoxicity|O .|O
Primary|O cortisol|O resistance|O accompanied|O by|O a|O reduction|O in|O glucocorticoid|B-protein receptors|I-protein in|O two|O members|O of|O the|O same|O family|O .|O
This|O report|O describes|O studies|O of|O a|O man|O suspected|O of|O having|O primary|O cortisol|O resistance|O .|O
This|O conclusion|O is|O based|O on|O his|O high|O plasma|O cortisol|O levels|O and|O high|O 24-h|O urinary|O 17-hydroxycorticosteroid|O and|O cortisol|O excretion|O ,|O plus|O the|O fact|O that|O he|O had|O no|O manifestations|O of|O Cushing|O 's|O syndrome|O .|O
Among|O family|O members|O tested|O ,|O his|O mother|O also|O had|O hypercortisolemia|O .|O
Both|O mother|O and|O son|O had|O high|O levels|O of|O unbound|O plasma|O cortisol|O ,|O but|O their|O plasma|O ACTH|O concentrations|O were|O within|O the|O normal|O range|O .|O
Both|O were|O partially|O resistant|O to|O dexamethasone|O adrenal|O suppression|O ,|O and|O both|O had|O mild|O hypertension|O without|O hypokalemia|O .|O
To|O study|O this|O apparent|O end-organ|O resistance|O to|O cortisol|O ,|O we|O examined|O the|O glucocorticoid|B-protein receptors|I-protein in|O peripheral|B-cell_type mononuclear|I-cell_type cells|I-cell_type .|O
Using|O whole|O cell|O assays|O ,|O glucocorticoid|B-protein receptors|I-protein in|O both|O patients|O were|O found|O to|O have|O reduced|O total|O binding|O capacity|O .|O
We|O conclude|O that|O these|O two|O patients|O ,|O members|O of|O the|O same|O family|O ,|O have|O primary|O cortisol|O resistance|O accompanied|O by|O a|O reduced|O number|O of|O glucocorticoid|B-protein receptors|I-protein .|O
[|O Glucocorticoid|B-protein receptors|I-protein and|O response|O to|O polychemotherapy|O in|O acute|O lymphatic|O leukemia|O ]|O
Glucocorticoid|B-protein receptor|I-protein (|O GR|B-protein )|O levels|O were|O quantified|O in|O leukemic|B-cell_type blasts|I-cell_type from|O peripheral|O blood|O of|O 86|O patients|O with|O acute|O lymphoblastic|O leukemia|O .|O
The|O subsequent|O achievement|O of|O complete|O remission|O after|O combination|O chemotherapy|O was|O correlated|O with|O high|O receptor|O levels|O .|O
Forty-seven|O of|O 50|O patients|O with|O leukemic|B-cell_type cells|I-cell_type containing|O more|O than|O 6|O ,|O 000|O receptor|O sites|O and|O 22|O of|O 36|O patients|O with|O cells|O containing|O less|O than|O 6|O ,|O 000|O receptor|O sites|O achieved|O remission|O .|O
The|O study|O of|O glucocorticoid|B-protein receptors|I-protein in|O leukemic|B-cell_type cells|I-cell_type may|O predict|O response|O to|O combination|O chemotherapy|O in|O patients|O with|O acute|O lymphoblastic|O leukemia|O .|O
Specific|O uptake|O of|O 1|O ,|O 25-dihydroxycholecalciferol|O by|O human|B-cell_type chronic|I-cell_type myeloid|I-cell_type leukemia|I-cell_type cells|I-cell_type .|O
We|O have|O examined|O mononuclear|B-cell_line cell|I-cell_line preparations|I-cell_line from|O patients|O with|O chronic|O myeloid|O leukemia|O [|O CML|O ]|O for|O binding|O of|O and|O response|O to|O 1|O ,|O 25-dihydroxycholecalciferol|O [|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O ]|O .|O
Whole|O cells|O specifically|O took|O up|O [|O 3H|O ]|O -1|O ,|O 25-|O (|O OH|O )|O 2D3|O with|O high|O affinity|O (|O Kd|O 3.6|O X|O 10|O (|O -11|O )|O M|O )|O and|O low|O capacity|O .|O
Subcellular|O fractionation|O of|O labeled|B-cell_line cells|I-cell_line showed|O that|O binding|O was|O restricted|O to|O cytosols|O and|O nuclei|O .|O
Sucrose|O gradient|O centrifugation|O of|O cells|O preincubated|O with|O [|O 3H|O ]|O -1|O ,|O 25-|O (|O OH|O )|O 2D3|O revealed|O a|O single|O 3.6S|O peak|O which|O was|O totally|O displaced|O with|O 100-fold|O excess|O nonradioactive|O hormone|O .|O
However|O ,|O we|O were|O unable|O to|O demonstrate|O specific|O binding|O of|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O by|O postlabeling|O standard|O cytosol|O preparations|O .|O
In|O addition|O ,|O cytosols|O prepared|O from|O a|O mixture|O of|O CML|B-cell_line cells|I-cell_line and|O 1|B-cell_line ,|I-cell_line 25-|I-cell_line (|I-cell_line OH|I-cell_line )|I-cell_line 2D3|I-cell_line receptor-positive|I-cell_line T47D|I-cell_line (|O human|O breast|O cancer|O )|O cells|O had|O less|O than|O 10|O %|O of|O the|O binding|O measured|O in|O T47D|B-cell_line cytosol|O alone|O .|O
However|O ,|O the|O levels|O of|O binding|O in|O T47D|B-cell_line cytosols|O were|O not|O reduced|O if|O the|O receptors|O were|O occupied|O with|O [|O 3H|O ]|O -1|O ,|O 25-|O (|O OH|O )|O 2D3|O prior|O to|O the|O addition|O of|O the|O CML|B-cell_line cytosols|O .|O
Thus|O ,|O CML|B-cell_line cells|I-cell_line appear|O to|O contain|O both|O the|O receptor|O for|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O and|O an|O unknown|O substance|O which|O prevents|O its|O detection|O following|O the|O preparation|O of|O cytosol|O .|O
Cells|O from|O patients|O with|O CML|O in|O the|O chronic|O phase|O specifically|O bound|O more|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O [|O 18.0|O +/-|O 3.2|O (|O S.E.|O )|O fmol/10|O (|O 7|O )|O cells|O ]|O than|O did|O those|O in|O acute|O myeloid|O transformation|O [|O 7.2|O +/-|O 1.5|O ]|O or|O than|O did|O cells|O from|O patients|O with|O acute|O myeloid|O leukemia|O [|O 2.6|O +/-|O 0.8|O ]|O .|O
Only|O cells|O from|O the|O first|O group|O of|O patients|O responded|O to|O the|O addition|O of|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O by|O differentiating|O along|O the|O monocyte-macrophage|O pathway|O .|O
We|O conclude|O that|O the|O differentiation-induction|O effect|O of|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O is|O likely|O to|O depend|O on|O adequate|O levels|O of|O receptor|O and|O that|O intact|B-cell_type cells|I-cell_type rather|O than|O cytosol|O preparations|O should|O be|O studied|O before|O cells|O of|O a|O particular|O tissue|O are|O designated|O as|O receptor|O negative|O .|O
Effect|O of|O cell|O cycle|O position|O on|O dexamethasone|O binding|O by|O mouse|B-cell_line and|I-cell_line human|I-cell_line lymphoid|I-cell_line cell|I-cell_line lines|I-cell_line :|O correlation|O between|O an|O increase|O in|O dexamethasone|O binding|O during|O S|O phase|O and|O dexamethasone|O sensitivity|O .|O
We|O determined|O the|O effect|O of|O cell|O cycle|O position|O on|O the|O amount|O of|O dexamethasone|O that|O was|O specifically|O bound|O by|O mouse|B-cell_line and|I-cell_line human|I-cell_line lymphoid|I-cell_line cell|I-cell_line lines|I-cell_line .|O
Cell|B-cell_line lines|I-cell_line that|O were|O either|O sensitive|O or|O resistant|O to|O growth|O inhibition|O by|O dexamethasone|O were|O compared|O .|O
Exponentially|B-cell_type growing|I-cell_type cells|I-cell_type were|O separated|O by|O centrifugal|O elutriation|O into|O fractions|O that|O corresponded|O to|O different|O positions|O in|O the|O cell|O cycle|O .|O
The|O cell|O cycle|O phase|O distribution|O of|O each|O fraction|O was|O estimated|O by|O flow|O cytometry|O and|O autoradiography|O .|O
The|O amount|O of|O dexamethasone|O bound|O per|O cell|O in|O each|O fraction|O was|O measured|O by|O a|O whole|O cell|O binding|O assay|O .|O
In|O three|O dexamethasone-sensitive|B-cell_line cell|I-cell_line lines|I-cell_line (|O two|O mouse|O and|O one|O human|O )|O ,|O we|O found|O that|O the|O amount|O of|O dexamethasone|O bound|O per|O cell|O increased|O 2-4-fold|O between|O G1|O phase|O and|O S|O phase|O ,|O and|O then|O decreased|O during|O G2/M|O phase|O .|O
Results|O were|O the|O same|O when|O the|O amount|O of|O dexamethasone|O bound|O per|O milligram|O of|O cell|B-protein protein|I-protein was|O measured|O .|O
Binding|O affinity|O was|O the|O same|O during|O G1|O phase|O and|O S|O phase|O ,|O but|O the|O proportion|O of|O bound|O dexamethasone|O that|O translocated|O to|O the|O nucleus|O was|O greater|O during|O S|O phase|O .|O
In|O contrast|O ,|O we|O found|O that|O the|O amount|O of|O dexamethasone|O bound|O per|O cell|O by|O three|O dexamethasone-resistant|B-cell_line cell|I-cell_line lines|I-cell_line (|O two|O mouse|O and|O one|O human|O )|O did|O not|O increase|O during|O S|O phase|O .|O
Our|O results|O indicate|O that|O cell|O cycle|O changes|O in|O dexamethasone|O binding|O are|O not|O simply|O related|O to|O changes|O in|O cell|B-protein protein|I-protein or|O cell|O volume|O during|O the|O cell|O cycle|O .|O
An|O increase|O in|O dexamethasone|O binding|O during|O S|O phase|O may|O be|O required|O for|O dexamethasone|O to|O inhibit|O cell|O growth|O ,|O and|O a|O failure|O of|O dexamethasone|O binding|O to|O increase|O during|O S|O phase|O might|O represent|O a|O new|O mechanism|O of|O dexamethasone|O resistance|O in|O lymphoid|B-cell_type cells|I-cell_type .|O
Presence|O and|O steroid|O inducibility|O of|O glutamine|B-protein synthetase|I-protein in|O human|B-cell_type leukemic|I-cell_type cells|I-cell_type .|O
Glutamine|B-protein synthetase|I-protein (|O EC|O 6.3.1.2|O ;|O GS|O )|O is|O present|O in|O lymphoblasts|B-cell_type from|O patients|O with|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O as|O well|O as|O in|O normal|B-cell_type peripheral|I-cell_type blood|I-cell_type lymphocytes|I-cell_type .|O
In|O 16|O out|O of|O 20|O ALL|O patients|O studied|O exposure|O of|O the|O cells|O to|O physiological|O concentrations|O of|O dexamethasone|O in|O vitro|O increased|O enzyme|B-protein activity|O above|O the|O control|O levels|O .|O
The|O increase|O was|O specific|O for|O glucocorticoid|B-protein receptor|I-protein ligands|O .|O
A|O direct|O correlation|O was|O found|O between|O the|O magnitude|O of|O glucocorticoid-mediated|O increase|O of|O GS|O activity|O and|O the|O cellular|O levels|O of|O specific|O glucocorticoid|B-protein receptors|I-protein assayed|O in|O the|O same|O cell|B-cell_type specimen|I-cell_type .|O
Moreover|O ,|O the|O basal|O levels|O of|O the|O enzyme|B-protein measured|O in|O cells|O prior|O to|O exposure|O to|O dexamethasone|O correlated|O negatively|O with|O receptor|O density|O .|O
It|O is|O suggested|O that|O the|O presence|O of|O steroid-inducible|B-protein GS|I-protein in|O ALL|B-cell_type cells|I-cell_type may|O prove|O to|O be|O a|O marker|O for|O functional|B-protein receptor|I-protein sites|I-protein .|O
Binding|O of|O progestins|O to|O the|O glucocorticoid|B-protein receptor|I-protein .|O
Correlation|O to|O their|O glucocorticoid-like|O effects|O on|O in|O vitro|O functions|O of|O human|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type .|O
A|O number|O of|O physiological|O and|O synthetic|O progestins|O were|O tested|O for|O their|O ability|O to|O compete|O with|O [|O 3H|O ]|O dexamethasone|O for|O the|O binding|O to|O the|O glucocorticoid|B-protein receptor|I-protein of|O human|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type and|O their|O ability|O to|O elicit|O glucocorticoid-like|O effects|O on|O the|O same|O cells|O .|O
As|O compared|O to|O the|O reference|O compound|O dexamethasone|O (|O relative|O receptor|O binding|O affinity|O defined|O as|O 100|O %|O )|O ,|O two|O potent|O synthetic|O progestins|O with|O a|O pregnane-type|O structure|O ,|O megestrol|O acetate|O and|O medroxyprogesterone|O acetate|O ,|O were|O found|O to|O display|O a|O considerable|O binding|O affinity|O towards|O the|O receptor|O (|O 46|O and|O 42|O %|O ,|O respectively|O )|O .|O
The|O relative|O binding|O affinity|O of|O the|O naturally|O occurring|O ligand|O ,|O cortisol|O ,|O to|O the|O receptor|O was|O clearly|O lower|O (|O 25|O %|O )|O .|O
The|O effective|O binding|O of|O medroxyprogesterone|O acetate|O to|O the|O glucocorticoid|B-protein receptor|I-protein was|O confirmed|O by|O direct|O binding|O studies|O utilizing|O a|O tritiated|O derivative|O of|O this|O steroid|O .|O
No|O evidence|O for|O the|O existence|O of|O a|O specific|O progesterone|B-protein receptor|I-protein in|O human|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type was|O obtained|O as|O judged|O by|O the|O results|O of|O competition|O experiments|O where|O a|O progesterone|O receptor-specific|O ligand|O [|O 3H|O ]|O Org|O 2058|O was|O used|O .|O
Medroxyprogesterone|O acetate|O and|O megestrol|O acetate|O also|O induced|O glucocorticoid-like|O effects|O on|O the|O lymphocyte|B-cell_type functions|O .|O
These|O included|O inhibition|O of|O the|O proliferative|O responses|O to|O the|O T-cell|B-protein mitogens|I-protein concanavalin|B-protein A|I-protein and|O phytohaemagglutinin|B-protein and|O an|O enhanced|O accumulation|O of|O immunoglobulin|B-cell_type secreting|I-cell_type cells|I-cell_type in|O pokeweed|B-cell_line mitogen-stimulated|I-cell_line cultures|I-cell_line .|O
The|O progestin|O effect|O appears|O to|O be|O mediated|O through|O a|O radiosensitive|O (|O suppressor|O )|O subpopulation|O of|O T|B-cell_type lymphocytes|I-cell_type .|O
In|O contrast|O ,|O the|O synthetic|O progestins|O related|O structurally|O to|O 19-nortestosterone|O ,|O norethisterone|O and|O d-norgestrel|O ,|O were|O virtually|O devoid|O of|O binding|O affinity|O towards|O the|O glucocorticoid|B-protein receptor|I-protein nor|O did|O they|O measurably|O influence|O the|O in|O vitro|O lymphocyte|B-cell_type functions|O .|O
These|O studies|O demonstrate|O that|O certain|O progestins|O in|O common|O clinical|O use|O probably|O possess|O inherent|O glucocorticoid|O activity|O and|O suggest|O that|O side|O effects|O attributable|O to|O this|O character|O (|O e.g.|O suppression|O of|O the|O pituitary-adrenal|O axis|O )|O might|O be|O expected|O when|O these|O compounds|O are|O used|O in|O pharmacological|O doses|O .|O
Metabolic|O and|O ultrastructural|O aspects|O of|O the|O in|O vitro|O lysis|O of|O chronic|B-cell_type lymphocytic|I-cell_type leukemia|I-cell_type cells|I-cell_type by|O glucocorticoids|O .|O
Human|B-cell_type chronic|I-cell_type lymphocytic|I-cell_type leukemia|I-cell_type (|I-cell_type CLL|I-cell_type )|I-cell_type cells|I-cell_type like|O prothymocytes|B-cell_type and|O immunoactivated|B-cell_type T-lymphocytes|I-cell_type are|O readily|O lysed|O in|O vitro|O by|O pharmacological|O concentrations|O of|O glucocorticoids|O such|O as|O cortisol|O ,|O whereas|O peripheral|B-cell_type blood|I-cell_type lymphocytes|I-cell_type and|O thymocytes|B-cell_type are|O unaffected|O by|O the|O hormone|B-protein .|O
In|O this|O study|O ,|O metabolic|O and|O ultrastructural|O aspects|O of|O the|O cortisol-induced|O killing|O process|O of|O CLL|B-cell_type cells|I-cell_type are|O recorded|O .|O
In|O vitro|O lysis|O was|O found|O to|O be|O temperature|O dependent|O and|O was|O detected|O only|O after|O 6|O to|O 8|O hr|O incubation|O with|O cortisol|O by|O means|O of|O the|O trypan|O blue|O exclusion|O test|O .|O
However|O ,|O 30|O min|O of|O incubation|O with|O cortisol|O at|O either|O 37|O degrees|O or|O 4|O degrees|O followed|O by|O the|O removal|O of|O the|O hormone|B-protein was|O still|O sufficient|O to|O induce|O the|O lytic|O process|O .|O
Ultrastructural|O studies|O demonstrated|O sequential|O changes|O in|O the|O cytoplasm|O ,|O including|O swelling|O of|O mitochondria|O and|O cytoplasmic|O decompartmentalization|O ,|O followed|O by|O loss|O of|O surface|O microvilli|O with|O the|O appearance|O of|O ``|O holes|O ''|O in|O the|O cell|O membrane|O ,|O and|O subsequent|O condensation|O of|O nuclear|B-DNA chromatin|I-DNA .|O
The|O large|O holes|O in|O the|O membrane|O appearing|O after|O 6|O hr|O of|O incubation|O with|O the|O hormone|B-protein may|O be|O the|O cause|O for|O the|O penetration|O of|O the|O viable|O stain|O into|O the|O dead|B-cell_type cells|I-cell_type ,|O as|O seen|O by|O light|O microscopy|O .|O
Addition|O of|O metabolic|O inhibitors|O including|O actinomycin|O D|O ,|O puromycin|O ,|O and|O cycloheximide|O following|O administration|O of|O cortisol|O resulted|O in|O inhibition|O of|O the|O cell|O lysis|O .|O
An|O excess|O of|O an|O antagonist|O such|O as|O cortexolone|O was|O found|O to|O inhibit|O the|O cortisol-induced|O cytolysis|O of|O the|O CLL|B-cell_line cells|I-cell_line .|O
It|O is|O suggested|O that|O the|O glucocorticoid-induced|O lysis|O of|O human|B-cell_line CLL|I-cell_line cells|I-cell_line is|O similar|O to|O the|O phenomenon|O observed|O in|O rat|B-cell_type or|I-cell_type murine|I-cell_type lymphocytes|I-cell_type and|O is|O mediated|O by|O interaction|O of|O the|O steroid|O molecule|O with|O the|O cytoplasmic|B-protein receptor|I-protein .|O
The|O resulting|O complex|O appears|O to|O activate|O specific|O gene|B-DNA (|O s|O )|O the|O products|O of|O which|O eventually|O cause|O cytolysis|O .|O
Glucocorticoid|B-protein receptors|I-protein in|O lymphoid|O tumors|O .|O
There|O is|O a|O range|O of|O levels|O of|O glucocorticoid|B-protein receptor|I-protein numbers|O seen|O in|O the|O various|O subclasses|O of|O acute|O lymphatic|O leukemia|O (|O ALL|O )|O .|O
This|O variability|O can|O not|O be|O explained|O by|O the|O known|O correlation|O between|O active|O cell|O proliferation|O and|O an|O increase|O in|O the|O number|O of|O receptors|O ,|O since|O the|O tumors|O with|O the|O highest|O growth|O fraction|O (|O i.e.|O ,|O Burkitt|O 's|O lymphoma|O and|O T-cell|O leukemia|O )|O tend|O to|O have|O lower|O average|O receptor|O numbers|O than|O do|O tumors|O with|O lower|O growth|O fractions|O such|O as|O common|O ALL|O .|O
All|O clinical|O specimens|O from|O patients|O with|O lymphatic|O leukemia|O have|O some|O measurable|O level|O of|O glucocorticoid|B-protein receptors|I-protein ;|O therefore|O ,|O the|O resistance|O seen|O in|O vivo|O can|O not|O be|O explained|O by|O the|O lack|O of|O receptors|O .|O
However|O ,|O there|O has|O been|O a|O positive|O correlation|O ,|O in|O our|O hands|O ,|O with|O receptor|O level|O and|O prognosis|O .|O
On|O the|O basis|O of|O in|O vitro|O models|O ,|O it|O is|O proposed|O that|O perhaps|O the|O high|B-cell_line receptor|I-cell_line cell|I-cell_line lines|I-cell_line (|O i.e.|O ,|O common|O ALL|O of|O childhood|O )|O have|O relative|O stability|O of|O their|O genetic|O material|O making|O glucocorticoid-resistant|O mutations|O less|O likely|O to|O occur|O in|O patients|O with|O these|O cells|O than|O in|O low-receptor|B-cell_line cell|I-cell_line lines|I-cell_line (|O i.e.|O ,|O T-cell|O leukemia|O )|O .|O
This|O greater|O genetic|O variability|O in|O the|O low-receptor|B-cell_line lines|I-cell_line could|O account|O for|O the|O earlier|O emergence|O of|O clinical|O glucocorticoid|O resistance|O in|O these|O patients|O .|O
[|O Tumor|O histology|O and|O steroid|B-protein receptors|I-protein in|O breast|O carcinoma|O ]|O
In|O Specimens|O of|O 115|O patients|O with|O breast|O cancer|O 4|O tumorparameters|O (|O tumorsize|O ,|O tumorboder|O ,|O nucleargrade|O ,|O lymphocytic|O stromal|O reaction|O )|O 3|O features|O of|O regional|O lymphnodes|O (|O sinushistiocytosis|O ,|O T-cellreaction|O ,|O lymphnode|O metastases|O )|O and|O estrogen|B-protein and|I-protein progesteron|I-protein receptors|I-protein were|O determined|O .|O
A|O strong|O sinushistiocytosis|O and|O T-cellreaction|O could|O be|O verified|O mainly|O in|O metastases|O in|O free|O lymphnodes|O .|O
The|O steroid|B-protein receptor|I-protein content|O does|O not|O correlate|O with|O histological|O parameters|O
Aldosterone-receptor|B-protein deficiency|O in|O pseudohypoaldosteronism|O .|O
Pseudohypoaldosteronism|O ,|O a|O syndrome|O characterized|O by|O salt|O wasting|O and|O failure|O to|O thrive|O ,|O usually|O presents|O in|O infancy|O as|O high|O urinary|O levels|O of|O sodium|O despite|O hyponatremia|O ,|O hyperkalemia|O ,|O hyperreninemia|O ,|O and|O elevated|O aldosterone|O levels|O .|O
We|O have|O investigated|O this|O syndrome|O for|O the|O possibility|O of|O abnormal|B-protein Type|I-protein I|I-protein or|O ``|B-protein mineralocorticoid-like|I-protein ''|I-protein receptors|I-protein ,|O which|O have|O intrinsic|O steroid|O specificity|O indistinguishable|O from|O that|O of|O renal|B-protein mineralocorticoid|I-protein receptors|I-protein and|O are|O found|O in|O many|O tissues|O and|O cells|B-cell_type ,|O including|O mononuclear|B-cell_type leukocytes|I-cell_type .|O
We|O have|O studied|O three|O patients|O with|O pseudohypoaldosteronism|O :|O the|O 28-year-old|O index|O case|O in|O Melbourne|O (|O Patient|O 1|O )|O and|O two|O siblings|O in|O Munich|O ,|O eight|O and|O two|O years|O of|O age|O (|O Patients|O 2|O and|O 3|O )|O ;|O clinically|O ,|O Patient|O 3|O had|O a|O less|O severe|O case|O than|O his|O sister|O .|O
Percoll-separated|B-cell_type control|I-cell_type monocytes|I-cell_type bound|O [|O 3H|O ]|O aldosterone|O with|O high|O affinity|O (|O Kd|O approximately|O 3|O nM|O )|O and|O limited|O capacity|O (|O 150|O to|O 600|O sites|O per|O cell|O )|O .|O
On|O repeated|O examination|O ,|O no|O [|O 3H|O ]|O aldosterone|O binding|O was|O found|O in|O monocytes|B-cell_type from|O Patients|O 1|O and|O 2|O ;|O in|O Patient|O 3|O ,|O the|O levels|O were|O 62|O sites|O per|O cell|O ,|O more|O than|O 2|O S.D.|O below|O those|O of|O the|O control|O .|O
Levels|O in|O the|O parents|O of|O the|O Munich|O patients|O (|O first|O cousins|O )|O were|O normal|O .|O
It|O appears|O that|O pseudohypoaldosteronism|O is|O caused|O by|O a|O Type|O I|O receptor|O defect|O ,|O that|O the|O defect|O may|O be|O complete|O or|O partial|O ,|O that|O transmission|O may|O be|O autosomal|O recessive|O ,|O and|O that|O the|O study|O of|O patients|O with|O pseudohypoaldosteronism|O may|O indicate|O physiologic|O roles|O for|O Type|B-protein I|I-protein receptors|I-protein in|O nonepithelial|O tissues|O .|O
Glucocorticoid|O inhibition|O of|O urokinase-like|B-protein plasminogen|I-protein activators|I-protein in|O cultured|B-cell_line human|I-cell_line lymphoblasts|I-cell_line .|O
Two|O human|B-cell_line lymphoblast|I-cell_line cell|I-cell_line lines|I-cell_line ,|O LICR-LON-HMy2|B-cell_line (|O HMy2|B-cell_line cells|I-cell_line )|O and|O GM4672A|B-cell_line cells|I-cell_line ,|O are|O moderately|O growth|O inhibited|O by|O dexamethasone|O (|O 1|O ,|O 4-pregnadien-9-fluoro-16|O alpha-methyl-11|O beta|O ,|O 17|O alpha|O ,|O 21-triol-3|O ,|O 20-dione|O )|O (|O Dex|O )|O .|O
Both|O cell|O types|O secrete|O a|O urokinase|B-protein (|I-protein UK|I-protein )|I-protein -like|I-protein plasminogen|I-protein activator|I-protein (|O PA|B-protein )|O .|O
Treatment|O of|O both|O HMy2|B-cell_line and|I-cell_line GM4672A|I-cell_line cells|I-cell_line with|O Dex|O for|O 1-4|O days|O inhibits|O extracellular|O PA|B-protein activity|O in|O a|O concentration-dependent|O manner|O ,|O being|O half-maximal|O at|O approximately|O 1|O X|O 10|O (|O -9|O )|O M|O .|O
Inhibition|O of|O PA|B-protein in|O both|O cell|O types|O is|O specific|O for|O active|O glucocorticoids|O ,|O and|O this|O specificity|O parallels|O the|O ability|O of|O various|O steroids|O to|O bind|O to|O glucocorticoid|B-protein receptors|I-protein .|O
HMy2|B-cell_line cell|I-cell_line PA|B-protein is|O fully|O suppressible|O by|O Dex|O ,|O whereas|O up|O to|O one|O third|O of|O the|O activator|O expressed|O by|O GM4672A|B-cell_line cells|I-cell_line is|O resistant|O to|O glucocorticoid|O inhibition|O .|O
Mixing|O experiments|O using|O a|O UK|O standard|O and|O conditioned|O media|O from|O Dex-treated|B-cell_line cells|I-cell_line suggest|O an|O absence|O of|O glucocorticoid-inducible|B-protein inhibitors|I-protein to|O UK|B-protein or|O plasmin|B-protein in|O both|O cell|O types|O .|O
However|O ,|O conditioned|O media|O from|O Dex-treated|B-cell_line GM4672A|I-cell_line cells|I-cell_line inhibits|O a|O portion|O of|O the|O homologous|O cellular|O activator|O in|O conditioned|O media|O from|O control|O GM4672A|B-cell_line cells|I-cell_line .|O
Thus|O ,|O low|O levels|O of|O glucocorticoid-inducible|B-protein inhibitors|I-protein may|O contribute|O to|O ,|O but|O can|O not|O fully|O account|O for|O ,|O Dex|O inhibition|O of|O GM4672A|B-protein PA|I-protein activity|O .|O
Glucocorticoid-inducible|B-protein inhibitors|I-protein in|O HMy2|B-cell_line cells|I-cell_line are|O either|O totally|O absent|O or|O are|O present|O at|O undetectable|O levels|O .|O
Thus|O ,|O regulation|O of|O UK-like|B-protein PAs|I-protein in|O HMy2|B-cell_line and|I-cell_line GM4672A|I-cell_line cells|I-cell_line differs|O with|O respect|O to|O the|O extent|O to|O which|O glucocorticoids|O inhibit|O constitutively|B-protein expressed|I-protein activator|I-protein levels|O ,|O as|O well|O as|O the|O possible|O contribution|O of|O glucocorticoid-inducible|B-protein inhibitors|I-protein to|O the|O regulatory|O process|O in|O GM4672A|B-cell_line cells|I-cell_line .|O
Characterization|O of|O aldosterone|O binding|O sites|O in|O circulating|B-cell_type human|I-cell_type mononuclear|I-cell_type leukocytes|I-cell_type .|O
Aldosterone|O binding|O sites|O in|O human|B-cell_line mononuclear|I-cell_line leukocytes|I-cell_line were|O characterized|O after|O separation|O of|O cells|O from|O blood|O by|O a|O Percoll|O gradient|O .|O
After|O washing|O and|O resuspension|O in|O RPMI-1640|O medium|O ,|O cells|O were|O incubated|O at|O 37|O degrees|O C|O for|O 1|O h|O with|O different|O concentrations|O of|O [|O 3H|O ]|O aldosterone|O plus|O a|O 100-fold|O concentration|O of|O RU-26988|O (|O 11|O alpha|O ,|O 17|O alpha-dihydroxy-17|O beta-propynylandrost-1|O ,|O 4|O ,|O 6-trien-3-one|O )|O ,|O with|O or|O without|O an|O excess|O of|O unlabeled|O aldosterone|O .|O
Aldosterone|O binds|O to|O a|O single|O class|O of|O receptors|O with|O an|O affinity|O of|O 2.7|O +/-|O 0.5|O nM|O (|O means|O +/-|O SD|O ,|O n|O =|O 14|O )|O and|O a|O capacity|O of|O 290|O +/-|O 108|O sites/cell|O (|O n|O =|O 14|O )|O .|O
The|O specificity|O data|O show|O a|O hierarchy|O of|O affinity|O of|O desoxycorticosterone|O =|O corticosterone|O =|O aldosterone|O greater|O than|O hydrocortisone|O greater|O than|O dexamethasone|O .|O
The|O results|O indicate|O that|O mononuclear|B-cell_type leukocytes|I-cell_type could|O be|O useful|O for|O studying|O the|O physiological|O significance|O of|O these|O mineralocorticoid|B-protein receptors|I-protein and|O their|O regulation|O in|O humans|O .|O
Mineralocorticoid|B-protein and|I-protein glucocorticoid|I-protein receptors|I-protein in|O circulating|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type of|O patients|O with|O primary|O hyperaldosteronism|O .|O
Mineralocorticoid|B-protein and|I-protein glucocorticoid|I-protein receptors|I-protein were|O measured|O in|O circulating|B-cell_type mononuclear|I-cell_type leukocytes|I-cell_type in|O 5|O patients|O affected|O by|O Conn|O 's|O syndrome|O (|O 3|O cases|O of|O bilateral|O adrenal|O hyperplasia|O and|O 2|O cases|O of|O adenoma|O plus|O unilateral|O hyperplasia|O )|O .|O
The|O number|O of|O the|O binding|O sites|O per|O cell|O resulted|O significantly|O lower|O (|O 189|O +/-|O 114|O ,|O mean|O +/-|O SD|O )|O ,|O as|O compared|O with|O the|O normal|O controls|O (|O 298|O +/-|O 105|O )|O .|O
The|O affinity|O of|O aldosterone|O for|O the|O receptor|O was|O found|O to|O be|O not|O different|O than|O that|O of|O healthy|O control|O subjects|O .|O
The|O capacity|O and|O the|O affinity|O of|O dexamethasone|O for|O glucocorticoid|B-protein receptors|I-protein ranged|O in|O the|O normal|O values|O .|O
These|O data|O suggest|O a|O possible|O down-regulation|O of|O mineralocorticoid|B-protein receptors|I-protein in|O humans|O .|O
Short-term|O and|O long-term|O effects|O of|O estrogen|O on|O lymphoid|O tissues|O and|O lymphoid|B-cell_type cells|I-cell_type with|O some|O remarks|O on|O the|O significance|O for|O carcinogenesis|O .|O
Estrogens|O have|O long|O been|O thought|O to|O play|O a|O role|O in|O regulating|O the|O immune|O system|O .|O
The|O difference|O in|O some|O types|O of|O immune|O responses|O between|O males|O and|O females|O is|O well-known|O ,|O as|O is|O the|O pronounced|O thymic|O involution|O induced|O by|O exogenous|O estrogens|O .|O
Estrogens|O stimulate|O some|O aspects|O of|O macrophage|B-cell_type activity|O and|O ,|O depending|O on|O dose|O and|O mitogen|B-protein ,|O inhibit|O or|O stimulate|O lymphocyte|O proliferative|O response|O in|O vitro|O .|O
Another|O example|O is|O the|O estrogen|O effect|O on|O the|O delayed|O type|O hypersensitivity|O response|O .|O
A|O broad|O review|O is|O given|O of|O such|O estrogen|O effects|O on|O lymphoid|B-cell_type tissue|I-cell_type and|O immune|O response|O .|O
Most|O of|O the|O studies|O published|O so|O far|O are|O phenomenological|O .|O
However|O ,|O the|O recent|O description|O of|O estrogen|B-protein receptors|I-protein in|O the|O thymus|O and|O in|O some|O lymphocyte|B-cell_line subpopulations|I-cell_line ,|O as|O well|O as|O a|O deeper|O understanding|O of|O regulating|O factors|O in|O the|O immune|O system|O ,|O open|O the|O possibility|O of|O a|O more|O detailed|O understanding|O of|O the|O estrogen|O mechanism|O of|O interference|O .|O
Estrogen|O effects|O in|O adults|O are|O reversible|O .|O
After|O treating|O neonatal|O mice|O with|O the|O synthetic|O estrogen|O diethylstilbestrol|O (|O DES|O )|O ,|O disturbances|O are|O induced|O in|O lymphocyte|B-cell_line populations|I-cell_line and|O lymphocyte|B-cell_type functions|O which|O are|O permanent|O and|O irreversible|O .|O
Lymphocytes|B-cell_type from|O adult|O ,|O neonatally|O DES-treated|O female|O mice|O have|O a|O reduced|O mitogen|O response|O to|O ConA|B-protein and|O LPS|B-protein (|O T|B-protein and|I-protein B|I-protein cell|I-protein mitogen|I-protein )|O and|O the|O delayed|O type|O hypersensitivity|O response|O is|O depressed|O .|O
A|O detailed|O analysis|O demonstrated|O a|O decreased|O T|B-cell_type helper|I-cell_type cell|I-cell_type population|O .|O
The|O activity|O of|O Natural|B-cell_type Killer|I-cell_type cells|I-cell_type is|O permanently|O reduced|O and|O this|O functional|O impairment|O is|O related|O to|O a|O decreased|O number|O of|O these|O cells|O ,|O in|O turn|O determined|O at|O the|O bone|O marrow|O level|O .|O
The|O same|O animals|O have|O an|O increased|O sensitivity|O to|O chemical|O carcinogens|O (|O methylcholanthrene|O )|O and|O they|O spontaneously|O develop|O epithelial|O changes|O in|O the|O uterine|O cervix|O which|O morphologically|O are|O similar|O to|O adenocarcinoma|O .|O
The|O association|O between|O estrogen-associated|O malignancy|O and|O estrogen|O effects|O in|O lymphocyte|B-cell_type functions|O deserves|O further|O study|O .|O
Drugs|O affecting|O the|O hormonal|O receptors|O of|O normal|B-cell_type and|I-cell_type leukaemic|I-cell_type peripheral|I-cell_type leucocytes|I-cell_type .|O
The|O authors|O investigated|O the|O behaviour|O of|O steroid|O hormone|O uptake|O in|O leukaemic|B-cell_type cells|I-cell_type (|O CML|B-cell_line ,|O CLL|B-cell_line ,|O AML|B-cell_line ,|O ALL|B-cell_line )|O ,|O in|O basal|O conditions|O and|O after|O incubation|O with|O drugs|O which|O modify|O the|O cellular|O concentration|O of|O cAMP|O ,|O PGE|O and|O PGF|O .|O
The|O results|O demonstrated|O the|O presence|O in|O leukaemic|B-cell_type cells|I-cell_type of|O an|O alteration|O in|O the|O incorporation|O of|O steroid|O hormones|O .|O
This|O alteration|O was|O scarcely|O modified|O by|O incubation|O with|O theophylline|B-protein ,|O which|O increases|O cellular|O concentration|O of|O cAMP|O .|O
On|O the|O other|O hand|O ,|O it|O was|O moderately|O counteracted|O by|O thioproline|O and|O was|O evidently|O inhibited|O by|O flurbiprofen|O ,|O which|O also|O reduced|O cellular|O concentrations|O of|O prostaglandins|O ,|O particularly|O PGE2|O ,|O with|O the|O exception|O of|O PGF2|O which|O showed|O a|O poor|O response|O .|O
Differences|O were|O observed|O in|O the|O behavior|O of|O hormonal|O uptake|O of|O CML|B-cell_line ,|O in|O contrast|O to|O that|O of|O AML|B-cell_line ,|I-cell_line CLL|I-cell_line and|I-cell_line ALL|I-cell_line peripheral|I-cell_line leucocytes|I-cell_line .|O
Human|O breast|O cancer|O and|O impaired|O NK|B-cell_type cell|I-cell_type function|O .|O
Recent|O advances|O in|O tumor|O immunology|O have|O led|O to|O the|O discovery|O of|O a|O new|O lymphoid|B-cell_type cell|I-cell_type with|O unique|O antitumor|O activity|O .|O
Natural|B-cell_type killer|I-cell_type (|I-cell_type NK|I-cell_type )|I-cell_type cells|I-cell_type form|O an|O antitumor|O surveillance|O system|O and|O appear|O to|O be|O vital|O in|O preventing|O tumor|O growth|O and|O metastasis|O in|O animal|O models|O .|O
We|O studied|O NK|B-cell_type activity|O in|O patients|O with|O benign|O and|O malignant|O breast|O disease|O ,|O using|O a|O chromium-51|O release|O microtiter|O cytotoxicity|O assay|O with|O K562|B-cell_line cells|I-cell_line as|O targets|O .|O
Compared|O with|O benign|O controls|O ,|O patients|O with|O malignancies|O had|O significantly|O depressed|O NK|B-cell_type -mediated|O lysis|O (|O P|O less|O than|O 0.01|O )|O .|O
Furthermore|O ,|O lysis|O in|O those|O with|O advanced|O disease|O (|O stages|O II|O ,|O III|O ,|O and|O IV|O )|O was|O significantly|O less|O than|O in|O those|O with|O limited|O disease|O (|O stage|O I|O )|O (|O P|O less|O than|O 0.01|O )|O .|O
NK|B-cell_type activity|O was|O not|O correlated|O to|O estrogen|O or|O progesterone|O receptor|O states|O .|O
Positive|O correlation|O of|O a|O depressed|O natural|O killer|O activity|O with|O the|O extent|O of|O tumor|O spread|O supports|O the|O concept|O of|O an|O NK|B-cell_type cell|I-cell_type immune|O surveillance|O system|O in|O breast|O cancer|O and|O emphasizes|O its|O importance|O in|O this|O malignancy|O .|O
Immunosuppressive|O effect|O of|O serum|O progesterone|O during|O pregnancy|O depends|O on|O the|O progesterone|O binding|O capacity|O of|O the|O lymphocytes|B-cell_type .|O
Cytotoxic|O activity|O and|O progesterone|O binding|O capacity|O of|O the|O lymphocytes|B-cell_type ,|O together|O with|O serum|O progesterone|O concentrations|O ,|O were|O determined|O in|O women|O with|O normal|O pregnancy|O or|O with|O a|O clinical|O diagnosis|O of|O threatened|O abortion|O or|O threatened|O premature|O labour|O .|O
The|O lymphocytes|O of|O women|O with|O threatened|O abortion|O or|O threatened|O premature|O labour|O showed|O significantly|O higher|O cytotoxic|O activity|O (|O P|O less|O than|O 0.001|O )|O and|O significantly|O lower|O progesterone|O binding|O capacity|O (|O P|O less|O than|O 0.001|O )|O than|O did|O lymphocytes|B-cell_type obtained|O from|O the|O healthy|O pregnant|O women|O .|O
Significant|O inverse|O correlation|O was|O found|O between|O progesterone|O binding|O capacity|O and|O cytotoxic|O activity|O of|O the|O lymphocytes|B-cell_type (|O P|O less|O than|O 0.001|O )|O ,|O but|O the|O progesterone|O concentration|O of|O the|O pregnancy|O serum|O appeared|O to|O have|O no|O influence|O on|O the|O other|O two|O parameters|O .|O
The|O findings|O indicate|O that|O intact|O progesterone|O binding|O capacity|O of|O the|O lymphocytes|B-cell_type is|O an|O essential|O factor|O for|O the|O manifestation|O of|O the|O blocking|O effect|O exerted|O by|O pregnancy|O serum|O on|O lymphocyte|B-cell_type cytotoxicity|O in|O vitro|O .|O
Serum|O sex|O steroid|O and|O peptide|O hormone|O concentrations|O ,|O and|O endometrial|O estrogen|O and|O progestin|O receptor|O levels|O during|O administration|O of|O human|B-protein leukocyte|I-protein interferon|I-protein .|O
Five|O normally|O cycling|O healthy|O women|O were|O given|O daily|O subcutaneous|O injections|O of|O human|B-protein leukocyte|I-protein interferon|I-protein (|O 3|O X|O 10|O (|O 6|O )|O units/day|O )|O from|O the|O 3rd|O through|O 23rd|O day|O of|O the|O menstrual|O cycle|O ,|O and|O serum|O steroid|O and|O peptide|O hormone|O concentrations|O monitored|O at|O 3-day|O intervals|O during|O the|O treatment|O and|O the|O preceding|O control|O cycle|O .|O
Concentrations|O of|O cytosol|B-protein and|I-protein nuclear|I-protein estrogen|I-protein receptors|I-protein (|O ERC|B-protein and|O ERN|B-protein ,|O respectively|O )|O and|O progestin|B-protein receptors|I-protein (|O PRC|B-protein and|O PRN|B-protein )|O were|O also|O measured|O from|O endometrial|O biopsies|O taken|O on|O the|O 24th|O day|O of|O the|O control|O and|O treatment|O cycle|O .|O
In|O addition|O ,|O an|O extensive|O monitoring|O of|O clinical|O chemical|O and|O hematological|O tests|O from|O the|O blood|O samples|O were|O performed|O .|O
Serum|O estradiol|O and|O progesterone|O concentrations|O were|O significantly|O decreased|O during|O the|O treatment|O cycle|O ,|O suggesting|O that|O interferon|B-protein interacts|O in|O vivo|O with|O the|O function|O of|O both|O FSH|O and|O LH|O .|O
No|O significant|O changes|O were|O observed|O in|O the|O serum|O peptide|O hormone|O concentrations|O measured|O (|O FSH|O ,|O LH|O ,|O prolactin|O ,|O insulin|O ,|O growth|O hormone|O and|O TSH|O )|O ;|O neither|O were|O the|O levels|O of|O endometrial|B-protein ERC|I-protein ,|I-protein ERN|I-protein ,|I-protein PRC|I-protein and|I-protein PRN|I-protein affected|O by|O interferon|B-protein administration|O .|O
As|O expected|O ,|O interferon|B-protein administration|O resulted|O in|O decreased|O leukocyte|B-cell_type counts|O .|O
Moreover|O ,|O an|O increasing|O tendency|O in|O the|O activities|O of|O serum|B-protein alkaline|I-protein phosphatase|I-protein and|O gamma-glutamyltransferase|B-protein during|O the|O interferon|B-protein therapy|O shows|O that|O interferon|B-protein may|O slightly|O interfere|O with|O the|O liver|O function|O .|O
These|O results|O suggest|O that|O one|O of|O the|O mechanisms|O by|O which|O interferon|B-protein treatment|O may|O affect|O the|O growth|O of|O hormone-dependent|O neoplasms|O could|O be|O the|O interaction|O with|O production|O and/or|O function|O of|O circulating|O hormonal|O compounds|O .|O
[|O Glucocorticoid|B-protein receptor|I-protein level|O in|O the|O blood|B-cell_type leukocytes|I-cell_type in|O different|O acute|O diseases|O ]|O
Content|O of|O glucocorticoid|B-protein receptors|I-protein in|O cytosol|O of|O blood|B-cell_type leukocytes|I-cell_type ,|O concentration|O of|O cortisol|O and|O amount|O of|O leukocytes|B-cell_type in|O blood|O were|O studied|O in|O 20|O patients|O with|O acute|O impairments|O within|O the|O second|O day|O of|O the|O disease|O .|O
Content|O of|O receptors|O in|O cytosol|O of|O blood|O leukocytes|O was|O studied|O using|O 3H-triamcinolone|O acetonide|O .|O
Distinct|O increase|O in|O amount|O of|O the|O leukocyte|B-protein glucocorticoid|I-protein receptors|I-protein was|O found|O in|O patients|O with|O poisoning|O by|O dichlorethane|O and|O hypnotic|O drugs|O under|O conditions|O of|O acute|O myocardial|O infarction|O .|O
In|O acute|O pancreatitis|O content|O of|O the|O leukocyte|B-protein receptors|I-protein was|O not|O altered|O as|O compared|O with|O controls|O .|O
Concentration|O of|O endogenous|O cortisol|O was|O increased|O in|O blood|O of|O all|O the|O patients|O ,|O except|O of|O the|O cases|O of|O acetate|O intoxication|O .|O
Reverse|O correlation|O was|O observed|O between|O concentration|O of|O cortisol|O in|O blood|O and|O content|O of|O glucocorticoid|O receptors|O in|O leukocytes|B-cell_type .|O
But|O in|O the|O patients|O with|O acute|O pancreatitis|O the|O decrease|O in|O content|O of|O leukocyte|B-protein glucocorticoid|I-protein receptors|I-protein was|O not|O observed|O although|O there|O was|O an|O increase|O in|O cortisol|O concentration|O in|O blood|O .|O
The|O role|O of|O glucocorticoid|B-protein receptors|I-protein in|O immunological|O processes|O under|O conditions|O of|O purulent|O complications|O and|O possibility|O to|O regulate|O the|O metabolism|O in|O leukocytes|B-cell_type
Therapeutic|O concentrations|O of|O glucocorticoids|O suppress|O the|O antimicrobial|O activity|O of|O human|B-cell_type macrophages|I-cell_type without|O impairing|O their|O responsiveness|O to|O gamma|B-protein interferon|I-protein .|O
By|O exposing|O human|B-cell_type blood-derived|I-cell_type macrophages|I-cell_type and|I-cell_type alveolar|I-cell_type macrophages|I-cell_type in|O vitro|O to|O dexamethasone|O ,|O we|O showed|O in|O these|O studies|O that|O glucocorticoids|O markedly|O suppress|O the|O antimicrobial|O activity|O of|O macrophages|B-cell_type but|O not|O macrophage|B-cell_type activation|O by|O lymphokines|B-cell_type .|O
As|O little|O as|O 2.5|O X|O 10|O (|O -8|O )|O mol/liter|O of|O dexamethasone|O prevented|O macrophages|B-cell_type from|O inhibiting|O germination|O of|O Aspergillus|O spores|O or|O from|O eliminating|O ingested|O bacteria|O such|O as|O Listeria|O ,|O Nocardia|O ,|O or|O Salmonella|O .|O
Damage|O to|O macrophage|B-cell_type function|O was|O inhibited|O by|O progesterone|O and|O appeared|O to|O be|O receptor-mediated|O .|O
In|O accordance|O with|O in|O vivo|O observations|O ,|O dexamethasone|O required|O 24-36|O h|O to|O suppress|O antimicrobial|O activity|O .|O
While|O glucocorticoids|O interfered|O with|O base-line|O activity|O of|O macrophages|B-cell_type ,|O dexamethasone|O concentrations|O comparable|O to|O drug|O levels|O in|O patients|O had|O no|O effect|O on|O macrophage|B-cell_type activation|O .|O
Proliferating|O lymphocytes|B-cell_type and|O gamma-interferon|B-protein thus|O increased|O the|O antimicrobial|O activity|O of|O phagocytes|B-cell_type exposed|O to|O glucocorticoids|O over|O that|O of|O control|O cells|O .|O
Macrophage|O activation|O and|O correction|O of|O the|O dexamethasone|O effect|O by|O gamma-interferon|B-protein ,|O however|O ,|O was|O dependent|O on|O the|O pathogen|O .|O
The|O lymphokine|B-protein enhanced|O the|O antimicrobial|O activity|O of|O dexamethasone-treated|B-cell_line macrophages|I-cell_line against|O Listeria|O and|O Salmonella|O but|O not|O against|O Aspergillus|O or|O Nocardia|O .|O
Dexamethasone-induced|O damage|O to|O the|O antimicrobial|O activity|O of|O human|B-cell_type macrophages|I-cell_type in|O vitro|O parallels|O observations|O that|O glucocorticoids|O render|O laboratory|O animals|O susceptible|O to|O listeriosis|O and|O aspergillosis|O by|O damaging|O resident|O macrophages|B-cell_line .|O
Suppression|O of|O macrophage|B-cell_type antimicrobial|O activity|O should|O thus|O be|O considered|O when|O treating|O patients|O with|O glucocorticoids|O ;|O its|O prevention|O by|O gamma-interferon|B-protein might|O be|O beneficial|O for|O some|O but|O not|O all|O pathogens|O .|O
Interleukin|B-protein 2|I-protein receptor|I-protein (|O Tac|B-protein antigen|I-protein )|O expression|O in|O HTLV-I-associated|O adult|O T-cell|B-cell_type leukemia|O .|O
Interleukin-2|B-protein (|O IL-2|B-protein )|O is|O a|O lymphokine|B-protein synthesized|O by|O some|O T-cells|B-cell_type following|O activation|O .|O
Resting|O T-cells|B-cell_type do|O not|O express|O IL-2|B-protein receptors|I-protein ,|O but|O receptors|O are|O rapidly|O expressed|O on|O T-cells|B-cell_type following|O interaction|O of|O antigens|O ,|O mitogens|O ,|O or|O monoclonal|B-protein antibodies|I-protein with|O the|O antigen-specific|B-protein T-cell|I-protein receptor|I-protein complex|I-protein .|O
Using|O anti-Tac|B-protein ,|O a|O monoclonal|B-protein antibody|I-protein that|O recognizes|O the|O IL-2|B-protein receptor|I-protein ,|O the|O receptor|O has|O been|O purified|O and|O shown|O to|O be|O a|O Mr|O 33|O ,|O 000|O peptide|O that|O is|O posttranslationally|O glycosylated|O to|O a|O Mr|O 55|O ,|O 000|O mature|O form|O .|O
Normal|O resting|O T-cells|B-cell_type and|O most|O leukemic|B-cell_line T-cell|I-cell_line populations|I-cell_line do|O not|O express|O IL-2|B-protein receptors|I-protein ;|O however|O ,|O the|O leukemic|B-cell_type cells|I-cell_type of|O the|O 11|O patients|O examined|O who|O had|O human|O T-cell|O lymphotropic|O virus-associated|O adult|O T-cell|O leukemia|O expressed|O the|O Tac|B-protein antigen|I-protein .|O
In|O human|B-cell_type T-cell|I-cell_type lymphotropic|I-cell_type virus-I|I-cell_type infected|I-cell_type cells|I-cell_type ,|O the|O Mr|O 42|O ,|O 000|O long|O open|B-protein reading|I-protein frame|I-protein protein|I-protein encoded|O in|O part|O by|O the|O pX|B-DNA region|I-DNA of|O this|O virus|O may|O act|O as|O a|O transacting|B-protein transcriptional|I-protein activator|I-protein that|O induces|O IL-2|B-DNA receptor|I-DNA gene|I-DNA transcription|O ,|O thus|O providing|O an|O explanation|O for|O the|O constant|O association|O of|O IL-2|B-protein receptor|I-protein expression|O with|O adult|O T-cell|O lymphotropic|O virus-I|O infection|O of|O lymphoid|B-cell_type cells|I-cell_type .|O
The|O constant|O expression|O of|O large|O numbers|O of|O IL-2|B-protein receptors|I-protein which|O may|O be|O aberrant|O may|O play|O a|O role|O in|O the|O uncontrolled|O growth|O of|O adult|B-cell_type T-cell|I-cell_type leukemia|I-cell_type cells|I-cell_type .|O
Two|O patients|O with|O Tac-positive|O adult|O T-cell|O leukemia|O have|O been|O treated|O with|O the|O anti-Tac|B-protein .|O
One|O of|O the|O patients|O had|O 6-|O and|O 3-mo|O remissions|O of|O his|O leukemia|O following|O two|O courses|O of|O therapy|O with|O this|O monoclonal|B-protein antibody|I-protein directed|O toward|O this|O growth|B-protein factor|I-protein receptor|I-protein .|O
Lymphocyte|B-cell_type glucocorticoid|B-protein receptor|I-protein binding|O in|O depressed|O patients|O with|O hypercortisolemia|O .|O
Despite|O elevated|O levels|O of|O serum|O and|O urinary|O cortisol|O ,|O patients|O with|O depressive|O illness|O manifest|O none|O of|O the|O clinical|O stigmata|O of|O glucocorticoid|O excess|O .|O
This|O hypercortisolemia|O in|O the|O absence|O of|O clinical|O effects|O suggests|O a|O state|O of|O hormone|O resistance|O and|O could|O be|O mediated|O by|O alterations|O in|O the|O glucocorticoid|B-protein receptor|I-protein .|O
Earlier|O studies|O have|O shown|O that|O small|O doses|O of|O glucocorticoids|O cause|O a|O decrease|O in|O glucocorticoid|B-protein receptor|I-protein binding|O in|O normal|O human|B-cell_type lymphocytes|I-cell_type .|O
White|O cells|O from|O depressed|O patients|O with|O significant|O hypercortisolemia|O would|O be|O expected|O to|O show|O a|O similar|O change|O in|O receptor|O concentration|O if|O peripheral|O tissues|O are|O adequately|O exposed|O to|O and|O sensitive|O to|O the|O hormone|O .|O
In|O this|O study|O we|O compared|O the|O binding|O of|O [|O 3H|O ]|O dexamethasone|O to|O lymphocytes|B-cell_type from|O normal|O subjects|O and|O depressed|O patients|O with|O hypercortisolemia|O .|O
Lymphocytes|B-cell_type from|O normal|O subjects|O had|O a|O mean|O receptor|O concentration|O of|O 10.2|O +/-|O 0.66|O fm/10|O (|O 6|O )|O cells|O (|O S.E.M.|O )|O and|O a|O dissociation|O constant|O of|O 4.8|O +/-|O 0.47|O nM|O .|O
Lymphocytes|B-cell_type from|O depressed|O patients|O with|O abnormal|O 0800|O h|O serum|O cortisol|O after|O dexamethasone|O had|O a|O mean|O receptor|O concentration|O of|O 8.8|O +/-|O 0.75|O fm/10|O (|O 6|O )|O cells|O ,|O which|O was|O not|O significantly|O different|O from|O that|O in|O lymphocytes|B-cell_type from|O normal|O subjects|O or|O from|O depressed|O subjects|O with|O normal|O post-dexamethasone|O cortisol|O levels|O (|O 9.4|O +/-|O 0.95|O fm/10|O (|O 6|O )|O cells|O )|O .|O
Lymphocytes|B-cell_type from|O depressed|O patients|O with|O elevated|O urinary|O free|O cortisol|O excretion|O (|O UFC|O )|O also|O had|O normal|O receptor|O concentration|O and|O binding|O affinity|O for|O dexamethasone|O .|O
The|O lack|O of|O a|O change|O in|O lymphocyte|B-cell_type glucocorticoid|B-protein receptor|I-protein concentration|O in|O the|O presence|O of|O cortisol|O excess|O suggests|O the|O possibility|O that|O hypercortisolemia|O in|O depressive|O illness|O represents|O a|O state|O of|O peripheral|O glucocorticoid|O resistance|O .|O
Structure|O and|O regulation|O of|O the|O glucocorticoid|B-protein hormone|I-protein receptor|I-protein .|O
The|O glucocorticoid|B-protein receptor|I-protein is|O an|O intracellular|B-protein protein|I-protein which|O possesses|O three|O distinct|O domains|O ,|O one|O that|O binds|O agonist|O and|O antagonist|O steroids|O ,|O one|O that|O binds|O DNA|O ,|O and|O one|O that|O binds|O anti-receptor|B-protein antibodies|I-protein and|O is|O required|O for|O glucocorticoid|O modulation|O of|O gene|O expression|O .|O
In|O intact|O cells|O ,|O receptor|O number|O ,|O affinity|O and|O activity|O can|O change|O in|O response|O to|O factors|O that|O bind|O to|O the|O receptor|O ,|O or|O that|O act|O indirectly|O through|O ill-defined|O mechanisms|O which|O may|O include|O resumption|O or|O arrest|O of|O cell|O cycling|O and|O variations|O in|O intracellular|O calcium|O ion|O concentrations|O .|O
Some|O of|O these|O factors|O appear|O to|O exert|O their|O effect|O by|O controlling|O critical|O receptor|O properties|O such|O as|O ATP-dependent|O phosphorylation|O ,|O integrity|O of|O thiol|B-protein groups|I-protein ,|O and|O exposure|O of|O key|B-protein amino|I-protein acid|I-protein residues|I-protein .|O
Glucocorticoid|O agonists|O promote|O the|O 'transformation|O '|O of|O the|O receptor|O into|O the|O DNA-binding|O state|O ,|O which|O is|O competent|O for|O modulating|O gene|O expression|O .|O
Glucocorticoid|O antagonists|O are|O steroids|O that|O interact|O with|O the|O receptor|O but|O either|O fail|O to|O produce|O a|O stable|B-protein complex|I-protein or|O produce|O a|O stable|B-protein but|I-protein inefficient|I-protein complex|I-protein .|O
Although|O substituent|O groups|O that|O confer|O agonist|O or|O antagonist|O activity|O to|O the|O steroid|O have|O been|O identified|O ,|O the|O molecular|O determinants|O of|O this|O difference|O at|O the|O receptor|O level|O remain|O unknown|O .|O
Most|O in|O vitro|O and|O in|O vivo|O data|O on|O receptor|O regulation|O can|O be|O accommodated|O by|O postulating|O the|O existence|O of|O an|O intracellular|O cycle|O that|O involves|O five|O states|O of|O the|O receptor|O .|O
The|O active|O free|O receptor|O is|O phosphorylated|O ,|O reduced|O ,|O and|O presumably|O oligomeric|O (|O state|O A|O )|O .|O
Following|O binding|O of|O an|O agonist|O (|O state|O B|O )|O ,|O it|O can|O become|O transformed|O by|O dissociation|O into|O its|O subunits|O and|O dephosphorylation|O (|O state|O C|O )|O .|O
The|O transformed|B-protein receptor|I-protein then|O interacts|O with|O chromatin|B-DNA (|O state|O D|O )|O .|O
Dissociation|O of|O the|O steroid|O and|O oxidation|O of|O receptor|B-protein thiol|I-protein group|I-protein (|O s|O )|O lead|O to|O the|O inactive|O receptor|O form|O (|O state|O E|O )|O .|O
Reduction|O and|O rephosphorylation|O of|O the|O receptor|O enable|O it|O to|O bind|O steroids|O again|O so|O that|O the|O cycle|O is|O closed|O .|O
Thermodynamics|O of|O steroid|O binding|O to|O the|O human|B-protein glucocorticoid|I-protein receptor|I-protein .|O
The|O thermodynamics|O of|O the|O interaction|O of|O glucocorticoids|O with|O their|O receptor|O were|O studied|O in|O cytosol|O from|O human|B-cell_type lymphoblastoid|I-cell_type cells|I-cell_type .|O
The|O rate|O and|O affinity|O constants|O of|O dexamethasone|O and|O cortisol|O between|O 0|O degree|O and|O 25|O degrees|O C|O were|O calculated|O by|O curve-fitting|O from|O time-course|O and|O equilibrium|O kinetics|O .|O
The|O data|O were|O consistent|O with|O a|O simple|O reversible|O bimolecular|O interaction|O .|O
Arrhenius|O and|O Va|O n't|O Hoff|O plots|O were|O curvilinear|O for|O both|O steroids|O .|O
At|O equilibrium|O ,|O the|O solution|O for|O the|O equation|O delta|O G|O =|O delta|O H|O -|O T|O X|O delta|O S|O (|O eqn.|O 1|O )|O was|O (|O in|O kJ|O X|O mol-1|O )|O -47|O =|O 36|O -|O 83|O (|O dexamethasone|O )|O and|O -42|O =|O -9|O -|O 33|O (|O cortisol|O )|O at|O 0|O degree|O C|O .|O
Enthalpy|O and|O entropy|O changes|O decreased|O quasi-linearly|O with|O temperature|O such|O that|O ,|O at|O 25|O degrees|O C|O ,|O the|O respective|O values|O were|O -50|O =|O -75|O +|O 25|O and|O -43|O =|O -48|O +|O 5|O .|O
Thus|O ,|O for|O both|O steroids|O ,|O the|O interaction|O was|O entropy-driven|O at|O low|O temperature|O and|O became|O entirely|O enthalpy-driven|O at|O 20|O degrees|O C|O .|O
Thermodynamic|O values|O for|O the|O transition|O state|O were|O calculated|O from|O the|O rate|O constants|O .|O
For|O the|O forward|O reaction|O ,|O eqn.|O (|O 1|O )|O gave|O 45|O =|O 84|O -|O 39|O (|O dexamethasone|O )|O and|O 46|O =|O 60|O -|O 14|O (|O cortisol|O )|O at|O 0|O degree|O C|O ,|O and|O 44|O =|O 24|O +|O 20|O (|O dexamethasone|O )|O and|O 46|O =|O 28|O +|O 18|O (|O cortisol|O )|O at|O 25|O degrees|O C|O .|O
These|O data|O fit|O quite|O well|O with|O a|O two-step|O model|O [|O Ross|O &|O Subramanian|O (|O 1981|O )|O Biochemistry|O 20|O ,|O 3096-3102|O ]|O proposed|O for|O ligand-protein|O interactions|O ,|O which|O involves|O a|O partial|O immobilization|O of|O the|O reacting|O species|O governed|O by|O hydrophobic|O forces|O ,|O followed|O by|O stabilization|O of|O the|O complex|O by|O short-range|O interactions|O .|O
On|O the|O basis|O of|O this|O model|O ,|O an|O analysis|O of|O the|O transition-state|O thermodynamics|O led|O to|O the|O conclusion|O that|O no|O more|O than|O half|O of|O the|O steroid|O molecular|O area|O is|O engaged|O in|O the|O binding|O process|O .|O
Cell|O cycle-related|O changes|O in|O number|O of|O T-lymphocyte|B-protein receptors|I-protein for|O glucocorticoids|O and|O insulin|O .|O
Enriched|O human|B-cell_type peripheral|I-cell_type T-lymphocytes|I-cell_type were|O stimulated|O with|O PHA|O and|O examined|O for|O variations|O in|O insulin|O and|O glucocorticoid|O (|O dexamethasone|O )|O receptor|O numbers|O during|O the|O early|O phases|O of|O the|O cell|O cycle|O .|O
Cells|O in|O G0|O ,|O G1a|O and|O G1b|O phases|O ,|O where|O the|O G1a|O -|O G1b|O transition|O is|O an|O Interleukin|B-protein 2|I-protein dependent|O event|O ,|O were|O quantitated|O by|O flow|O cytometry|O .|O
Few|O but|O significant|O numbers|O of|O glucocorticoid|B-protein receptors|I-protein (|O 2700/cell|O )|O and|O no|O insulin|B-protein receptors|I-protein (|O -1/cell|O )|O were|O found|O in|O the|O resting|O (|O G0|O )|O phase|O .|O
As|O cells|O entered|O the|O G1a|O phase|O the|O specific|O binding|O of|O dexamethasone|O increased|O and|O of|O insulin|O took|O place|O .|O
Although|O the|O specific|O binding|O further|O increased|O as|O T-cells|B-cell_type entered|O the|O G1b|O phase|O (|O as|O measured|O at|O 44|O h|O of|O incubation|O and|O using|O hydroxyurea-treated|B-cell_line cells|I-cell_line )|O ,|O the|O major|O changes|O in|O the|O specific|O binding|O of|O dexamethasone|O took|O place|O during|O the|O period|O 16|O -|O 20|O h|O after|O stimulation|O .|O
Based|O on|O these|O findings|O ,|O it|O is|O concluded|O that|O both|O receptor|O types|O (|O cell|B-protein membrane|I-protein and|I-protein cytoplasmic|I-protein receptors|I-protein )|O are|O being|O formed|O and|O increased|O at|O G1|O phase|O prior|O to|O cell|O proliferation|O ,|O indicating|O the|O importance|O of|O G1|O phase|O in|O immunoregulation|O .|O
Glucocorticoid|B-protein receptors|I-protein and|O cortico-sensitivity|O in|O a|O human|B-cell_line clonal|I-cell_line monocytic|I-cell_line cell|I-cell_line line|I-cell_line ,|O CM-SM|B-cell_line .|O
CM-SM|B-cell_line is|O a|O clonal|B-cell_line line|I-cell_line of|O human|B-cell_type precursor|I-cell_type mononuclear|I-cell_type phagocytes|I-cell_type inducible|O to|O macrophage|B-cell_type differentiation|O in|O response|O to|O the|O tumor|O promoter|O phorbol|O ester|O 12-O-tetradecanoyl-phorbol-13-acetate|O (|O TPA|O )|O .|O
Untreated|O CM-SM|O cells|O contain|O single|O class|O ,|O high-affinity|O (|O KD|O =|O 4.0|O X|O 10|O (|O -9|O )|O M|O )|O glucocorticoid-specific|O receptor|O sites|O (|O approximately|O 60|O ,|O 000|O per|O cell|O )|O ,|O as|O measured|O by|O a|O whole|O cell|O assay|O ,|O at|O 37|O degrees|O C|O ,|O using|O [|O 3H|O ]|O triamcinolone|O acetonide|O (|O TA|O )|O .|O
Exposure|O of|O CM-SM|B-cell_line to|O dexamethasone|O (|O DEX|O )|O produced|O a|O progressive|O ,|O dose-|O and|O time-related|O series|O of|O changes|O in|O CM-SM|B-cell_line cell|O growth|O ,|O saturation|O density|O ,|O morphology|O ,|O and|O functional|O properties|O ,|O with|O half-maximal|O effects|O at|O about|O 10|O (|O -9|O )|O M|O for|O DEX|O .|O
TA-receptor|O sites|O rapidly|O decreased|O (|O about|O 70|O %|O )|O after|O DEX|O treatment|O ,|O without|O any|O apparent|O change|O in|O steroid|O specificity|O and|O affinity|O .|O
After|O 5|O days|O in|O culture|O with|O a|O saturating|O concentration|O (|O 3.6|O X|O 10|O (|O -8|O )|O M|O )|O of|O hormone|O ,|O the|O cells|O reached|O a|O saturation|O density|O of|O about|O 9.0|O X|O 10|O (|O 6|O )|O viable|O cells/ml|O (|O about|O 4.0|O X|O 10|O (|O 6|O )|O viable|O cells/ml|O in|O the|O controls|O )|O ,|O while|O the|O modal|O volume|O of|O the|O resulting|O cell|B-cell_line population|I-cell_line was|O approximately|O 60|O %|O ,|O as|O compared|O to|O the|O volume|O of|O untreated|B-cell_line cells|I-cell_line .|O
DEX-treated|B-cell_line cells|I-cell_line appeared|O less|O differentiated|O than|O controls|O ,|O as|O assessed|O by|O combined|O morphologic|O ,|O antigenic|O ,|O and|O cytoenzymatic|O analyses|O .|O
DEX|O almost|O completely|O inhibited|O TPA|O activation|O of|O the|O following|O macrophage|B-cell_type functions|O :|O adherency|O to|O the|O culture|O plate|O ,|O expression|O of|O lysosomal|B-protein enzymes|I-protein ,|O Fc|B-protein and|I-protein C3|I-protein receptors|I-protein ,|O and|O stimulation|O of|O phagocytosis|O .|O
After|O removal|O of|O DEX|O ,|O the|O cells|O ,|O within|O a|O few|O passages|O ,|O returned|O to|O a|O state|O apparently|O identical|O to|O the|O untreated|O controls|O and|O could|O be|O induced|O to|O macrophage|B-cell_type differentiation|O in|O response|O to|O TPA|O .|O
Acute|O lymphoblastic|O leukemia|O in|O children|O :|O current|O status|O ,|O controversies|O ,|O and|O future|O perspective|O .|O
Disease-free|O survival|O (|O DFS|O )|O in|O childhood|O ALL|O is|O 60|O %|O ,|O and|O survival|O in|O good|O ,|O average|O ,|O and|O poor|O prognostic|O groups|O defined|O by|O initial|O WBC|O and|O age|O is|O 90|O ,|O 60|O ,|O and|O 45|O %|O ,|O respectively|O .|O
Additional|O immunological|O ,|O morphological|O ,|O biochemical|O ,|O cytokinetic|O ,|O and|O cytogenetic|O factors|O have|O been|O identified|O ,|O illustrating|O the|O heterogeneity|O of|O ALL|O and|O its|O derivation|O from|O malignant|B-cell_line clones|I-cell_line at|O various|O stages|O of|O differentiation|O and|O with|O varying|O rates|O of|O proliferation|O .|O
Of|O biologic|O importance|O ,|O these|O factors|O may|O refine|O further|O the|O characteristic|O features|O of|O clinically-determined|O prognostic|O groups|O .|O
Multivariate|O analysis|O of|O large|O prospective|O trials|O with|O homogeneous|O therapy|O will|O be|O required|O to|O determine|O the|O independent|O prognostic|O importance|O of|O these|O factors|O .|O
Current|O treatment|O strategies|O in|O ALL|O include|O (|O 1|O )|O tailoring|O therapy|O and|O its|O intensity|O to|O prognostic|O groups|O ;|O (|O 2|O )|O multiple-drug|O combinations|O in|O induction|O ;|O (|O 3|O )|O early|O use|O of|O intrathecal|O (|O IT|O )|O methotrexate|O (|O MTX|O )|O ;|O (|O 4|O )|O CNS|O prophylaxis|O with|O IT|O MTX|O alone|O in|O good|O prognosis|O patients|O and|O combined|O cranial|O radiation|O (|O CXRT|O )|O ,|O 1800|O rads|O plus|O IT|O MTX|O ,|O in|O average|O and|O poor|O prognosis|O patients|O .|O
Current|O studies|O show|O a|O CNS|O relapse|O rate|O of|O 5|O %|O in|O all|O prognostic|O groups|O .|O
Late|O neuropsychological|O defects|O caused|O by|O cranial|O XRT|O and|O IT|O MTX|O have|O prompted|O programs|O designed|O to|O reduce|O the|O potential|O late|O toxicity|O of|O CNS|O prophylaxis|O .|O
More|O pronounced|O in|O younger|O children|O ,|O these|O abnormalities|O include|O decreased|O IQ|O ,|O visual-motor|O incoordination|O ,|O poor|O performance|O in|O mathematics|O ,|O and|O memory|O dysfunction|O .|O
Until|O 1980|O ,|O more|O intensive|O induction|O ,|O consolidation|O ,|O and|O maintenance|O therapy|O had|O failed|O to|O prolong|O DFS|O in|O children|O with|O a|O poor|O prognosis|O .|O
In|O West|O Germany|O (|O Berlin-Frankfurt-Muenster|O protocol|O )|O a|O 70|O to|O 75|O %|O DFS|O is|O seen|O in|O all|O patients|O regardless|O of|O initial|O WBC|O ,|O suggesting|O that|O effective|O therapy|O will|O override|O prognostic|O factors|O .|O
Ultra-high-dose|O MTX|O ,|O without|O cranial|O radiation|O ,|O is|O also|O showing|O promise|O in|O poor|O prognosis|O patients|O .|O
Other|O issues|O include|O the|O optimal|O duration|O of|O therapy|O ,|O the|O role|O of|O testicular|O biopsies|O ,|O and|O prophylactic|O testicular|O radiation|O .|O
Recent|O studies|O suggest|O that|O prognostic|O factors|O lose|O their|O significance|O after|O 2|O years|O of|O continuous|O complete|O remission|O and|O that|O 2|O years|O of|O maintenance|O therapy|O is|O adequate|O .|O
Bilateral|O open-wedge|O testicular|O biopsies|O have|O identified|O occult|O testicular|O disease|O in|O 8|O to|O 10|O %|O of|O males|O .|O
A|O unified|O approach|O to|O children|O with|O leukemia/lymphoma|O ,|O a|O group|O with|O a|O particularly|O poor|O prognosis|O ,|O utilizing|O NHL-type|O therapy|O may|O be|O more|O effective|O than|O conventional|O ALL|O therapy|O .|O
(|O ABSTRACT|O TRUNCATED|O AT|O 400|O WORDS|O )|O
Glucocorticoid|B-protein receptor|I-protein and|O in|O vitro|O sensitivity|O to|O steroid|O hormones|O in|O human|O lymphoproliferative|O diseases|O and|O myeloid|O leukemia|O .|O
The|O glucocorticoid|B-protein receptor|I-protein (|O GR|B-protein )|O quantitation|O by|O a|O whole-cell|O assay|O and/or|O cytosol|O technique|O and|O the|O in|O vitro|O sensitivity|O to|O steroids|O have|O been|O assessed|O in|O peripheral|B-cell_type blood|I-cell_type cells|I-cell_type from|O normal|O donors|O and|O patients|O with|O chronic|O lymphatic|O leukemia|O (|O CLL|O )|O ,|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O ,|O lymphosarcoma|O cell|O leukemia|O (|O LSCL|O )|O ,|O acute|O nonlymphatic|O leukemia|O (|O ANLL|O )|O ,|O and|O chronic|O myeloid|O leukemia|O (|O CML|O )|O .|O
Within|O the|O lymphoproliferative|O diseases|O ,|O ALL|B-cell_line cells|I-cell_line exhibited|O the|O highest|O GR|B-protein concentration|O (|O regardless|O of|O the|O method|O used|O )|O and|O the|O highest|O in|O vitro|O inhibition|O of|O spontaneous|O [|O 3H|O ]|O thymidine|O (|O [|O 3H|O ]|O TdR|O )|O uptake|O by|O glucocorticoids|O .|O
A|O significant|O relationship|O between|O GR|B-protein concentration|O (|O whole-cell|O assay|O )|O and|O in|O vitro|O sensitivity|O to|O dexamethasone|O was|O also|O found|O .|O
On|O the|O contrary|O ,|O CLL|B-cell_line cells|I-cell_line presented|O the|O highest|O sensitivity|O to|O glucocorticoids|O in|O PHA-stimulated|B-cell_line cell|I-cell_line cultures|I-cell_line .|O
Cells|O from|O the|O only|O two|O ALL|O patients|O who|O did|O not|O undergo|O a|O remission|O after|O glucocorticoid-inclusive|O chemotherapy|O had|O both|O the|O lowest|O in|O vitro|O sensitivity|O to|O dexamethasone|O and|O the|O lowest|O GR|O concentration|O with|O whole-cell|O assay|O .|O
Concerning|O myeloid|O leukemia|O ,|O ANLL|O patients|O had|O GR|B-protein concentrations|O slightly|O higher|O than|O those|O found|O in|O the|O ALL|O group|O but|O exhibited|O the|O lowest|O degree|O of|O inhibition|O of|O spontaneous|O [|O 3H|O ]|O TdR|O uptake|O by|O dexamethasone|O (|O stimulatory|O effects|O occurred|O in|O some|O cases|O )|O .|O
CML|B-cell_line cells|I-cell_line exhibited|O an|O inhibition|O degree|O by|O in|O vitro|O glucocorticoids|O significantly|O higher|O than|O that|O of|O ANLL|B-cell_line cells|I-cell_line but|O not|O different|O from|O that|O of|O lymphoproliferative|O diseases|O .|O
No|O clear|O relationship|O among|O GR|O pattern|O ,|O in|O vitro|O cell|O sensitivity|O to|O glucocorticoids|O ,|O and|O clinicohematologic|O parameters|O was|O observed|O in|O myeloid|O leukemia-bearing|O patients|O .|O
Glucocorticoid|B-protein receptors|I-protein and|O in|O vitro|O corticosensitivity|O of|O peanut-positive|B-cell_line and|I-cell_line peanut-negative|I-cell_line human|I-cell_line thymocyte|I-cell_line subpopulations|I-cell_line .|O
In|O 6|O human|O thymus|O glands|O ,|O the|O immature|O subset|O of|O thymocytes|B-cell_type was|O separated|O from|O the|O more|O mature|O one|O ,|O by|O differential|O peanut|O lectin|O agglutination|O .|O
These|O 2|O cell|O subpopulations|O were|O analyzed|O for|O glucocorticoid|B-protein receptor|I-protein content|O by|O using|O a|O whole|O cell|O assay|O ,|O with|O (|O 3H|O )|O -triamcinolone|O acetonide|O as|O tracer|O .|O
The|O unagglutinated|B-cell_type thymocytes|I-cell_type (|O peanut|O negative|O )|O contained|O about|O 2|O times|O more|O receptor|O sites|O per|O cell|O than|O agglutinated|O (|O peanut|O positive|O )|O ones|O (|O 7650|O +/-|O 1550|O S.D.|O verus|O 3195|O +/-|O 896|O S.D.|O )|O .|O
The|O affinity|O for|O steroid|O was|O similar|O in|O both|O cell|O subsets|O ,|O as|O was|O the|O stereospecificity|O for|O glucocorticoids|O ,|O the|O time-course|O of|O steroid-receptor|O association|O ,|O and|O cytoplasmic|O to|O nuclear|O translocation|O .|O
Despite|O the|O greater|O number|O of|O glucocorticoid|B-protein receptor|I-protein sites|O ,|O the|O peanut-negative|B-cell_line thymocyte|I-cell_line subpopulation|I-cell_line did|O not|O differ|O from|O the|O peanut-positive|B-cell_line one|O in|O its|O sensitivity|O to|O the|O inhibitory|O effects|O of|O triamcinolone|O acetonide|O ,|O as|O determined|O by|O measurements|O of|O the|O incorporation|O of|O radiolabeled|O precursors|O of|O protein|O and|O DNA|O .|O
Moreover|O ,|O the|O peanut-negative|B-cell_line subset|I-cell_line appeared|O more|O resistant|O in|O vitro|O to|O the|O steroid-induced|O cell|O lysis|O as|O compared|O to|O the|O peanut-positive|B-cell_line one|O .|O
Thus|O ,|O our|O data|O suggest|O that|O glucocorticoid|O receptor|O density|O and|O corticosensitivity|O are|O not|O directly|O correlated|O and|O that|O the|O number|O of|O glucocorticoid|B-protein receptor|I-protein sites|O may|O be|O dependent|O on|O the|O degree|O of|O immunologic|O maturation|O
Defective|O binding|O and|O function|O of|O 1|B-protein ,|I-protein 25-dihydroxyvitamin|I-protein D3|I-protein receptors|I-protein in|O peripheral|B-cell_type mononuclear|I-cell_type cells|I-cell_type of|O patients|O with|O end-organ|O resistance|O to|O 1|O ,|O 25-dihydroxyvitamin|O D|O .|O
Lectin-induced|O DNA|O synthesis|O by|O peripheral|B-cell_type mononuclear|I-cell_type cells|I-cell_type from|O 17|O normal|O donors|O was|O inhibited|O (|O 40-60|O %|O )|O by|O 1|O ,|O 25-dihydroxyvitamin|O D3|O (|O 1|O ,|O 25|O [|O OH|O ]|O 2D3|O )|O at|O physiological|O concentrations|O (|O 10|O (|O -10|O )|O -10|O (|O -9|O )|O M|O )|O .|O
The|O lymphocytes|B-cell_type acquire|O specific|O receptors|O for|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O upon|O activation|O by|O the|O lectins|B-protein .|O
This|O process|O precedes|O the|O inhibitory|O effect|O of|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O .|O
We|O studied|O lymphocytes|B-cell_type from|O six|O patients|O from|O four|O different|O kindreds|O with|O the|O syndrome|O of|O hereditary|O end-organ|O resistance|O to|O 1|O ,|O 25|O (|O OH|O )|O 2D|O (|O the|O so-called|O vitamin|O D-dependent|O rickets|O type|O II|O )|O .|O
In|O five|O patients|O (|O three|O kindreds|O )|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type did|O not|O acquire|O receptors|O for|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O upon|O phytohemagglutinin-induced|O activation|O .|O
Moreover|O ,|O in|O contrast|O to|O normal|B-cell_type lymphocytes|I-cell_type ,|O the|O mitogenic|O stimulation|O of|O these|O patients|O '|O lymphocytes|B-cell_type by|O phytohemagglutinin|B-protein and|O concanavalin|O A|O was|O not|O inhibited|O by|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O .|O
Activated|O lymphocytes|B-cell_type of|O the|O sixth|O patient|O from|O a|O fourth|O kindred|O exhibited|O normal|O binding|O of|O [|O 3H|O ]|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O but|O the|O hormone|O failed|O to|O inhibit|O the|O mitogenic|O stimulation|O .|O
A|O similar|O pattern|O of|O the|O vitamin|O D|O effector|O system|O was|O previously|O observed|O in|O fibroblasts|O cultured|O from|O skin|O biopsies|O of|O the|O same|O group|O of|O patients|O .|O
The|O conclusions|O from|O these|O findings|O are|O :|O (|O a|O )|O the|O inhibition|O of|O mitogenic|O stimulation|O by|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O is|O mediated|O by|O specific|B-protein functional|I-protein receptors|I-protein to|O the|O hormone|O ;|O and|O (|O b|O )|O the|O receptors|O for|O 1|O ,|O 25|O (|O OH|O )|O 2D3|O in|O mononuclear|B-cell_type cells|I-cell_type are|O probably|O controlled|O genetically|O by|O the|O same|O mechanisms|O as|O the|O effector|O system|O in|O well-characterized|O target|O organs|O of|O the|O hormone|O ,|O such|O as|O intestine|O and|O kidney|O .|O
Glucocorticoid|B-protein receptors|I-protein of|O mononuclear|B-cell_type leukocytes|I-cell_type from|O myasthenia|O gravis|O patients|O .|O
The|O present|O study|O was|O performed|O to|O analyse|O glucocorticoid|B-protein receptor|I-protein (|O GR|B-protein )|O binding|O in|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type leukocytes|I-cell_type (|O MNL|B-cell_type )|O from|O 39|O myasthenia|O gravis|O (|O MG|O )|O patients|O (|O unoperated|O patients|O (|O n|O =|O 13|O )|O ,|O thymectomized|O patients|O (|O n|O =|O 14|O )|O and|O patients|O receiving|O glucocorticoids|O :|O thymectomized|O (|O n|O =|O 11|O )|O and|O unoperated|O (|O n|O =|O 6|O ]|O .|O
A|O whole|O cell|O binding|O assay|O with|O 3|O (|O H|O )|O dexamethasone|O was|O used|O .|O
GR|B-protein mean|O values|O were|O significantly|O higher|O in|O the|O MNL|B-cell_type of|O MG|O patients|O (|O thymectomized|O or|O not|O )|O not|O receiving|O glucocorticoid|O than|O in|O the|O MNL|B-cell_type of|O healthy|O donors|O .|O
Affinity|O was|O within|O the|O normal|O range|O .|O
Sex|O ,|O age|O or|O clinical|O forms|O of|O illness|O did|O not|O influence|O the|O results|O .|O
In|O patients|O receiving|O prednisone|O (|O Pd|O )|O the|O GR|B-protein values|O were|O significantly|O lower|O than|O in|O MG|O patients|O without|O Pd|O therapy|O ,|O independent|O of|O Pd|O dose|O or|O time|O of|O administration|O .|O
No|O differences|O in|O receptor|O binding|O between|O normal|O subjects|O and|O MG|O patients|O receiving|O Pd|O have|O been|O found|O .|O
Immunological|O interference|O of|O high|O dose|O corticosteroids|O .|O
High-dose|O corticosteroids|O (|O HDC|O )|O will|O influence|O cellular|O as|O well|O as|O humoral|O participants|O of|O the|O immune|O response|O .|O
The|O lymphoid|O tissue|O will|O decrease|O in|O size|O and|O weight|O after|O prolonged|O treatment|O with|O HDC|O .|O
Lymphocyte|O functions|O will|O be|O impaired|O .|O
Reduced|O synthesis|O of|O B-|B-cell_type as|I-cell_type well|I-cell_type as|I-cell_type T-lymphocytes|I-cell_type will|O be|O seen|O .|O
The|O inhibitory|O effect|O on|O B-cell|B-cell_type function|O can|O be|O observed|O both|O as|O decreased|O serum|O levels|O of|O immunoglobulins|B-protein and|O as|O impaired|O binding|O of|O antibodies|B-protein and|O complement|O to|O the|O cellular|O surface|O .|O
Reduced|O T-cell|B-cell_type function|O indicated|O by|O impaired|O stimulation|O by|O PHA|B-protein and|O porkweed|B-protein as|O well|O as|O by|O impaired|O lymphokinin|O effects|O on|O leukocyte|B-cell_type migration|O inhibition|O has|O been|O reported|O .|O
Reduced|O lymphocyte|O adherence|O to|O antigen|O and|O suppressed|O lymphocyte|O reaction|O have|O also|O been|O observed|O .|O
Humoral|O factors|O involved|O in|O chemotaxis|O ,|O opsonisation|O ,|O phagocytosis|O ,|O vascular|O permeability|O leading|O to|O leakage|O of|O fluid|O and|O cells|O and|O factors|O involved|O in|O lysis|O of|O antigens|O are|O impaired|O .|O
This|O can|O be|O explained|O partly|O by|O the|O observed|O reduced|O complement|O activation|O via|O the|O alternative|O as|O well|O as|O the|O classical|O pathway|O in|O association|O with|O HDC|O therapy|O .|O
Acute|O processes|O with|O increased|O vascular|O permeability|O and|O accumulation|O of|O leukocytes|B-cell_type as|O impairing|O factors|O could|O be|O influenced|O beneficially|O by|O HDC|O therapy|O .|O
This|O positive|O effect|O can|O be|O seen|O in|O treatment|O of|O septic|O shock|O or|O rejection|O of|O a|O transplant|O .|O
However|O ,|O if|O sepsis|O or|O rejection|O is|O not|O rapidly|O reversed|O ,|O complications|O such|O as|O multisystem|O organ|O failure|O and|O bacteremia|O are|O prone|O to|O appear|O .|O
Identification|O of|O human|B-protein leukemic|I-protein glucocorticoid|I-protein receptors|I-protein using|O affinity|O labeling|O and|O anti-human|B-protein glucocorticoid|I-protein receptor|I-protein antibodies|I-protein .|O
Antisera|O raised|O against|O human|B-protein lymphoid|I-protein glucocorticoid|I-protein receptors|I-protein were|O used|O in|O combination|O with|O the|O glucocorticoid|O receptor|O affinity|O label|O [|O 3H|O ]|O dexamethasone|O 21-mesylate|O [|O (|O 3H|O ]|O DM|O )|O to|O identify|O the|O glucocorticoid|B-protein receptors|I-protein of|O the|O human|B-cell_line B-lymphoblastoid|I-cell_line cell|I-cell_line line|I-cell_line IM-9|B-cell_line and|O the|O human|B-cell_line T-cell|I-cell_line leukemic|I-cell_line cell|I-cell_line line|I-cell_line CEM-C7|B-cell_line .|O
Antisera|O were|O obtained|O following|O immunization|O of|O New|O Zealand|O White|O rabbits|O with|O [|B-protein 3H|I-protein ]|I-protein triamcinolone|I-protein acetonide|I-protein [|I-protein (|I-protein 3H|I-protein ]|I-protein TA|I-protein )|I-protein -glucocorticoid|I-protein receptor|I-protein complexes|I-protein partially|O purified|O by|O two-stage|O DNA-cellulose|O chromatography|O .|O
The|O presence|O of|O anti-human|B-protein glucocorticoid|I-protein receptor|I-protein antibodies|I-protein was|O verified|O by|O :|O (|O a|O )|O adsorption|O of|O [|B-protein 3H|I-protein ]|I-protein TA-receptor-antibody|I-protein complexes|I-protein to|O Protein|B-protein A|I-protein ;|O (|O b|O )|O a|O shift|O to|O higher|O apparent|O molecular|O weight|O in|O the|O elution|O position|O from|O Sephacryl|O S300|O of|O [|B-protein 3H|I-protein ]|I-protein TA-receptor|I-protein complexes|I-protein incubated|O with|O immune|O serum|O ;|O and|O (|O c|O )|O the|O ability|O of|O immune|O serum|O to|O displace|O [|B-protein 3H|I-protein ]|I-protein TA-receptor|I-protein complexes|I-protein on|O sucrose|O gradients|O .|O
These|O antibodies|B-protein also|O recognized|O rat|O liver|O and|O murine|B-protein S49|I-protein cell|I-protein glucocorticoid|I-protein receptors|I-protein .|O
Sodium|O dodecyl|O sulfate-polyacrylamide|O gel|O electrophoresis|O of|O [|O 3H|O ]|O DM-labeled|O IM-9|O cytosol|O identified|O a|O major|O competable|O band|O with|O a|O molecular|O weight|O of|O approximately|O 90|O ,|O 000|O ,|O three|O minor|O competable|O components|O with|O molecular|O weights|O of|O approximately|O 78|O ,|O 000|O ,|O approximately|O 51|O ,|O 000|O ,|O and|O approximately|O 38|O ,|O 500|O ,|O and|O at|O least|O 21|O other|O noncompetable|O components|O .|O
Following|O immunoprecipitation|O of|O [|O 3H|O ]|O DM-labeled|O cytosol|O with|O immune|O serum|O ,|O only|O the|O Mr|O 90|O ,|O 000|O and|O 78|O ,|O 000|O components|O were|O seen|O .|O
Sodium|O dodecyl|O sulfate-polyacrylamide|O gel|O electrophoresis|O of|O [|O 3H|O ]|O DM-labeled|O CEM-C7|O cytosol|O revealed|O a|O larger|O number|O of|O [|O 3H|O ]|O DM-labeled|O components|O .|O
However|O ,|O after|O immunoprecipitation|O of|O [|O 3H|O ]|O DM-labeled|O CEM-C7|O cytosol|O ,|O a|O predominant|O competable|O component|O with|O a|O molecular|O weight|O of|O 90|O ,|O 000|O was|O easily|O identified|O .|O
This|O component|O was|O markedly|O diminished|O when|O cytosols|O from|O the|O glucocorticoid|B-cell_line receptor-deficient|I-cell_line cell|I-cell_line line|I-cell_line ICR-27|B-cell_line were|O used|O .|O
Thus|O ,|O the|O combination|O of|O affinity|O labeling|O and|O anti-human|B-protein glucocorticoid|I-protein receptor|I-protein antibodies|I-protein is|O capable|O of|O providing|O direct|O physical|O identification|O of|O human|B-protein lymphoid|I-protein glucocorticoid|I-protein receptors|I-protein .|O
Effect|O of|O thymosin|O on|O glucocorticoid|B-protein receptor|I-protein activity|O and|O glucocorticoid|O sensitivity|O of|O human|B-cell_type thymocytes|I-cell_type .|O
Incubation|O with|O thymosin|O fraction|O 5|O ,|O (|O TMS|O F5|O at|O 300|O micrograms/ml|O )|O a|O partially|O purified|O thymic|O factor|O ,|O reduced|O the|O steroid|O binding|O activity|O of|O human|B-cell_type infant|I-cell_type thymocytes|I-cell_type from|O 9.6|O +/-|O 2.1|O fmole/ml|O to|O 5.0|O +/-|O 2.0|O fmole/ml|O .|O
The|O glucocorticoid|B-protein receptor|I-protein activity|O in|O normal|O infant|O thymocytes|O was|O found|O to|O be|O 2|O ,|O 146|O +/-|O 726|O (|O s.d.|O )|O sites|O per|O cell|O with|O dissociation|O constant|O of|O 1.4|O +/-|O 0.6|O X|O 10|O (|O -8|O )|O M|O .|O
TMS|O F5|O also|O increased|O the|O resistance|O of|O human|O thymocytes|O to|O the|O cytolytic|O effect|O of|O dexamethasone|O (|O 2.5|O X|O 10|O (|O -8|O )|O M|O )|O to|O 168.6|O +/-|O 30.2|O %|O of|O control|O (|O P|O less|O than|O 0.01|O )|O .|O
In|O animals|O ,|O medullary|B-cell_type and|I-cell_type peripheral|I-cell_type blood|I-cell_type T|I-cell_type cells|I-cell_type are|O more|O resistant|O to|O glucocorticoids|O than|O immature|B-cell_type thymic|I-cell_type T|I-cell_type cells|I-cell_type .|O
The|O results|O show|O that|O thymosin|O can|O induce|O changes|O consistent|O with|O differentiation|O in|O human|B-cell_type thymocytes|I-cell_type .|O
These|O in|O vitro|O results|O are|O consistent|O with|O a|O physiological|O role|O of|O thymosin|O in|O intrathymic|O T|O cell|O maturation|O in|O man|O .|O
Incubation|O of|O a|O human|B-cell_line malignant|I-cell_line thymus|I-cell_line derived|I-cell_line T|I-cell_line cell|I-cell_line line|I-cell_line (|O MOLT|B-cell_line 3|I-cell_line )|O with|O TMS|O F5|O also|O resulted|O in|O a|O significant|O reduction|O of|O the|O number|O of|O steroid|O binding|O sites|O to|O 44.2|O +/-|O 15.3|O %|O of|O control|O (|O P|O less|O than|O 0.05|O )|O ,|O but|O TMS|O F5|O did|O not|O significantly|O reduce|O the|O glucocorticoid|O sensitivity|O of|O MOLT|B-cell_line 3|I-cell_line cells|I-cell_line .|O
Specific|B-protein high-affinity|I-protein receptors|I-protein for|O 1|O ,|O 25-dihydroxyvitamin|O D3|O in|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type :|O presence|O in|O monocytes|B-cell_type and|O induction|O in|O T|B-cell_type lymphocytes|I-cell_type following|O activation|O .|O
Human|B-cell_type peripheral|I-cell_type blood|I-cell_type monocytes|I-cell_type have|O high|O affinity|O binding|O sites|O for|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O (|O Kd|O 0.14|O nM|O ,|O sedimentation|O coefficient|O 3.7S|O )|O .|O
Resting|B-cell_type human|I-cell_type peripheral|I-cell_type blood|I-cell_type T|I-cell_type lymphocytes|I-cell_type ,|O however|O ,|O do|O not|O have|O a|O demonstrable|O 1|B-protein ,|I-protein 25-|I-protein (|I-protein OH|I-protein )|I-protein 2D3|I-protein receptor|I-protein .|O
After|O activation|O with|O phytohemagglutinin|B-protein the|O T|B-cell_type cells|I-cell_type exhibit|O the|O receptor|O within|O 24|O h|O ,|O and|O this|O expression|O is|O blocked|O by|O cycloheximide|O .|O
The|O receptor|O in|O activated|B-cell_type T|I-cell_type lymphocytes|I-cell_type has|O a|O sedimentation|O coefficient|O of|O 3.7S|O and|O a|O high|O affinity|O (|O Kd|O 0.10|O nM|O )|O for|O the|O ligand|O .|O
Effects|O of|O chronic|O glucocorticoid|O excess|O in|O man|O on|O insulin|O binding|O to|O circulating|B-cell_type cells|I-cell_type :|O differences|O between|O endogenous|O and|O exogenous|O hypercorticism|O .|O
We|O measured|O [|O 125I|O ]|O insulin|O binding|O to|O circulating|B-cell_type monocytes|I-cell_type or|I-cell_type erythrocytes|I-cell_type from|O 16|O patients|O with|O chronic|O glucocorticoid|O excess|O ,|O 9|O chronically|O treated|O with|O prednisone|O and|O 7|O with|O adrenocortical|O hyperfunction|O .|O
With|O monocytes|B-cell_type ,|O [|O 125I|O ]|O insulin|O binding|O was|O iincreased|O in|O all|O patients|O .|O
Analysis|O of|O binding|O data|O indicated|O that|O increased|O binding|O in|O patients|O treated|O with|O prednisone|O was|O due|O to|O an|O ncrease|O in|O receptor|O concentration|O ,|O whereas|O in|O patients|O with|O adrenocortical|O hyperfunction|O ,|O it|O was|O due|O to|O an|O increase|O in|O receptor|O affinity|O .|O
With|O erythrocytes|O from|O patients|O with|O adrenocortical|O hyperfunction|O there|O was|O an|O increase|O in|O receptor|O affinity|O and|O a|O decrease|O in|O receptor|O concentration|O ,|O so|O that|O the|O binding|O of|O [|O 125I|O ]|O insulin|O was|O normal|O .|O
The|O disparity|O of|O results|O between|O endogenous|O and|O exogenous|O hypercorticism|O ,|O between|O the|O two|O cell|O types|O ,|O and|O between|O the|O present|O studies|O and|O previous|O studies|O suggest|O that|O the|O effects|O of|O glucocorticoid|O excess|O on|O the|O insulin|B-protein receptor|I-protein are|O extremely|O complex|O and|O wide-ranging|O and|O that|O in|O this|O condition|O ,|O extrapolations|O in|O humans|O from|O data|O with|O circulating|B-cell_type cells|I-cell_type to|O liver|O and|O muscle|O may|O not|O be|O appropriate|O .|O
Reduced|O level|O of|O cellular|B-protein glucocorticoid|I-protein receptors|I-protein in|O patients|O with|O anorexia|O nervosa|O .|O
Specific|O glucocorticoid|B-protein receptors|I-protein were|O measured|O in|O circulating|O mononuclear|B-cell_type leukocytes|I-cell_type from|O 12|O patients|O with|O anorexia|O nervosa|O and|O 21|O healthy|O control|O subjects|O .|O
Cells|O from|O patients|O were|O found|O to|O contain|O a|O significantly|O (|O p|O less|O than|O 0.01|O )|O lower|O level|O of|O glucocorticoid|B-protein receptor|I-protein (|O 3830|O +/-|O 210|O sites/cell|O ,|O mean|O +/-|O SE|O )|O than|O those|O from|O controls|O (|O 4930|O +/-|O 250|O sites/cell|O )|O .|O
A|O partial|O glucocorticoid|B-protein receptor|I-protein defect|O may|O well|O explain|O the|O abnormal|O cortisol|O metabolism|O and|O glucocorticoid|O resistance|O commonly|O found|O in|O patients|O with|O anorexia|O nervosa|O .|O
Regulation|O of|O the|O glucocorticoid|B-protein receptor|I-protein in|O human|B-cell_type lymphocytes|I-cell_type .|O
The|O presence|O of|O a|O glucocorticoid|B-protein receptor|I-protein in|O human|B-cell_type lymphocytes|I-cell_type is|O well|O established|O ,|O but|O factors|O affecting|O its|O regulation|O have|O not|O been|O described|O .|O
Using|O a|O competitive|O binding|O whole|O cell|O assay|O ,|O we|O have|O examined|O the|O binding|O of|O [|O 3H|O ]|O -dexamethasone|O at|O 24|O and|O 37|O degrees|O C|O in|O untreated|O normal|O subjects|O and|O in|O healthy|O subjects|O taking|O various|O glucocorticoid|O preparations|O .|O
At|O 24|O degrees|O C|O normal|B-cell_type human|I-cell_type lymphocytes|I-cell_type had|O 6000|O binding|O sites/cell|O and|O a|O dissociation|O constant|O of|O 4|O x|O 10|O (|O -9|O )|O M|O .|O
The|O administration|O of|O 1|O mg|O of|O dexamethasone|O ,|O 5|O mg|O of|O prednisone|O ,|O and|O 37.5|O mg|O of|O cortisone|O acetate|O resulted|O in|O a|O 30|O %|O decrease|O in|O binding|O sites|O after|O 1|O week|O with|O no|O change|O in|O binding|O affinity|O .|O
No|O changes|O in|O the|O number|O of|O binding|O sites|O was|O noted|O before|O 1|O week|O and|O the|O diminished|O number|O persisted|O for|O 1|O week|O after|O discontinuation|O of|O glucocorticoid|O treatment|O .|O
Lymphocytes|B-cell_type from|O hospitalized|O patients|O taking|O 40-60|O mg|O of|O dexamethasone|O daily|O demonstrated|O the|O same|O change|O in|O number|O of|O binding|O sites|O that|O was|O seen|O in|O normal|O subjects|O taking|O 1|O mg|O of|O dexamethasone|O .|O
When|O binding|O assays|O were|O carried|O out|O at|O physiologic|O temperature|O there|O was|O the|O same|O decrease|O in|O number|O of|O binding|O sites|O after|O dexamethasone|O administration|O ,|O and|O in|O addition|O ,|O there|O was|O a|O two-fold|O increase|O in|O binding|O affinity|O .|O
Glucocorticoid|O administration|O results|O in|O a|O time-dependent|O decrease|O in|O the|O number|O of|O lymphocyte|O glucocorticoid|O binding|O sites|O that|O is|O independent|O of|O the|O type|O of|O glucocorticoid|O administered|O .|O
This|O is|O the|O first|O in|O vivo|O demonstration|O that|O glucocorticoids|O modulate|O their|O own|O receptors|O in|O man|O .|O
Immunoglobulin|O localization|O in|O benign|O and|O malignant|O lesions|O of|O the|O human|O mammary|O gland|O .|O
Using|O direct|O imunofluorescence|O ,|O lesions|O from|O 266|O human|O breast|O specimens|O were|O studied|O for|O the|O presence|O of|O IgA|O ,|O IgM|O ,|O or|O IgG|O localization|O .|O
The|O lesions|O included|O benign|O elements|O from|O 66|O subcutaneous|O mastectomy|O specimens|O in|O which|O the|O absence|O of|O simultaneous|O breast|O malignancy|O was|O documented|O ,|O primary|O breast|O carcinomas|O from|O 153|O mastectomy|O specimens|O ,|O and|O 47|O biopsies|O containing|O metastatic|O breast|O cancer|O .|O
A|O statistically|O significant|O association|O of|O IgA|B-protein and|O IgM|B-protein with|O benign|O lesions|O was|O contrasted|O to|O the|O association|O of|O IgG|B-protein with|O malignant|O lesions|O .|O
In|O both|O primary|O and|O metastatic|O lesions|O ,|O IgG|B-protein localization|O was|O associated|O with|O estrogen-receptor-poor|O primary|O cancers|O as|O compared|O with|O estrogen-receptor-rich|O primary|O cancers|O .|O
Among|O primary|O breast|O cancer|O patients|O ,|O IgG|B-protein localization|O in|O the|O tumor|O correlated|O with|O relative|O lymphopenia|O .|O
A|O shorter|O disease-free|O interval|O was|O noted|O in|O association|O with|O IgG|B-protein localization|O among|O the|O metastatic|O breast|O lesions|O .|O
No|O statistically|O significant|O association|O between|O stage|O of|O disease|O and|O immunoglobulin|O presence|O was|O demonstrable|O .|O
Moderate-to-severe|O intraductal|O epithelial|O hyperplasias|O were|O more|O often|O associated|O with|O immunoglobulin|B-protein G|I-protein localization|O that|O were|O other|O benign|O lesions|O
Correlation|O of|O steroid|B-protein receptors|I-protein with|O histologic|O differentiation|O in|O mammary|O carcinoma|O .|O
A|O Singapore|O experience|O .|O
Cancer|O of|O the|O breast|O is|O the|O most|O common|O tumor|O in|O females|O in|O Singapore|O ,|O with|O the|O rate|O of|O 20.7|O per|O 100|O ,|O 000|O per|O year|O (|O 1977|O estimate|O )|O ,|O which|O is|O predicted|O to|O increase|O to|O 29.8|O per|O 100|O ,|O 000|O women|O per|O year|O by|O 1995|O .|O
A|O detailed|O histopathologic|O review|O of|O 50|O primary|O breast|O cancer|O tumors|O analyzed|O for|O estrogen|B-protein receptor|I-protein (|O ER|B-protein )|O level|O was|O carried|O out|O and|O a|O variety|O of|O morphologic|O features|O correlated|O with|O ER|B-protein results|O to|O identify|O any|O factors|O that|O will|O improve|O the|O management|O and|O prognosis|O for|O breast|O cancer|O .|O
Cytosol|O was|O incubated|O with|O 3H-estradiol|O in|O the|O presence|O and|O absence|O of|O cold|O diethylstilbestrol|O ,|O and|O bound|O and|O free|O hormone|O were|O separated|O by|O Dextran-coated|O charcoal|O method|O .|O
Tumors|O binding|O more|O than|O 5|O fmol/mg|O cytosol|B-protein protein|I-protein were|O classified|O as|O ER|B-protein -positive|O .|O
Progesterone|B-protein receptor|I-protein (|O PR|B-protein )|O level|O was|O analyzed|O in|O some|O specimens|O with|O the|O use|O of|O a|O similar|O method|O .|O
Most|O of|O the|O patients|O were|O Chinese|O (|O 90|O %|O )|O .|O
Three|O patients|O were|O Malays|O ,|O one|O was|O Indian|O ,|O and|O one|O was|O European|O in|O this|O series|O .|O
Results|O indicated|O that|O there|O was|O strong|O correlation|O between|O ER|B-protein level|O ,|O age|O ,|O and|O histologic|O grade|O of|O the|O tumors|O .|O
No|O correlation|O existed|O between|O absence|O or|O presence|O of|O lymph|O node|O metastases|O and|O ER|B-protein .|O
Although|O there|O was|O a|O trend|O for|O ER|B-protein -positive|O tumors|O to|O have|O a|O low-grade|O lymphocytic|O infiltration|O ,|O the|O difference|O was|O not|O statistically|O significant|O .|O
Mononuclear|B-cell_type cells|I-cell_type infiltrating|O human|O mammary|O carcinomas|O :|O immunohistochemical|O analysis|O with|O monoclonal|B-protein antibodies|I-protein .|O
Breast|O carcinomas|O were|O examined|O by|O the|O immunoperoxidase|O technique|O using|O antisera|O specific|O for|O lymphocyte|B-cell_type subsets|I-cell_type ,|O monocytes|B-cell_type ,|O NK|B-cell_type cells|I-cell_type and|O major|B-protein histocompatibility|I-protein antigens|I-protein (|O HLA-A|B-protein ,|O -B|B-protein ,|O -C|O ;|O Ia-like|B-protein )|O .|O
Sixty-four|O per|O cent|O of|O the|O patients|O had|O a|O moderate|O or|O strong|O mononuclear|O cell|O infiltration|O ,|O 77|O %|O of|O the|O patients|O without|O mononuclear|B-cell_type cell|I-cell_type infiltration|O had|O receptors|O for|O estrogens|O as|O compared|O to|O 51|O %|O of|O the|O patients|O with|O infiltration|O .|O
The|O majority|O of|O the|O infiltrating|B-cell_type mononuclear|I-cell_type cells|I-cell_type were|O T|B-cell_type cells|I-cell_type ;|O generally|O the|O OKT8|B-cell_line cells|I-cell_line were|O predominant|O .|O
The|O Leu|O 3A/OKT8|O cell|O ratio|O was|O not|O related|O to|O histological|O type|O ,|O tumor|O size|O ,|O age|O of|O the|O patient|O or|O presence|O of|O metastases|O .|O
Some|O of|O the|O T|O cells|O had|O the|O Ia|B-protein antigen|I-protein and|O were|O thus|O probably|O activated|O .|O
The|O B|B-cell_type cells|I-cell_type were|O either|O absent|O or|O less|O numerous|O than|O the|O T|O cells|O .|O
There|O was|O no|O relation|O between|O their|O distribution|O and|O the|O various|O parameters|O studied|O .|O
A|O few|O monocytes|B-cell_type were|O heterogeneous|O according|O to|O their|O markers|O (|O OKM|B-protein I|I-protein and|O acid|O phosphatase|O )|O .|O
In|O 6|O cases|O only|O there|O was|O a|O strong|O infiltration|O of|O mononuclear|B-cell_type cells|I-cell_type positive|O for|O acid|B-protein phosphatase|I-protein .|O
The|O number|O of|O the|O natural|B-cell_type killer|I-cell_type cells|I-cell_type was|O also|O low|O .|O
Only|O a|O few|O mononuclear|O infiltrating|O cells|O had|O receptors|O for|O transferrin|O .|O
There|O was|O a|O positive|O correlation|O between|O the|O inflammatory|O infiltration|O and|O the|O presence|O of|O HLA|B-protein class-I|I-protein antigens|I-protein on|O tumor|B-cell_type cell|I-cell_type s|O .|O
Some|O of|O the|O antisera|O specific|O for|O lymphocyte|B-cell_type subsets|I-cell_type also|O stained|O the|O breast|B-cell_type carcinoma|I-cell_type cells|I-cell_type .|O
The|O great|O variations|O in|O the|O subsets|O of|O mononuclear|B-cell_type cells|I-cell_type in|O breast|O carcinomas|O may|O correspond|O to|O various|O systems|O of|O defense|O against|O neoplasm|O .|O
A|O case|O of|O male|O pseudohermaphroditism|O with|O normal|O androgen|B-protein receptor|I-protein binding|O and|O 47|O ,|O XYY|O karyotype|O .|O
A|O case|O of|O male|O pseudohermaphroditism|O with|O 47|O ,|O XYY|O karyotype|O in|O blood|O and|O cutaneous|B-cell_type fibroblasts|I-cell_type is|O described|O .|O
The|O plasma|O testosterone|O response|O to|O HCG|O stimulation|O was|O slightly|O below|O the|O normal|O range|O on|O two|O occasions|O suggesting|O a|O deficit|O of|O gonadal|O function|O .|O
A|O study|O of|O the|O receptors|O for|O dihydrotestosterone|O in|O fibroblasts|B-cell_type of|O genital|O and|O nongenital|O skin|O showed|O a|O normal|O concentration|O of|O receptors|O in|O genital|O skin|O ;|O 5-alpha-reductase|B-protein activity|O in|O fibroblasts|B-cell_type of|O the|O genital|O skin|O was|O low|O ,|O but|O the|O plasma|O relationship|O testosterone/dihydrotestosterone|O under|O HCG|O stimulation|O was|O normal|O .|O
The|O diagnostic|O possibility|O of|O a|O complete|O testicular|O feminization|O syndrome|O with|O normal|O receptors|O for|O dihydrotestosterone|O is|O commented|O on|O .|O
1|O ,|O 25-Dihydroxyvitamin|O D3|O inhibits|O antigen-induced|O T|B-cell_type cell|I-cell_type activation|O .|O
The|O proliferative|O response|O of|O murine|B-cell_type spleen|I-cell_type and|I-cell_type thymus|I-cell_type cells|I-cell_type to|O antigen|B-protein but|O not|O to|O lectin|B-protein was|O inhibited|O by|O the|O active|O metabolite|O of|O vitamin|O D3|O ,|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O .|O
To|O directly|O examine|O the|O effect|O of|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O on|O T|B-cell_type cell|I-cell_type activation|O in|O the|O absence|O of|O other|O complicating|O interactions|O ,|O we|O utilized|O a|O panel|O of|O cloned|O Ia-restricted|B-cell_line T|I-cell_line cell|I-cell_line hybridomas|I-cell_line that|O secrete|O IL|B-protein 2|I-protein on|O activation|O by|O cloned|O Ia-bearing|B-cell_type stimulator|I-cell_type cells|I-cell_type (|O TA3|B-cell_type )|O or|O when|O stimulated|O by|O mitogen|O .|O
Physiologic|O concentrations|O of|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O (|O 0.01|O to|O 0.1|O nm|O )|O inhibited|O the|O antigen-induced|O secretion|O of|O IL|O 2|O by|O several|O of|O these|O T|B-cell_line cell|I-cell_line hybridomas|I-cell_line .|O
This|O inhibition|O was|O dependent|O on|O the|O concentration|O of|O the|O free|O hormone|O and|O could|O be|O overcome|O by|O increasing|O the|O number|O of|O Ia-bearing|B-cell_line stimulator|I-cell_line cells|I-cell_line used|O .|O
Pretreatment|O of|O the|O T|B-cell_line hybridoma|I-cell_line but|O not|O the|O TA3|B-cell_line stimulator|I-cell_line cell|I-cell_line with|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O resulted|O in|O inhibition|O of|O activation|O .|O
These|O results|O are|O consistent|O with|O the|O finding|O that|O specific|O 1|B-protein ,|I-protein 25-|I-protein (|I-protein OH|I-protein )|I-protein 2D3|I-protein receptors|I-protein are|O present|O on|O the|O T|O cell|O hybridomas|O but|O are|O lacking|O in|O TA3|B-cell_line cells|I-cell_line .|O
1|O ,|O 25-|O (|O OH|O )|O 2D3|O failed|O ,|O however|O ,|O to|O inhibit|O the|O activation|O of|O the|O T|B-cell_line cell|I-cell_line hybridomas|I-cell_line by|O lectin|B-protein or|O by|O an|O anti-Thy-1|B-protein antibody|I-protein .|O
These|O findings|O suggest|O that|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O may|O be|O interfering|O with|O early|O events|O of|O antigen-induced|O T|B-cell_type cell|I-cell_type activation|O ,|O perhaps|O by|O hindering|O T|B-cell_type cell|I-cell_type recognition|O of|O the|O relevant|O antigen|O on|O stimulator|O cell|O surfaces|O .|O
This|O system|O should|O prove|O useful|O in|O studying|O the|O molecular|O mechanisms|O by|O which|O 1|O ,|O 25-|O (|O OH|O )|O 2D3|O acts|O to|O inhibit|O T|O cell|O activation|O and|O subsequent|O IL|B-protein 2|I-protein production|O .|O
Glucocorticoid|B-protein receptors|I-protein and|O steroid|O sensitivity|O in|O normal|O and|O neoplastic|O human|O lymphoid|O tissues|O :|O a|O review|O .|O
The|O determination|O of|O estrogen|B-protein and|I-protein progesterone|I-protein receptors|I-protein in|O breast|O cancer|O has|O been|O shown|O to|O be|O useful|O in|O predicting|O the|O response|O to|O endocrine|O therapy|O .|O
Given|O their|O well-known|O inhibitory|O effects|O on|O lymphoid|O tissue|O ,|O glucocorticoids|O have|O been|O used|O widely|O in|O the|O treatment|O of|O leukemia|O .|O
Given|O these|O facts|O ,|O over|O the|O last|O 10|O years|O ,|O several|O investigators|O have|O measured|O the|O number|O of|O glucocorticoid|B-protein receptors|I-protein in|O normal|O and|O neoplastic|O lymphoid|O tissue|O to|O see|O whether|O their|O number|O correlated|O with|O glucocorticoid|O responsiveness|O in|O vitro|O or|O in|O vivo|O .|O
No|O clear|O correlation|O could|O be|O established|O between|O the|O level|O of|O glucocorticoid|B-protein receptor|I-protein and|O the|O in|O vitro|O action|O of|O steroids|O in|O normal|O and|O neoplastic|O lymphoid|O tissue|O .|O
In|O contrast|O ,|O attempts|O to|O correlate|O glucocorticoid|B-protein receptor|I-protein levels|O in|O acute|O lymphocytic|O leukemia|O to|O in|O vivo|O steroid|O responsiveness|O and|O immunological|O type|O using|O the|O whole-cell-binding|O assay|O for|O receptor|O determination|O and|O selecting|O the|O patients|O according|O to|O age|O and|O immunological|O criteria|O have|O been|O more|O successful|O .|O
[|O Glucocorticoid|B-protein receptors|I-protein in|O normal|B-cell_type human|I-cell_type lymphocytes|I-cell_type ]|O
Glucocorticoid|B-cell_type (|I-cell_type GC|I-cell_type )|I-cell_type receptors|I-cell_type were|O studied|O in|O intact|O lymphocytes|B-cell_type from|O 11|O donors|O .|O
GC|O binding|O parameters|O were|O found|O to|O be|O highly|O reproducible|O in|O repeated|O experiments|O with|O lymphocytes|B-cell_type .|O
It|O was|O shown|O that|O GC|B-protein receptors|I-protein in|O donors|O '|O lymphocytes|B-cell_type could|O be|O distributed|O into|O two|O different|O classes|O similarly|O to|O the|O pattern|O seen|O in|O skin|B-cell_type fibroblasts|I-cell_type .|O
Human|B-cell_type lymphocytes|I-cell_type are|O an|O adequate|O object|O for|O studying|O genetically|O determined|O variability|O of|O GC|B-protein receptors|I-protein and|O its|O clinical|O importance|O .|O
Specific|O estrogen|B-protein binding|I-protein sites|I-protein in|O human|B-cell_type lymphoid|I-cell_type cells|I-cell_type and|O thymic|B-cell_type cells|I-cell_type .|O
The|O binding|O of|O estrogen|O in|O preparations|O of|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type ,|I-cell_type as|O well|O as|O by|O splenic|B-cell_type and|I-cell_type thymic|I-cell_type cells|I-cell_type is|O demonstrated|O by|O three|O different|O approaches|O (|O Dextran-coated|O charcoal|O method|O ,|O whole|O cell|O assay|O ,|O and|O gel|O filtration|O on|O a|O sepharose|O 4B|O column|O )|O .|O
Scatchard|O 's|O analysis|O of|O [|O 3H|O ]|O -moxestrol|O (|O R2858|O )|O and|O [|O 3H|O ]|O -estradiol|O binding|O proves|O the|O existence|O of|O a|O single|O class|O of|O receptor|B-protein sites|I-protein having|O a|O dissociation|O constant|O of|O 0.18-2.4|O X|O 10|O (|O -9|O )|O M|O .|O
Physicochemical|O properties|O of|O the|O binder|O ,|O including|O binding|O capacity|O and|O steroid|O specificity|O ,|O are|O quite|O similar|O to|O those|O reported|O for|O the|O thymus|O of|O small|O mammalian|O species|O or|O human|O thymoma|O .|O
Administration|O of|O fibroblast|B-protein interferon|I-protein to|O patients|O with|O advanced|O breast|O cancer|O :|O possible|O effects|O on|O skin|O metastasis|O and|O on|O hormone|B-protein receptors|I-protein .|O
Eleven|O patients|O with|O metastasized|O breast|O cancer|O received|O 8|O intramuscular|O injections|O of|O 6|O x|O 10|O (|O 6|O )|O units|O of|O human|B-protein fibroblast|I-protein interferon|I-protein over|O a|O period|O of|O 40|O days|O .|O
The|O injections|O did|O not|O cause|O local|O irritation|O or|O inflammation|O .|O
Fever|O occurred|O in|O only|O 1|O of|O the|O 11|O patients|O .|O
Although|O several|O types|O of|O metastases|O were|O monitored|O ,|O only|O skin|O nodules|O consistently|O (|O 10|O out|O of|O 11|O patients|O )|O exhibited|O changes|O that|O were|O suggestive|O of|O a|O therapeutic|O effect|O of|O the|O treatment|O regimen|O :|O either|O a|O simple|O decrease|O in|O size|O of|O some|O nodules|O or|O central|O necrosis|O accompanied|O by|O an|O inflammatory|O reaction|O .|O
NK-activity|O of|O peripheral|B-cell_type blood|I-cell_type leukocytes|I-cell_type was|O significantly|O increased|O after|O administration|O of|O the|O first|O dose|O ;|O the|O effect|O of|O subsequent|O injections|O was|O less|O clear|O .|O
Receptors|O for|O estrogens|O and|O progestogens|O were|O increased|O in|O the|O tumor|O biopsies|O of|O 2|O out|O of|O 2|O and|O 5|O out|O of|O 6|O patients|O tested|O respectively|O .|O
Decreased|O glucocorticoid|B-protein receptor|I-protein binding|O in|O adrenal|O insufficiency|O .|O
To|O examine|O the|O effect|O of|O glucocorticoid|O deficiency|O on|O the|O glucocorticoid|B-protein receptor|I-protein ,|O we|O examine|O the|O binding|O of|O [|O 3H|O ]|O dexamethasone|O to|O lymphocytes|B-cell_type in|O normal|O subjects|O and|O patients|O with|O adrenal|O insufficiency|O before|O and|O after|O glucocorticoid|O replacement|O therapy|O .|O
Using|O a|O whole|O cell|O competitive|O binding|O assay|O ,|O normal|B-cell_type human|I-cell_type lymphocytes|I-cell_type had|O 5977|O +/-|O 1487|O (|O mean|O +/-|O SD|O )|O binding|O sites/cell|O and|O a|O dissociation|O constant|O of|O 10|O +/-|O 2|O nM|O .|O
Lymphocytes|B-cell_type from|O patients|O with|O untreated|O adrenal|O insufficiency|O had|O fewer|O binding|B-protein sites|I-protein (|O 3364|O +/-322|O )|O and|O a|O 2-fold|O increase|O in|O binding|O affinity|O (|O 5.4|O +/-|O 0.9|O mM|O )|O .|O
The|O administration|O of|O conventional|O replacement|O doses|O of|O cortisone|O acetate|O for|O 6|O months|O caused|O no|O change|O in|O receptor|O number|O ,|O but|O was|O associated|O with|O a|O decrease|O in|O binding|O affinity|O toward|O normal|O .|O
After|O long|O term|O glucocorticoid|O replacement|O therapy|O ,|O binding|O parameters|O were|O similar|O to|O those|O in|O patients|O before|O treatment|O .|O
The|O physiological|O implications|O of|O the|O decreased|O receptor|O number|O and|O increased|O binding|O affinity|O in|O adrenal|O insufficiency|O remain|O to|O be|O elucidated|O .|O
Glucocorticoid|B-protein receptor|I-protein concentrations|O and|O terminal|O transferase|B-protein activity|O as|O indicators|O of|O prognosis|O in|O acute|O non-lymphocytic|O leukaemia|O .|O
Activity|O of|O terminal|B-protein deoxynucleotidyl|I-protein transferase|I-protein (|O TdT|B-protein )|O ,|O adenosine|B-protein deaminase|I-protein ,|O and|O 5'nucleotidase|B-protein and|O the|O cellular|O concentration|O of|O glucocorticoid|B-protein (|I-protein dexamethasone|I-protein )|I-protein receptor|I-protein were|O determined|O in|O 25|O patients|O with|O acute|O non-lymphocytic|O leukaemia|O .|O
All|O patients|O were|O treated|O according|O to|O a|O common|O protocol|O .|O
Increased|O activity|O of|O TdT|B-protein (|O greater|O than|O 0.1|O unit/microgram|O DNA|O )|O was|O found|O in|O 11|O patients|O .|O
This|O group|O of|O patients|O was|O shown|O to|O have|O higher|O remission|O and|O survival|O rates|O (|O p|O =|O 0.06|O )|O compared|O with|O patients|O with|O low|O activity|O of|O TdT|O .|O
The|O glucocorticoid|B-protein receptor|I-protein concentration|O of|O the|O leukaemic|B-cell_type blast|I-cell_type cells|I-cell_type ranged|O from|O 0|O to|O 0.94|O fmol/microgram|O DNA|O .|O
Thirteen|O patients|O had|O blast|B-cell_type cells|I-cell_type with|O a|O glucocorticoid|B-protein receptor|I-protein concentration|O over|O 0.22|O fmol/microgram|O DNA|O .|O
These|O patients|O had|O significantly|O increased|O remission|O and|O survival|O rates|O (|O p|O =|O 0.006|O )|O compared|O with|O those|O with|O a|O low|O receptor|O concentration|O .|O
This|O finding|O can|O not|O be|O explained|O by|O a|O difference|O in|O sensitivity|O to|O glucocorticoids|O since|O these|O were|O not|O used|O as|O therapeutic|O agents|O .|O
Adenosine|B-protein deaminase|I-protein and|O 5'nucleotidase|B-protein activities|O both|O varied|O within|O two|O orders|O of|O magnitude|O .|O
No|O correlation|O could|O be|O found|O between|O activities|O of|O these|O enzymes|O and|O remission|O or|O survival|O rate|O .|O
These|O results|O show|O that|O measurements|O of|O TdT|B-protein activity|O and|O the|O glucocorticoid|B-protein receptor|I-protein concentration|O yield|O valuable|O prognostic|O information|O in|O acute|O non-lymphocytic|O leukaemia|O
[|O 3H|O ]|O cortivazol|O :|O a|O unique|O high|O affinity|O ligand|O for|O the|O glucocorticoid|B-protein receptor|I-protein .|O
Cortivazol|O (|O CVZ|O )|O and|O deacylcortivazol|O (|O DAC|O )|O are|O pyrazolosteroids|O with|O potent|O glucocorticoid|O activity|O .|O
In|O previous|O work|O we|O showed|O that|O DAC|O is|O 40-fold|O more|O potent|O than|O dexamethasone|O (|O DEX|O )|O in|O lysing|O leukemic|B-cell_type lymphoblasts|I-cell_type .|O
To|O assess|O the|O interaction|O between|O these|O atypical|O steroids|O and|O the|O glucocorticoid|B-protein receptor|I-protein ,|O we|O examined|O the|O binding|O of|O [|O 3H|O ]|O CVZ|O to|O cytosol|O from|O glucocorticoid-sensitive|B-cell_line and|I-cell_line -resistant|I-cell_line variants|I-cell_line of|O the|O human|B-cell_line leukemic|I-cell_line cell|I-cell_line line|I-cell_line CEM|B-cell_line C7|I-cell_line .|O
In|O glucocorticoid-sensitive|B-cell_line cells|I-cell_line [|O 3H|O ]|O CVZ|O causes|O a|O 2-fold|O induction|O of|O glutamine|B-protein synthetase|I-protein and|O binds|O to|O a|O protein|O in|O the|O 4.6|O S|O region|O of|O high|O salt|O sucrose|O gradients|O .|O
On|O DEAE-cellulose|O chromatography|O ,|O [|B-protein 3H|I-protein ]|I-protein CVZ-receptor|I-protein complexes|I-protein show|O a|O shift|O from|O high|O (|O 0.25|O M|O KP|O )|O to|O low|O salt|O (|O 0.09|O M|O KP|O )|O eluting|O forms|O upon|O activation|O .|O
CVZ|O competes|O for|O a|O 97|O ,|O 000-dalton|O protein|O labeled|O by|O [|O 3H|O ]|O dexamethasone|O mesylate|O .|O
Scatchard|O analysis|O of|O the|O binding|O of|O [|O 3H|O ]|O CVZ|O in|O glucocorticoid-sensitive|B-cell_line cells|I-cell_line revealed|O a|O curvilinear|O plot|O which|O resolved|O into|O high|O (|O 0.4|O nM|O )|O and|O low|O (|O 11|O nM|O )|O affinity|O components|O .|O
The|O receptor|O concentration|O of|O the|O low|O affinity|O site|O (|O 0.30|O pmol/mg|O protein|O )|O was|O approximately|O twice|O that|O of|O the|O high|B-protein affinity|I-protein site|I-protein (|O 0.14|O pmol/mg|O protein|O )|O .|O
Dissociation|O experiments|O with|O dilution|O and/or|O excess|O unlabeled|O CVZ|O supported|O the|O presence|O of|O independent|O sites|O .|O
In|O contrast|O ,|O the|O binding|O of|O [|O 3H|O ]|O DEX|O to|O C7|O cytosol|O revealed|O a|O single|O class|O of|O binding|O sites|O (|O Kd|O =|O 1.9|O nM|O ;|O receptor|O concentration|O ,|O 0.46|O pmol/mg|O protein|O )|O .|O
Examination|O of|O the|O binding|O of|O [|O 3H|O ]|O CVZ|O using|O 10|O (|O -5|O )|O M|O DEX|O as|O the|O competing|O ligand|O showed|O that|O DEX|O binds|O only|O to|O the|O low|O affinity|O site|O detected|O by|O [|O 3H|O ]|O CVZ|O .|O
In|O cytosol|O from|O a|O glucocorticoid-resistant|B-cell_line cell|I-cell_line line|I-cell_line with|O virtually|O no|O [|O 3H|O ]|O DEX|O binding|O ,|O [|O 3H|O ]|O CVZ|O detected|O a|O single|O high|B-protein affinity|I-protein binding|I-protein site|I-protein that|O was|O similar|O in|O dissociation|O constant|O (|O 0.8|O nM|O )|O and|O receptor|O concentration|O (|O 0.13|O pmol/mg|O protein|O )|O to|O the|O high|B-protein affinity|I-protein site|I-protein detected|O in|O the|O glucocorticoid-sensitive|B-cell_line cell|I-cell_line line|I-cell_line C7|B-cell_line .|O
A|O controlled|O pore|O glass|O bead|O assay|O for|O the|O measurement|O of|O cytoplasmic|B-protein and|I-protein nuclear|I-protein glucocorticoid|I-protein receptors|I-protein .|O
An|O assay|O for|O the|O quantitation|O of|O cytoplasmic|B-protein and|I-protein nuclear|I-protein glucocorticoid|I-protein receptors|I-protein in|O lymphoid|O tissue|O has|O been|O developed|O using|O controlled|O pore|O glass|O (|O CPG|O )|O beads|O .|O
Soluble|O receptor|B-protein --|I-protein 3H-steroid|I-protein complex|I-protein (|O cytosol|O or|O nuclear|O extract|O )|O is|O adsorbed|O quantitatively|O within|O the|O crevasses|O of|O porous|O glass|O beads|O .|O
Excess|O labeled|O steroid|O as|O well|O as|O most|O non-specifically|O bound|O steroid|O is|O easily|O washed|O away|O ,|O leaving|O the|O hormone-receptor|B-protein complex|I-protein retained|O by|O the|O beads|O .|O
Bound|O 3H-steroid|O is|O eluted|O with|O ethanol|O and|O measured|O for|O radioactivity|O .|O
This|O procedure|O which|O is|O simple|O ,|O rapid|O ,|O and|O highly|O reproducible|O is|O carried|O out|O using|O frozen|O samples|O (|O stable|O for|O many|O months|O )|O containing|O as|O few|O as|O 1|O X|O 10|O (|O 7|O )|O cells|O .|O
A|O comparison|O of|O the|O CPG|O assay|O to|O dextran|O coated|O charcoal|O and|O a|O whole|O cell|O assay|O demonstrates|O that|O CPG|O and|O dextran|O coated|O charcoal|O give|O equivalent|O measurements|O of|O cytosolic|B-protein receptor|I-protein concentration|O ,|O while|O the|O CPG|O and|O whole|O cell|O assays|O provide|O equivalent|O values|O for|O total|O receptor|O content|O .|O
Plasmacytoid|O blast|O crisis|O in|O B-cell|B-cell_type chronic|O lymphocytic|O leukemia|O :|O effect|O of|O estradiol|O on|O growth|O and|O differentiation|O in|O vitro|O .|O
Evolution|O of|O a|O case|O of|O chronic|O lymphocytic|O leukemia|O (|O CLL|O )|O into|O blast|O crisis|O was|O found|O to|O be|O characterized|O by|O three|O unusual|O features|O (|O 1|O )|O the|O phenotype|O of|O the|O emerging|B-cell_type blast|I-cell_type cells|I-cell_type was|O that|O of|O pre-plasmacytoid|B-cell_type cells|I-cell_type as|O shown|O by|O plasma|O cell|O morphology|O and|O an|O immunological|O phenotype|O corresponding|O partially|O with|O CLL-|B-cell_type or|I-cell_type intermediate|I-cell_type B-cells|I-cell_type ,|O partially|O with|O plasma|B-cell_type cells|I-cell_type (|O terminal|B-protein transferase|I-protein -|O ,|O common|O acute|B-protein lymphocytic|I-protein leukemia|I-protein antigen|I-protein -|O ,|O Ia+|B-protein ,|O surface|B-protein immunoglobulin|I-protein heavy|I-protein chains|I-protein -|O ,|O surface|B-protein kappa|I-protein light|I-protein chains|I-protein +|O ,|O intracytoplasmic|B-protein immunoglobulin|I-protein A+|I-protein and|I-protein G+|I-protein ,|O BA-1+|B-protein ,|O polyclonal|O gammaglobulin|O production|O )|O ;|O (|O 2|O )|O cytogenetic|O analysis|O of|O spontaneous|O metaphases|O revealed|O that|O in|O addition|O to|O the|O typical|O CLL|O abnormality|O ,|O trisomy|O 12|O ,|O in|O all|O of|O the|O cells|O ,|O an|O additional|O translocation|O between|O chromosomes|B-DNA 14|I-DNA and|I-DNA 17|I-DNA was|O present|O in|O 40|O %|O with|O a|O presumptive|O breakpoint|O on|O chromosome|B-DNA 14|I-DNA (|O q12-3|O )|O never|O described|O before|O (|O commonly|O q32|O )|O and|O (|O 3|O )|O the|O progression|O of|O the|O disease|O was|O associated|O with|O a|O striking|O increase|O in|O the|O expression|O by|O the|O transformed|B-cell_type cells|I-cell_type of|O specific|O binding|O sites|O for|O estradiol|O (|O E2|O )|O due|O to|O an|O actual|O increase|O in|O total|O cellular|B-protein receptor|I-protein proteins|I-protein and|O not|O to|O a|O change|O in|O receptor|O affinity|O for|O E2|O .|O
The|O functional|O status|O of|O the|O steroid|B-protein receptors|I-protein was|O confirmed|O by|O nuclear|O transfer|O of|O the|O cytoplasmic|B-protein hormone-receptor|I-protein complex|I-protein upon|O temperature|O activation|O .|O
Since|O the|O rise|O in|O E2-receptor|B-protein display|O paralleled|O a|O large|O increase|O in|O the|O proliferative|O activity|O of|O the|O cells|O as|O well|O as|O a|O change|O in|O their|O maturation|O status|O the|O question|O was|O raised|O as|O to|O whether|O the|O E2-receptor|B-protein should|O be|O considered|O as|O a|O physiological|O marker|O of|O growth|O rate|O or|O of|O cellular|O differentiation|O .|O
Exposure|O of|O the|O patient|O 's|O blast|B-cell_type cells|I-cell_type to|O E2|O in|O vitro|O resulted|O in|O cessation|O of|O cell|O growth|O following|O at|O least|O one|O mitosis|O after|O addition|O of|O the|O inducer|O as|O seen|O from|O the|O replacement|O of|O the|O large|B-cell_type blasts|I-cell_type by|O small|O CLL-like|B-cell_type cells|I-cell_type without|O definite|O signs|O of|O alteration|O of|O the|O differentiation|O status|O .|O
This|O suggests|O the|O association|O of|O E2-receptor|B-protein expression|O with|O control|O of|O growth|O rather|O than|O cell|O maturation|O .|O
Multiple|O forms|O and|O fragments|O of|O cytosolic|B-protein glucocorticoid|I-protein receptors|I-protein from|O human|B-cell_type leukemic|I-cell_type cells|I-cell_type and|O normal|B-cell_type lymphocytes|I-cell_type .|O
Therapy|O with|O glucocorticoids|O is|O generally|O more|O effective|O in|O acute|O lymphoblastic|O leukemia|O than|O in|O other|O types|O of|O human|O leukemia|O .|O
Previous|O studies|O ,|O however|O ,|O have|O not|O revealed|O any|O consistent|O relationship|O between|O clinical|O responsiveness|O and|O the|O cellular|O or|O cytosolic|O concentration|O of|O glucocorticoid-binding|B-protein sites|I-protein .|O
The|O objectives|O of|O this|O study|O were|O to|O determine|O whether|O there|O are|O intrinsic|O structural|O differences|O among|O the|O glucocorticoid|B-protein receptors|I-protein in|O various|O types|O of|O leukemic|B-cell_type cells|I-cell_type and|O normal|B-cell_type lymphocytes|I-cell_type and|O to|O investigate|O the|O role|O of|O endogenous|B-protein peptidases|I-protein in|O receptor|O degradation|O .|O
Cytosols|O were|O prepared|O from|O fresh|B-cell_type or|I-cell_type rapidly|I-cell_type frozen|I-cell_type leukocytes|I-cell_type from|O 6|O healthy|O adults|O and|O 35|O high-risk|O leukemia|O patients|O (|O median|O white|O blood|O cell|O count|O ,|O 150|O ,|O 000|O cells/microliter|O ;|O median|O age|O ,|O 13|O years|O )|O .|O
Receptors|O were|O labeled|O with|O [|O 3H|O ]|O triamcinolone|O acetonide|O and|O quantitated|O by|O charcoal-dextran|O treatment|O or|O Sephadex|O LH-20|O chromatography|O .|O
Mean|O and|O median|O cytosolic|O receptor|O concentrations|O in|O 12|O acute|O lymphoblastic|O leukemia|O specimens|O lacking|O the|O standard|O B-cell|O or|O T-cell|O markers|O (|O ``|O null|O cells|O ''|O )|O were|O approximately|O 4-fold|O higher|O than|O in|O 23|O other|O leukemic|B-cell_type cell|I-cell_type specimens|I-cell_type .|O
No|O other|O consistent|O differences|O in|O receptor|O content|O were|O observed|O .|O
Agarose|O filtration|O and|O ultracentrifugation|O in|O hypotonic|O buffers|O containing|O 20|O mM|O Na2MoO4|O revealed|O complexes|O of|O similar|O size|O and|O shape|O in|O all|O clinical|O specimens|O tested|O and|O two|O established|O leukemic|B-cell_line cell|I-cell_line lines|I-cell_line .|O
They|O had|O Stokes|O radii|O (|O Rs|O )|O of|O 8.1|O +/-|O 0.5|O (|O S.D.|O )|O nm|O (|O n|O =|O 50|O )|O ,|O sedimentation|O coefficients|O of|O 9.5|O +/-|O 0.3S|O (|O n|O =|O 40|O )|O ,|O molecular|O weights|O of|O approximately|O 330|O ,|O 000|O ,|O and|O axial|O ratios|O (|O a/b|O )|O of|O approximately|O 12|O .|O
In|O hypertonic|O ,|O molybdate-free|O buffer|O ,|O these|O oligomeric|B-protein complexes|I-protein were|O dissociated|O into|O subunits|O with|O Rs|O of|O 5.9|O +/-|O 0.3|O nm|O (|O n|O =|O 12|O )|O and|O a/b|O of|O 11|O to|O 12|O ,|O as|O observed|O previously|O for|O other|O receptors|O .|O
Fragmentation|O of|O the|O oligomer|B-protein and|O the|O subunit|B-protein was|O evident|O in|O some|O cytosols|O .|O
High|O activities|O of|O peptidases|B-protein of|O various|O specificities|O were|O detected|O in|O leukemic|O cell|O cytosols|O ,|O as|O in|O other|O cytosols|O ,|O by|O fluorometric|O assays|O with|O derivatives|O of|O 7-amino-4-methylcoumarin|O .|O
Receptor|O cleavage|O by|O these|O and|O other|O endogenous|B-protein enzymes|I-protein may|O account|O for|O previous|O observations|O of|O ``|O abnormal|O ''|O receptors|O in|O cytosols|O from|O some|O leukemic|B-cell_type specimens|I-cell_type .|O
We|O conclude|O that|O intrinsic|O structural|O defects|O in|O the|O receptors|O are|O unlikely|O explanations|O for|O the|O unresponsiveness|O of|O some|O types|O of|O leukemia|O to|O steroid|O therapy|O .|O
Glucocorticoid|B-protein receptor|I-protein number|O and|O intracellular|O water|O space|O .|O
In|O order|O to|O elucidate|O the|O relationship|O between|O cell|O water|O content|O and|O number|O of|O glucocorticoid|B-protein receptors|I-protein ,|O eleven|O normal|O and|O malignant|B-cell_type lymphoid|I-cell_type or|I-cell_type myelomonocytic|I-cell_type cell|I-cell_type types|I-cell_type originating|O from|O mouse|O ,|O rat|O and|O man|O were|O investigated|O .|O
The|O cellular|O water|O space|O was|O measured|O with|O 3H2O|O ,|O and|O glucocorticoid|B-protein receptor|I-protein number|O was|O measured|O in|O a|O whole-cell|O binding|O assay|O with|O [|O 3H|O ]|O dexamethasone|O at|O 30|O and|O 37|O degrees|O C|O .|O
The|O intracellular|O water|O phase|O concentration|O of|O glucocorticoid|B-protein receptors|I-protein (|O around|O 40|O nmol/l|O cell|O water|O )|O ,|O and|O the|O dependence|O of|O receptor|O affinity|O on|O temperature|O were|O similar|O in|O normal|B-cell_type and|I-cell_type malignant|I-cell_type rodent|I-cell_type and|I-cell_type human|I-cell_type cells|I-cell_type .|O
It|O is|O concluded|O that|O comparisons|O of|O glucocorticoid|B-protein receptor|I-protein levels|O are|O best|O made|O on|O the|O basis|O of|O intracellular|B-protein receptor|I-protein concentrations|O .|O
Covalent|O labeling|O of|O rat|B-cell_type thymocyte|I-cell_type and|O human|B-protein lymphoid|I-protein glucocorticoid|I-protein receptor|I-protein .|O
Lymphoid|B-cell_type cells|I-cell_type contain|O specific|O receptors|B-protein for|O glucocorticoids|O .|O
We|O have|O used|O [|O 3H|O ]|O dexamethasone-21-mesylate|O to|O label|O covalently|O glucocorticoid|B-protein receptors|I-protein in|O rat|B-cell_type thymic|I-cell_type lymphocytes|I-cell_type and|O in|O neoplastic|B-cell_type cells|I-cell_type obtained|O from|O patients|O with|O acute|O lymphoblastic|O leukemia|O and|O malignant|O lymphoma|O .|O
The|O covalently|O labeled|O glucocorticoid|B-protein receptors|I-protein were|O identified|O by|O polyacrylamide|O gel|O electrophoresis|O (|O in|O the|O presence|O of|O 0.1|O %|O sodium|O dodecyl|O sulfate|O )|O .|O
In|O cytosolic|O fractions|O prepared|O from|O rat|B-cell_type thymic|I-cell_type lymphocytes|I-cell_type ,|O [|O 3H|O ]|O -dexamethasone-21-mesylate|O labels|O a|O protein|O (|O Mr|O approximately|O equal|O to|O 95|O ,|O 000|O )|O which|O was|O identified|O as|O the|O glucocorticoid|B-protein receptor|I-protein by|O the|O following|O criteria|O :|O (|O a|O )|O labeling|O of|O this|O moiety|O is|O inhibited|O by|O treatment|O with|O a|O 100-fold|O molar|O excess|O of|O glucocorticoids|O ,|O such|O as|O dexamethasone|O and|O triamcinolone|O acetonide|O ;|O and|O (|O b|O )|O the|O covalently|O labeled|O Mr|O approximately|O equal|O to|O 95|O ,|O 000|O protein|O is|O activated|O (|O by|O heating|O at|O 20|O degrees|O for|O 30|O min|O )|O to|O a|O form|O that|O binds|O to|O DNA-cellulose|O .|O
When|O intact|B-cell_type thymocytes|I-cell_type are|O treated|O with|O [|O 3H|O ]|O dexamethasone-21-mesylate|O ,|O an|O Mr|O approximately|O equal|O to|O 95|O ,|O 000|O moiety|O is|O also|O labeled|O covalently|O .|O
Approximately|O 35|O %|O of|O the|O glucocorticoid|B-protein receptors|I-protein can|O be|O labeled|O covalently|O when|O intact|O thymocytes|B-cell_type are|O treated|O with|O 100|O nM|O [|O 3H|O ]|O dexamethasone-21-mesylate|O for|O 30|O min|O at|O 4|O degrees|O .|O
Neoplastic|B-cell_type cells|I-cell_type from|O acute|O lymphoblastic|O leukemia|O and|O malignant|O lymphoma|O were|O treated|O with|O [|O 3H|O ]|O dexamethasone-21-mesylate|O .|O
In|O all|O samples|O ,|O an|O Mr|O approximately|O equal|O to|O 95|O ,|O 000|O moiety|O was|O labeled|O covalently|O ;|O labeling|O was|O inhibited|O by|O excess|O glucocorticoid|O .|O
Smaller|B-protein moieties|I-protein were|O also|O identified|O by|O competition|O experiments|O ;|O these|O may|O represent|O proteolytic|B-protein fragments|I-protein of|O the|O Mr|O approximately|O equal|O to|O 95|O ,|O 000|O receptor|O .|O
Thus|O ,|O in|O rat|B-cell_type and|I-cell_type human|I-cell_type lymphoid|I-cell_type cells|I-cell_type ,|O [|O 3H|O ]|O dexamethasone-21-mesylate|O can|O be|O used|O to|O label|O covalently|O the|O glucocorticoid|B-protein receptor|I-protein .|O
The|O association|O of|O cytosol|O oestrogen|B-protein and|I-protein progesterone|I-protein receptors|I-protein with|O histological|O features|O of|O breast|O cancer|O and|O early|O recurrence|O of|O disease|O .|O
Two|O hundred|O and|O eighty-eight|O primary|O breast|O tumours|O were|O examined|O for|O the|O presence|O or|O absence|O of|O oestrogen|B-protein (|I-protein REc|I-protein )|I-protein and|I-protein progesterone|I-protein (|I-protein RPc|I-protein )|I-protein receptors|I-protein .|O
Analysis|O has|O shown|O a|O relative|O interdependence|O between|O the|O steroid|B-protein receptor|I-protein status|O of|O primary|O breast|O cancer|O and|O other|O prognostic|O variables|O such|O as|O histological|O grade|O ,|O lymphocytic|O infiltration|O and|O tumour|O elastosis|O .|O
There|O were|O significant|O associations|O between|O epithelial|O cellularity|O ,|O stromal|O fibrosis|O and|O the|O value|O of|O REc|B-protein in|O those|O tumours|O in|O which|O the|O receptor|O was|O present|O .|O
Cellularity|O and|O fibrosis|O were|O unrelated|O to|O the|O presence|O or|O absence|O of|O oestrogen|B-protein receptor|I-protein .|O
By|O contrast|O ,|O neither|O the|O presence|O or|O absence|O nor|O the|O value|O of|O RPc|B-protein could|O be|O related|O to|O cellularity|O or|O fibrosis|O .|O
The|O value|O of|O REc|B-protein and|O RPc|B-protein analysis|O as|O an|O indicator|O of|O prognosis|O was|O examined|O in|O a|O sub-group|O of|O 175|O patients|O receiving|O no|O additional|O treatment|O following|O mastectomy|O .|O
Overall|O relapse-free|O survival|O (|O RFS|O )|O was|O no|O different|O for|O those|O patients|O with|O receptors|O compared|O to|O those|O without|O them|O (|O REc|B-protein P|O =|O 0.11|O ,|O RPc|O P|O =|O 0.7|O )|O .|O
There|O was|O no|O difference|O in|O RFS|O of|O receptor|O positive|O and|O negative|O tumours|O when|O the|O axillary|O node|O status|O was|O taken|O into|O account|O .|O
Clinical|O implications|O of|O glucocorticoid|B-protein receptors|I-protein in|O human|O leukemia|O .|O
Normal|B-cell_type lymphoid|I-cell_type cells|I-cell_type contain|O glucocorticoid|B-protein receptor|I-protein .|O
A|O variety|O of|O stimuli|O that|O activate|O these|O cells|O also|O induce|O increases|O in|O receptor|O concentration|O .|O
Similar|O glucocorticoid|B-protein receptors|I-protein can|O be|O detected|O in|O lymphoid|B-cell_type cells|I-cell_type from|O patients|O with|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O .|O
Absence|O of|O the|O glucocorticoid|B-protein receptor|I-protein (|O usually|O found|O in|O treated|O patients|O )|O predicts|O lack|O of|O glucocorticoid|O responsiveness|O .|O
Furthermore|O ,|O in|O our|O hands|O ,|O glucocorticoid|B-protein receptor|I-protein levels|O correlate|O with|O the|O duration|O of|O complete|O remission|O in|O ALL|O (|O though|O not|O in|O other|O forms|O of|O leukemia|O )|O .|O
This|O association|O is|O independent|O of|O cell|O type|O ,|O age|O ,|O sex|O ,|O or|O initial|O leukocyte|B-cell_type count|O .|O
The|O level|O of|O receptor|O shows|O a|O negative|O correlation|O with|O increasing|O aggressiveness|O of|O the|O tumor|O (|O null-cell|O leukemia|O greater|O than|O T-cell|O leukemia|O greater|O than|O Burkitt|O 's|O lymphoma|O )|O .|O
Corticosteroid-mediated|O immunoregulation|O in|O man|O .|O
Glucocorticoids|O have|O profound|O and|O complex|O effects|O on|O the|O human|O immune|O response|O .|O
However|O ,|O the|O precise|O mechanisms|O of|O the|O corticosteroid-induced|O immunoregulation|O in|O man|O have|O not|O been|O precisely|O defined|O .|O
Intracytoplasmic|B-protein corticosteroid-specific|I-protein receptors|I-protein appear|O to|O be|O an|O important|O common|O pathway|O for|O steroid-induced|O changes|O ,|O but|O variations|O of|O receptor|O parameters|O do|O not|O account|O for|O the|O multifaceted|O effects|O on|O the|O immune|O system|O .|O
Human|B-cell_type circulating|I-cell_type mononuclear|I-cell_type cells|I-cell_type redistribute|O out|O of|O the|O intravascular|O compartment|O following|O treatment|O with|O corticosteroids|O .|O
Although|O certain|O components|O at|O this|O redistribution|O phenomenon|O have|O been|O well-characterized|O ,|O the|O importance|O of|O this|O compartmental|O cellular|O shift|O with|O respect|O to|O the|O mechanisms|O of|O corticosteroid-induced|O immunoregulation|O are|O less|O well-defined|O .|O
Recent|O observations|O that|O activated|B-cell_type lymphocytes|I-cell_type may|O be|O sensitive|O to|O the|O lytic|O effects|O of|O glucocorticoids|O suggest|O that|O under|O certain|O situations|O the|O elimination|O of|O selected|O subsets|O of|O cells|O may|O be|O a|O relevant|O mechanism|O of|O corticosteroid-mediated|O immunoregulation|O in|O man|O .|O
Corticosteroid-mediated|O effects|O on|O monocyte|B-cell_type function|O may|O be|O an|O important|O mechanism|O of|O drug-induced|B-cell_type immunoregulation|I-cell_type in|O monocyte-dependent|B-cell_type responses|I-cell_type .|O
In|O some|O experimental|O conditions|O ,|O corticosteroids|O inhibit|O Interleukin|B-protein 1|I-protein production|O by|O monocytes|B-cell_type .|O
The|O immunoregulatory|O effects|O of|O corticosteroids|O on|O lymphocyte|B-cell_type immune|O responses|O are|O complex|O .|O
In|O vitro|O corticosteroids|O appear|O to|O selectively|O affect|O early|O immunoregulatory|O events|O as|O opposed|O to|O altering|O an|O established|O response|O .|O
Multiple|O sites|O of|O steroid-induced|O modulations|O of|O human|B-cell_type B|I-cell_type cell|I-cell_type responses|O have|O been|O defined|O .|O
Human|B-cell_line lymphoid|I-cell_line cell|I-cell_line lines|I-cell_line and|O glucocorticoids|O :|O II|O .|O
Whole|O cell|O and|O cytoplasmic|O binding|O properties|O of|O lymphoblastoid|B-cell_line ,|I-cell_line leukaemia|I-cell_line and|I-cell_line lymphoma|I-cell_line lines|I-cell_line .|O
The|O glucocorticoid|O binding|O properties|O of|O 18|O human|B-cell_line lymphoid|I-cell_line cell|I-cell_line lines|I-cell_line (|O HLCL|B-cell_line )|O have|O been|O investigated|O .|O
The|O specificity|O of|O steroid|O binding|O was|O confirmed|O with|O various|O glucocorticoid|O agonists|O and|O antagonists|O .|O
A|O gradation|O in|O whole|O cell|O and|O cytoplasmic|O glucocorticoid|O binding|O capacity|O was|O observed|O in|O the|O different|O cell|O line|O types|O :|O lymphoblastoid|B-cell_line greater|O than|O lymphoma|B-cell_line greater|O than|O leukaemia|B-cell_line .|O
The|O cytoplasmic|B-protein receptors|I-protein of|O leukaemia|B-cell_line and|I-cell_line lymphoblastoid|I-cell_line lines|I-cell_line appeared|O to|O contain|O both|O proteinaceous|O and|O phospholipid|O components|O .|O
Cytoplasmic|B-protein steroid-receptor|I-protein complexes|I-protein exhibited|O a|O wide|O range|O of|O sedimentation|O coefficients|O (|O 8.5-11.3S|O )|O in|O low|O ionic|O strength|O buffer|O but|O there|O was|O no|O correlation|O with|O cell|O line|O type|O or|O glucocorticoid|O sensitivity|O .|O
Activation|O of|O these|O complexes|O by|O heat|O (|O 37|O degrees|O C|O )|O or|O exposure|O to|O high|O ionic|O strength|O buffer|O (|O 0.3|O M|O NaCl|O )|O induced|O nuclear|O binding|O of|O steroid|O but|O only|O complexes|O in|O high|O ionic|O strength|O buffer|O manifested|O changes|O in|O sedimentation|O coefficient|O .|O
No|O correlation|O was|O observed|O between|O the|O level|O or|O nature|O of|O glucocorticoid|O binding|O and|O the|O cytolethal|O or|O cytostatic|O responsiveness|O of|O HLCL|B-cell_line to|O glucocorticoid|O treatment|O in|O vitro|O .|O
The|O resistance|O to|O cytolethal|O effects|O can|O not|O be|O ascribed|O to|O a|O failure|O of|O cells|O to|O take|O up|O and|O bind|O steroid|O or|O to|O significant|O differences|O in|O the|O molecular|O species|O of|O cytoplasmic|B-protein receptors|I-protein present|O .|O
The|O molecular|O mechanisms|O by|O which|O glucocorticoids|O achieve|O cytolethal|O responses|O in|O human|B-cell_type lymphoid|I-cell_type cells|I-cell_type
CD28|B-protein -mediated|O activation|O in|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type T|I-cell_type cells|I-cell_type :|O enhanced|O levels|O of|O reactive|O oxygen|O intermediates|O and|O c-Rel|B-protein nuclear|O translocation|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
We|O have|O analyzed|O the|O effect|O of|O complete|O T|O cell|O activation|O (|O anti-CD3|B-protein plus|O anti-CD28|B-protein )|O on|O the|O activation|O of|O NF-kappaB|B-protein in|O CD45RA+|B-cell_type (|I-cell_type naive|I-cell_type )|I-cell_type and|I-cell_type CD45RO+|I-cell_type (|I-cell_type memory/effector|I-cell_type )|I-cell_type T|I-cell_type cells|I-cell_type .|O
Long|O exposure|O (|O 24|O h|O )|O induced|O stronger|O NF-kappaB|B-protein DNA|O binding|O in|O CD45RA+|B-cell_type cells|I-cell_type than|O in|O CD45RO+|B-cell_type cells|I-cell_type .|O
Analysis|O of|O the|O nuclear|B-protein c-Rel|I-protein protein|I-protein indicated|O that|O after|O anti-CD3+anti-CD28|O stimulation|O the|O level|O of|O c-Rel|B-protein was|O higher|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
Analysis|O of|O the|O cytoplasmic|O inhibitor|O IkappaBalpha|B-protein indicated|O that|O anti-CD3+anti-CD28|O stimulation|O induced|O a|O long-lasting|O degradation|O in|O CD45RA+|B-cell_type cells|I-cell_type but|O in|O CD45RO+|B-cell_type cells|I-cell_type the|O degradation|O process|O was|O more|O rapid|O .|O
Because|O the|O CD28|O costimulus|O is|O known|O to|O induce|O the|O production|O of|O reactive|O oxygen|O intermediates|O (|O ROIs|O )|O ,|O the|O intracellular|O ROI|O levels|O in|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type cells|I-cell_type were|O compared|O by|O flow|O cytometry|O .|O
ROIs|O were|O produced|O in|O both|O cell|O types|O ,|O but|O more|O strongly|O in|O CD45RA+|B-cell_type cells|I-cell_type .|O
The|O data|O presented|O in|O this|O study|O further|O emphasize|O the|O differences|O between|O CD45RA+|B-cell_type and|I-cell_type CD45RO+|I-cell_type T|I-cell_type lymphocytes|I-cell_type in|O ROI-dependent|O signaling|O pathways|O .|O
Ikaros|B-protein in|O hemopoietic|B-cell_line lineage|I-cell_line determination|O and|O homeostasis|O .|O
Studies|O on|O the|O molecular|O mechanisms|O that|O control|O hemopoietic|O differentiation|O have|O focused|O on|O signaling|O cascades|O and|O nuclear|O effectors|O that|O drive|O this|O complex|O developmental|O system|O in|O a|O regulated|O fashion|O .|O
Here|O we|O review|O the|O role|O of|O Ikaros|B-protein ,|O the|O founding|O member|O of|O a|O unique|O family|O of|O zinc|B-protein finger|I-protein transcription|I-protein factors|I-protein in|O this|O developmental|O process|O .|O
Studies|O on|O an|O Ikaros|B-protein null|O mutation|O have|O revealed|O an|O essential|O role|O for|O this|O factor|O in|O lymphoid|B-cell_type cell|I-cell_type fate|O determination|O and|O at|O subsequent|O branch|O points|O of|O the|O T|B-cell_type cell|I-cell_type differentiation|O pathway|O .|O
Differences|O in|O the|O phenotypes|O of|O a|O null|O and|O a|O dominant|O negative|O (|O DN|O )|O Ikaros|O mutation|O provide|O insight|O into|O a|O regulatory|O network|O through|O which|O Ikaros|B-protein proteins|I-protein exert|O their|O effects|O in|O development|O .|O
In|O addition|O a|O comparative|O analysis|O of|O the|O hemopoietic|B-cell_type stem|I-cell_type cell|I-cell_type and|O precursor|O compartment|O resulting|O from|O the|O two|O Ikaros|B-protein mutations|O reveals|O a|O profound|O yet|O not|O absolute|O requirement|O for|O Ikaros|B-protein in|O the|O production|O and|O differentiation|O of|O these|O populations|O .|O
Overexpression|O of|O p65|O and|O c-Jun|O substitutes|O for|O B7-1|O costimulation|O by|O targeting|O the|O CD28RE|B-DNA within|O the|O IL-2|B-DNA promoter|I-DNA .|O
The|O role|O of|O Rel|B-protein and|O activation|B-protein protein-1|I-protein (|O AP-1|B-protein )|O in|O IL-2|B-DNA promoter|I-DNA activity|O in|O B7-1-|B-cell_type and|I-cell_type leukocyte|I-cell_type function-associated|I-cell_type Ag-3|I-cell_type (|I-cell_type LFA.|I-cell_type 3|I-cell_type )|I-cell_type -costimulated|I-cell_type T|I-cell_type cells|I-cell_type has|O been|O evaluated|O .|O
We|O demonstrate|O that|O overexpression|O of|O c-Jun|B-protein but|O not|O c-Fos|B-protein increases|O IL-2|B-DNA promoter|I-DNA activity|O in|O both|O B7-1-|B-cell_type and|I-cell_type LFA-3-costimulated|I-cell_type Jurkat|I-cell_type T|I-cell_type cells|I-cell_type .|O
Cotransfection|O of|O both|O c-Jun|O and|O c-Fos|O substitutes|O for|O B7-1|O costimulation|O in|O driving|O an|O activation|B-DNA protein-1|I-DNA response|I-DNA element|I-DNA but|O not|O for|O the|O IL-2|B-DNA promoter|I-DNA .|O
Overexpression|O of|O Rel|B-protein proteins|I-protein demonstrated|O that|O p65-expressing|B-cell_line Jurkat|I-cell_line cells|I-cell_line transcribed|O equally|O well|O a|O nuclear|B-DNA factor|I-DNA kappabeta|I-DNA reporter|I-DNA construct|I-DNA when|O costimulated|O with|O B7-1|B-protein or|O LFA-3|B-protein ,|O but|O transcription|O of|O IL-2|B-DNA promoter|I-DNA or|O CD28|B-DNA response|I-DNA element|I-DNA (|I-DNA CD28RE|I-DNA )|I-DNA -driven|I-DNA reporters|I-DNA was|O superior|O in|O B7-1-costimulated|B-cell_line cells|I-cell_line .|O
Combined|O expression|O of|O c-Jun|B-protein and|O p65|B-protein induced|O vigorous|O transcription|O of|O IL-2|B-DNA promoter-|I-DNA and|I-DNA CD28RE-driven|I-DNA reporter|I-DNA constructs|I-DNA in|O both|O LFA-3-|B-cell_type and|I-cell_type B7-1-costimulated|I-cell_type Jurkat|I-cell_type cells|I-cell_type .|O
Mutating|O the|O CD28RE|B-DNA but|O not|O the|O upstream|B-DNA nuclear|I-DNA factor|I-DNA kappabeta-binding|I-DNA site|I-DNA in|O the|O IL-2|B-DNA promoter|I-DNA reduced|O B7-1|B-protein -driven|O transcription|O >|O 90|O %|O .|O
The|O results|O implicates|O a|O major|O role|O of|O the|O CD28RE|B-DNA in|O the|O integration|O of|O p65|B-protein /|O c-Jun|B-protein -mediated|O transcription|O within|O the|O IL-2|B-DNA promoter|I-DNA .|O
We|O suggest|O that|O the|O transition|O from|O an|O autocrine|O LFA-3|B-protein -driven|O immune|O response|O to|O a|O B7|O --|O induced|O paracrine|O immune|O response|O involves|O the|O activation|O of|O c-Jun|B-protein and|O p65|B-protein ,|O which|O target|O the|O CD28RE|B-DNA region|O of|O the|O IL-2|B-DNA promoter|I-DNA .|O
Defects|O in|O actin-cap|O formation|O in|O Vav-deficient|O mice|O implicate|O an|O actin|O requirement|O for|O lymphocyte|O signal|O transduction|O .|O
BACKGROUND|O :|O Antigen-receptor|O interactions|O on|O lymphocytes|B-cell_type result|O in|O local|O clustering|O of|O actin|B-protein ,|O receptors|O and|O signaling|O molecules|O into|O an|O asymmetric|O membrane|O structure|O termed|O a|O cap|O .|O
Although|O actin|O polymerization|O is|O known|O to|O be|O required|O ,|O the|O mechanisms|O underlying|O cap|O formation|O are|O unclear|O .|O
We|O have|O studied|O the|O events|O underlying|O cap|O formation|O using|O mice|O bearing|O a|O null|O mutation|O in|O vav|B-DNA (|O vav|B-DNA -/-|O )|O ,|O a|O gene|O that|O encodes|O a|O guanine-nucleotide|B-protein exchange|I-protein factor|I-protein for|O the|O GTPase|B-protein Rac|I-protein .|O
RESULTS|O :|O Lymphocytes|B-cell_type from|O vav|B-DNA -/-|O mice|O failed|O to|O form|O T-cell|O receptor|O caps|O following|O activation|O and|O had|O a|O defective|O actin|O cytoskeleton|O .|O
The|O vav-/-|B-cell_type T|I-cell_type cells|I-cell_type were|O deficient|O in|O interleukin-2|O (|O IL-2|O )|O production|O and|O proliferation|O ,|O and|O the|O peak|O of|O Ca2+|O mobilization|O was|O reduced|O although|O of|O normal|O duration|O .|O
Activation|O of|O Jun|B-protein N-terminal|I-protein kinase|I-protein or|O stress-activated|B-protein kinase|I-protein (|O JNK|B-protein or|O SAPK|B-protein )|O and|O mitogen-activated|B-protein protein|I-protein kinase|I-protein (|O MAPK|B-protein )|O and|O the|O induction|O of|O the|O transcription|B-protein factor|I-protein NF-ATc1|B-DNA and|I-DNA egr-1|I-DNA genes|I-DNA was|O normal|O .|O
Despite|O the|O reduced|O Ca2+|O mobilization|O ,|O translocation|O of|O cytoplasmic|B-protein NF-ATc|I-protein to|O the|O nucleus|O was|O normal|O ,|O reflecting|O that|O the|O lower|O levels|O of|O Ca2+|O in|O vav-/-|B-cell_type cells|I-cell_type were|O still|O sufficient|O to|O activate|O calcineurin|B-protein .|O
Treatment|O of|O lymphocytes|B-cell_type with|O cytochalasin|O D|O ,|O which|O blocks|O actin|O polymerization|O ,|O inhibited|O cap|O formation|O and|O produced|O defects|O in|O signaling|O and|O IL-2|O transcriptional|O induction|O in|O response|O to|O antigen-receptor|O signaling|O that|O were|O nearly|O identical|O to|O those|O seen|O in|O vav-/-|B-cell_type cells|I-cell_type .|O
In|O transfection|O studies|O ,|O either|O constitutively|O active|O Vav|B-protein or|O Rac|B-protein could|O complement|O constitutively|O active|O calcineurin|B-protein to|O activate|O NF-AT-dependent|O transcription|O .|O
CONCLUSIONS|O :|O These|O results|O indicate|O that|O Vav|B-protein is|O required|O for|O cap|O formation|O in|O lymphocytes|B-cell_type .|O
Furthermore|O ,|O the|O correlation|O between|O cap|O formation|O ,|O IL-2|O production|O and|O proliferation|O supports|O the|O hypothesis|O that|O an|O actin-dependent|O pathway|O is|O a|O source|O of|O specialized|O growth|O regulatory|O signals|O .|O
CD14|B-protein -dependent|O activation|O of|O human|B-cell_type endothelial|I-cell_type cells|I-cell_type by|O Bacteroides|O fragilis|O outer|O membrane|O .|O
We|O studied|O the|O capacity|O of|O isolated|O Bacteriodes|O fragilis|O outer|O membrane|O ,|O B.|O fragilis|O NCTC9343|O lipopolysaccharide|O (|O LPS|O ;|O endotoxin|O )|O ,|O and|O B.|O fragilis|O NCTC9343|O capsular|O polysaccharides|O to|O activate|O human|O umbilical|O vein|O endothelial|O cell|O (|O HUVEC|O )|O monolayers|O .|O
To|O assess|O HUVEC|O activation|O ,|O E-selectin|B-protein expression|O was|O measured|O by|O enzyme-linked|O immunosorbent|O assay|O (|O ELISA|O )|O ,|O Northern|O blot|O analysis|O for|O E-selectin-specific|B-RNA mRNA|I-RNA ,|O and|O electrophoretic|O gel|O mobility|O shift|O assay|O (|O EMSA|O )|O for|O NF-kappa|B-protein B|I-protein ,|O a|O transcription|B-protein factor|I-protein necessary|O for|O E-selectin|B-DNA gene|I-DNA activation|O .|O
Exposure|O of|O HUVECs|B-cell_type to|O B.|O fragilis|O outer|O membrane|O fractions|O ,|O separated|O from|O other|O components|O of|O the|O B.|O fragilis|O cell|O wall|O by|O isopycnic|O ,|O sucrose|O gradient|O centrifugation|O ,|O significantly|O increased|O surface|O expression|O of|O E-selectin|B-protein and|O induced|O functional|O endothelial|B-cell_type cell|I-cell_type -dependent|O leukocyte|O adhesion|O .|O
B.|O fragilis|O outer|O membranes|O induced|O translocation|O of|O NF-kappa|B-protein B|I-protein to|O HUVEC|O nuclei|O and|O accumulation|O of|O E-selectin|B-RNA mRNA|I-RNA in|O HUVEC|O cytoplasm|O .|O
E-selectin|O expression|O induced|O by|O B.|O fragilis|O outer|O membranes|O was|O not|O blocked|O by|O polymixin|O B|O .|O
In|O contrast|O ,|O E-selectin|O expression|O induced|O by|O outer|O membrane|O fractions|O purified|O from|O E.|O coli|O was|O competitively|O inhibited|O by|O polymixin|O B|O .|O
Neither|O purified|O B.|O fragilis|O LPS|O ,|O a|O prominent|O constituent|O of|O the|O outer|O membrane|O ,|O nor|O purified|O B.|O fragilis|O capsular|O polysaccharides|O induced|O HUVEC|O activation|O .|O
Two|O different|O monoclonal|B-protein antibodies|I-protein directed|O against|O human|B-protein CD14|I-protein completely|O inhibited|O B.|O fragilis|O outer|O membrane-induced|O NF-kappa|B-protein B|I-protein activation|O ,|O E-selectin|O transcription|O ,|O and|O E-selectin|O surface|O expression|O .|O
We|O conclude|O that|O the|O outer|O membrane|O component|O of|O the|O B.|O fragilis|O cell|O wall|O contains|O a|O proinflammatory|O factor|O (|O s|O )|O ,|O that|O is|O not|O LPS|O ,|O which|O induces|O human|B-cell_type endothelial|I-cell_type cell|I-cell_type activation|O by|O a|O soluble|O CD14|B-protein -dependent|O mechanism|O .|O
NF-kappaB|B-protein protects|O HIV-1-infected|O myeloid|B-cell_type cells|I-cell_type from|O apoptosis|O .|O
HIV-1|O infection|O of|O primary|B-cell_type monocytic|I-cell_type cells|I-cell_type and|O myeloid|B-cell_line cell|I-cell_line lines|I-cell_line results|O in|O sustained|O NF-kappaB|O activation|O .|O
Recently|O ,|O NF-kappaB|O induction|O has|O been|O shown|O to|O play|O a|O role|O in|O protecting|O cells|O from|O programmed|O cell|O death|O .|O
In|O the|O present|O study|O ,|O we|O sought|O to|O investigate|O whether|O constitutive|O NF-kappaB|B-protein activity|O in|O chronically|O HIV-1-infected|O promonocytic|B-cell_line U937|I-cell_line (|I-cell_line U9-IIIB|I-cell_line )|I-cell_line and|I-cell_line myeloblastic|I-cell_line PLB-985|I-cell_line (|I-cell_line PLB-IIIB|I-cell_line )|I-cell_line cells|I-cell_line affects|O apoptotic|O signaling|O .|O
TNFalpha|B-protein and|O cycloheximide|O caused|O infected|O cells|O to|O undergo|O apoptosis|O more|O rapidly|O than|O parental|B-cell_line U937|I-cell_line and|O PLB-985|B-cell_line cells|I-cell_line .|O
Inhibition|O of|O TNFalpha|B-protein -induced|O NF-kappaB|O activation|O using|O the|O antioxidant|O N-acetylcysteine|O (|O NAC|O )|O resulted|O in|O increased|O apoptosis|O in|O both|O U937|B-cell_line and|I-cell_line U9-IIIB|I-cell_line cells|I-cell_line ,|O while|O preactivation|O of|O NF-kappaB|B-protein with|O the|O non-apoptotic|B-protein inducer|I-protein IL-1beta|I-protein caused|O a|O relative|O decrease|O in|O apoptosis|O .|O
Inhibition|O of|O constitutive|O NF-kappaB|B-protein activity|O in|O U9-IIIB|B-cell_line and|I-cell_line PLB-IIIB|I-cell_line cells|I-cell_line also|O induced|O apoptosis|O ,|O suggesting|O that|O NF-kappaB|B-cell_type protects|I-cell_type cells|I-cell_type from|O a|O persistent|O apoptotic|O signal|O .|O
TNFalpha|B-protein plus|O NAC|O treatment|O resulted|O in|O a|O marked|O decrease|O in|O Bcl-2|B-protein protein|I-protein levels|O in|O HIV-1-infected|B-cell_type cells|I-cell_type ,|O coupled|O with|O an|O increase|O in|O Bax|B-protein protein|I-protein compared|O to|O uninfected|O cells|O ,|O suggesting|O that|O the|O difference|O in|O susceptibility|O to|O TNFalpha|B-protein -induced|O apoptosis|O may|O relate|O to|O the|O differences|O in|O relative|O levels|O of|O Bcl-2|B-protein and|O Bax|B-protein .|O
The|O protective|O role|O of|O NF-kappaB|B-protein in|O blocking|O TNFalpha-|O and|O HIV-1-induced|O apoptosis|O was|O supported|O by|O studies|O in|O Jurkat|B-cell_line T|I-cell_line cells|I-cell_line engineered|O to|O express|O IkappaB|B-protein alpha|I-protein repressor|I-protein mutants|I-protein (|O TD-IkappaB|B-protein )|O under|O the|O control|O of|O a|O tetracycline-responsive|B-DNA promoter|I-DNA .|O
Cells|O underwent|O apoptosis|O in|O response|O to|O TNFalpha|B-protein only|O when|O NF-kappaB|O activation|O was|O inhibited|O by|O TD-IkappaB|B-protein expression|O .|O
As|O was|O observed|O for|O the|O U9-IIIB|B-cell_line cells|I-cell_line ,|O TNFalpha|B-protein treatment|O also|O induced|O a|O marked|O decrease|O in|O Bcl-2|B-protein protein|I-protein levels|O in|O TD-IkappaB|B-cell_type expressing|I-cell_type cells|I-cell_type .|O
These|O experiments|O demonstrate|O that|O apoptotic|O signaling|O is|O perturbed|O in|O HIV-1-infected|O U9-IIIB|B-cell_line cells|I-cell_line and|O indicate|O that|O NF-kappaB|O activation|O may|O play|O an|O additional|O protective|O role|O against|O HIV-1-induced|O apoptosis|O in|O myeloid|B-cell_type cells|I-cell_type .|O
Human|B-cell_type normal|I-cell_type peripheral|I-cell_type blood|I-cell_type B-lymphocytes|I-cell_type are|O deficient|O in|O DNA-dependent|O protein|O kinase|O activity|O due|O to|O the|O expression|O of|O a|O variant|O form|O of|O the|O Ku86|B-protein protein|I-protein .|O
The|O heterodimeric|O Ku|B-protein protein|I-protein ,|O which|O comprises|O a|O 86|B-protein kDa|I-protein (|I-protein Ku86|I-protein )|I-protein amd|O a|O 70|B-protein kDa|I-protein (|I-protein Ku70|I-protein )|I-protein subunits|I-protein ,|O is|O an|O abundant|O nuclear|B-protein DNA-binding|I-protein protein|I-protein which|O binds|O in|O vitro|O to|O DNA|B-DNA termini|I-DNA without|O sequence|O specificity|O .|O
Ku|B-protein is|O the|O DNA-targeting|B-protein component|I-protein of|O the|O large|O catalytic|B-protein sub-unit|I-protein of|O the|O DNA-dependent|B-protein protein|I-protein kinase|I-protein complex|I-protein (|O DNA-PK|B-protein [|I-protein CS|I-protein ]|I-protein )|O ,|O that|O plays|O a|O critical|O role|O in|O mammalian|O double-strand|O break|O repair|O and|O lymphoid|O V|O (|O D|O )|O J|O recombination|O .|O
By|O using|O electrophoretic|O mobility|O shift|O assays|O ,|O we|O demonstrated|O that|O in|O addition|O to|O the|O major|B-protein Ku|I-protein x|I-protein DNA|I-protein complex|I-protein usually|O detected|O in|O cell|O line|O extracts|O ,|O a|O second|O complex|O with|O faster|O electrophoretic|O mobility|O was|O observed|O in|O normal|O peripheral|B-cell_type blood|I-cell_type lymphocytes|I-cell_type (|O PBL|B-cell_type )|O extracts|O .|O
The|O presence|O of|O this|O faster|B-protein migrating|I-protein complex|I-protein was|O restricted|O to|O B|B-cell_type cells|I-cell_type among|O the|O circulating|B-cell_type lymphocyte|I-cell_type population|I-cell_type .|O
Western|O blot|O analysis|O revealed|O that|O B|B-cell_type cells|I-cell_type express|O a|O variant|O form|O of|O the|O Ku86|B-protein protein|I-protein with|O an|O apparent|O molecular|O weight|O of|O 69|O kDa|O ,|O and|O not|O the|O 86|B-protein kDa-|I-protein full-length|I-protein protein|I-protein .|O
Although|O the|O heterodimer|B-protein Ku70/variant-Ku86|I-protein binds|O to|O DNA-ends|B-DNA ,|O this|O altered|O form|O of|O the|O Ku|B-protein heterodimer|I-protein has|O a|O decreased|O ability|O to|O recruit|O the|O catalytic|B-protein component|I-protein of|O the|O complex|O ,|O DNA-PK|B-protein (|I-protein CS|I-protein )|I-protein ,|O which|O contributes|O to|O an|O absence|O of|O detectable|O DNA-PK|O activity|O in|O B|B-cell_type cells|I-cell_type .|O
These|O data|O provide|O a|O molecular|O basis|O for|O the|O increased|O sensitivity|O of|O B|B-cell_type cells|I-cell_type to|O ionizing|O radiation|O and|O identify|O a|O new|O mechanism|O of|O regulation|O of|O DNA-PK|O activity|O that|O operates|O in|O vivo|O .|O
Co-stimulation|O of|O human|B-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type with|O IL-2|B-protein and|O anti-CD3|B-protein monoclonal|I-protein antibodies|I-protein induces|O phosphorylation|O of|O CREB|B-protein .|O
Phosphorylation|O of|O the|O cAMP-response|B-protein element|I-protein binding|I-protein protein|I-protein CREB|I-protein within|O 1|O h|O of|O CD2|B-protein but|O not|O CD3|B-protein cross-linking|O of|O human|B-cell_type PBMC|I-cell_type was|O recently|O demonstrated|O .|O
The|O absence|O of|O P-CREB|B-protein following|O CD3|O cross-linking|O was|O unexpected|O ,|O as|O other|O laboratories|O reported|O increased|O phosphorylation|O of|O CREB|B-protein following|O CD3|O cross-linking|O of|O the|O Jurkat|B-cell_line lymphocyte|I-cell_line cell|I-cell_line line|I-cell_line .|O
Due|O to|O Jurkat|B-cell_line T-cells|I-cell_line being|O IL-2-independent|O ,|O it|O was|O postulated|O that|O IL-2|B-protein might|O provide|O a|O necessary|O co-stimulus|O for|O phosphorylation|O of|O CREB|B-protein in|O primary|B-cell_type lymphocytes|I-cell_type .|O
Therefore|O ,|O P-CREB|B-protein was|O evaluated|O following|O co-stimulation|O of|O human|B-cell_type PBMC|I-cell_type through|O the|O IL-2|B-protein and|I-protein CD2|I-protein or|I-protein CD3|I-protein receptors|I-protein .|O
IL-2|B-protein did|O not|O further|O augment|O phosphorylation|O of|O CREB|B-protein following|O CD2|O cross-linking|O .|O
However|O ,|O while|O neither|O IL-2|B-protein nor|O CD3|O cross-linking|O alone|O induced|O P-CREB|B-protein ,|O a|O 4.5-fold|O increase|O in|O phosphorylation|O of|O CREB|B-protein within|O 1|O h|O of|O IL-2/CD3|O co-stimulation|O was|O observed|O .|O
Phosphorylation|O was|O not|O associated|O with|O the|O induction|O of|O cAMP|O ,|O and|O inhibition|O of|O PKA|O signaling|O had|O no|O effect|O on|O P-CREB|B-protein .|O
Consistent|O with|O signal|O transduction|O through|O p56lck|B-protein or|O p59fyn|B-protein ,|O inhibition|O of|O PTK|O signaling|O reduced|O phosphorylation|O 50|O %|O .|O
Interestingly|O ,|O inhibiting|O PKC|O signaling|O with|O calphostin|O C|O further|O increased|O P-CREB|O levels|O 3-fold|O over|O that|O observed|O in|O IL-2/CD3|B-cell_type co-stimulated|I-cell_type cells|I-cell_type not|O pretreated|O with|O a|O PKC|O inhibitor|O .|O
In|O contrast|O to|O previous|O studies|O performed|O in|O the|O absence|O of|O exogenous|B-protein IL-2|I-protein ,|O no|O increase|O in|O binding|O of|O CREB|B-protein to|O a|O 32P-labeled|O oligonucleotide|O probe|O was|O observed|O by|O electrophoretic|O mobility|O shift|O assay|O .|O
These|O data|O suggest|O that|O the|O IL-2|B-protein and|O CD3|B-protein signaling|O pathways|O provide|O a|O necessary|O and|O co-operative|O stimulus|O promoting|O phosphorylation|O of|O CREB|B-protein following|O receptor|O cross-linking|O .|O
HIV-1|O infection|O induces|O a|O selective|O reduction|O in|O STAT5|O protein|O expression|O .|O
HIV-1|O infection|O is|O accompanied|O by|O qualitative|O and|O quantitative|O defects|O in|O CD4+|B-cell_type T|I-cell_type lymphocytes|I-cell_type .|O
Loss|O of|O immune|O function|O in|O HIV|O patients|O is|O usually|O associated|O with|O a|O profound|O dysregulation|O of|O cytokine|B-protein production|O .|O
To|O investigate|O whether|O cytokine|B-protein signaling|O defects|O occur|O during|O HIV|O infection|O ,|O PHA|B-cell_type blasts|I-cell_type from|O healthy|O human|O donors|O were|O infected|O with|O two|O strains|O of|O HIV-1|O and|O screened|O for|O the|O expression|O of|O STAT|B-protein proteins|I-protein used|O in|O cytokine|B-protein signaling|O .|O
A|O selective|O decrease|O in|O STAT5B|B-protein was|O seen|O 8|O days|O after|O infection|O with|O the|O BZ167|O dual-tropic|O HIV|O isolate|O ,|O but|O not|O with|O the|O Ba-L|O ,|O M-tropic|O strain|O .|O
Based|O on|O these|O findings|O ,|O purified|B-cell_type T|I-cell_type cells|I-cell_type from|O HIV-infected|O patients|O in|O different|O stages|O of|O disease|O were|O also|O tested|O for|O STAT|O expression|O ;|O decreases|O in|O STAT5A|B-protein ,|O STAT5B|B-protein ,|O and|O STAT1alpha|B-protein were|O observed|O in|O all|O patients|O .|O
The|O reduction|O in|O STATs|B-protein seen|O in|O vivo|O and|O in|O vitro|O after|O HIV|O infection|O may|O contribute|O to|O the|O loss|O of|O T|B-cell_type cell|I-cell_type function|O in|O HIV|O disease|O .|O
Transcription|B-protein factors|I-protein that|O regulate|O monocyte|B-cell_type /|O macrophage|B-cell_type differentiation|O .|O
Although|O all|O the|O cells|O in|O an|O organism|O contain|O the|O same|O genetic|O information|O ,|O differences|O in|O the|O cell|O phenotype|O arise|O from|O the|O expression|O of|O lineage-specific|B-DNA genes|I-DNA .|O
During|O myelopoiesis|O ,|O external|O differentiating|O signals|O regulate|O the|O expression|O of|O a|O set|O of|O transcription|B-protein factors|I-protein .|O
The|O combined|O action|O of|O these|O transcription|B-protein factors|I-protein subsequently|O determines|O the|O expression|O of|O myeloid-specific|B-DNA genes|I-DNA and|O the|O generation|O of|O monocytes|B-cell_type and|O macrophages|B-cell_type .|O
In|O particular|O ,|O the|O transcription|B-protein factor|I-protein PU.1|I-protein has|O a|O critical|O role|O in|O this|O process|O .|O
We|O review|O the|O contribution|O of|O several|O transcription|B-protein factors|I-protein to|O the|O control|O of|O macrophage|B-cell_type development|O
Transcription|B-protein factor|I-protein LKLF|I-protein is|O sufficient|O to|O program|O T|O cell|O quiescence|O via|O a|O c-Myc|O --|O dependent|O pathway|O .|O
T|B-cell_type lymphocytes|I-cell_type circulate|O in|O a|O quiescent|O state|O until|O they|O encounter|O cognate|B-protein antigen|I-protein bound|O to|O the|O surface|O of|O an|O antigen-presenting|B-cell_type cell|I-cell_type .|O
The|O molecular|O pathways|O that|O regulate|O T|O cell|O quiescence|O remain|O largely|O unknown|O .|O
Here|O we|O show|O that|O forced|O expression|O of|O the|O lung|B-protein Kruppel-like|I-protein transcription|I-protein factor|I-protein (|O LKLF|B-protein )|O in|O Jurkat|B-cell_line T|I-cell_line cells|I-cell_line is|O sufficient|O to|O program|O a|O quiescent|O phenotype|O characterized|O by|O decreased|O proliferation|O ,|O reduced|O cell|O size|O and|O protein|O synthesis|O and|O decreased|O surface|O expression|O of|O activation|O markers|O .|O
Conversely|O ,|O LKLF-deficient|B-cell_type peripheral|I-cell_type T|I-cell_type cells|I-cell_type produced|O by|O gene|O targeting|O showed|O increased|O proliferation|O ,|O increased|O cell|O size|O and|O enhanced|O expression|O of|O surface|O activation|O markers|O in|O vivo|O .|O
LKLF|B-protein appeared|O to|O function|O ,|O at|O least|O in|O part|O ,|O by|O decreasing|O expression|O of|O the|O proto-oncogene|B-DNA encoding|O c-Myc|B-protein .|O
Forced|O expression|O of|O LKLF|B-protein was|O associated|O with|O markedly|O decreased|O c-Myc|B-protein expression|O .|O
In|O addition|O ,|O many|O effects|O of|O LKLF|B-protein expression|O were|O mimicked|O by|O expression|O of|O the|O dominant-negative|B-protein MadMyc|I-protein protein|I-protein and|O rescued|O by|O overexpression|O of|O c-Myc|B-protein .|O
Thus|O ,|O LKLF|B-protein is|O both|O necessary|O and|O sufficient|O to|O program|O quiescence|O in|O T|B-cell_type cells|I-cell_type and|O functions|O ,|O in|O part|O ,|O by|O negatively|O regulating|O a|O c-Myc|O --|O dependent|O pathway|O .|O
HTLV-1|B-protein p12|I-protein (|I-protein I|I-protein )|I-protein protein|I-protein enhances|O STAT5|O activation|O and|O decreases|O the|O interleukin-2|B-protein requirement|O for|O proliferation|O of|O primary|B-cell_type human|I-cell_type peripheral|I-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type .|O
The|O p12|B-protein (|I-protein I|I-protein )|I-protein protein|I-protein ,|O encoded|O by|O the|O pX|B-DNA open|I-DNA reading|I-DNA frame|I-DNA I|I-DNA of|O the|O human|O T-lymphotropic|O virus|O type|O 1|O (|O HTLV-1|O )|O ,|O is|O a|O hydrophobic|B-protein protein|I-protein that|O localizes|O to|O the|O endoplasmic|O reticulum|O and|O the|O Golgi|O .|O
Although|O p12|B-protein (|I-protein I|I-protein )|I-protein contains|O 4|O minimal|O proline-rich|O ,|O src|B-protein homology|I-protein 3-binding|I-protein motifs|I-protein (|O PXXP|B-protein )|O ,|O a|O characteristic|O commonly|O found|O in|O proteins|O involved|O in|O signaling|O pathways|O ,|O it|O has|O not|O been|O known|O whether|O p12|B-protein (|I-protein I|I-protein )|I-protein has|O a|O role|O in|O modulating|O intracellular|O signaling|O pathways|O .|O
This|O study|O demonstrated|O that|O p12|B-protein (|I-protein I|I-protein )|I-protein binds|O to|O the|O cytoplasmic|B-protein domain|I-protein of|O the|O interleukin-2|B-protein receptor|I-protein (|I-protein IL-2R|I-protein )|I-protein beta|I-protein chain|I-protein that|O is|O involved|O in|O the|O recruitment|O of|O the|O Jak1|B-protein and|I-protein Jak3|I-protein kinases|I-protein .|O
As|O a|O result|O of|O this|O interaction|O ,|O p12|B-protein (|I-protein I|I-protein )|I-protein increases|O signal|B-protein transducers|I-protein and|I-protein activators|I-protein of|I-protein transcription|I-protein 5|I-protein (|O STAT5|B-protein )|O DNA|O binding|O and|O transcriptional|O activity|O and|O this|O effect|O depends|O on|O the|O presence|O of|O both|O IL-2R|B-protein beta|I-protein and|I-protein gamma|I-protein (|I-protein c|I-protein )|I-protein chains|I-protein and|O Jak3|B-protein .|O
Transduction|O of|O primary|B-cell_line human|I-cell_line peripheral|I-cell_line blood|I-cell_line mononuclear|I-cell_line cells|I-cell_line (|O PBMCs|B-cell_type )|O with|O a|O human|B-DNA immunodeficiency|I-DNA virus|I-DNA type|I-DNA 1-based|I-DNA retroviral|I-DNA vector|I-DNA expressing|O p12|B-protein (|I-protein I|I-protein )|I-protein also|O resulted|O in|O increased|O STAT5|B-protein phosphorylation|O and|O DNA|O binding|O .|O
However|O ,|O p12|B-protein (|I-protein I|I-protein )|I-protein could|O increase|O proliferation|O of|O human|B-cell_type PBMCs|I-cell_type only|O after|O stimulation|O of|O T-cell|B-protein receptors|I-protein by|O treatment|O of|O cells|O with|O low|O concentrations|O of|O alphaCD3|B-protein and|I-protein alphaCD28|I-protein antibodies|I-protein .|O
In|O addition|O ,|O the|O proliferative|O advantage|O of|O p12|B-cell_type (|I-cell_type I|I-cell_type )|I-cell_type -transduced|I-cell_type PBMCs|I-cell_type was|O evident|O mainly|O at|O low|O concentrations|O of|O IL-2|B-protein .|O
Together|O ,|O these|O data|O indicate|O that|O p12|B-protein (|I-protein I|I-protein )|I-protein may|O confer|O a|O proliferative|O advantage|O on|O HTLV-1-infected|B-cell_type cells|I-cell_type in|O the|O presence|O of|O suboptimal|O antigen|O stimulation|O and|O that|O this|O event|O may|O account|O for|O the|O clonal|O proliferation|O of|O infected|B-cell_type T|I-cell_type cells|I-cell_type in|O vivo|O .|O
(|O Blood.|O 2001|O ;|O 98|O :|O 823-829|O )|O
Single|O dose|O intranasal|O administration|O of|O retinal|B-protein autoantigen|I-protein generates|O a|O rapid|O accumulation|O and|O cell|O activation|O in|O draining|O lymph|O node|O and|O spleen|O :|O implications|O for|O tolerance|O therapy|O .|O
BACKGROUND/AIMS|O :|O A|O single|O intranasal|O delivery|O of|O retinal|B-protein autoantigen|I-protein suppresses|O effectively|O experimental|O autoimmune|O uveoretinitis|O (|O EAU|O )|O .|O
To|O further|O unravel|O underlying|O mechanisms|O the|O authors|O wished|O to|O determine|O ,|O firstly|O ,|O the|O kinetics|O of|O antigen|O delivery|O and|O ,|O secondly|O ,|O the|O early|O cellular|O responses|O involved|O in|O the|O initial|O stages|O of|O nasal|O mucosal|O tolerance|O induction|O .|O
METHODS|O :|O Flow|O cytometry|O ,|O cell|O proliferation|O assays|O ,|O and|O microscopy|O were|O used|O to|O track|O antigen|B-protein following|O a|O single|O ,|O intranasal|O dose|O of|O Alexa-488|B-protein labelled|I-protein retinal|I-protein antigen|I-protein .|O
RESULTS|O :|O A|O rapid|O accumulation|O of|O antigen|B-protein within|O both|O superficial|O cervical|O lymph|O nodes|O (|O SCLN|O )|O and|O spleen|O was|O observed|O after|O 30|O minutes|O .|O
Significant|O proliferative|O responses|O to|O IRBP|O were|O elicited|O by|O 48|O hours|O indicating|O that|O systemic|O priming|O of|O naive|B-cell_type T|I-cell_type cells|I-cell_type to|O retinal|B-protein antigen|I-protein had|O occurred|O .|O
Cell|O activation|O was|O further|O confirmed|O by|O immunoprecipitation|O studies|O ,|O which|O demonstrated|O phosphorylation|O of|O STAT4|B-protein but|O not|O STAT6|B-protein in|O both|O lymph|O nodes|O and|O spleen|O .|O
However|O ,|O at|O 24|O hours|O ,|O STAT4|O heterodimerisation|O with|O STAT|B-protein 3|I-protein was|O only|O observed|O in|O spleen|O .|O
CONCLUSIONS|O :|O The|O results|O provide|O novel|O evidence|O that|O following|O a|O single|O intranasal|O application|O rapid|O transfer|O of|O antigen|B-protein occurs|O .|O
Resulting|O T|O cell|O proliferation|O develops|O consequent|O to|O differential|O cell|O signalling|O in|O SCLN|O and|O spleen|O .|O
Further|O understanding|O of|O these|O underlying|O cellular|O mechanisms|O ,|O in|O particular|O as|O is|O inferred|O by|O the|O results|O the|O contribution|O of|O local|O versus|O systemic|O tolerance|O induction|O ,|O may|O assist|O in|O strategies|O to|O clinically|O apply|O mucosal|O tolerance|O therapy|O successfully|O .|O
Regulation|O of|O interleukin|B-protein (|I-protein IL|I-protein )|I-protein -18|I-protein receptor|I-protein alpha|I-protein chain|I-protein expression|O on|O CD4|B-cell_type (|I-cell_type +|I-cell_type )|I-cell_type T|I-cell_type cells|I-cell_type during|O T|O helper|O (|O Th|O )|O 1/Th2|O differentiation|O .|O
Critical|O downregulatory|O role|O of|O IL-4|B-protein .|O
Interleukin|B-protein (|I-protein IL|I-protein )|I-protein -18|I-protein has|O been|O well|O characterized|O as|O a|O costimulatory|B-protein factor|I-protein for|O the|O induction|O of|O IL-12-mediated|B-protein interferon|I-protein (|I-protein IFN|I-protein )|I-protein -gamma|I-protein production|O by|O T|B-cell_type helper|I-cell_type (|I-cell_type Th|I-cell_type )|I-cell_type 1|I-cell_type cells|I-cell_type ,|O but|O also|O can|O induce|O IL-4|O production|O and|O thus|O facilitate|O the|O differentiation|O of|O Th2|B-cell_type cells|I-cell_type .|O
To|O determine|O the|O mechanisms|O by|O which|O IL-18|B-protein might|O regulate|O these|O diametrically|O distinct|O immune|O responses|O ,|O we|O have|O analyzed|O the|O role|O of|O cytokines|B-protein in|O the|O regulation|O of|O IL-18|B-protein receptor|I-protein alpha|I-protein chain|I-protein (|O IL-18Ralpha|B-protein )|O expression|O .|O
The|O majority|O of|O peripheral|B-cell_type CD4|I-cell_type (|I-cell_type +|I-cell_type )|I-cell_type T|I-cell_type cells|I-cell_type constitutively|O expressed|O the|O IL-18Ralpha|B-protein .|O
Upon|O antigen|O stimulation|O in|O the|O presence|O of|O IL-12|B-protein ,|O marked|O enhancement|O of|O IL-18Ralpha|B-protein expression|O was|O observed|O .|O
IL-12|B-protein -mediated|O upregulation|O of|O IL-18Ralpha|B-protein required|O IFN-gamma|B-protein .|O
Activated|B-cell_type CD4|I-cell_type (|I-cell_type +|I-cell_type )|I-cell_type T|I-cell_type cells|I-cell_type that|O expressed|O low|O levels|O of|O IL-18Ralpha|B-protein could|O produce|O IFN-gamma|B-protein when|O stimulated|O with|O the|O combination|O of|O IL-12|B-protein and|O IL-18|B-protein ,|O while|O CD4|B-cell_type (|I-cell_type +|I-cell_type )|I-cell_type cells|I-cell_type which|O expressed|O high|O levels|O of|O IL-18Ralpha|B-protein could|O respond|O to|O IL-18|B-protein alone|O .|O
In|O contrast|O ,|O T|O cell|O stimulation|O in|O the|O presence|O of|O IL-4|B-protein resulted|O in|O a|O downregulation|O of|O IL-18Ralpha|B-protein expression|O .|O
Both|O IL-4|B-cell_type (|I-cell_type -/|I-cell_type )|I-cell_type -|I-cell_type and|I-cell_type signal|I-cell_type transducer|I-cell_type and|I-cell_type activator|I-cell_type of|I-cell_type transcription|I-cell_type (|I-cell_type Stat|I-cell_type )|I-cell_type 6|I-cell_type (|I-cell_type -/|I-cell_type )|I-cell_type -|I-cell_type T|I-cell_type cells|I-cell_type expressed|O higher|O levels|O of|O IL-18Ralpha|B-protein after|O TCR|O stimulation|O .|O
Furthermore|O ,|O activated|B-cell_type T|I-cell_type cells|I-cell_type from|O Stat6|O (|O -/|O )|O -|O mice|O produced|O more|O IFN-gamma|B-protein in|O response|O to|O IL-18|B-protein than|O wild-type|O controls|O .|O
Thus|O ,|O positive/negative|O regulation|O of|O the|O IL-18Ralpha|B-protein by|O the|O major|O inductive|O cytokines|B-protein (|O IL-12|B-protein and|O IL-4|B-protein )|O determines|O the|O capacity|O of|O IL-18|B-protein to|O polarize|O an|O immune|O response|O .|O
Glucocorticoid-regulated|B-protein transcription|I-protein factors|I-protein .|O
Glucocorticoids|O are|O the|O most|O effective|O antiinflammatory|O drugs|O used|O in|O the|O treatment|O of|O asthma|O .|O
They|O act|O by|O binding|O to|O a|O specific|O receptor|O (|O GR|B-protein )|O that|O ,|O upon|O activation|O ,|O translocates|O to|O the|O nucleus|O and|O either|O increases|O (|O transactivates|O )|O or|O decreases|O (|O transrepresses|O )|O gene|O expression|O .|O
Inhibition|O of|O pro-inflammatory|B-protein transcription|I-protein factors|I-protein such|O as|O activator|B-protein protein|I-protein (|I-protein AP|I-protein )|I-protein -1|I-protein ,|O signal|B-protein transducers|I-protein and|I-protein activators|I-protein of|I-protein transcription|I-protein (|O STATs|B-protein )|O ,|O nuclear|B-protein factor|I-protein of|I-protein activated|I-protein T|I-protein cells|I-protein (|O NFAT|B-protein )|O and|O nuclear|B-protein factor|I-protein (|I-protein NF|I-protein )|I-protein -kappa|I-protein B|I-protein is|O thought|O to|O be|O a|O major|O action|O of|O glucocorticoids|O .|O
Acetylation|O of|O histones|B-protein allows|O unwinding|O of|O the|O local|B-DNA DNA|I-DNA structure|I-DNA and|O enables|O RNA|B-protein polymerase|I-protein II|I-protein to|O enhance|O gene|O transcription|O .|O
Histone|O acetylation|O is|O regulated|O by|O a|O balance|O between|O the|O activity|O of|O histone|B-protein acetyltransferases|I-protein (|O HATs|B-protein )|O and|O histone|B-protein deacetylases|I-protein (|O HDACs|B-protein )|O .|O
GR|B-protein acts|O as|O a|O direct|O inhibitor|O of|O NF-kappa|O B-induced|O HAT|O activity|O and|O also|O by|O recruiting|O HDAC2|B-protein to|O the|O NF-kappa|B-protein B/HAT|I-protein complex|I-protein .|O
A|O sub-group|O of|O patients|O with|O glucocorticoid-insensitive|O asthma|O have|O an|O inability|O to|O induce|O histone|O acetylation|O in|O response|O to|O dexamethasone|O suggesting|O reduced|O expression|O of|O a|O GR-specific|B-protein HAT|I-protein .|O
This|O suggests|O that|O pharmacological|O manipulation|O of|O specific|O histone|O acetylation|O status|O is|O a|O potentially|O useful|O approach|O for|O the|O treatment|O of|O inflammatory|O diseases|O .|O
Identification|O of|O the|O precise|O mechanism|O by|O which|O activated|B-protein GR|I-protein recruits|O HDAC2|B-protein may|O reveal|O new|O targets|O for|O the|O development|O of|O drugs|O that|O may|O dissociate|O the|O antiinflammatory|O actions|O of|O glucocorticoids|O from|O their|O side|O effects|O that|O are|O largely|O due|O to|O gene|O induction|O .|O
Copyright|O Academic|O Press|O .|O
Differential|O ultraviolet-B-induced|O immunomodulation|O in|O XPA|O ,|O XPC|O ,|O and|O CSB|O DNA|O repair-deficient|O mice|O .|O
Ultraviolet|O B|O irradiation|O has|O serious|O consequences|O for|O cellular|O immunity|O and|O can|O suppress|O the|O rejection|O of|O skin|O tumors|O and|O the|O resistance|O to|O infectious|O diseases|O .|O
DNA|O damage|O plays|O a|O crucial|O role|O in|O these|O immunomodulatory|O effects|O of|O ultraviolet|O B|O ,|O as|O impaired|O repair|O of|O ultraviolet-B-induced|O DNA|O damage|O has|O been|O shown|O to|O cause|O suppression|O of|O cellular|O immunity|O .|O
Ultraviolet-B-induced|O DNA|O damage|O is|O repaired|O by|O the|O nucleotide|O excision|O repair|O mechanism|O very|O efficiently|O .|O
Nucleotide|O excision|O repair|O comprises|O two|O subpathways|O :|O transcription-coupled|O and|O global|O genome|O repair|O .|O
In|O this|O study|O the|O immunologic|O consequences|O of|O specific|O nucleotide|O excision|O repair|O defects|O in|O three|O mouse|O models|O ,|O XPA|O ,|O XPC|O ,|O and|O CSB|O mutant|O mice|O ,|O were|O investigated|O .|O
XPA|O mice|O carry|O a|O total|O nucleotide|O excision|O repair|O defect|O ,|O whereas|O XPC|O and|O CSB|O mice|O only|O lack|O global|O genome|O and|O transcription-coupled|O nucleotide|O excision|O repair|O ,|O respectively|O .|O
Our|O data|O demonstrate|O that|O cellular|O immune|O parameters|O in|O XPA|O ,|O XPC|O ,|O and|O CSB|O mice|O are|O normal|O compared|O with|O their|O wild-type|O (|O control|O )|O littermates|O .|O
This|O may|O indicate|O that|O the|O reported|O altered|O cellular|O responses|O in|O xeroderma|O pigmentosum|O patients|O are|O not|O constitutive|O but|O could|O be|O due|O to|O external|O factors|O ,|O such|O as|O ultraviolet|O B|O .|O
Upon|O exposure|O to|O ultraviolet|O B|O ,|O only|O XPA|O mice|O are|O very|O sensitive|O to|O ultraviolet-B-induced|O inhibition|O of|O Th1-mediated|O contact|O hypersensitivity|O responses|O and|O interferon-gamma|B-protein production|O in|O skin|O draining|O lymph|O nodes|O .|O
Lipopolysaccharide-stimulated|O tumor|B-protein necrosis|I-protein factor|I-protein alpha|I-protein and|O interleukin-10|B-protein production|O are|O significantly|O augmented|O in|O both|O XPA|O and|O CSB|O mice|O after|O ultraviolet|O B|O exposure|O .|O
Lymph|O node|O cell|O numbers|O were|O increased|O very|O significantly|O in|O XPA|O ,|O mildly|O increased|O in|O CSB|O ,|O and|O not|O in|O XPC|O mice|O .|O
In|O general|O XPC|O mice|O do|O not|O exhibit|O any|O indication|O of|O enhanced|O ultraviolet|O B|O susceptibility|O with|O regard|O to|O the|O immune|O parameters|O analyzed|O .|O
These|O data|O suggest|O that|O both|O global|O genome|O repair|O and|O transcription-coupled|O repair|O are|O needed|O to|O prevent|O immunomodulation|O by|O ultraviolet|O B|O ,|O whereas|O transcription-coupled|O repair|O is|O the|O major|O DNA|O repair|O subpathway|O of|O nucleotide|O excision|O repair|O that|O prevents|O the|O acute|O ultraviolet-B-induced|O effects|O such|O as|O erythema|O .|O
Biomechanical|O strain|O induces|O class|O a|O scavenger|B-protein receptor|I-protein expression|O in|O human|B-cell_type monocyte/macrophages|I-cell_type and|O THP-1|B-cell_type cells|I-cell_type :|O a|O potential|O mechanism|O of|O increased|O atherosclerosis|O in|O hypertension|O .|O
BACKGROUND|O :|O Although|O hypertension|O is|O an|O important|O risk|O factor|O for|O the|O development|O of|O atherosclerosis|O ,|O the|O mechanisms|O for|O this|O interaction|O are|O incompletely|O described|O .|O
Previous|O studies|O have|O suggested|O that|O biomechanical|O strain|O regulates|O macrophage|O phenotype|O .|O
We|O tested|O the|O hypothesis|O that|O biomechanical|O strain|O can|O induce|O expression|O of|O the|O class|B-protein A|I-protein scavenger|I-protein receptor|I-protein (|O SRA|B-protein )|O ,|O an|O important|O lipoprotein|B-protein receptor|I-protein in|O atherogenesis|O .|O
METHODS|O AND|O RESULTS|O :|O Human|B-cell_type monocyte/macrophages|I-cell_type or|O THP-1|B-cell_type cells|I-cell_type were|O cultured|O in|O a|O device|O that|O imposes|O uniform|O biaxial|O cyclic|O 1-Hz|O strains|O of|O 0|O %|O ,|O 1|O %|O ,|O 2|O %|O ,|O or|O 3|O %|O ,|O and|O SRA|B-protein expression|O was|O analyzed|O .|O
Mechanical|O strains|O induced|O SRA|B-RNA mRNA|I-RNA (|O 3.5+/-0.6-fold|O at|O 3|O %|O strain|O for|O 48|O hours|O ,|O P|O <|O 0.01|O )|O and|O SRA|B-protein protein|I-protein in|O THP-1|B-cell_type cells|I-cell_type in|O an|O amplitude-dependent|O manner|O .|O
This|O induction|O was|O accompanied|O by|O augmented|O expression|O of|O the|O class|B-protein B|I-protein scavenger|I-protein receptor|I-protein CD36|I-protein (|O 2.8+/-0.3-fold|O ,|O P|O <|O 0.001|O )|O but|O not|O by|O increased|O peroxisome|B-protein proliferator-activated|I-protein receptor-gamma|I-protein expression|O .|O
To|O evaluate|O this|O effect|O in|O vivo|O ,|O apolipoprotein|O E|O (|O -/-|O )|O mice|O were|O randomly|O assigned|O to|O receive|O standard|O chow|O ,|O a|O high-cholesterol|O diet|O ,|O or|O a|O high-cholesterol|O diet|O with|O hypertension|O induced|O by|O angiotensin|O II|O infusion|O for|O 8|O weeks|O .|O
Immunohistochemistry|O revealed|O that|O among|O macrophages|B-cell_type in|O atherosclerotic|O lesions|O of|O the|O aorta|O ,|O the|O proportion|O of|O macrophages|B-cell_type with|O SRA|B-protein expression|O was|O highest|O in|O hypertensive|O animals|O on|O a|O high-cholesterol|O diet|O (|O 43.9+/-0.7|O %|O ,|O versus|O 12.0+/-2.0|O %|O for|O normotensive|O animals|O on|O a|O high-cholesterol|O diet|O and|O 4.7+/-4.7|O %|O for|O animals|O on|O standard|O chow|O ;|O P|O <|O 0.001|O )|O .|O
CONCLUSIONS|O :|O Biomechanical|O strain|O induces|O SRA|B-protein expression|O by|O monocyte/macrophages|B-cell_type ,|O suggesting|O a|O novel|O mechanism|O for|O promotion|O of|O atherosclerosis|O in|O hypertensive|O patients|O .|O
High|O glucose|O induces|O MCP-1|O expression|O partly|O via|O tyrosine|O kinase-AP-1|O pathway|O in|O peritoneal|B-cell_type mesothelial|I-cell_type cells|I-cell_type .|O
BACKGROUND|O :|O High|O glucose|O in|O peritoneal|O dialysis|O solutions|O has|O been|O implicated|O in|O the|O pathogenesis|O of|O peritoneal|O fibrosis|O in|O chronic|O ambulatory|O peritoneal|O dialysis|O (|O CAPD|O )|O patients|O .|O
However|O ,|O the|O mechanisms|O are|O not|O very|O clear|O .|O
Peritoneal|B-cell_type macrophages|I-cell_type seem|O to|O participate|O in|O the|O process|O of|O peritoneal|O fibrosis|O and|O monocyte|B-protein chemoattractant|I-protein protein-1|I-protein (|O MCP-1|B-protein )|O plays|O a|O key|O role|O in|O the|O recruitment|O of|O monocytes|B-cell_type toward|O the|O peritoneal|O cavity|O .|O
However|O ,|O little|O is|O known|O about|O the|O effect|O of|O high|O glucose|O on|O MCP-1|B-protein expression|O and|O its|O signal|O transduction|O pathway|O in|O human|B-cell_type peritoneal|I-cell_type mesothelial|I-cell_type cells|I-cell_type .|O
METHODS|O :|O Mesothelial|B-cell_type cells|I-cell_type were|O cultured|O with|O glucose|O (|O 5|O to|O 100|O mmol/L|O )|O or|O mannitol|O chronically|O for|O up|O to|O seven|O days|O .|O
MCP-1|B-protein expression|O of|O mRNA|O and|O protein|O was|O measured|O by|O Northern|O blot|O analysis|O and|O enzyme-linked|O immunosorbent|O assay|O (|O ELISA|O )|O .|O
Chemotactic|O activity|O of|O high-glucose-conditioned|O culture|O supernatant|O was|O measured|O by|O chemotactic|O assay|O .|O
To|O examine|O the|O roles|O of|O the|O transcription|B-protein factors|I-protein activator|B-protein protein-1|I-protein (|O AP-1|B-protein )|O and|O nuclear|B-protein factor-kappaB|I-protein (|O NF-kappaB|B-protein )|O ,|O electrophoretic|O mobility|O shift|O assay|O (|O EMSA|O )|O was|O performed|O .|O
RESULTS|O :|O Glucose|O induced|O MCP-1|B-RNA mRNA|I-RNA expression|O in|O a|O time-|O and|O dose-dependent|O manner|O .|O
MCP-1|B-protein protein|I-protein in|O cell|O culture|O supernant|O was|O also|O increased|O .|O
Equivalent|O concentrations|O of|O mannitol|O had|O no|O significant|O effect|O .|O
High-glucose-conditioned|O supernatant|O possessed|O an|O increased|O chemotactic|O activity|O for|O monocytes|B-cell_type ,|O which|O was|O neutralized|O by|O anti-MCP-1|B-protein antibody|I-protein .|O
EMSA|O revealed|O that|O glucose|O increased|O the|O AP-1|B-protein binding|O activity|O in|O a|O time-|O and|O dose-dependent|O manner|O ,|O but|O not|O NF-kappaB|B-protein .|O
Curcumin|O ,|O an|O inhibitor|O of|O AP-1|B-protein ,|O dose-dependently|O suppressed|O the|O induction|O of|O MCP-1|B-RNA mRNA|I-RNA by|O high|O glucose|O .|O
Tyrosine|O kinase|O inhibitors|O such|O as|O genistein|O (|O 12.5|O to|O 50|O micromol/L|O )|O and|O herbimycin|O A|O (|O 0.1|O to|O 1|O micromol/L|O )|O inhibited|O the|O high-glucose-induced|O MCP-1|B-RNA mRNA|I-RNA expression|O in|O a|O dose-dependent|O manner|O ,|O and|O also|O suppressed|O the|O high-glucose-induced|O AP-1|B-protein binding|O activity|O .|O
CONCLUSIONS|O :|O :|O High|O glucose|O induced|O mesothelial|O MCP-1|B-protein expression|O partly|O via|O the|O tyrosine|O kinase-|O AP-1|B-protein pathway|O .|O
Signal|O thresholds|O and|O modular|O synergy|O during|O expression|O of|O costimulatory|O molecules|O in|O B|B-cell_type lymphocytes|I-cell_type .|O
We|O analyzed|O intracellular|O pathways|O modulating|O surface|O densities|O of|O CD80|B-protein and|O CD86|B-protein in|O B|B-cell_type cells|I-cell_type activated|O through|O ligation|O of|O the|O Ag|B-protein receptor|I-protein ,|O and|O the|O adhesion|B-protein molecule|I-protein CD54|B-protein .|O
Whereas|O B|B-protein cell|I-protein Ag|I-protein receptor|I-protein (|O BCR|B-protein )|O cross-linking|O alone|O stimulated|O increased|O expression|O of|O CD86|B-protein ,|O up-regulation|O of|O CD80|B-protein required|O dual|O stimulation|O with|O anti-IgM|B-protein and|O anti-CD54|B-protein .|O
The|O principal|O downstream|O component|O contributed|O by|O BCR|B-protein signaling|O ,|O toward|O both|O CD80|B-protein and|O CD86|B-protein induction|O ,|O was|O the|O elevated|O concentration|O of|O free|O cytoplasmic|O Ca|O (|O 2+|O )|O ,|O recruited|O by|O way|O of|O capacitative|O influx|O .|O
This|O alone|O was|O sufficient|O to|O generate|O an|O increase|O in|O CD86|B-protein levels|O .|O
However|O ,|O CD80|B-protein enhancement|O required|O the|O concerted|O action|O of|O both|O intracellular|O Ca|O (|O 2+|O )|O concentration|O and|O CD54-initiated|O pathways|O .|O
The|O nexus|O between|O anti-IgM|O and|O anti-CD54|O stimulation|O ,|O in|O the|O context|O of|O CD80|B-protein regulation|O ,|O was|O identified|O to|O involve|O a|O self-propagating|O process|O of|O sequential|O synergy|O .|O
The|O first|O step|O involved|O amplified|O accumulation|O of|O intracellular|O cAMP|O ,|O as|O a|O result|O of|O cross-talk|O between|O BCR|B-protein -mobilized|O Ca|O (|O 2+|O )|O and|O CD54-derived|O signals|O .|O
This|O then|O facilitated|O a|O second|O synergistic|O interaction|O between|O Ca|O (|O 2+|O )|O and|O cAMP|O ,|O culminating|O in|O CD80|B-protein expression|O .|O
Our|O findings|O of|O distinct|O signal|O transducer|O requirements|O ,|O with|O the|O added|O consequences|O of|O cross-talk|O ,|O offers|O an|O explanation|O for|O variable|O modulation|O of|O costimulatory|O molecule|O expression|O in|O response|O to|O diverse|O physiological|O stimuli|O .|O
Importantly|O ,|O these|O results|O also|O reveal|O how|O concentration|O threshold|O barriers|O for|O recruitment|O of|O individual|O second|O messengers|O can|O be|O overcome|O by|O constructive|O convergence|O of|O signaling|O modules|O .|O
The|O role|O of|O Epstein-Barr|O virus|O in|O neoplastic|O transformation|O .|O
In|O this|O review|O ,|O we|O focus|O on|O new|O data|O from|O basic|O ,|O translational|O and|O clinical|O research|O relating|O to|O the|O Epstein-Barr|O virus|O (|O EBV|O )|O .|O
Beside|O its|O well-known|O tropism|O for|O B|B-cell_type lymphocytes|I-cell_type and|O epithelial|B-cell_type cells|I-cell_type ,|O EBV|O also|O infects|O T|B-cell_type lymphocytes|I-cell_type ,|O monocytes|B-cell_type and|O granulocytes|B-cell_type .|O
After|O primary|O infection|O ,|O EBV|O persists|O throughout|O the|O life|O span|O in|O resting|B-cell_type memory|I-cell_type B|I-cell_type cells|I-cell_type ,|O from|O where|O it|O is|O reactivated|O upon|O breakdown|O of|O cellular|O immunity|O .|O
In|O the|O process|O of|O neoplastic|O transformation|O ,|O the|O EBV-encoded|B-DNA latent|I-DNA membrane|I-DNA protein|I-DNA 1|I-DNA (|I-DNA LMP1|I-DNA )|I-DNA oncogene|I-DNA represents|O the|O major|O driving|O force|O .|O
LMP1|B-protein acts|O like|O a|O constitutively|B-protein activated|I-protein receptor|I-protein of|O the|O tumor|B-protein necrosis|I-protein factor|I-protein receptor|I-protein family|I-protein and|O allows|O the|O amplification|O or|O bypassing|O of|O physiological|O regulatory|O signals|O through|O direct|O and|O indirect|O interactions|O with|O proteins|O of|O the|O tumor|B-protein necrosis|I-protein factor|I-protein receptor-associated|I-protein factor|I-protein (|I-protein TRAF|I-protein )|I-protein family|I-protein .|O
TRAF2|B-protein -mediated|O NF-kappaB|B-protein activation|O ,|O AP-1|B-protein induction|O and|O JAK3|B-protein /|O STAT|B-protein activation|O may|O result|O in|O sustained|O proliferation|O leading|O to|O lymphoma|B-cell_line .|O
The|O ability|O of|O LMP1|B-protein to|O suppress|O germinal|O center|O formation|O and|O its|O capacity|O to|O mediate|O its|O own|O transcriptional|O activation|O shed|O new|O light|O on|O the|O pathogenesis|O of|O EBV-associated|O latency|O type|O II|O lymphoproliferations|O like|O Hodgkin|O 's|O disease|O and|O angioimmunoblastic|O lymphadenopathy|O .|O
The|O carboxy|B-protein terminus|I-protein of|O LMP1|B-protein is|O also|O a|O reliable|O marker|O for|O individual|O EBV|O strain|O identification|O and|O thus|O offers|O new|O possibilities|O in|O tracing|O the|O molecular|O events|O leading|O to|O posttransplant|O lymphoproliferative|O disorders|O (|O PTLDs|O )|O .|O
Cytotoxic|B-cell_type T|I-cell_type lymphocytes|I-cell_type directed|O against|O well-characterized|O epitopes|O of|O EBV|B-DNA latency|I-DNA genes|I-DNA represent|O an|O already|O successful|O and|O promising|O therapeutic|O approach|O to|O EBV-associated|B-cell_line lymphomas|I-cell_line ,|O in|O particular|O PTLDs|O
Interferon-alpha|B-protein drives|O T|O cell-mediated|O immunopathology|O in|O the|O intestine|O .|O
The|O ability|O of|O interferon|B-protein (|I-protein IFN|I-protein )|I-protein -alpha|I-protein to|O induce|O autoimmunity|O and|O exacerbate|O Th1|O diseases|O is|O well|O known|O .|O
We|O have|O recently|O described|O enhanced|O expression|O of|O IFN-alpha|B-protein in|O the|O mucosa|O of|O patients|O with|O celiac|O disease|O (|O CD|O )|O ,|O a|O gluten-sensitive|O Th1-mediated|O enteropathy|O ,|O characterized|O by|O villous|O atrophy|O and|O crypt|O cell|O hyperplasia|O .|O
Previous|B-Junk studies|O from|O this|O laboratory|O have|O shown|O that|O T|B-cell_type cell|I-cell_type activation|O in|B-Junk explant|B-Junk cultures|O of|O human|O fetal|O gut|O can|O also|O result|O in|O villous|O atrophy|O and|O crypt|O cell|O hyperplasia|O .|O
We|B-Junk have|O ,|O therefore|O ,|O examined|O changes|B-Junk that|O take|O place|O in|O explant|O cultures|O of|O human|O fetal|O gut|O after|O activation|O of|O T|B-cell_type cells|I-cell_type with|O anti-CD3|B-protein and/or|O IFN-alpha|B-protein .|O
We|B-Junk show|I-Junk that|I-Junk activation|O of|O T|B-cell_type cells|I-cell_type with|O anti-CD3|B-protein alone|O elicits|O a|O small|O IFN-gamma|B-protein and|O TNF-alpha|B-protein response|O with|O no|O tissue|O injury|O .|O
Similarly|B-Junk ,|I-Junk no|O changes|O are|O seen|O in|O explants|O cultured|O with|O IFN-alpha|B-protein alone|O .|O
However|O ,|O addition|O of|O IFN-alpha|B-protein with|O anti-CD3|B-protein results|O in|O enhanced|B-Junk Th1|O response|O and|O crypt|O cell|O hyperplasia|O .|O
This|O is|O associated|O with|O enhanced|O phosphorylation|O of|O STAT1|B-protein ,|O STAT3|B-protein ,|O and|O Fyn|B-protein ,|I-protein a|I-protein Src|I-protein homology|I-protein tyrosine|I-protein kinase|I-protein ,|O which|O interacts|O with|O both|O TCR|B-Junk and|O IFN-alpha|O signal|O components|O .|O
Together|B-Junk these|O data|O indicate|O that|O IFN-alpha|B-protein can|O facilitate|O activation|O of|O Th1-reactive|B-cell_type cells|I-cell_type in|O the|O gut|O and|O drive|O immunopathology|O .|O
Suppression|O of|O tumor|B-protein necrosis|I-protein factor|I-protein alpha|I-protein production|O by|O cAMP|B-Junk in|O human|B-cell_type monocytes|I-cell_type :|B-Junk dissociation|O with|O mRNA|O level|O and|O independent|O of|O interleukin-10|B-protein .|O
BACKGROUND|O :|O Elevation|O of|O cellular|O cAMP|O inhibits|O lipopolysaccharide|O (|O LPS|O )|O -stimulated|O tumor|B-protein necrosis|I-protein factor|I-protein alpha|I-protein (|O TNF-alpha|B-protein )|O production|O and|O increases|O the|O expression|O of|O interleukin|B-protein (|I-protein IL|I-protein )|I-protein -10|I-protein in|O mononuclear|B-cell_type cells|I-cell_type .|O
TNF-alpha|B-DNA gene|I-DNA expression|O obligates|O activation|O of|O the|O transcription|B-protein factor|I-protein nuclear|B-protein factor|I-protein kappaB|I-protein (|O NF-kappaB|B-protein )|O .|O
Exogenous|O IL-10|B-protein inhibits|O NF-kappaB|B-protein in|O monocytes|B-cell_type and|O thus|O attenuates|O TNF-alpha|B-protein production|O .|O
We|O examined|O the|O role|O of|O endogenous|O IL-10|B-protein in|O the|O regulation|O of|O NF-kappaB|B-protein activation|O and|O TNF-alpha|B-protein production|O in|O human|B-cell_type monocytes|I-cell_type by|O cAMP|O .|O
METHODS|O :|O Human|B-cell_type monocytes|I-cell_type were|O stimulated|O with|O Escherichia|B-Junk coli|O LPS|O (|O 100|B-Junk ng/ml|B-Junk )|O with|O and|O without|O forskolin|O (|B-Junk FSK|B-Junk ,|O 50|O microM|O )|O or|O dibutyryl|O cyclic|O AMP|O (|O dbcAMP|B-Junk ,|O 100|O microM|O )|O .|O
Cytokine|B-protein (|O TNF-alpha|B-protein and|O IL-10|B-protein )|O release|O was|O measured|O by|O immunoassay|O .|O
TNF-alpha|B-RNA mRNA|I-RNA was|O measured|O by|O reverse|O transcription|O polymerase|O chain|O reaction|O ,|O and|O NF-kappaB|B-protein DNA|O binding|O activity|O was|O assessed|O by|O gel|O mobility|O shift|O assay|O .|O
RESULTS|O :|O cAMP-elevating|O agents|O inhibited|O LPS-stimulated|O TNF-alpha|B-protein release|O (|O 0.77|B-Junk +/-|O 0.13|B-Junk ng/10|B-Junk (|O 6|O )|O cells|O in|O LPS|O +|O dbcAMP|O and|O 0.68|O +/-|O 0.19|O ng/10|O (|O 6|O )|O cells|O in|O LPS|B-Junk +|B-Junk FSK|O ,|O both|O P|B-Junk <|B-Junk 0.05|O vs|B-Junk 1.61|O +/-|B-Junk 0.34|O ng/10|O (|O 6|O )|O cells|O in|O LPS|O alone|O )|O .|O
Conversely|B-Junk ,|O cAMP|O enhanced|O LPS-stimulated|O IL-10|B-protein release|O (|O 100|O +/-|O 21.5|O pg/10|O (|O 6|O )|O cells|O in|O LPS|O +|O dbcAMP|O and|O 110|O +/-|O 25.2|O pg/10|O (|O 6|O )|O cells|O in|O LPS|O +|O FSK|O ,|O both|O P|O <|O 0.05|O vs|O 53.3|O +/-|O 12.8|O pg/10|O (|O 6|O )|O cells|O in|O LPS|O alone|O )|O .|O
Neither|B-Junk TNF-alpha|B-RNA mRNA|I-RNA expression|O nor|B-Junk NF-kappaB|B-protein activation|O stimulated|O by|O LPS|O was|O inhibited|O by|O the|O cAMP-elevating|O agents|O .|O
Neutralization|O of|O IL-10|B-protein with|O a|O specific|O antibody|B-protein did|O not|O attenuate|O the|I-Junk effect|I-Junk of|I-Junk cAMP-elevating|O agents|O on|O TNF-alpha|B-protein production|O .|O
CONCLUSION|O :|O The|O results|O indicate|O that|O cAMP|O inhibits|O LPS-stimulated|O TNF-alpha|B-protein production|O through|O a|O posttranscriptional|O mechanism|O that|O is|O independent|O of|O endogenous|O IL-10|B-protein .|O
Copyright|O 2001|O Academic|O Press|O .|O
Activation|O of|O the|O p21|B-DNA (|I-DNA CIP1/WAF1|I-DNA )|I-DNA promoter|I-DNA by|O bone|B-protein morphogenetic|I-protein protein-2|I-protein in|O mouse|B-Junk B|B-cell_line lineage|I-cell_line cells|I-cell_line .|O
BMPs|B-protein exert|O a|O negative|B-Junk growth|I-Junk effect|I-Junk on|O various|O types|O of|O cells|O .|O
We|O have|O previously|O reported|O that|O BMP-2|B-protein inhibited|O the|O growth|O of|O HS-72|B-cell_line mouse|I-cell_line hybridoma|I-cell_line cells|I-cell_line by|O inducing|O p21|O (|O CIP1/WAF1|O )|O expression|O .|O
In|O the|O present|O study|O ,|O we|O demonstrated|O that|O BMP-2|B-protein activated|O the|O mouse|O p21|B-DNA (|I-DNA CIP1/WAF1|I-DNA )|I-DNA promoter|I-DNA in|O HS-72|B-cell_line cells|I-cell_line ,|O and|O that|O a|O 29-base|B-DNA pair|I-DNA (|I-DNA b|I-DNA )|I-DNA region|I-DNA of|O the|O promoter|O (|O -1928/-1900|B-Junk relative|O to|O the|O TATA|B-DNA box|I-DNA )|O ,|O conserved|O between|O mice|O and|O humans|O ,|O was|O responsive|O to|O BMP-2|B-protein as|O well|O as|O expression|O of|O Smad1|B-protein ,|O Smad4|B-protein ,|O and|O constitutively|O active|O mutants|O of|O BMP|B-protein type|I-protein I|I-protein receptors|I-protein .|O
Furthermore|O ,|O an|O oligonucleotide|O containing|O the|O 29-b|B-DNA region|I-DNA was|O found|O to|O be|O associated|O with|O Smad4|B-protein and|O phosphorylated|B-protein Smad1|I-protein in|O the|O nuclear|O extract|O of|O BMP-2|B-protein -stimulated|O HS-72|B-cell_line cells|I-cell_line .|O
These|O results|O suggested|O that|O BMP-2|B-protein might|O activate|O p21|O (|O CIP1/WAF1|O )|O transcription|O by|O inducing|O a|O binding|O of|O Smad4|B-protein and|O Smad1|B-protein to|O the|O 29-b|B-DNA region|I-DNA in|O HS-72|B-cell_line cells|I-cell_line .|O
Dendritic|B-cell_type cell|I-cell_type development|O from|O common|O myeloid|B-cell_type progenitors|I-cell_type .|O
Dendritic|B-cell_type cells|I-cell_type (|O DCs|B-cell_type )|O are|O professional|O antigen-presenting|B-cell_type cells|I-cell_type which|O both|O initiate|O adaptive|O immune|O responses|O and|O control|O tolerance|O to|O self-antigens|B-protein .|O
It|O has|O been|O suggested|O that|O these|O different|O effects|O on|O responder|O cells|O depend|O on|O subsets|O of|O DCs|B-cell_type arising|O from|O either|O myeloid|O or|O lymphoid|O hematopoietic|O origins|O .|O
In|O this|O model|O ,|O CD8|B-cell_type alpha+|I-cell_type Mac-1-|I-cell_type DCs|I-cell_type are|O supposed|O to|O be|O of|O lymphoid|O while|O CD8|B-cell_type alpha-|I-cell_type Mac-1+|I-cell_type DCs|I-cell_type are|O supposed|O to|O be|O of|O myeloid|O origin|O .|O
Here|B-Junk we|O summarize|O our|O findings|O that|O both|O CD8|B-cell_type alpha+|I-cell_type and|I-cell_type CD8|I-cell_type alpha-|I-cell_type DCs|I-cell_type can|O arise|O from|O clonogenic|B-cell_type common|I-cell_type myeloid|I-cell_type progenitors|I-cell_type (|O CMPs|B-cell_type )|O in|O both|O thymus|O and|O spleen|O .|O
Therefore|O CD8|B-protein alpha|I-protein expression|O DCs|B-cell_type does|O not|O indicate|O a|O lymphoid|O origin|O and|O differences|O among|O CD8|B-cell_type alpha+|I-cell_type and|I-cell_type CD8|I-cell_type alpha-|I-cell_type DCs|I-cell_type might|O rather|O reflect|O maturation|O status|O than|O ontogeny|O .|O
On|O the|O basis|O of|O transplantation|O studies|O ,|O it|O seems|O likely|O that|O most|O of|O the|O DCs|B-cell_type in|O secondary|O lymphoid|O organs|O and|O a|O substantial|O fraction|O of|O thymic|B-cell_type DCs|I-cell_type are|O myeloid-derived|O .|O
Macrophage|O stimulation|O with|O Murabutide|O ,|O an|O HIV-suppressive|O muramyl|O peptide|O derivative|O ,|O selectively|O activates|O extracellular|B-protein signal-regulated|I-protein kinases|I-protein 1|I-protein and|I-protein 2|I-protein ,|O C/EBPbeta|B-protein and|O STAT1|B-protein :|O role|O of|O CD14|B-protein and|O Toll-like|B-protein receptors|I-protein 2|I-protein and|I-protein 4|I-protein .|O
The|O smallest|O unit|O of|O bacterial|O peptidoglycans|O known|O to|O be|O endowed|O with|O biological|O activities|O is|O muramyl|O dipeptide|O (|O MDP|O )|O .|O
A|B-Junk clinically|O acceptable|O synthetic|O derivative|O of|O MDP|O ,|O namely|O murabutide|O (|O MB|O )|O ,|O has|O been|O found|O to|O present|O interesting|O pharmacological|O properties|O and|O to|O suppress|O HIV-1|O replication|O in|O monocyte-derived|B-cell_type macrophages|I-cell_type (|O MDM|B-cell_type )|O .|O
We|O have|O addressed|O the|O signaling|O events|O activated|O in|O MDM|B-cell_type following|O stimulation|O with|O either|O MB|O or|O the|O potent|O immunostimulant|O LPS|O .|O
We|O also|O examined|O whether|O signaling|O by|O muramyl|O peptides|O involves|O the|O use|O of|O cell|B-protein surface|I-protein receptors|I-protein ,|O including|O CD14|B-protein and|O Toll-like|B-protein receptor|I-protein 2|I-protein (|O TLR2|B-protein )|O or|O TLR4|B-protein that|O are|O known|O to|O be|O signal-transducing|B-protein receptors|I-protein for|O other|O bacterial|O cell|O wall|O components|O .|O
We|O demonstrate|O that|O ,|O unlike|O LPS|O ,|O the|O safe|O immunomodulator|O MB|O selectively|O activates|O extracellular|B-protein signal-regulated|I-protein kinases|I-protein (|I-protein Erk|I-protein )|I-protein 1/2|I-protein ,|O in|O the|O absence|O of|O detectable|O Jun|B-protein N-terminal|I-protein kinase|I-protein (|O JNK|B-protein )|O or|O p38|B-protein mitogen-activated|I-protein kinase|I-protein activation|O .|O
Furthermore|O ,|O STAT1|B-protein activation|O but|O weak|O or|O no|O activation|O of|O STAT3|B-protein or|O STAT5|B-protein respectively|O ,|O could|O be|O detected|O in|O MB-stimulated|B-cell_type MDM|I-cell_type .|O
Using|O MonoMac6|B-cell_line cells|I-cell_line ,|O we|O observed|O high|O C/EBPbeta|B-protein and|O AP-1|B-protein but|O weaker|O and|O transient|O NF-kappaB|B-protein activation|O by|O MB|O .|O
Moreover|O ,|O the|O truncated|O form|O of|O C/EBPbeta|B-protein ,|O known|O to|O repress|O HIV-1|O transcription|O ,|O was|O detected|O in|O extracts|O from|O MB-treated|B-cell_line THP-1|I-cell_line cells|I-cell_line .|O
Surprisingly|O ,|O neither|O MB|O nor|O MDP|O were|O able|O to|O transduce|O signals|O via|O CD14|B-protein and|O TLR2|B-protein or|I-protein 4|I-protein .|O
These|O findings|O present|O major|O differences|O in|O the|O early|O cell|O activation|O process|O between|O LPS|O and|O muramyl|O peptides|O ,|O and|O strongly|O argue|O for|O the|O implication|O of|O co-receptors|B-protein other|O than|O TLR2|B-protein and|O TLR4|B-protein in|O mediating|O the|O signaling|O events|O induced|O by|O defined|O subunits|O of|O bacterial|O peptidoglycans|O .|O
Nuclear|B-protein peroxisome|I-protein proliferator-activated|I-protein receptors|I-protein alpha|I-protein and|I-protein gamma|I-protein have|O opposing|O effects|O on|O monocyte|O chemotaxis|O in|O endometriosis|O .|O
The|O peroxisome|B-protein proliferator-activated|I-protein receptors|I-protein (|I-protein PPARs|I-protein )|I-protein alpha|I-protein and|I-protein gamma|I-protein are|O nuclear|B-protein receptors|I-protein that|O play|O important|O roles|O in|O inflammatory|O diseases|O like|O ulcerative|O colitis|O and|O arthritis|O .|O
In|O this|O study|O ,|O we|O examined|O the|O possible|O role|O of|O PPARs|B-protein in|O macrophage|O attraction|O into|O the|O peritoneal|O cavity|O of|O patients|O with|O endometriosis|O .|O
We|O identified|O PPAR-alpha|B-RNA and|I-RNA -gamma|I-RNA messenger|O RNA|O by|O RT-PCR|O and|O protein|O by|O immunoblotting|O of|O lysates|O of|O peritoneal|B-cell_type macrophages|I-cell_type and|O monocytic|B-cell_line U937|I-cell_line cells|I-cell_line .|O
Using|O immunocytochemistry|O ,|O we|O localized|O PPAR-alpha|B-protein and|I-protein -gamma|I-protein within|O the|O nuclei|O of|O both|O cell|O types|O .|O
Monocyte|O chemotactic|O activity|O of|O peritoneal|O fluid|O from|O patients|O with|O endometriosis|O was|O quantified|O in|O Boyden|O chambers|O .|O
Migration|O of|O U937|B-cell_line cells|I-cell_line was|O increased|O by|O WY|O 14643|O and|O reduced|O by|O rosiglitazone|O .|O
Peritoneal|O fluid|O from|O patients|O with|O endometriosis|O activated|O U937|B-cell_line cells|I-cell_line transiently|O transfected|O with|O a|O PPAR-alpha/GAL4|B-DNA luciferase|I-DNA reporter|I-DNA .|O
By|O contrast|O ,|O peritoneal|O fluid|O did|O not|O cause|O significant|O activation|O of|O PPAR-gamma/GAL4|B-DNA constructs|I-DNA .|O
The|O U937|B-cell_line cells|I-cell_line transiently|O transfected|O with|O a|O PPAR|B-DNA response|I-DNA element|I-DNA luciferase|I-DNA reporter|I-DNA showed|O disease|O stage-dependent|O up-regulation|O when|O treated|O with|O peritoneal|O fluid|O from|O patients|O with|O endometriosis|O .|O
Treatment|O with|O peritoneal|O fluid|O from|O healthy|O controls|O down-regulated|O PPAR|O response|O element|O transactivation|O .|O
We|O conclude|O that|O peritoneal|O fluid|O of|O endometriosis|O patients|O contains|O activators|O of|O PPAR-alpha|B-protein that|O stimulate|O macrophage|O chemotaxis|O .|O
Inhibitors|O of|O PPAR-alpha|B-protein or|O activators|O of|O PPAR-gamma|B-protein could|O be|O developed|O for|O the|O treatment|O of|O inflammation|O associated|O with|O endometriosis|O .|O
Long-term-impaired|O expression|O of|O nuclear|B-protein factor-kappa|I-protein B|I-protein and|O I|B-protein kappa|I-protein B|I-protein alpha|I-protein in|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type of|O trauma|O patients|O .|O
Nuclear|B-protein factor|I-protein (|I-protein NF|I-protein )|I-protein -kappa|I-protein B|I-protein expression|O and|O dimer|O characteristics|O were|O studied|O in|O peripheral|B-cell_type blood|I-cell_type mononuclear|I-cell_type cells|I-cell_type (|O PBMCs|B-cell_type )|O of|O major-trauma|O patients|O and|O healthy|O controls|O .|O
Analysis|O of|O PBMCs|B-cell_type on|O days|O 1|O ,|O 3|O ,|O 5|O ,|O and|O 10|O after|O trauma|O revealed|O that|O expression|O of|O both|O p65p50|B-protein heterodimers|I-protein and|O p50p50|B-protein homodimers|I-protein was|O significantly|O reduced|O compared|O with|O that|O in|O controls|O .|O
In|O vitro|O lipopolysaccharide|O (|O LPS|O )|O stimulation|O of|O PBMCs|B-cell_type induced|O NF-kappa|O B|O translocation|O .|O
However|O ,|O throughout|O the|O survey|O ,|O p65p50|O activation|O remained|O significantly|O lower|O in|O trauma|O patients|O than|O in|O controls|O .|O
After|O LPS|O stimulation|O in|O vitro|O ,|O the|O p65p50/p50p50|O ratio|O was|O significantly|O lower|O in|O PBMCs|B-cell_type from|O trauma|O patients|O than|O from|O healthy|O controls|O .|O
The|O ex|O vivo|O expression|O of|O I|B-protein kappa|I-protein B|I-protein alpha|I-protein was|O higher|O in|O PBMCs|B-cell_type of|O controls|O than|O of|O trauma|O patients|O .|O
LPS|O did|O not|O induce|O I|O kappa|O B|O expression|O in|O PBMCs|B-cell_type from|O trauma|O patients|O ,|O but|O strong|O induction|O was|O obtained|O with|O staphylococci|O ,|O suggesting|O that|O this|O defect|O is|O not|O universal|O and|O depends|O on|O the|O nature|O of|O the|O activating|O signal|O .|O
Although|O no|O direct|O correlation|O was|O found|O between|O levels|O of|O interleukin-10|B-protein or|O transforming|B-protein growth|I-protein factor-beta|I-protein and|O NF-kappa|B-protein B|I-protein ,|O these|O immunosuppressive|B-protein cytokines|I-protein were|O significantly|O elevated|O in|O trauma|O patients|O by|O 10|O days|O after|O admission|O .|O
The|O long-term|O low-basal|O and|O LPS-induced|O nuclear|O translocation|O of|O NF-kappa|B-protein B|I-protein recalled|O long-term|O immunoparalysis|O observed|O in|O patients|O with|O severe|O inflammatory|O stress|O such|O as|O trauma|O .|O
Hepatic|O ischemia-reperfusion|O injury|O .|O
BACKGROUND|O :|O The|O morbidity|O associated|O with|O liver|O transplantation|O and|O major|O hepatic|O resections|O is|O partly|O a|O result|O of|O ischemia-reperfusion|O injury|O .|O
DATA|O SOURCES|O :|O The|O entire|O world|O literature|O on|O the|O subject|O was|O searched|O via|O Medline|O .|O
Keywords|O included|O reperfusion|O injury|O ,|O transplantation|O ,|O liver|O resection|O ,|O nitric|O oxide|O ,|O endothelin|O ,|O cytokines|B-protein ,|O Kupffer|B-cell_type cells|I-cell_type ,|O ischemic/ischaemic|O preconditioning|O ,|O and|O nuclear|B-protein factor-kappa|I-protein B|I-protein .|O
CONCLUSIONS|O :|O An|O imbalance|O between|O endothelin|O and|O nitric|O oxide|O levels|O results|O in|O failure|O of|O the|O hepatic|O microcirculation|O at|O the|O onset|O of|O reperfusion|O .|O
Activation|O of|O nuclear|B-protein factor-kappa|I-protein B|I-protein in|O the|O liver|O promotes|O proinflammatory|B-protein cytokine|I-protein and|O adhesion|B-protein molecule|I-protein synthesis|O .|O
These|O result|O in|O oxygen-derived|O free|O radical|O production|O and|O neutrophil|O recruitment|O ,|O further|O contributing|O to|O cellular|O injury|O .|O
Various|O therapeutic|O modalities|O acting|O on|O the|O above|O mediators|O have|O been|O successfully|O used|O to|O attenuate|O reperfusion|O injury|O in|O animal|O models|O of|O hepatic|O transplantation|O and|O resection|O .|O
Application|O of|O the|O knowledge|O gained|O from|O animal|O models|O of|O hepatic|O ischemia-reperfusion|O to|O the|O clinical|O setting|O will|O improve|O the|O outcome|O of|O hepatic|O surgery|O .|O
Down-regulation|O of|O IL-12|B-DNA p40|I-DNA gene|I-DNA in|O Plasmodium|O berghei-infected|O mice|O .|O
We|O analyzed|O the|O mechanism|O that|O causes|O suppression|O of|O IL-12|B-DNA p40|I-DNA gene|I-DNA induction|O during|O Plasmodium|O berghei|O infection|O .|O
Although|O IL-12|B-protein together|O with|O IFN-gamma|B-protein plays|O an|O important|O role|O in|O protection|O against|O pathogenic|O infection|O ,|O the|O IL-12|B-protein p70|I-protein protein|I-protein production|O of|O infected|B-cell_type macrophages|I-cell_type is|O lower|O than|O that|O by|O the|O uninfected|B-cell_type macrophages|I-cell_type .|O
We|O showed|O in|O the|O present|O study|O that|O the|O induction|O of|O IL-12|B-DNA p40|I-DNA gene|I-DNA but|O not|O IL-12|B-DNA p35|I-DNA gene|I-DNA in|O macrophages|B-cell_type of|O P.|O berghei-infected|O mice|O was|O profoundly|O inhibited|O .|O
The|O inhibition|O was|O induced|O by|O interaction|O with|O macrophages|B-cell_type that|O had|O contacted|O with|O P.|B-cell_type berghei-infected|I-cell_type erythrocytes|I-cell_type and|O was|O mediated|O by|O a|O soluble|O factor|O ,|O IL-10|B-protein .|O
There|O was|O comparable|O activation|O of|O NF-kappaB|B-protein in|O uninfected|B-cell_type and|I-cell_type infected|I-cell_type cells|I-cell_type .|O
The|O induction|O of|O IFN-regulatory|B-DNA factor-1|I-DNA gene|I-DNA was|O comparable|O in|O transcription|O level|O in|O uninfected|B-cell_type and|I-cell_type infected|I-cell_type cells|I-cell_type ,|O while|O the|O unidentified|O complex|O formation|O of|O IFN-regulatory|B-protein factor-1|I-protein was|O observed|O in|O infected|B-cell_type cells|I-cell_type .|O
Therefore|O ,|O the|O inhibition|O of|O the|O IL-12|B-DNA p40|I-DNA gene|I-DNA induction|O appeared|O to|O be|O regulated|O at|O transcriptional|O regulation|O level|O of|O the|O gene|O .|O
The|O Friend|B-protein of|I-protein GATA|I-protein proteins|I-protein U-shaped|O ,|O FOG-1|B-protein ,|O and|O FOG-2|B-protein function|O as|O negative|O regulators|O of|O blood|O ,|O heart|O ,|O and|O eye|O development|O in|O Drosophila|O .|O
Friend|B-protein of|I-protein GATA|I-protein (|I-protein FOG|I-protein )|I-protein proteins|I-protein regulate|O GATA|O factor-activated|O gene|O transcription|O .|O
During|O vertebrate|O hematopoiesis|O ,|O FOG|B-protein and|I-protein GATA|I-protein proteins|I-protein cooperate|O to|O promote|O erythrocyte|O and|O megakaryocyte|O differentiation|O .|O
The|O Drosophila|B-protein FOG|I-protein homologue|I-protein U-shaped|I-protein (|O Ush|B-protein )|O is|O expressed|O similarly|O in|O the|O blood|O cell|O anlage|O during|O embryogenesis|O .|O
During|O hematopoiesis|O ,|O the|O acute|O myeloid|O leukemia|O 1|O homologue|O Lozenge|B-cell_type and|I-cell_type Glial|I-cell_type cells|I-cell_type missing|O are|O required|O for|O the|O production|O of|O crystal|B-cell_type cells|I-cell_type and|O plasmatocytes|B-cell_type ,|O respectively|O .|O
However|O ,|O additional|O factors|O have|O been|O predicted|O to|O control|O crystal|O cell|O proliferation|O .|O
In|O this|O report|O ,|O we|O show|O that|O Ush|B-protein is|O expressed|O in|O hemocyte|B-cell_type precursors|I-cell_type and|O plasmatocytes|B-cell_type throughout|O embryogenesis|O and|O larval|O development|O ,|O and|O the|O GATA|B-protein factor|I-protein Serpent|I-protein is|O essential|O for|O Ush|B-protein embryonic|O expression|O .|O
Furthermore|O ,|O loss|O of|O ush|O function|O results|O in|O an|O overproduction|O of|O crystal|B-cell_type cells|I-cell_type ,|O whereas|O forced|O expression|O of|O Ush|B-protein reduces|O this|O cell|O population|O .|O
Murine|B-protein FOG-1|I-protein and|I-protein FOG-2|I-protein also|O can|O repress|O crystal|O cell|O production|O ,|O but|O a|O mutant|O version|O of|O FOG-2|B-protein lacking|O a|O conserved|O motif|O that|O binds|O the|O corepressor|B-protein C-terminal|I-protein binding|I-protein protein|I-protein fails|O to|O affect|O the|O cell|O lineage|O .|O
The|O GATA|B-protein factor|I-protein Pannier|I-protein (|O Pnr|B-protein )|O is|O required|O for|O eye|O and|O heart|O development|O in|O Drosophila|O .|O
When|O Ush|B-protein ,|O FOG-1|B-protein ,|O FOG-2|B-protein ,|O or|O mutant|B-protein FOG-2|I-protein is|O coexpressed|O with|O Pnr|B-protein during|O these|O developmental|O processes|O ,|O severe|O eye|O and|O heart|O phenotypes|O result|O ,|O consistent|O with|O a|O conserved|O negative|O regulation|O of|O Pnr|B-protein function|O .|O
These|O results|O indicate|O that|O the|O fly|O and|O mouse|O FOG|B-protein proteins|I-protein function|O similarly|O in|O three|O distinct|O cellular|O contexts|O in|O Drosophila|O ,|O but|O may|O use|O different|O mechanisms|O to|O regulate|O genetic|O events|O in|O blood|O vs|O .|O cardial|B-cell_line or|I-cell_line eye|I-cell_line cell|I-cell_line lineages|I-cell_line
The|O RING|B-protein finger|I-protein protein|I-protein Siah-1|B-protein regulates|O the|O level|O of|O the|O transcriptional|B-protein coactivator|I-protein OBF-1|B-protein .|O
The|O transcriptional|B-protein coactivator|I-protein OBF-1|B-protein ,|O which|O interacts|O with|O Oct-1|B-protein and|O Oct-2|B-protein and|O the|O octamer|B-DNA site|I-DNA DNA|I-DNA ,|O has|O been|O shown|O to|O be|O critical|O for|O development|O of|O a|O normal|O immune|O response|O and|O the|O formation|O of|O germinal|O centers|O in|O secondary|O lymphoid|O organs|O .|O
Here|O we|O have|O identified|O the|O RING|B-protein finger|I-protein protein|I-protein Siah-1|B-protein as|O a|O protein|O interacting|O specifically|O with|O OBF-1|B-protein .|O
This|O interaction|O is|O mediated|O by|O the|O C-terminal|B-protein part|O of|O Siah-1|B-protein and|O by|O residues|O in|O the|O N-terminus|B-protein of|O OBF-1|B-protein ,|O partly|O distinct|O from|O the|O residues|O required|O for|O formation|O of|O a|O complex|O with|O the|O Oct|B-protein POU|I-protein domains|I-protein and|O the|O DNA|O .|O
Interaction|O between|O Siah-1|B-protein and|O OBF-1|B-protein leads|O to|O downregulation|O of|O OBF-1|O protein|O level|O but|O not|O mRNA|O ,|O and|O to|O a|O corresponding|O reduction|O in|O octamer|O site-dependent|O transcription|O activation|O .|O
Inhibition|O of|O the|O ubiquitin-proteasome|O pathway|O in|O B|B-cell_type cells|I-cell_type leads|O to|O elevated|O levels|O of|O OBF-1|B-protein protein|I-protein .|O
Furthermore|O ,|O in|O immunized|O mice|O ,|O OBF-1|B-protein protein|I-protein amounts|O are|O dramatically|O increased|O in|O primary|B-cell_type activated|I-cell_type B|I-cell_type cells|I-cell_type ,|O without|O concomitant|O increase|O in|O OBF-1|B-RNA mRNA|I-RNA .|O
These|O data|O suggest|O that|O Siah-1|B-protein is|O part|O of|O a|O novel|O regulatory|O loop|O controlling|O the|O level|O of|O OBF-1|B-protein protein|I-protein in|O B|B-cell_type cells|I-cell_type .|O
The|O beta-catenin|O --|O TCF-1|O pathway|O ensures|O CD4|B-cell_type (|I-cell_type +|I-cell_type )|I-cell_type CD8|I-cell_type (|I-cell_type +|I-cell_type )|I-cell_type thymocyte|I-cell_type survival|O .|O
The|O association|O of|O trans-acting|B-protein T|I-protein cell|I-protein factors|I-protein (|O TCFs|B-protein )|O or|O lymphoid|B-protein enhancer|I-protein factor|I-protein 1|I-protein (|O LEF-1|B-protein )|O with|O their|O coactivator|O beta-catenin|O mediates|O transient|O transcriptional|O responses|O to|O extracellular|O Wnt|O signals|O .|O
We|O show|O here|O that|O T|O cell|O maturation|O depends|O on|O the|O presence|O of|O the|O beta-catenin|B-protein --|I-protein binding|I-protein domain|I-protein in|O TCF-1|B-protein .|O
This|O domain|O is|O necessary|O to|O mediate|O the|O survival|O of|O immature|O CD4|B-cell_type (|I-cell_type +|I-cell_type )|I-cell_type CD8|I-cell_type (|I-cell_type +|I-cell_type )|I-cell_type double-positive|I-cell_type (|I-cell_type DP|I-cell_type )|I-cell_type thymocytes|I-cell_type .|O
Accelerated|O spontaneous|O thymocyte|O death|O in|O the|O absence|O of|O TCF-1|B-protein correlates|O with|O aberrantly|O low|O expression|O of|O the|O anti-apoptotic|B-protein protein|I-protein Bcl-x|B-protein (|I-protein L|I-protein )|I-protein .|O
Increasing|O anti-apoptotic|O effectors|O in|O thymocytes|B-cell_type by|O the|O use|O of|O a|O Bcl-2|B-DNA transgene|I-DNA rescued|O TCF-1-deficient|B-cell_type DP|I-cell_type thymocytes|I-cell_type from|O apoptosis|O .|O
Thus|O ,|O TCF-1|B-protein ,|O upon|O association|O with|O beta-catenin|O ,|O transiently|O ensures|O the|O survival|O of|O immature|B-cell_type T|I-cell_type cells|I-cell_type ,|O which|O enables|O them|O to|O generate|O and|O edit|O T|B-protein cell|I-protein receptor|I-protein (|I-protein TCR|I-protein )|I-protein alpha|I-protein chains|I-protein and|O attempt|O TCR|B-protein -mediated|O positive|O selection|O .|O
TRAIL/Apo2L|B-protein ligand|I-protein selectively|O induces|O apoptosis|O and|O overcomes|O drug|O resistance|O in|O multiple|O myeloma|O :|O therapeutic|O applications|O .|O
Multiple|O myeloma|O (|O MM|O )|O remains|O incurable|O and|O novel|O treatments|O are|O urgently|O needed|O .|O
Preclinical|O in|O vitro|O and|O in|O vivo|O evaluations|O were|O performed|O to|O assess|O the|O potential|O therapeutic|O applications|O of|O human|O recombinant|O tumor|B-protein necrosis|I-protein factor|I-protein (|I-protein TNF|I-protein )|I-protein -related|I-protein apoptosis-inducing|I-protein ligand/Apo2|I-protein ligand|I-protein (|O TRAIL/Apo2L|B-protein )|O in|O MM|O .|O
TRAIL/Apo2L|B-protein potently|O induced|O apoptosis|O of|O MM|B-cell_type cells|I-cell_type from|O patients|O and|O the|O majority|O of|O MM|B-cell_line cell|I-cell_line lines|I-cell_line ,|O including|O cells|O sensitive|O or|O resistant|O to|O dexamethasone|O (|O Dex|O )|O ,|O doxorubicin|O (|O Dox|O )|O ,|O melphalan|O ,|O and|O mitoxantrone|O .|O
TRAIL/Apo2L|B-protein also|O overcame|O the|O survival|O effect|O of|O interleukin|B-protein 6|I-protein on|O MM|B-cell_type cells|I-cell_type and|O did|O not|O affect|O the|O survival|O of|O peripheral|B-cell_type blood|I-cell_type and|I-cell_type bone|I-cell_type marrow|I-cell_type mononuclear|I-cell_type cells|I-cell_type and|O purified|B-cell_type B|I-cell_type cells|I-cell_type from|O healthy|O donors|O .|O
The|O status|O of|O the|O TRAIL|B-protein receptors|I-protein (|O assessed|O by|O immunoblotting|O and|O flow|O cytometry|O )|O could|O not|O predict|O TRAIL|O sensitivity|O of|O MM|B-cell_type cells|I-cell_type .|O
The|O anti-MM|O activity|O of|O TRAIL/Apo2L|B-protein was|O confirmed|O in|O nu/xid/bg|O mice|O xenografted|O with|O human|B-cell_type MM|I-cell_type cells|I-cell_type ;|O TRAIL|B-protein (|O 500|O microg|O intraperitoneally|O daily|O for|O 14|O days|O )|O was|O well|O tolerated|O and|O significantly|O suppressed|O the|O growth|O of|O plasmacytomas|B-cell_type .|O
Dox|O up-regulated|O the|O expression|O of|O the|O TRAIL|B-protein receptor|I-protein death|B-protein receptor|I-protein 5|I-protein (|O DR5|B-protein )|O and|O synergistically|O enhanced|O the|O effect|O of|O TRAIL|B-protein not|O only|O against|O MM|B-cell_type cells|I-cell_type sensitive|O to|O ,|O but|O also|O against|O those|O resistant|O to|O ,|O Dex-|O or|O Dox-induced|O apoptosis|O .|O
Nuclear|O factor|O (|O NF|O )|O -kappaB|O inhibitors|O ,|O such|O as|O SN50|O (|O a|O cell-permeable|O inhibitor|O of|O the|O nuclear|O translocation|O and|O transcriptional|O activity|O of|O NF-kappaB|B-protein )|O or|O the|O proteasome|O inhibitor|O PS-341|O ,|O enhanced|O the|O proapoptotic|O activity|O of|O TRAIL/Apo2L|B-protein against|O TRAIL-sensitive|B-cell_type MM|I-cell_type cells|I-cell_type ,|O whereas|O SN50|O reversed|O the|O TRAIL|O resistance|O of|O ARH-77|B-cell_type and|I-cell_type IM-9|I-cell_type MM|I-cell_type cells|I-cell_type .|O
Importantly|O ,|O normal|B-cell_type B|I-cell_type lymphocytes|I-cell_type were|O not|O sensitized|O to|O TRAIL|B-protein by|O either|O Dox|O ,|O SN50|O ,|O or|O PS-341|O .|O
These|O preclinical|O studies|O suggest|O that|O TRAIL/Apo2L|B-protein can|O overcome|O conventional|O drug|O resistance|O and|O provide|O the|O basis|O for|O clinical|O trials|O of|O TRAIL|B-protein -based|O treatment|O regimens|O to|O improve|O outcome|O in|O patients|O with|O MM|O .|O
(|O Blood.|O 2001|O ;|O 98|O :|O 795-804|O )|O
CD28|B-protein costimulation|O is|O required|O not|O only|O to|O induce|O IL-12|B-protein receptor|I-protein but|O also|O to|O render|O janus|B-protein kinases/STAT4|I-protein responsive|O to|O IL-12|B-protein stimulation|O in|O TCR-triggered|B-cell_type T|I-cell_type cells|I-cell_type .|O
The|O activation|O of|O resting|B-cell_type T|I-cell_type cells|I-cell_type for|O the|O acquisition|O of|O various|O functions|O depends|O on|O whether|O CD28|O costimulatory|O signals|O are|O provided|O upon|O T|O cell|O receptor|O stimulation|O .|O
Here|O ,|O we|O investigated|O how|O CD28|O costimulation|O functions|O to|O allow|O TCR|B-protein -triggered|O resting|B-cell_type T|I-cell_type cells|I-cell_type to|O acquire|O IL-12|B-protein responsiveness|O .|O
When|O T|B-cell_type cells|I-cell_type are|O stimulated|O with|O low|O doses|O of|O anti-CD3|B-protein mAb|I-protein ,|O CD28|O costimulation|O was|O required|O for|O the|O optimal|O levels|O of|O IL-12|B-protein receptor|I-protein (|O IL-12R|B-protein )|O expression|O .|O
However|O ,|O stimulation|O of|O T|B-cell_type cells|I-cell_type with|O high|O doses|O of|O anti-CD3|B-protein alone|O induced|O comparable|O levels|O of|O IL-12R|B-protein expression|O to|O those|O induced|O upon|O CD28|O costimulation|O .|O
Nevertheless|O ,|O there|O was|O a|O substantial|O difference|O in|O IL-12|B-protein responsiveness|O between|O these|O two|O groups|O of|O T|B-cell_type cells|I-cell_type :|O compared|O to|O anti-CD28-costimulated|B-cell_type T|I-cell_type cells|I-cell_type ,|O T|B-cell_type cells|I-cell_type that|O were|O not|O costimulated|O with|O anti-CD28|B-protein exhibited|O decreased|O levels|O of|O Janus|B-protein kinases|I-protein (|O JAK|B-protein )|O JAK2/TYK2|B-protein and|O STAT4|B-protein phosphorylation|O and|O IFN-y|O production|O following|O IL-12|B-protein stimulation|O .|O
Importantly|O ,|O STAT6|O phosphorylation|O following|O IL-4|O stimulation|O was|O not|O decreased|O in|O anti-CD28-uncostimulated|B-cell_type T|I-cell_type cells|I-cell_type .|O
These|O resutls|O indicate|O that|O CD28|O costimulation|O not|O only|O contributes|O to|O up-regulating|O IL-12R|B-protein expression|O but|O is|O also|O required|O to|O render|O JAKs/STAT4|B-protein responsive|O to|O IL-12|B-protein stimulation|O .|O
Constitutively|O activated|O Akt-1|B-protein is|O vital|O for|O the|O survival|O of|O human|B-cell_type monocyte-differentiated|I-cell_type macrophages|I-cell_type .|O
Role|O of|O Mcl-1|B-protein ,|O independent|O of|O nuclear|B-protein factor|I-protein (|I-protein NF|I-protein )|I-protein -kappaB|I-protein ,|O Bad|B-protein ,|O or|O caspase|O activation|O .|O
Recent|O data|O from|O mice|O deficient|O for|O phosphatase|B-protein and|O tensin|B-DNA homologue|I-DNA deleted|O from|O chromosome|B-DNA 10|I-DNA or|O src|B-protein homology|I-protein 2|I-protein domain-containing|I-protein 5|I-protein '|I-protein inositol|I-protein phosphatase|I-protein ,|O phosphatases|B-protein that|O negatively|O regulate|O the|O phosphatidylinositol|B-protein 3-kinase|I-protein (|O PI3K|B-protein )|O pathway|O ,|O revealed|O an|O increased|O number|O of|O macrophages|B-cell_type in|O these|O animals|O ,|O suggesting|O an|O essential|O role|O for|O the|O PI3K|B-protein pathway|O for|O macro-phage|B-cell_type survival|O .|O
Here|O ,|O we|O focused|O on|O the|O role|O of|O the|O PI3K-regulated|B-protein serine/threonine|I-protein kinase|I-protein Akt-1|B-protein in|O modulating|O macrophage|B-cell_type survival|O .|O
Akt-1|B-protein was|O constitutively|O activated|O in|O human|B-cell_type macrophages|I-cell_type and|O addition|O of|O the|O PI3K|B-protein inhibitor|O ,|O LY294002|O ,|O suppressed|O the|O activation|O of|O Akt-1|B-protein and|O induced|O cell|O death|O .|O
Furthermore|O ,|O suppression|O of|O Akt-1|B-protein by|O inhibition|O of|O PI3K|B-protein or|O a|O dominant|B-protein negative|I-protein (|I-protein DN|I-protein )|I-protein Akt-1|I-protein resulted|O in|O loss|O of|O mitochondrial|O transmembrane|O potential|O ,|O activation|O of|O caspases-9|B-protein and|I-protein -3|I-protein ,|O and|O DNA|O fragmentation|O .|O
The|O effects|O of|O PI3K|B-protein inhibition|O were|O reversed|O by|O the|O ectopic|O expression|O of|O constitutively|O activated|O Akt-1|B-protein or|O Bcl-x|B-protein (|I-protein L|I-protein )|I-protein .|O
Inhibition|O of|O PI3K|B-protein /Akt-1|O pathway|O either|O by|O LY294002|O or|O DN|B-protein Akt-1|I-protein had|O no|O effect|O on|O the|O constitutive|O or|O inducible|O activation|O of|O nuclear|B-protein factor|I-protein (|I-protein NF|I-protein )|I-protein -kappaB|I-protein in|O human|B-cell_type macrophages|I-cell_type .|O
However|O ,|O after|O inhibition|O of|O the|O PI3K|B-protein /|O Akt-1|B-protein pathway|O ,|O a|O marked|O decrease|O in|O the|O expression|O of|O the|O antiapoptotic|B-protein molecule|I-protein Mcl-1|B-protein ,|O but|O not|O other|O Bcl-2|B-protein family|I-protein members|I-protein was|O observed|O ,|O and|O Mcl-1|B-protein rescued|O macrophages|B-cell_type from|O LY294002-induced|O cell|O death|O .|O
Further|O ,|O inhibition|O of|O Mcl-1|B-protein by|O antisense|O oligonucleotides|O ,|O also|O resulted|O in|O macrophage|B-cell_type apoptosis|O .|O
Thus|O ,|O our|O findings|O demonstrate|O that|O the|O constitutive|O activation|O of|O Akt-1|B-protein regulates|O macrophage|B-cell_type survival|O through|O Mcl-1|B-protein ,|O which|O is|O independent|O of|O caspases|B-protein ,|O NF-kappaB|B-protein ,|O or|O Bad|B-protein .|O
GRbeta|O expression|O in|O nasal|B-cell_type polyp|I-cell_type inflammatory|I-cell_type cells|I-cell_type and|O its|O relationship|O to|O the|O anti-inflammatory|O effects|O of|O intranasal|O fluticasone|O .|O
BACKGROUND|O :|O Nasal|O polyposis|O disease|O is|O an|O inflammatory|O disorder|O with|O intense|O eosinophilic|O infiltration|O of|O respiratory|O mucosa|O that|O is|O often|O difficult|O to|O control|O with|O topical|O steroids|O .|O
Recent|O evidence|O suggests|O that|O overexpression|O of|O the|O glucocorticoid|B-protein receptor|I-protein splice|I-protein variant|I-protein GRbeta|B-protein in|O inflammatory|B-cell_type cells|I-cell_type might|O contribute|O to|O steroid|O insensitivity|O in|O diseases|O such|O as|O asthma|O .|O
OBJECTIVE|O :|O The|O purposes|O of|O this|O investigation|O were|O to|O determine|O whether|O nasal|B-cell_type polyp|I-cell_type (|I-cell_type NP|I-cell_type )|I-cell_type inflammatory|I-cell_type cells|I-cell_type overexpress|O GRbeta|B-protein and|O to|O examine|O whether|O GRbeta|B-protein overexpression|O is|O associated|O with|O insensitivity|O to|O the|O potent|O topical|O steroid|O fluticasone|O propionate|O (|O FP|O )|O .|O
METHODS|O :|O Biopsies|O were|O obtained|O from|O 10|O subjects|O with|O NPs|O before|O and|O 4|O weeks|O after|O treatment|O with|O intranasal|O FP|O .|O
Middle|O turbinates|O biopsies|O from|O 6|O healthy|O ,|O nonallergic|O subjects|O served|O as|O normal|O controls|O .|O
Biopsies|O were|O immunostained|O for|O inflammatory|O cell|O markers|O as|O well|O as|O GRbeta|B-protein and|O probed|O for|O various|O cytokine|B-RNA mRNA|I-RNA .|O
The|O anti-inflammatory|O response|O to|O FP|O was|O examined|O in|O relation|O to|O pretreatment|O levels|O of|O GRbeta|O expression|O .|O
RESULTS|O :|O The|O total|O numbers|O of|O inflammatory|B-cell_type cells|I-cell_type were|O increased|O in|O NPs|B-cell_type .|O
The|O percentage|O of|O inflammatory|B-cell_type cells|I-cell_type expressing|O GRbeta|B-protein was|O also|O increased|O (|O 40.5|O %|O +/-|O 19.2|O %|O vs|O 16.1|O %|O +/-|O 4.0|O %|O ,|O P|O =.009|O )|O .|O
GRbeta|B-protein expression|O in|O NPs|B-cell_type was|O almost|O exclusive|O to|O T|B-cell_type lymphocytes|I-cell_type ,|O eosinophils|B-cell_type ,|O and|O macrophages|B-cell_type .|O
An|O inverse|O correlation|O was|O observed|O between|O the|O baseline|O inflammatory|O cell|O GRbeta|B-protein expression|O and|O the|O reduction|O after|O FP|O treatment|O in|O EG2-positive|B-cell_type eosinophils|I-cell_type ,|O CD4-positive|B-cell_type T|I-cell_type lymphocytes|I-cell_type ,|O endothelial|O VCAM-1|B-protein expression|O ,|O and|O IL-4|B-cell_type mRNA-positive|I-cell_type cells|I-cell_type .|O
NPs|B-cell_type that|O were|O ``|O FP-insensitive|O ''|O in|O terms|O of|O suppression|O of|O eosinophil|B-cell_type numbers|O (|O major|B-protein basic|I-protein protein|I-protein -positive|O )|O had|O a|O significantly|O greater|O percentage|O of|O GRbeta-positive|B-cell_type inflammatory|I-cell_type cells|I-cell_type ,|O a|O higher|O ratio|O of|O GRbeta-positive/GRalpha-positive|B-cell_type cells|I-cell_type ,|O and|O increased|O numbers|O of|O GRbeta-positive|B-cell_type eosinophils|I-cell_type and|O macrophages|B-cell_type in|O comparison|O with|O those|O that|O were|O ``|O FP-sensitive.|O ''|O
``|B-cell_type FP-insensitive|I-cell_type ''|I-cell_type NPs|I-cell_type also|O demonstrated|O a|O higher|O percentage|O of|O IL-5-positive|B-cell_type inflammatory|I-cell_type cells|I-cell_type expressing|O GRbeta|B-protein before|O and|O after|O FP|O treatment|O .|O
CONCLUSION|O :|O GRbeta|B-protein expression|O appears|O to|O be|O a|O marker|O of|O steroid|O insensitivity|O in|O NPs|B-cell_type .|O
Expression|O of|O GRbeta|B-protein by|O NP|B-cell_type inflammatory|I-cell_type cells|I-cell_type ,|O particularly|O T|B-cell_type cells|I-cell_type and|O eosinophils|B-cell_type ,|O might|O render|O them|O resistant|O to|O suppression|O by|O topical|O steroids|O and|O thereby|O contribute|O to|O persistent|O NP|B-cell_type inflammation|O .|O
Transcriptional|O regulation|O of|O galectin-10|B-protein (|O eosinophil|B-protein Charcot-Leyden|I-protein crystal|I-protein protein|I-protein )|O :|O a|O GC|B-DNA box|I-DNA (|O -44|O to|O -50|O )|O controls|O butyric|O acid|O induction|O of|O gene|O expression|O .|O
Galectin-10|B-protein (|O gal-10|B-protein ,|O also|O known|O as|O Charcot-Leyden|B-protein crystal|I-protein protein|I-protein )|O is|O a|O member|O of|O the|O galectin|B-protein family|I-protein of|O beta-galactoside|B-protein binding|I-protein proteins|I-protein that|O is|O expressed|O uniquely|O in|O eosinophilic|B-cell_type and|I-cell_type basophilic|I-cell_type leukocytes|I-cell_type .|O
To|O gain|O a|O better|O understanding|O of|O galectin|O gene|O expression|O ,|O we|O present|O an|O analysis|O of|O the|O transcriptional|O regulation|O of|O the|O gene|O encoding|O gal-10|B-protein .|O
Analysis|O of|O the|O minimal|B-DNA promoter|I-DNA revealed|O nine|O consensus-binding|B-DNA sites|I-DNA for|O transcription|B-protein factors|I-protein ,|O including|O several|O that|O are|O also|O found|O in|O the|O minimal|B-DNA promoters|I-DNA of|O galectins|B-DNA -1|I-DNA ,|I-DNA -2|I-DNA ,|I-DNA and|I-DNA -3|I-DNA .|O
The|O decrease|O in|O gal-10|O promoter|O activity|O after|O disruption|O of|O either|O the|O GC|B-DNA box|I-DNA (|O -44|O to|O -50|O )|O or|O the|O Oct|B-DNA site|I-DNA (|O -255|O to|O -261|O )|O suggests|O that|O these|O sites|O ,|O along|O with|O the|O previously|O characterized|O GATA|B-DNA and|I-DNA EoTF|I-DNA sites|I-DNA ,|O are|O necessary|O for|O full|O promoter|O activity|O .|O
By|O supershift|O analysis|O ,|O we|O demonstrate|O binding|O of|O the|O transcription|B-protein factors|I-protein Sp1|B-protein and|O Oct1|B-protein to|O the|O consensus|B-DNA GC|I-DNA box|I-DNA and|O the|O Oct|B-DNA site|I-DNA ,|O respectively|O .|O
Similar|O to|O gal-1|B-DNA ,|O gal-10|O expression|O is|O induced|O by|O butyric|O acid|O ,|O an|O effect|O that|O is|O lost|O upon|O ablation|O of|O the|O GC|B-DNA box|I-DNA .|O
Additionally|O ,|O we|O demonstrate|O AML3|O binding|O to|O the|O consensus|B-DNA AML|I-DNA site|I-DNA and|O YY1|B-protein binding|I-protein to|O the|O Inr|B-DNA sequence|I-DNA ,|O both|O elements|O functioning|O as|O silencers|O in|O the|O gal-10|B-DNA promoter|I-DNA .|O
Tumour-stromal|O interactions|O .|O
Role|O of|O the|O stroma|O in|O mammary|O development|O .|O
Mammary|O development|O depends|O on|O branching|O morphogenesis|O ,|O namely|O the|O bifurcation|O and|O extension|O of|O ductal|O growth|O points|O (|O end|O buds|O )|O and|O secretory|O lobules|O into|O a|O more|O or|O less|O fatty|O stroma|O .|O
Because|O breast|O carcinomas|O are|O overwhelmingly|O ductal|O in|O origin|O ,|O this|O review|O focuses|O on|O stromal|O influences|O guiding|O postnatal|O ductal|O development|O and|O there|O is|O only|O the|O briefest|O account|O of|O the|O role|O of|O embryonic|O stroma|O (|O mesenchyme|O )|O .|O
The|O stroma|O as|O the|O necessary|O target|O for|O endocrine|O mammogens|O and|O the|O source|O of|O stimulatory|O growth|O factors|O is|O described|O and|O the|O importance|O of|O mammary|O epithelium-induced|O modifications|O of|O the|O periductal|O stroma|O is|O emphasized|O .|O
Evidence|O is|O presented|O that|O if|O they|O are|O to|O grow|O ,|O end|O buds|O must|O condition|O proximal|O fatty|O stroma|O by|O recruiting|O white|B-cell_type blood|I-cell_type cells|I-cell_type as|O well|O as|O inducing|O stromal|O cell|O division|O and|O ,|O possibly|O ,|O estrogen|B-protein receptors|I-protein .|O
The|O induction|O of|O a|O fibrous|O stromal|O tunic|O around|O the|O end|O bud|O is|O described|O and|O its|O likely|O role|O as|O a|O complex|O ductal|O morphogen|O is|O discussed|O ;|O a|O possible|O role|O in|O growth|O inhibition|O is|O also|O considered|O .|O
Although|O the|O signals|O governing|O fibrotic|O induction|O ,|O ductal|O morphogenesis|O ,|O and|O growth|O inhibition|O are|O unknown|O ,|O a|O role|O for|O transforming|O growth|B-protein factor-beta|I-protein is|O highly|O likely|O and|O is|O discussed|O .|O
Finally|O ,|O a|O need|O for|O new|O conceptual|O and|O experimental|O approaches|O to|O understanding|O stromal-epithelial|O signaling|O is|O discussed|O .|O
Adipophilin|B-protein is|O a|O sensitive|O marker|O for|O lipid|O loading|O in|O human|B-cell_type blood|I-cell_type monocytes|I-cell_type .|O
Adipophilin|B-protein ,|O a|O marker|O of|O lipid|O accumulation|O initially|O described|O in|O adipocytes|B-cell_type ,|O was|O recently|O shown|O to|O be|O induced|O in|O macrophage|B-cell_type foam|I-cell_type cells|I-cell_type .|O
We|O found|O that|O even|O freshly|B-cell_type isolated|I-cell_type blood|I-cell_type monocytes|I-cell_type express|O adipophilin|B-protein and|O that|O the|O amount|O of|O adipophilin|B-protein protein|I-protein is|O variable|O in|O monocytes|B-cell_type from|O different|O healthy|O individuals|O .|O
However|O ,|O the|O physiological|O expression|O of|O adipophilin|B-protein does|O not|O correlate|O with|O the|O levels|O of|O free|O fatty|O acids|O ,|O cholesterylesters|O or|O free|O cholesterol|O .|O
Enzymatically|B-protein modified|I-protein low-density|I-protein lipoprotein|I-protein (|O E-LDL|B-protein )|O induces|O rapid|O foam|O cell|O formation|O in|O monocytes|B-cell_type and|O upregulates|O adipophilin|B-protein mRNA|O and|O protein|O within|O 2|O h|O of|O incubation|O .|O
This|O rapid|O induction|O of|O adipophilin|B-protein is|O accompanied|O by|O a|O significant|O increase|O of|O free|O fatty|O acids|O in|O monocytes|B-cell_type incubated|O with|O E-LDL|B-protein .|O